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Abstract 
Carbohydrates play a crucial role in metabolism, cell recognition, cell differentiation, and 
adhesion processes. Therefore, these molecules represent a potent source for the 
development of new treatments against many different diseases with an unmet medical need. 
However, compounds of this class have major inherent drawbacks related to their chemical 
structure. Carbohydrates are complex and hydrophilic structures with a large polar surface 
area, which commonly results in poor pharmacokinetic (PK) properties including low oral 
bioavailability and short plasma half-life due to fast renal clearance. To overcome the poor PK 
properties of the natural ligands, specific structural modifications have to be implemented in 
the drug development process from the beginning.  
Improvements of newly synthesized compounds have to be constantly monitored with in vitro 
and in vivo PK measurements, allowing a direct feedback for further structural modifications. 
To this purpose, a PADMET platform (Physicochemical properties, Absorption, Distribution, 
Metabolism, Elimination, Toxicity) of in vitro assays, addressing different aspects that influence 
the PK properties of a molecule was developed and optimized. The intestinal absorption is a 
major hurdle to achieve sufficient oral bioavailability of carbohydrate mimetics and 
therefore,the focus of this work is set on the permeability of carbohydrate mimetic by passive 
permeation or active transport.  
In this thesis, three different targets for the development of potent lead structures starting 
from natural carbohydrates are discussed: 
• E-selectin is a lectin expressed on endothelial cells upon an inflammatory stimulus and 
is crucial for the recruitment of leukocytes to the side of inflammation. Therefore, E-
selectin has been recognized as a potent target for the treatment of various diseases 
with an inflammatory component. The carbohydrate epitope recognized by E-selectin 
is the tetrasaccharide sialyl Lewisx (sLex). For the treatment of chronic inflammatory 
diseases, an oral administration is of interest. However, the development of an orally 
bioavailable E-selectin antagonist from sLex is challenging due to its chemical properties. 
To overcome the hurdle of insufficient intestinal absorption, an ester prodrug strategy 
and a bioisosteric replacement were followed and further evaluated by in vivo PK 
studies in mice. The ester prodrug approach resulted in insufficient oral bioavailability 
  
but improvement of the apparent plasma half-life, whereas the bioisosteric approach 
lead to the first orally bioavailable E-selectin antagonist. 
• Uropathogenic Eschericha coli (UPEC) are the main cause of urinary tract infections 
(UTI). UPEC are expressing the virulence factor FimH on the distal tip of type 1 fimbriae, 
which binds to mannosides on the luminal surface of the bladder to prevent bacteria 
from being washed out by urine flow. FimH is therefore a promising target for an 
antiadhesive treatment of UTIs in order to replace current antibiotic treatment 
strategies. In this work, known biphenyl-α-D-manno-pyranosides were further 
developed in terms of affinity and in vitro PK properties. 
• Sialic acids bound or in free circulation are regulated by sialyltransferases and 
neuraminidases (NEU). Selective inhibitors for the human neuraminidase NEU3 is of 
interest to study the physiological and pathophysiological role of neuraminidases and 
further evaluate the potential to develop therapeutics. Here, the development of 
specific NEU3 inhibitors, as well as the attempt to optimize their PK properties is 
reported. 
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1 Carbohydrate mimetics 
Carbohydrates are one of the most important energy sources of the human metabolism. In 
addition, they are also important as structural element and as cell surface epitopes involved 
in numerous cell recognition and differentiation processes. Every single human cell is coated 
with complex carbohydrate structures linked to proteins (® glycoproteins, proteoglycans) 
and lipids (® glycolipids), forming a glycocalyx layer up to 100 nm in thickness (1-4). The 
structural variability of the glycocalyx is a consequence of different monosaccharides existing 
in the pyranose or furanose form, which are linked in α- or β-configuration and different 
regiochemistry. This variability is needed for specific cell-cell interactions and differentiation 
of cells in various processes (5). To promote specific interactions between cells in physiological 
and pathological processes, carbohydrate-binding proteins, so-called lectins, recognize 
specific epitopes of the glycocalyx (6, 7). Furthermore, carbohydrates are recognized by 
bacteria and viruses during infection cycles, and can lead to autoimmune diseases, when 
antibodies recognizing endogenous carbohydrate moieties are formed (8-10).  
Therefore, the enzymatic metabolism of carbohydrates (i), the active transport of 
carbohydrates across membrane barriers by transporters (ii), the composition and reduction 
of glycans by transferases (iii) and hydrolases (iv), and the recognition of carbohydrate 
epitopes by lectins (v) or antibodies (vi) are all potential targets for the treatment and 
prevention of carbohydrate-related diseases (11). Although important in numerous 
pathological processes, only a small fraction of therapeutics on the market are derived from 
carbohydrates. This is partially due to the poor pharmacokinetic properties inherently linked 
to the chemical space that must be covered to address carbohydrate targets. Carbohydrates 
are hydrophilic and contain many hydrogen bond (H-bond) donors, leading to insufficient 
passive permeability across the lipid membranes of the enterocytes necessary for oral 
bioavailability. Furthermore, when administered parenterally, carbohydrates suffer from fast 
renal excretion leading to short plasma half-lives.  
The pharmacokinetic parameters required for carbohydrate-derived drugs are highly 
dependent on the site of action. For example, marketed inhibitors of the α-glycosidase in the 
brush border of the small intestine (acarbose, miglitol, voglibose) do not require oral 
bioavailability to reach their therapeutic target (12-14). Additionally, carbohydrate-derived 
Carbohydrate mimetics   
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drugs applied by injection do not need to be permeable if acting on extracellular targets, but 
have to overcome problems related to short half-life. Thus, Fondaparinux, an antithrombotic 
agent selectively inhibiting coagulation factor Xa and Rivipansel, a pan-selectin inhibitor used 
for the treatment of vaso-occlusive crisis in sickle cell patients, are administered by 
intravenously and have both sufficient long half-lives due to high plasma protein binding (15, 
16). 
1.1 Orally bioavailable carbohydrate mimetics 
To increase passive permeability and intestinal absorption as a first step to achieve oral 
bioavailability of a carbohydrate-derived drug, a consequent reduction of the polar surface 
area and addition of lipophilicity is needed. In Figure 1.1, currently approved orally 
bioavailable carbohydrate mimetics are listed. All compounds are derived from 
monosaccharides and achieved their selectivity and oral bioavailability primarily via the 
aglycone.  
The iminosugar Miglustat (1), a glucosylceramide synthase inhibitor used for the treatment of 
Gaucher and Niemann Pick disease, shows high oral bioavailability by passive diffusion in 
mammalians (17). Although not studied, the low molecular weight below 250 Da would allow 
paracellular diffusion to achieve the high oral bioavailability (18). Zidovudine (2) is the first 
approved representative of nucleotide reverse-transcriptase inhibitors (NRTIs) used in retro-
viral therapies against acquired immunodeficiency syndrome (AIDS) (19). By modifying the 
ribose unit of nucleosides, NRTIs stop the elongation of DNA on the 3’ position of ribose. 
Zidovudine and other NRTIs show generally moderate to good oral bioavailability due to 
passive permeation, but also active transport by nucleoside transporters in the small intestine 
(20, 21). The antiepileptic drug Topiramate (3) exceeds its anticonvulsant effects due to 
different pharmacodynamics properties, i.e. an inhibitory effect on voltage-gated Na+ and Ca2+ 
channels, glutamate-activated ion channels, and variable modulatory effects on γ-
aminobutyric acid (GABA)-activated ion channels (22). High oral bioavailability was achieved 
by reducing the hydrophilicity of the D-fructose moiety by two acetonide groups, which, in 
addition, lock the pyranose moiety in a “twist-boat” conformation, that is conducive to the 
pharmacological effects (23).  
In order to treat diabetes mellitus type 2, the reabsorption of glucose in the kidneys can be 
blocked by specific inhibitors of sodium dependent glucose transporter 2 (SGLT2). 
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Dapagliflozine (4) was the first approved SGLT2 inhibitor, exhibiting a large lipophilic aglycone, 
responsible for selectivity and intestinal absorption (24, 25). Natural and unnatural O-
glucosidic SGLT2 inhibitors showed metabolic instability in the intestinal brush border due to 
the presence of β-glucosidases. Therefore, the development of potent compounds was 
focused on metabolically more robust C-aryl glucosides (26, 27).  
The neuraminidase inhibitor Oseltamivir (5) for the prophylaxis and treatment of influenza 
virus infections is the carbohydrate mimetic, which underwent the most consequent 
reduction of the polar surface to achieve oral bioavailability. Starting from the natural 
substrate sialic acid, the hydrophilic glycerol side chain was replaced by a lipophilic isopentoxy 
moiety, the hydroxyl group at the 2 position was eliminated and an ethyl ester prodrug was 
formed (28). The prodrug shows an oral bioavailability of approximately 80% and the bioactive 
principle is released after hydrolysis by carboxylesterases (29). 
  
Figure 1.1 Orally bioavailable carbohydrate mimetic drugs currently on the market. 
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1.2 Projects presented in this thesis 
1.2.1 E-selectin antagonists  
The lectin E-selectin is expressed on the endothelium upon an inflammatory stimulus (30, 31). 
By interacting with glycoprotein ligands on leukocytes, E-selectin promotes rolling of these 
leukocytes on the endothelial surface. This first step initiates the inflammatory cascade to 
promote firm adhesion and transmigration of leukocytes to the site of inflammation. Thus, 
the inflammatory cascade is forming a vital defense mechanism in the event of injuries or 
infections. However, when excessively used, it can turn deleterious in numerous diseases with 
an inflammatory component, such as stroke, psoriasis or asthma (32). Therefore, blocking 
selectins with an antagonist and, as a consequence, interrupting the inflammatory cascade 
has been recognized as a promising therapeutic approach for the treatment of inflammatory 
diseases (33). 
The carbohydrate epitope recognized by E-selectin is the tetrasaccharide sialyl Lewisx (sLex) 
(34). Carbohydrate mimetics of sLex are currently investigated in clinical trials, but due to poor 
oral bioavailability they have to be administered intravenously (35, 36). For the treatment of 
chronic inflammatory diseases, an oral administration to reduce the administration burden of 
patients is more convenient. The development an orally bioavailable E-selectin antagonist is, 
however, challenging, since carbohydrate mimetics with sufficient pharmacokinetic 
properties have to be designed from the tetrasaccharide lead structure sLex, which possesses 
most unfavorable physicochemical properties. The evaluation of novel, in-house synthesized 
antagonists is described in chapter 3. 
1.2.2 FimH antagonists  
Around 75 % of all urinary tract infections (UTIs) are caused by uropathogenic E. coli (UPEC). 
UPEC are expressing the virulence factor FimH, a bacterial lectin presented on the distal tip of 
type 1 fimbriae (37). FimH binds to mannosides on the luminal surface of the bladder and 
therefore prevents the bacteria from being washed out during micturition (38). UTIs are 
treated with antibiotics, but the increasing antibiotic resistance urges for new treatment 
options (39). The challenge of developing FimH antagonists is, that after oral absorption, the 
molecule has to be excreted via the bladder without undergoing metabolism. Previous work 
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showed the high potential to treat UTIs by FimH antagonists and further progress is presented 
in chapter 4 (40). 
1.2.3 Human neuraminidase 3 inhibitors 
The concentration of sialic acids in humans, either bound to residues or in free circulation, is 
highly regulated, guided by sialyltransferases and neuraminidases (41). Four different human 
neuraminidases (NEU1-4) have been identified, each with its own specificity, expression 
pattern and modulations (42). The development of selective inhibitors for human 
neuraminidases NEU1-4 is of interest, not only for the development of potential therapeutics 
against different diseases where overexpression of neuraminidases is involved, but also in the 
study of physiological and pathophysiological role of neuraminidases. To conduct in vitro 
studies in cell lines, as well as in vivo studies, antagonists need to emphasize cellular 
membrane permeation and oral bioavailability. Therefore, the pharmacokinetic properties of 
neuraminidase inhibitors have to be evaluated. The development of selective neuraminidase 
3 inhibitors is presented in chapter 5.  
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2 Oral bioavailability of carbohydrate mimetics 
Oral dosing of a drug is the most convenient administration route and is enhancing the patient 
compliance and is reducing the risk of complications. Especially for the treatment of diseases, 
which do not require acute hospitalization, an oral administration is indicated to improve the 
patient’s quality of life (1, 2). Therefore, we strive for orally bioavailable carbohydrate 
mimetics in the different projects discussed in this thesis.  
Oral bioavailability is defined as the extent of a drug reaching systematic circulation (fraction 
F) after giving an oral dosage form (3). To reach the systemic circulation, the drug has to 
overcome different physical (e.g. membranes), physicochemical (e.g. solubility, stability) and 
biological (e.g. metabolism, transporters) barriers summarized in Figure 2.1 (4). 
 
Figure 2.1 Barriers to overcome to achieve oral bioavailability. 
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The impact of different parameters that affect oral bioavailability can be assessed with the 
Biopharmaceutics Drug Distribution and Classification System (BDDCS) (5, 6). According to the 
permeability and solubility data, BDDCS divides the drugs in four classes (Table 2.1). As 
previously discussed, carbohydrate mimetics t are often showing disadvantageous 
pharmacokinetic properties due to their hydrophilic character, leading to insufficient passive 
permeability but good aqueous solubility. Therefore, the molecules developed during the 
course of this thesis predominantly belong to BDDCS class 3, which is characterized by a strong 
influence of active transport mechanisms in the absorptive direction and possible efflux 
transport (7). Thus, the permeation over the intestinal membrane either actively or passively 
is the key challenge to overcome for our goal to achieve orally bioavailable carbohydrate 
mimetics. 
Table 2.1 Biopharmaceutics Drug Distribution and Classification System (BDDCS) adapted from Shugarts et al. (7). 
 High solubility Low solubility 
Hi
gh
 p
er
m
ea
bi
lit
y 
Class 1 
• Extensive metabolism 
• Minimal transporter effects 
Class 2 
• Extensive metabolism 
• Efflux transporter effects 
predominate in the gut, 
while absorptive and efflux 
transporter effects occur 
the in liver 
Lo
w
 p
er
m
ea
bi
lit
y  
Class 3 
• Poor metabolism 
• Absorptive transporter 
effects predominate (but 
may be modulated by efflux 
transporters) 
Class 4 
• Poor metabolism 
• Absorptive and efflux 
transporter effects could be 
important 
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The oral bioavailability F of a drug is measured by comparing the concentration in systemic 
circulation after oral dosage (per os, PO) with intravenous dosing (IV), under the assumption 
that after IV administration, 100 % of the drug reached circulation (8, 9). After a correction for 
the applied dose D, a determination of the concentration over time (area under the curve, 
AUC) gives the oral bioavailability F of a drug in percent (Equation 1).  !"# = 100	 ∙ 	)*+,-	∙	./0		)*+/0	∙	.,-       (eq. 1) 
The oral bioavailability is a key parameter affecting the systemic exposure of a drug. To which 
extent and time the drug is present at the therapeutic target is dependent on a complex puzzle 
of different physicochemical, physiological and biological parameters, which are summarized 
as pharmacokinetic properties. These properties are divided into five parts (PADME). The 
toxicity of a drug is often included additionally into this set of properties, since the toxicity 
limits the dosage of the drug (10, 11). In this case, the abbreviation PADMET is used: 
• Physicochemical properties 
• Absorption 
• Distribution 
• Metabolism 
• Elimination 
• Toxicity 
Insufficient pharmacokinetic properties causing a lack of sufficient exposure and thus efficacy, 
were the major cause of failure in clinical trials for a long time. After specific physicochemical 
and biochemical profiling were implemented in the drug development process, the failures of 
clinical trials due to pharmacokinetic reasons were reduced to less than 10% (12, 13). To 
identify possible drawbacks of the molecule and to successfully introduce beneficial structural 
modifications, the implementation of in vitro evaluation methods has to take place in an early 
phase of drug development. Our group started to establish a PADMET platform with the 
purpose to profile carbohydrate mimetics and improve their pharmacokinetic properties in 
2007. Dr. Mattias Wittwer started this endeavor, which was then further expanded by Dr. 
Simon Kleeb, Dr. Jacqueline Bezençon, and myself. The current version of the platform is 
summarized in Table 2.2. The overall aim of our PADMET platform is to predict the 
pharmacokinetic properties of lead structures and to adapt the standard PADMET evaluation 
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to a new compound class, the carbohydrate mimetics. Herein, the implemented methods are 
summarized, and their predictive power and limitations are discussed with a focus on 
physicochemical properties, absorption and metabolism.  
  
Oral bioavailability of carbohydrate mimetics   
 23 
Table 2.2 Assays in the PADMET platform to predict pharmacokinetic properties of carbohydrate mimetics. 
Property Assay 
Physicochemical properties 
LogD7.4 Miniature shake flask method 
pKa 1H-NMR spectroscopy 
Solubility Kinetic solubility 
Thermodynamic solubility 
Preformulations 
Absorption 
Gastrointestinal stability Simulated gastrointestinal fluids 
Permeability and transport Parallel artificial membrane assay (PAMPA) 
Caco-2 cell-based permeability assay 
Distribution 
Plasma protein binding Equilibrium dialysis 
Metabolism 
Phase I metabolism Human, rat or mouse liver microsomes 
Phase II metabolism Human, rat or mouse liver cytosol and microsomes 
Elimination  
No specific assay. Implemented in metabolism and distribution assays 
Toxicity 
Cell toxicity MTT-assay 
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2.1 Physicochemical properties 
Structural properties of molecules are easily accessible and include valuable information to 
predict and interpret their pharmacokinetic behavior. Lipinski et al. and Veber et al. analyzed 
the structural properties of molecules succeeding or failing in clinical studies and summarized 
their findings in rules (Table 2.3) (14, 15). Although Lipinski clearly stated that up to two 
violations of his rule still allow oral availability and many exceptions have been published, the 
rule of 5 had a large impact on drug development. Many libraries for high throughput 
screening in industries were adjusted to Lipinski’s and Veber’s rules as hard cut off criteria, 
reducing the chemical space used for the initial screening (16). Nevertheless, these rules are 
an easy to apply guidance indicating possible risk factors during the drug discovery process 
(17).  
Table 2.3 Rules to predict oral bioavailability from structural properties 
Lipinski’s rule of five Veber’s rule  
Molecular weight (MW) < 500 Da Rotatable bonds < 10 
Hydrogen bond donors < 5 Polar surface area (PSA) < 140 Å2 
Hydrogen bond acceptor < 10 
clogP < 5 
2.1.1 Lipophilicity 
The lipophilicity of a molecule in its uncharged form is quantified by the octanol-water 
partition coefficient logP or, for ionized species, by the distribution coefficient logD  at a 
specific pH value (18). Thus, the lipophilicity of a compound at a given pH is dependent on the 
pKa of the molecule. An appropriate lipophilicity is a prerequisite to support the transfer of a 
molecule from the extracellular aqueous solution into a cell membrane and is therefore 
needed for transcellular transport. Furthermore, the lipophilicity has an impact on drug 
binding to plasma or tissue proteins to modify the volume of distribution and plasma half-life 
(19, 20). However, high lipophilicity can lead to problems regarding solubility and metabolic 
stability (21, 22). As a result, a majority of orally bioavailable and marketed drugs have a logP 
value between 1 and 4 (23). 
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The lipophilicity of a molecule can easily be predicted by in silico tools (24, 25) using structural 
parameters as proposed e.g. by Moriguchi (26). However, structural elements specific for 
carbohydrate mimetics, such as overlapping polar surfaces from neighboring hydroxyl groups 
and intramolecular hydrogen bonds, are often not implemented in those in silico tools. For in 
vitro measurements, different approaches are being used, e.g. high-pressure liquid 
chromatography (HP-LC) or artificial membranes (27-29). The method of choice for the logD 
determination in the PADMET-platform was the shake flask approach with a water and 
octanol phase. With this gold standard method, the distribution coefficient logD is determined 
in the solvents of choice by direct measurement and therefore without intrinsic errors.  The 
drawback of the method is the inaccuracy for highly lipophilic (logD > 3.5) but also hydrophilic 
(logD < -1.5) compounds due to the high influence of standard measurement errors in these 
regions. The shake flask method was used to determine the lipophilicity of all molecules 
presented in this thesis with adapted protocols for each manuscript and publication.  
2.1.2 pKa 
The dissociation constant pKa of acids defines the degree of ionization of a molecule in 
aqueous solution at a given pH value. When the pH is equal to the pKa value, 50% of the 
uncharged and charged species are present (18). Since ionized molecules are more polar than 
their neutral counterparts, the pKa is an important characteristic affecting various properties, 
such as solubility, permeability, plasma protein binding, and excretion (30). The pKa can either 
be predicted by in silico tools or measured, for example by electropotentiometric methods 
(31, 32). Dr. Jacqueline Bezençon revisited the determination of pKa by 1H-NMR spectroscopy 
(33), which is integrated into the PADMET-platform. 
2.1.3 Solubility 
The solubility of a compound is a thermodynamic property defined by the equilibrium of a 
substance in its solid state and its dissolved form in the liquid phase. A compound must be 
dissolved to create a concentration gradient that drives passive transport through the 
intestinal membranes. Furthermore, the solubility of a compound determines the upper limit 
of its concentration to be used in assays. Therefore, the solubility of the compound has to be 
screened early in the drug development process (9, 34). Numerous factors define solubility, 
namely the solvent and its composition (addition of co-solvents, ions, proteins), the pH value, 
and the temperature (35-37). Besides the intrinsic properties of the drug affecting the 
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solubility (e.g. molecular size, lipophilicity, pKa), other factors such as crystal packing, particle 
size of the crystal, melting point and additives influence solubility (38, 39). The solubility 
required for an oral administration depends on the required dose, but generally should be 
above 0.5 mg/mL, assuming moderate affinity and permeability (34).  
Different techniques to determine the solubility of a compound have been developed and 
evaluated. For each assay it is important, that the analyte is present in solid state and dissolved 
form to provide the equilibrium.  
Kinetic solubility 
With the increasing number of compounds moving into drug discovery and development, 
kinetic solubility measurements have gained importance to meet the high throughput needs 
(40). These methods use high concentration stock solutions of the compounds dissolved in 
dimethyl sulfoxide (DMSO). Precipitation is induced by adding the stock solution to a buffer 
solution, with a subsequent analysis of the supernatant. For high throughput, this approach is 
very useful, but has some intrinsic limitations, since the obtained kinetic solubility is not taking 
the solid state and polymorphism of the molecule into account. Additionally, supersaturation 
may occur and the organic solvent DMSO present in the final solution can enhance the 
apparent solubility. Therefore, the measured kinetic solubility tends to be increased 
compared to other measurements and the predicted pharmacokinetic properties of a 
molecule can therefore be overestimated (41). Kinetic solubility measurements for FimH 
antagonists are discussed in chapter 4. 
Thermodynamic solubility 
The thermodynamic solubility is usually determined by the shake flask method, where an 
excess of solid compound is added to solvent to form a saturated solution. Aliquots are 
filtered, and the concentration of the supernatant is determined. This technique is considered 
to be the gold standard for solubility measurements (10). Major drawbacks are the large 
compound consumption, as well as the time-consuming measurements, since for slowly 
dissolving compounds, it takes a long time to reach the equilibrium (42). The method was used 
to determine the solubility of E-selectin and neuraminidase 3 inhibitors, discussed chapters 3 
and 5. 
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Preformulation 
If the solubility of a compound is insufficient to reach the required assay concentration, 
preformulation is needed. Especially for pharmacokinetic studies with intravenous dosing, a 
complete dissolution of the compound is mandatory, because the injection of a precipitate 
can lead to embolism (43). A set of different co-solvents (e.g. DMSO), surfactants (e.g. Tween 
80) and complexing agents (e.g. cyclodextrin) are available to be used individually or in 
combination to formulate a solution without precipitate. To minimize the side effects of the 
injected vehicle, the maximal concentration of each co-solvent used in the pharmacokinetic 
studies for E-selectin antagonists was chosen according to a study published by Thackaberry 
et al. (44). 
2.2 Absorption 
After being orally administered, the active ingredient of a drug has to surpass numerous 
barriers of the gastrointestinal tract to reach the therapeutic target. The gastrointestinal organ 
system consists of different parts, each with its own physiological and physical environments 
(9). The majority of drugs are absorbed by transcellular transport across the enterocytes of 
the small intestines, composed of duodenum, jejunum and ileum. To reach the small 
intestines, the molecule has to be dissolved in the intestinal lumen and has to be stable in the 
stomach and duodenum. Therefore, the stability in the gastrointestinal tract, as well as the 
permeability across the intestinal membranes has to be assessed (4). 
2.2.1 Gastrointestinal stability 
In the stomach and/or the small intestine, a swallowed tablet disperses, and the drug is 
dissolved. Fasted or fed state of these organs is largely influencing physiology and residence 
time (Table 2.4). The effects of food on stability and absorption can be positive or negative. 
For example, highly lipophilic compounds maybe more likely to be absorbed in fed state, 
whereas actively transported molecule can suffer from reduced absorption in fed state due to 
a saturation of the transport system (9, 45, 46). In early drug development, the fasted state is 
preferred for in vivo studies in animals and first in human trials, because this state shows less 
variability and is easier to standardize. Therefore, in the PADMET-platform, the focus 
regarding stability of carbohydrate mimetics is on gastrointestinal environments of the fasted 
state. 
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Table 2.4 Physiological differences of the gastrointestinal tract in fasted and fed state (18, 45, 47, 48). 
 Stomach Small intestine 
Fasted Fed Fasted Fed 
pH 1 2-5 6.5 5 
Residence time 20 min 3-4 h 3-4 h Up to 24 h 
Enzymatic activity low high low  high 
 
Simulated gastric fluid 
The acidic condition in the stomach is necessary for the function of the gastrointestinal tract. 
It is needed to activate pepsin from pepsinogen, to denature proteins, and as a natural barrier 
against bacterial infections (49). Hydrochloric acid, excreted by proton pumps from the 
stomach glands, is responsible for the acidity of the stomach and can lead to a chemical 
hydrolysis of carbohydrates(50). Therefore, to test acid stability of compounds, an HCl 
environment with or without pepsin is used. The results obtained for E-selectin antagonists 
are discussed in manuscript 1 and 3. 
Simulated intestinal fluid 
In the first part of the small intestine called duodenum, the gastric acid is neutralized by 
bicarbonate excretion from Brunner’s glands. Furthermore, bile acid for the uptake of fatty 
acids and pancreatin, a mixture of amylases, proteases and lipases, is added in order to digest 
food ingredients. However, this enzyme mixture can be disruptive for drugs. Especially ester 
bonds can be cleaved by lipases, hydrolyzing ester prodrugs before intestinal absorption (51). 
This effect is studied and discussed in manuscript 1. 
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2.2.2 Permeability 
The majority of nutrients and drugs are absorbed in the small intestine, particular in the 
jejunum and ileum. The surface of the small intestine is enlarged by villi covered by epithelial 
cells, which form microvilli on their apical surface, leading to a total surface of more than 
100 m2 over the three to four meter length of small intestine (9, 52). The surface is covered 
by glycoproteins, leading to a partial negative charge and an unstirred layer mucus coat. For 
the membrane transfer through the epithelial cells of the small intestines (enterocytes) 
various pathways have to be considered as described in Figure 2.2. These pathways are used 
either separately or in combination, making the prediction of the absorption process highly 
difficult (53). 
 
Figure 2.2 Absorption pathways through enterocytes along the concentration gradient (53). 
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Passive permeability 
Passive permeability is driven by a concentration gradient, either paracellularly through tight 
junctions or transcellularly through epithelial cells. It depends on structural properties and 
lipophilicity of the molecules. Compared to active transport, it is only slightly influenced by 
stereochemical variability (18). The key structural properties analyzed by Lipinski and Veber 
(2.1 Physicochemical properties) are predictive for passive transcellular permeability (14, 15). 
Paracellular permeation through tight junctions, however, requires different properties, i.e. 
molecular weight below 250 Da and hydrophilicity (54). For both the trans- as well the 
paracellular pathway, solubility plays a significant role, since it controls drug concentration in 
the intestinal lumen. However, unlike for the paracellular route, transcellular permeation can 
also be influenced by active transport or drug metabolizing enzymes (18). 
For the transcellular permeation, drugs have to pass the phospholipid bilayer of the cells. This 
membrane barrier can be artificially mimicked in a parallel artificial membrane permeation 
assay (PAMPA) allowing the study of isolated passive permeability and is therefore widely 
applied in drug development (55). It can be performed in a high throughput format and often 
correlates well with in vivo results (56). Therefore, PAMPA was used to assess the permeability 
of carbohydrate mimetics in all manuscripts, however with specifically adapted methods for 
individual projects. Since PAMPA uses an artificial membrane and was developed using drug-
like molecules and not carbohydrate mimetics, the results obtained for our molecules have to 
be handled with care and verification by other methods (e.g. Caco-2 cell assay) is required.  
Active Transport 
In addition to passive permeation, compounds can also pass membranes via carrier-mediated 
pathways. These pathway plays a crucial role for compounds not passing membranes 
passively due to high molecular weight, low lipophilicity or ionization (53). The carrier-
mediated transport needs a direct interaction of the compound with a protein embedded in 
phospholipid bilayer. Therefore, carrier-mediated transport is substrate specific, saturable, 
and can be inhibited (9). The transport can be divided into facilitated and active transport. 
Facilitators do not require an energy source and are providing better permeation over the 
membrane along the concentration gradient. In contrast, active transporters are capable to 
transport a compound against its concentration gradient and therefore rely on an energy 
source (57). Symporters and antiporters are using the concentration gradient of another 
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molecule as driving force, whereas primary active transporter usually use adenosine-5’-
triphosphate (ATP) as source of energy (58).  
Active transport can therefore be in the absorptive and secretory direction. Efflux 
transporters, such as the ABC transporter P-glycoprotein (P-gp) exhibit a protective function 
by excreting xenobiotics back into the intestinal lumen and therefore can have a large effect 
on compounds with low passive permeability, especially at low doses (59). At high 
concentrations, P-gp can be saturated, but only for drugs with sufficient solubility. 
Furthermore, the expression of P-gp increases from the jejunum to the distal ileum. 
Transporters involved in the active uptake of compounds are mainly peptide transporter 1 
(PEPT1) and members of the organic anion transporting polypeptide family (OATP) (57). They 
are responsible for the uptake of organic anions, di- and tripeptides. In addition, drugs can be 
specifically designed to target these transporters for enhanced orally bioavailability (60). 
For the assessment of active transport an assay based on a colon carcinoma cell line (Caco-2) 
is used, allowing the measurement of the permeation rate in both directions (61). This assay 
offers the opportunity to measure permeability in an elaborated system offering good 
correlation of measured permeability Papp and oral absorption in man (62). Since Caco-2 cell 
express several transport systems simultaneously, other systems or transfected cell lines are 
preferred to evaluate the effect of a single transporter. Other drawbacks of the Caco-2 cell 
based model are the expression of enzymes differing from those of human enterocytes (e.g. 
human esterase CES1 for the study of ester prodrugs) and time-consuming and expensive 
handling (63). The Caco-2 cell based assay was used for E-selectin and FimH antagonists in 
chapter 3 and 4. 
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2.3 Distribution 
Once in circulation, the compound distributes into tissues. This process is described by the 
volume of distribution VD (Equation 2), where the total amount of the given dose DIV is divided 
by the extrapolated concentration at time-point zero C0. This gives an artificial number 
reflecting the ‘apparent volume of distribution’ for the compound. Compounds showing 
pronounced distribution into body tissues and low blood concentrations will also have a large 
VD (64). 1. = 	./0+2      (eq.2 ) 
2.3.1 Plasma Protein Binding (PPB) 
Furthermore, compounds in circulation can bind to tissue or plasma components or remain 
unbound in the aqueous environment. Only the unbound fraction can interact with its target 
and, therefore, exhibit a therapeutic effect. This unbound fraction, however, is also available 
for metabolism or elimination. The affinity towards plasma proteins is generally weak and 
characterized by a fast association and dissociation. High or low PPB does not influence in-
vivo efficacy as the effect on clearance and apparent potency by changes in free fraction will 
cancel out. Therefore, protein binding is not supposed to be an optimization parameter. Thus, 
structural optimization to improve pharmacokinetic properties in lead development projects 
should aim at increasing total drug exposure. This can be achieved by improving solubility, 
permeability and metabolic stability but not by increasing protein binding, i.e. unbound or 
bound fraction (65-67). 
The most important plasma proteins involved in drug binding are human serum albumin 
(HSA), α1-acid glycoprotein (α-AGP) and lipoproteins (4). For approx. 50% of 222 analyzed 
marketed drugs high PPB of more than 90 % was found, i.e. high plasma protein binding is 
occurring frequently (68). 
Several methods for determining in vitro PPB are available, e.g. equilibrium dialysis, 
ultracentrifugation, ultrafiltration, microdialysis and surface plasmon resonance (69, 70). 
Equilibrium dialysis was chosen for our PADMET-platform, since it is generally accepted as 
gold standard (71). The principle is a two-chamber system separated by a semipermeable 
dialysis membrane. In one chamber, plasma proteins are added and after the equilibrium 
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between bound and unbound state has been established, the compound concentration in the 
chamber without plasma proteins is measured.  
2.4  Metabolism and first pass elimination 
Following absorption across the gut lumen, nutrients and drugs are transported along the 
portal vein to the liver where they encounter the first pass metabolism before reaching 
systemic blood circulation. Therefore, oral bioavailability of a compounds is also highly 
dependent on the enzymes recognizing the structure, the abundance of these enzymes and 
their metabolic rate (9).  
The liver is the primary side for metabolism of xenobiotics, playing a central role in 
pharmacokinetics and toxicity. The liver is organized in lobules, an almost hexagonal cluster 
of hepatocytes connected to portal triads, which contain small branches of the portal vein, 
liver artery and bile duct. These lobules receive oxygenated arterial blood from the liver artery, 
as well as the nutrition rich blood from the portal vein (25% arterial, 75% nutrition rich blood). 
The bile duct transports bile acids as well as metabolites to the gall bladder and further to the 
duodenum (72).  
Xenobiotics, including drugs and toxins, tend to be lipophilic, enabling passive transport 
through lipid membranes and compartments. Therefore, distribution and excretion of those 
molecules are difficult to control. One goal of metabolizing enzymes is to increase the polarity 
of xenobiotics, improving their water solubility and excretability (9). The metabolic enzymes 
can be divided into those introducing a new polar functional group by oxidation, reduction or 
hydrolysis (phase I metabolism) and those introducing new hydrophilic moieties by 
conjugation to endogenous molecules (phase II metabolism). Which metabolic pathways 
xenobiotics undergo is highly dependent on their structure; thus direct conjugation by phase 
II metabolism is especially observed for compounds already containing polar groups such as 
carbohydrate mimetics (Figure 2.3)(73). Sufficient metabolic stability is a prerequisite to 
achieve high concentrations in the systemic circulation over an extended time period. In 
contrast, if the compound is applied as a prodrug, a metabolic transformation is needed for 
the release of the active principle (74). Therefore, the metabolic profile of each drug candidate 
has to be carefully evaluated. 
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Figure 2.3 Most relevant phase I and II metabolism in hepatocyte. 
2.4.1 Phase I metabolism 
New functional groups such as hydroxyls, amines or carboxylic acids are introduced by phase 
I enzymes, leading to higher hydrophilicity compared to the parent compound. Phase I 
enzymes include cytochrome P450s (CYP450s), flavin monooxygenases (FMOs) 
dehydrogenases, reductases, and esterases (75).  
Cytochrome P450s 
The CYP450 superfamily, located on the endoplasmatic reticulum of hepatocytes, makes the 
largest contribution to phase I metabolism. These proteins are also present in other 
extrahepatic tissues such as small intestine, colon, kidneys, and lung (76). CYP450 enzymes 
contain a heme group coordinating an iron ion, which is responsible for the catalytic 
monooxygenation of substrates with two electrons provided by cytochrome reductases(77). 
The CYP450 superfamily consists of approximately two thousands of subtypes, expressed in 
different tissues and species, with just a few isoenzymes mainly responsible for the 
metabolism of xenobiotics in man (e.g. CYP3A4, CYP2D6, CYP2C9) (78). These isoenzymes are 
therefore of interest when a new compound is either metabolized by or interacts with one of 
those enzymes. Furthermore, possible polymorphism of these enzymes makes it crucial to 
know the metabolic pathway of new compounds (78).  
To study the metabolic pathway of new compounds, in silico tools were developed (79). These 
tools often recognize potential soft spots of molecules. However, for new substance classes, 
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including carbohydrate mimetics, the results obtained with in silico tools are generally 
insufficient.  
Several in vitro tools using liver microsomes, S9 fractions or liver slides from different species 
are available (80). Liver microsomes are the most common way to evaluate the metabolic 
behavior and therefore were chosen for the PADMET-platform. By adding the co-factor 
nicotinamide adenine dinucleotide phosphate (NADPH), cytochrome reductases are able to 
provide two electrons to activate CYP450 and the metabolic stability of the molecule can be 
assessed over time. Furthermore, metabolites can be extracted and identified or used for 
further studies. This assay format was used to measure the metabolic stability of E-selectin 
antagonists. 
Carboxylesterases (CES) 
Carboxylesterases are hydrolyzing esters to the corresponding carboxylic acids and alcohols. 
The multigene family of mammalian carboxylesterases is divided into 5 major subfamilies 
(CES1-5), of which CES1 and CES2 contribute the most to the metabolic activity (81). The tissue 
expression pattern and the substrate specificity of CES1 and CES2 show significant differences. 
CES1 preferably hydrolyzes substrate with a large acyl and small alcohol moiety but is also 
capable of hydrolyzing esters with both large alcohol and acyl moieties. In contrast, CES2 
recognizes substrates with large alcohol group and small acyl moiety (82). Both 
carboxylesterase families are present in hepatocytes, but only CES2 is present in enterocytes 
(83, 84).  
Carboxylesterases play a crucial role in the bioconversion of ester prodrugs (74). Hydrolysis of 
ester prodrugs in the enterocytes during absorption into the more hydrophilic carboxylic acid 
can reduce oral bioavailability of the active principle (84). Therefore, it is crucial to evaluate 
the hydrolysis of ester prodrug and an enzymatic specificity for CES1 is preffered. In liver 
microsomes, both isoenzymes CES1 and CES2 are present. Thus, the hydrolysis of ester 
prodrugs and their enzymatic specificity can be studied with the use of selective inhibitors of 
CES1 or CES2 (FimH antagonists, Publication 1) The hydrolysis and specificity of E-selectin ester 
prodrug was tested in recombinant carboxylesterases (Manuscript 1). 
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2.4.2 Phase II metabolism 
Phase II metabolism comprises conjugation reactions of xenobiotics, which involve the 
covalent transfer of a polar endogenous compound such as glucuronic acid, glutathione, 
sulphate or acetyl to a suitable functional group on the substrate (9). These conjugations 
require a nucleophilic group on the xenobiotic, which can but does not have to be formed by 
phase I metabolism (73). In the majority of the cases, the large hydrophilic conjugate leads to 
biological inactivation of the parent compound and to increased biliary or renal elimination.  
UDP-glucuronyltransferases (UGT) 
UDP-glucuronyltransferases (UGT) catalyze a reaction referred to as “glucuronidation” by 
conjugating glucuronic acid, derived from the cofactor UDP-α-D-glucuronic acid (UDPGA), with 
a substrate bearing a suitable functional group, such as alcohols, carboxylic acids, amines, 
thiols and acidic carbon atoms. The conjugation occurs in a second order nucleophilic 
substitution (SN2) mechanism leading to β-configuration (85). The majority of UGTs are 
expressed in the endoplasmatic reticulum of hepatocytes (86). Thus, glucuronidation of 
xenobiotics can be studied with liver microsomes in the presence of the co-factor UDPGA (87).  
Besides CYP450s, UGTs are the most frequently occurring enzymes metabolizing xenobiotics 
(85). Additionally, carbohydrate mimetics, such as dapagliflozine and other gliflozines are 
partly glucuronidated without prior phase I metabolism (88). Whether direct glucuronidation 
plays an important role in the metabolism of E-selectin antagonists has been tested in 
manuscript 1. 
Sulfotransferases (ST) 
Sulfotransferases (STs) are responsible for the sulfation of xenobiotics and endogenous 
substances. STs catalyze the transfer of a hydrophilic sulfuryl group from the co-factor 3’-
phosphoadenosine 5’-phospho-sulfate (PAPS) to amine and hydroxyl substrates and can be 
divided in two subclasses. Cytosolic STs sulfate small compounds, primarily hormones and 
xenobiotics, whereas membrane bound STs sulfate carbohydrates and proteins (89). To assess 
the metabolic behavior of carbohydrate mimetics, both classes of STs have to be considered 
to be active. For example, the natural ligand of E-selectin sLex is a substrate of membrane 
bound ST, but more lipophilic E-selectin antagonists can additionally be a target by cytosolic 
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STs (90). Therefore, the metabolic stability of E-selectin antagonists by adding PAPS to liver 
microsomes and liver cytosol was investigated (manuscript 1). 
2.5 Elimination 
The elimination of xenobiotics, can involve two main routes, i.e. elimination by 
metabolism/chemical modification or elimination by secretion as unchanged drug. Drug 
metabolizing enzymes are responsible for the first route, while drug transporters are 
mediating the latter route. The majority of drugs are inactivated by metabolism, and the 
metabolites are then excreted. Carbohydrate mimetics, however, are hydrophilic and polar, 
not prone to metabolism and therefore mostly eliminated as unchanged form by the renal 
pathway (91, 92). Especially for FimH antagonists (Chapter 8), with the bladder as target, the 
renal elimination is of major importance (93, 94). 
2.5.1 Renal elimination 
The kidney’s physiological role is not only the excretion of xenobiotics, toxins, and 
metabolites, but also the control of body fluids, electrolytes and blood pressure as well as the 
reabsorption of important nutrients. The functional parts of the kidney are nephrons, each 
consisting of a glomerulus and renal tubuli. Primary urine, which is formed by glomerular 
filtration, is then further processed by active and passive reabsorption and secretion of water, 
nutrients, and other compounds (95). The glomerular filtration is size dependent. Larger 
molecules (> 5 kDa) and molecules bound to albumin or other plasma proteins are not filtered 
(96, 97). Once the renal tubuli are reached, compounds can be reabsorbed back to circulation 
either actively or passively. For passive reabsorption, lipophilicity (logD7.4) larger than 1 and 
the rule of 5 parameters by Lipinski are important factors. Membrane bound transporters 
responsible for active reabsorption are similar to those found in the small intestine (98). 
2.6  Toxicity 
Toxicity of a substance is quantified by the degree of ‘adverse events’ it can cause to the 
organism. Toxic side effects are a major reason for the attrition rate of drugs during clinical 
phases (13). The field of toxicity is highly complex, since toxic effects are often cell-, organ-, 
and species specific. To reduce the risk of toxicity during drug development, an integrated 
implementation of qualified and validated in silico, in vitro, and in vivo tools is necessary (99). 
This systematic assessment of the toxic potential of new drug candidates requires a lot of 
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resources and therefore is rarely executed by academic groups. However, by maximizing the 
selectivity towards the intended target and by measuring the acute cell toxicity the risk of 
toxic side effects can be reduced substantially. 
2.6.1 Cell Toxicity 
Acute cell toxicity is easily assessable and gives primary information on the toxic potential of 
a compound (100). Several assays are available and the MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) cell toxicity assay was chosen for the PADMET-platform (101). 
The assay is based on a color reaction of metabolically active HepG2 cells reducing the yellow 
tetrazolium MTT. As a result, intracellular purple formazan is formed which can be solubilized 
and quantified by a spectrophotometric readout (102). This assay allows to measure the cell 
viability at certain time points with or without analyte added. 
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3 E-selectin antagonists 
3.1 Leukocytes adhesion cascade 
The recruitment of leukocytes to the side of inflammation is crucial for host defence and repair 
mechanisms. This process is highly regulated due to its importance and the potential of self-
damage, triggered by an excessive reaction of the immune system. In Figure 3.1, the leukocyte 
adhesion cascade is illustrated (1). Initial inflammatory stimuli are expressed by pathogens 
during infection or by cell damages. Infective pathogens are recognised by their expression of 
exogenous pathogen-associated molecular pattern molecules (PAMP’s). Non-infectious cell 
damage leads to the leak of intracellular damage associated molecular pattern molecules 
(DAMP’s), such as DNA and RNA fragments (2). PAMP’s and DAMP’s are sensed by innate 
pattern recognition receptors (PRRs), located on sentinel cells of the immune system, such as 
macrophages and dendritic cells (3). The interaction with PRRs leads to an inflammatory 
response orchestrated by proinflammatory cytokines such as tumour necrosis factor (TNF), 
interleukins (IL)-1, and IL-6 causing redness, swelling, heat, pain and loss of tissue function as 
symptoms of the inflammatory response (4).  
Furthermore, the presence of these inflammatory stimuli in a tissue upregulate cell adhesion 
molecules (CAMs) in the endothelial cells of the blood vessels. A member of CAMs are selectins, 
which are presented on the luminal membrane in order to recruit leukocytes to the site of 
inflammation (5). 
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Figure 3.1 Schematic illustration of inflammation induced leukocyte extravasation to affected tissues, initiated by 
selectins. An inflammatory stimulus leads to the upregulation of selectins on the endothelial surface of blood 
vessels adjacent to the inflammatory stimulus (1). Free flowing leukocytes adhere via their selectin ligands, 
resulting in their rolling along the vessel wall. This rolling is associated with a decrease of their flowing velocity and 
integrin activation (2). This leads to firm attachment of leukocytes (3), initiating extravasation (4) to the adjacent 
tissue. Once present in the inflammatory tissue, leukocytes produce new inflammatory mediators (5). Adapted 
from Springer et al. (1). 
3.2 Selectins 
Selectins are C-type lectins (calcium dependent carbohydrate binding proteins), belonging to 
the type 1 transmembrane protein family. The selectin family consists of three subtypes, E-, P- 
and L-selectin, which are involved in cell adhesion and cell trafficking to specific tissues (6, 7). 
E-, P- and L-selectin share a common overall structure shown in  
Figure 3.2. The calcium dependent N-terminal lectin domain is responsible for binding the 
selectin ligands and is located extracellular, pointing towards the vascular lumen. For P- and L-
selectin, the lectin domain is composed of 100 amino acid residues whereas in E-selectin, 
consists of 120 amino acid residues. The lectin domain is followed by an epidermal growth 
factor like domain (EGF). Together, the two domains form the minimum requirement for 
selectin binding activity (8). The binding domain is connected via a varying number of short 
consensus repeats (SCR) to the membrane anchor (9). The intracellular C-terminus forms a 17-
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35 amino acid long cytosolic tail responsible for cell signalling and forms interactions with the 
cytoskeleton (10, 11).  
In a first phase of inflammation, P-selectin is responsible for the initiation of the leukocyte 
diapedesis. P-selectin is stored in granules (Weibel-Palade bodies) of vascular cells, allowing a 
quick release after stimulation (12). In a later phase, E-selectin is newly synthesized via the 
NFκB-pathway (13) upon induction by TNFα or IL-1 and then released to the cell surface. In 
contrast to P-selectin, E-selectin is not stored in advance and hence, its expression on the cell 
surface is delayed approximately 4-6 hours after inflammatory stimulation (14). The third 
member of the selectin family, L-selectin, is exclusively presented on lymphocytes and is 
involved in lymphocyte migration to secondary lymphoid organs by binding to the 
corresponding ligand on high endothelial cells (15). 
 
 
Figure 3.2 L-, P- and E-selectin. Each member of the selectin family consists of a intracellular domain (ICD), 
transmembrane domain (TMD), a different number of short census repeats (SCR; 2 in L-selectin, 9 in P-selectin 
and 6 in E-selectin), an epidermal growth factor like domain (EGF) and the lectin domain, which is responsible for 
the recognition of sLex containing structures. 
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3.3 The role of E-selectin in inflammatory diseases 
Inflammation and the resulting leukocyte extravasation are crucial to protect the tissues from 
pathogenic infection or for the healing process after mechanical, thermic or chemical tissue 
damage. Nevertheless, excessive and faulty regulated leukocyte extravasation can lead to a 
massive destruction of healthy tissue (9). 
Therefore, E-selectin is involved in different pathophysiological processes with an inflammatory 
component, such as asthma bronchiale or rheumatoid arthritis due excessive leukocyte 
extravasation (9, 16, 17). E-selectin overexpression is furthermore involved in the pathology of 
cardiovascular diseases like arteriosclerosis, myocardial infarction, reperfusion injury and 
hypertension (18-21). In various cancers, E-selectin is involved in the formation of metastasis 
of cancer cells by inducing the extravasation of metastatic cancer cells in other tissues, for 
example in dormant breast cancer micrometastases (22-24). Selectins are also associated with 
sickle cell adhesion in sickle cell disease (SCD) patients leading to vaso-occlusive crisis (VOC), a 
disseminated, extremely painful thrombosis in small vessels (25). 
3.4 E-selectin antagonists 
The carbohydrate epitope recognized by E-selectin is the tetrasaccharide sialyl Lewisx (sLex, 1) 
as part of glycan structures of selectin ligands present on leukocytes (26). sLex binds to the 
carbohydrate recognition domain (CRD) of E-selectin by forming a highly coordinated hydrogen 
bond network, typical for carbohydrate lectin interactions. Mainly the hydroxyl groups of the 
fucose and galactose moiety, as well as the carboxylic acid of sialic acid are involved in the 
binding network as shown in Figure 3.3 (27). The binding of sLex is predominantly entropically 
driven, since the binding of the rigid sLex leads to the release of numerous water molecules into 
bulk water. The low binding affinity (800 µM) is due to an enthalpy penalty caused by 
desolvation costs which is not compensated by the enthalpy gain from the formation of the 
hydrogen bond network (28).  
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Figure 3.3 A Crystal structure of sLex binding to E-selectin with EGF and two SCR domains (PDB: 4CSY). B The 
binding mode of sLex (1) and E-selectin. sLex consists of N-acetyl-neuraminic acid (sialic acid, Neu5Ac), galactose 
(Gal), glucosamine (GlcNAc) and fucose (Fuc). Beneficial hydrogen bonds between E-selectin and the ligand are 
represented in dotted lines. Adapted from Binder et al.(27). 
E-selectin antagonists are designed starting from the natural ligand sLex (1). In order to achieve 
drug-like properties, not only increased affinity is required but additionally sufficient plasma 
half-life and if possible, oral bioavailability is aspired. sLex (1) has very poor pharmacokinetic 
properties, failing Lipinski’s rule of five and Veber’s rule in every respect (29, 30). Therefore, for 
the development of E-selectin antagonists, the focus is on reduction of the complexity and 
hydrophilicity without losing the pre-organization of the core structure. In the case of the pan-
selectin inhibitor Rivipansel (Figure 3.4, 2), sufficient plasma half-life was achieved by adding a 
suramin fragment (31). Rivipansel does not only have a good plasma half-life, but the suramin 
fragment improves binding to P-selectin and thus leads to pan-selectin antagonism. It 
successfully completed phase 2 clinical trials for the treatment of vaso-occlusive crisis (VOC) in 
sickle cell disease patients (32). Whereas Rivipansel is administered intravenously, an oral 
treatment would be preferable for chronic inflammatory diseases with a strong correlation to 
E-selectin overexpression. Reducing the hydrophilicity and complexity of the core structure led 
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to CGP69669A (3) (33). Compound 3 exhibits an improved affinity (60 µM for E-selectin), a 
reduced molecular weight and polarity, and is therefore a good starting point for further lead 
optimisation processes. 
 
Figure 3.4 E-selectin antagonists Rivipansel (2) and GCP69669A (3). 
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3.5 Results and discussion: E-selectin antagonists 
A large variety of E-selectin antagonists were synthesized with the goal to improve their 
physicochemical and pharmacokinetic properties and analysed in the PADMET-Platform (Figure 
3.5). The starting point of the modifications is compound 3, a well-known mimic of the 
tetrasaccharide sLex (1) (33). The C4- and C5-hydroxyl groups of galactose and the three 
hydroxyl groups of fucose are strongly involved in the hydrogen bond network upon E-selectin 
binding and their modification does not lead to higher affinity (27). Therefore, most 
modifications were done in order to replace the hydrophilic carboxylic acid by either ester 
prodrugs (manuscript 1) or amides (manuscript 2). Other modifications of the lactic acid 
moiety, the galactose 2-position, the lipophilic linker and the fucose moiety addressed specific 
properties such as affinity, stability or lipophilicity issues.  
 
Figure 3.5 Various modifications of E-selectin antagonist analyzed for physicochemical and pharmacokinetic 
parameters in the PADMET-Platform. The best antagonists were obtained when the various modifications were 
combined in one molecule. X is either H or an aliphatic or aromatic residue.  
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3.5.1  Physicochemical properties 
The influence of the polar surface area 
The polar surface areas (PSA) of carbohydrates are large due to the numerous consecutive H-
bond donating hydroxyl-groups. Combining the PSA of the galactose and fucose moiety already 
results in a PSA of 167.5 Å2, which is above the threshold allowing oral bioavailability according 
to Veber et al. (29). Additional PSA is added from the carboxylic acid moiety or bioisosteres 
thereof and results in a total PSA of 180 to 200 Å2 for most selectin antagonists. Since the 
hydrophilic core structure is similar for all compounds and the additional moieties are of 
lipophilic character, a correlation between PSA and clogP does not exist (Figure 3.6) 
 
Figure 3.6 Plot of PSA [Å2] versus clogP of E-selectin antagonists. PSA and clogP were calculated using MarvinSketch 
Version 16.10.10.0. Polar surface area was calculated using a fragment approach according to Ertl et al. and clogP 
was calculated with the consensus method. The dashed line indicates the cut-off value of 140 Å2 used by Veber et 
al. to predict oral bioavailability (29, 34). 
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Consequent minimization of the PSA led to compound 4. Even though this compound has a PSA 
below the threshold of 140 Å2, the compound does not show sufficient permeability in PAMPA 
and Caco-2 cells as shown in comparison with compound 3 (Table 3.1). Furthermore, the 
affinity is strongly reduced due to the missing lactic acid residue and therefore, this approach 
was no longer followed.  
Table 3.1 Reduction of PSA of E-selectin antagonists. PSA was calculated using MarvinSketch version 16.10.10.0 
and using a fragment approach according to Ertl et al. (34). LogD7.4 (octanol-water distribution coefficient) values 
were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. Effective permeability (Pe), i.e. 
the diffusion through an artificial membrane was determined by the parallel artificial membrane permeability 
assay (PAMPA) in quadruplicate at pH 7.4 and thresholds for moderate and high absorption potential are -6.3 and 
-5.7, respectively (35). Errors are given as the standart deviation.  
Compound MW 
[g/mol] 
PSA 
[Å2] 
logD7.4  PAMPA 
logPe 
[log cm/s] 
 
600.6 196.4 < 1.5 < -10 
 
512.6 135.6 1.5 ± 0.2 -7.1 ± 0.1 
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The influence of lipophilicity on permeability 
The starting point for the lead optimization process is 3, exhibiting a molecular weight (MW) of 
600.68 Da and an experimental logD7.4 below -1.5. Due to the hydrophilic core structure formed 
by the galactose and fucose moieties, an increased lipophilicity can mainly be realized by the 
addition of peripheral lipophilic modifications. This trend can be visualized by plotting the 
experimental logD7.4 against the MW of the molecules (Figure 3.7). For orally bioavailable, 
marketed drugs, the MW threshold of 500 Da has been the most often violated rule of 5 (30), 
indicating that slightly increased MWs still allow sufficient permeability (36). Nevertheless, 
lipophilic modifications have to be carefully evaluated. 
 
Figure 3.7 Plot of MW [Da] versus logD7.4. Data represents the mean only with a maximal standard deviation of 
0.2. LogD7.4 values were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate, compounds 
with an experimental logD7.4 value below -1.5 are excluded from the graph due to the detection limits of the 
method. Uncharged (filled dots) and carboxylic acids (hollow dots) are divided in two subgroups due to the charge 
present at pH 7.4. The dashed lines represent the linear regression between MW and logD7.4. Both slopes of the 
regression lines are significantly non-zero with p < 0.0001 for neutral compounds and p = 0.02 for carboxylic acids. 
  
500 600 700 800
-2
-1
0
1
2
3
4
5
Neutral Compounds
Carboxilic Acids
Molecular weight [Da]
lo
gD
7.
4
E-selectin antagonists  
 54 
The lipophilicity of a molecule is the driving force for integration into the phospholipid bilayer 
of a membrane as the first step to permeate the membrane (37). Especially for carbohydrate 
mimetics, sufficient lipophilic moieties have to be added to ensure passive permeation by the 
transcellular route. In Figure 3.8, the strong correlation of the passive permeability measured 
in a parallel artificial membrane permeation assay (PAMPA) and the lipophilicity of E-selectin 
antagonists is shown. All molecules showing a moderate or high absorption potential in PAMPA 
have a logD7.4 of 2.0 or above.  
 
Figure 3.8 Plot of logD7.4 versus effective permeation logPe. Data represents the mean only with a maximal 
standard deviation of 0.2 for the logD7.4 and 0.2 for logPe for molecules within the range of the thresholds. logD7.4 
values were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate; compounds with an 
experimental logD7.4 below -1.5 are excluded from the graph due to the detection limits of the method. logPe 
(effective permeability) was determined by diffusion through an artificial membrane in PAMPA in quadruplicate 
at pH 7.4 and compounds with a measured logPe of -10 or below are excluded due to the detection limits of the 
assay. The thresholds for high and moderate absorption potential are indicated according to Avdeef et al. (35). 
The dashed slope represents the linear regression between logD7.4 and logPe and is significantly non-zero with p < 
0.0001.  
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The permeability of promising compounds was further measured in a Caco-2 cell based assay 
to evaluate, if active transport is involved during the absorption process. The permeation of the 
compounds in the absorptive (AB, uptake, filled dots) and secretory (BA, efflux, hollow dots) 
direction are plotted against the lipophilicity of the molecule in Figure 3.9. Increasing the 
lipophilicity of E-selectin antagonists leads predominantly to an increase of the efflux, with an 
efflux ratio (efflux divided by uptake) up to 50 for certain molecules. The main reason for this 
observation is probably due to the increased incorporation into the membrane of lipophilic 
compounds, leading to higher activity of P-gp, a major efflux transporter recognizing 
predominantly xenobiotics in the membrane (38). Besides the majority of E-selectin antagonists 
showing active efflux, some amidic antagonists showed active uptake. These results are further 
discussed in manuscript 2, and are pointing out the importance of a cell-based assay 
implemented in the PADMET-platform. 
 
Figure 3.9 Plot of logD7.4 versus apparent permeation logPapp. Data represents the mean only with a maximal 
standard deviation of 0.2 for the logD7.4 and 0.2 for logPapp for molecules within the range of the thresholds. LogD7.4 
values were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. logPapp (apparent 
permeability) was assessed by permeation through a Caco-2 cell monolayer in the absorptive (apical to basolateral, 
uptake) and secretory (basolateral to apical, efflux) directions in triplicate. The thresholds for high and moderate 
absorption potentials for the absorptive direction are indicated according to Hou et al. (39). The dashed slope 
represents the linear regression between logD7.4 and logPapp for both directions, i.e. uptake and efflux. The linear 
regression is not significantly non-zero for the uptake with p = 0.19 and for efflux it is significantly non-zero with 
p < 0.0001. 
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3.5.2  Structural characteristics of E-selectin antagonists 
The effects of fluorinated fucose 
Due to the hydrophilic character of their core structure, E-selectin antagonists generally show 
good solubility, i.e. > 10 mM in aqueous buffer. However, for analogues with a fluorinated 
fucose moiety the pharmacokinetic properties, especially the solubility, are largely influenced 
as illustrated with the antagonists 5 and 6 (Table 3.2). The fluorinated antagonist 6 is more 
lipophilic compared to the unfluorinated analogue 5, but the increased lipophilicity does 
influence passive permeation measured in PAMPA. Furthermore, the unfluorinated 5 is at least 
thirty times more soluble than 6. This could be due to the core stabilization and therefore 
allowing easier stacking of the fluorinated compound in crystalline form. Further structural 
consequences triggered by fluorination are discussed in manuscript 3.  
Table 3.2 The effect of fluorinated fucose moiety on physicochemical properties of E-selectin antagonists. LogD7.4 
values were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. The thermodynamic 
solubility was determined in HAB1 buffer at pH 7.4 in triplicate. Effective permeability (Pe), i.e. the diffusion 
through an artificial membrane was determined by PAMPA in quadruplicate at pH 7.4. Errors are given as the 
standard deviation. 
Compound logD7.4 
 
Solubility 
[µM] 
PAMPA 
logPe 
[log cm/s] 
 
1.4 ± 0.1 > 10 mM -8.6 ± 0.1 
 
2.1 ± 0.1 312 ± 24 µM -8.3 ± 0.1 
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Intramolecular hydrogen bonds 
The reduction of the PSA and therefore the hydrophilicity of the core structure of E-selectin 
antagonists should be improving physicochemical properties. That the removal of hydroxyl 
groups is not always beneficial is shown in the example of compound 7 and 8 ( 
Table 3.3). By replacing the C4-hydroxyl of galactose with fluorine in compound 8, the 
lipophilicity surprisingly drops by 1 order of magnitude compared to 7. Since the PSA is reduced, 
other structural properties must be responsible for the observed loss in lipophilicity. In 
compound 7, the carboxylic acid is able to form an intramolecular hydrogen bond with C4-
hydroxyl of galactose and therefore induces a reduction of the apparent hydrophilic surface. 
Preventing this intramolecular hydrogen bond leads to an increase in hydrophilicity. Further 
structural influences of hydroxyl groups in carbohydrates and their effects on physicochemical 
properties in E-selectin antagonists are discussed in manuscript 4. 
Table 3.3 The influence of replacing C4-hydroxyl by fluorine on physicochemical properties. LogD7.4 values were 
determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. Pe (effective permeability) was 
determined in the PAMPA (parallel artificial membrane permeability assay), measuring diffusion through an 
artificial membrane in quadruplicate at pH 7.4. PSAs were calculated using MarvinSketch version 16.10.10.0 using 
a fragment approach according to Ertl et al. (34). 
Compound MW 
[g/mol] 
logD7.4 PAMPA logPe 
[log cm/s] 
PSA  
[Å2] 
 
718.23 1.0 ± 0.1 <-10 206.9 
 
720.76 0.0 ± 0.1 <-10 190.3 
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3.5.3  Substructures of E-selectin antagonists (Master thesis of Roman Koch) 
For a further understanding of the absorption potential of modified E-selectin antagonists, 
partial substructures of compound 7 were synthesized (9-15, Figure 3.10). 7 is not permeating 
over an artificial membrane in PAMPA, even though it has a reasonable lipophilicity with a 
logD7.4 of 1.0. Furthermore, 7 violates the Lipinski’s rule of five by the number of hydrogen 
donors, acceptors and the molecular weight.  
 
Figure 3.10 Partial structures 9-15 of antagonist 7 screened for pharmacokinetic properties. 
 
Table 3.4 summarizes the physicochemical properties of the partial structures 9 - 15. All tested 
molecules are highly soluble and compounds 9 10, 11, 12 and 15 fulfill all criteria of the rule of 
five, all other violate two criteria. However, according the PAMPA classification, only the 
lipophilic compound 11 can be expected to be highly permeable. The permeation properties of 
15 are still good and compound 12 is just below the cut-off of -6.3 with a logPe of -6.5.  All the 
other substances did not show sufficient permeability at pH 7.4.  
The Caco-2 cell permeation assay showed similar results, ranking compound 11 as the most 
permeable of all tested compounds, followed by compound 15. All the other compounds had 
a Papp below the cut-off of 2*10-6. Similar to the PAMPA results, compound 12 did not reach 
the cut-off for medium permeation. 
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However, compound 13 performed surprisingly well in the Caco-2 cell assay compared with the 
PAMPA results with an apparent permeability Papp of around 1*10-6 cm/s, which is only a factor 
of two below the cut-off. In the PAMPA assay, 13 had a logPe around -9, which means almost 
no permeation at all. In the Caco-2 monolayer assay, the apparent permeability of 13 is 
approximately 3.5 times higher than the rate of excretion, suggesting active uptake. 13 consist 
of a 2-O-benzoylated galactoside moiety linked with a C2 linker to a fucose. The corresponding 
non-benzoylated derivatives did not show active intake. This suggests, that the benzoyl group 
in the galactose moiety is involved in this observed active transport. Nevertheless, this set of 
tested compounds shows the difficulty to get oral bioaviable E-selectin antagonists containing 
two carbohydrate moieties.  
Table 3.4 Physicochemical and permeability properties of fragments 9-15 and E-selectin antagonist 7. Solubility 
was determined in a kinetic approach in triplicate. LogD7.4 were determined at pH 7.4 by a miniaturized shake flask 
procedure in sextuplicate. Pe = effective permeability: The diffusion through an artificial membrane was 
determined by PAMPA in quadruplicate at pH 7.4  and thresholds for moderate and high absorption potential are 
-6.3 and -5.7, respectively (35). Permeation through a cell monolayer was assessed by a Caco-2 cell assay in the 
absorptive (apical to basolateral, uptake AB) and secretory (basolateral to apical, efflux BA) directions in triplicates 
and the efflux ratio was determined by dividing efflux by uptake permeability. Thresholds for moderate and high 
absorption potential for the absorptive direction are 2 and 20 *10-6 cm/s, respectively (39). 
Cpd. Solubility 
[µg/mL] 
logD7.4 
 
PAMPA 
logPe 
[log cm/s] 
Caco2-cell 
Papp [10
-6 cm/s] 
   uptake AB efflux BA efflux ratio 
7 >1000 1.0 ± 0.1 < -10 0.4 ± 0.5 1.2 ± 0.6  
9 >1000 < -1.5 -9.8 ± 0.5 0.04 ± 0.01 0.023 ±0.01 0.59 
10 >1000 -1,3 ± 0,2 -7.2 ± 0.5 0.46 ± 0.14 0.49 ± 0.05 1.06 
11 >1000 2.5 ± 0.1 -4.3 ± 0.0 22.2 ± 0.92 45.6 ± 1.7 2.06 
12 >1000 -0.4 ± 0.2 -6.5 ± 0.0 0.95 ± 0.12 1.53 ± 0.08 1.61 
13 >1000 0.4 ± 0.1 -8.8 ± 0.3 1.2 ± 0.4 0.35 ± 0.03 0.29 
14 798 ± 59 < -1.5 < -10 0.17 ± 0.03 0.08 ± 0.01 2.21 
15 798 ± 136 -0.2 ± 0.1 -5.7 ± 0.0 10.5 ± 1.5 13.9 ± 0.5 1.33 
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3.7 Manuscript 1: E-selectin antagonist ester prodrug approach 
In this manuscript, the physicochemical and pharmacokinetic properties of ester prodrugs was 
evaluated in vitro. The focus of the work was on the stability of the molecule during the 
gastrointestinal passage, the permeability and the metabolic pathway in liver microsomes. In 
vitro results were further evaluated by oral bioavailability studies in mice. 
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Introduction 
Upon an inflammatory stimulus, a family of cell adhesion molecules (CAMs), among others E-
selectin, are upregulated on endothelial cells (1, 2). By interacting with their glycoprotein 
ligands located on leukocytes, E-selectin can mediate the rolling of these leukocytes on the 
endothelial surface. This first step of the inflammatory cascade is followed by firm adhesion 
and finally transmigration to the site of inflammation (2, 3). There, the inflammatory stimulus 
is abolished with oxidative agents, proteases and cytokines. However, when this vital defense 
mechanism in the event of injuries or infections is excessively used, it can turn deleterious in 
numerous diseases with an inflammatory component as e.g. stroke, psoriasis or asthma (4, 5). 
Therefore, blocking E-selectin with a selectin antagonist and as a consequence interrupt the 
whole inflammatory cascade has been recognized as a promising therapeutic approach for the 
treatment of inflammatory diseases (6). 
The main epitope recognized by E-selectin is the tetrasaccharide sialyl Lewisx (sLex) as part of 
glycan structures of selectin ligands present on leukocytes (2). Because sLex has only a 
moderate affinitiy (KD 800 μM), and far from drug-like pharmacokinetic properties, 
glycomimetics have been developed (7). A successful example is the selectin antagonist 
Rivipansel currently in clinical phase 3 evaluation for the treatment of vaso-occlusive crisis 
(VOC) in cickle cell anemia patients (8, 9). Since Rivipansel is not orally bioavailable, an 
intravenous administration is required. However, for chronic inflammatory diseases with a 
strong correlation to E-selectin overexpression, such as arthrosclerosis, rheumatoid arthritis 
and psoriasis, an orally bioavailable treatment would be preferable (10-14). 
With carbohydrates as lead structures, inherent problems regarding oral bioavailability are 
inevitable, mainly because their large polar surface area and their hydrophilicity (15). Although 
the replacement or removal of polar groups, which are not part of the pharmacophores, lead 
to a substantial reduction of hydrophilicity (®1) (16), the corresponding glycomimetics still 
violate parameters usually predictive for oral availability [rule of five by Lipinski (17) and Veber’s 
rules (18)]. Specifically, the carboxylic acid function crucial for the interaction with E-selectin 
prevents oral bioavailability. In summary, since a further reduction of the polarity or size of the 
glycomimetic 1 is accompanied by a loss of affinity, other approaches to reach sufficient 
lipophilicity and permeability are required (19, 20). 
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A common approach to overcome insufficient lipophilicity of carboxylic acids are ester prodrugs 
which are hydrolyzed by carboxylesterases upon absorption to release the active principle (21). 
To reach their target on endothelial cells adjacent to an inflammatory stimulus, ester prodrugs 
of E-selectin antagonists should be stable in the gastrointestinal environment and the 
enterocytes of the small intestine. Once the prodrug is either actively or passively absorbed, 
the active principle has to be released by hydrolysis (22, 23). In the present study, ester 
prodrugs based on E-selectin antagonist 1 using aliphatic promoieties were synthesized and 
evaluated their potential for oral bioavailability in vitro and in vivo. In a second step, the best 
prodrug solutions were applied to recently identified E-selectin antagonists with improved 
affinities but still insufficient pharmacokinetic properties (Manuscript 3,4 and 5). 
Results 
Different linear, branched and cyclic aliphatic ester prodrugs of the carboxylic acid 1 were 
synthesized (® 2a–m) and their absorption potential and metabolic stability were screened 
(Figure 1). Prodrugs with more than three carbons in the promoiety exhibit logPe values in a 
parallel artificial permeation assay (PAMPA) indicative for a moderate (with four carbons in the 
promoiety) to a high absorption potential (with 5 or more carbon atoms in the promoiety) 
(Figure 1B) (24, 25). Furthermore, the passive permeation is depending only on the number of 
carbon atoms and not of the constitution of the promoiety. Compounds showing moderate to 
high permeability in PAMPA were further assessed in a cell-based permeation model using 
colon adenocarcinoma (Caco-2) cells to determine active transport mechanism, i.e. uptake 
(apical to basolateral; a-b) and efflux (b-a) permeability (Figure 1C) (26, 27). Unfortunately, all 
compounds exhibit active efflux with an efflux ratio (b-a/a-b) over 2.0, leading to an absorption 
below the threshold for a moderate absorption potential. Overall, the efflux ratio and the 
absolute uptake were better for prodrugs containing cyclic and branched promoieties 
compared to linear promoieties.  
The metabolic stability of the ester prodrugs 2a-m was assessed with human liver microsomes 
(28) (Figure 1D). Similar to PAMPA, the shape of the promoieties has a minor effect on the ester 
hydrolysis, except for 2m, when the bulky cyclohexylester leads to slower metabolic release. 
Slow hydrolysis of the ester prodrug is favorable for carbohydrate mimetics, due to the likely 
fast renal excretion of the active principle (29). Over all, ester prodrug with cyclic promieties 
2k-m performed best and were chosen for further hydrolysis studies (Figure 1E). These esters 
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are stable in gastric acid, but are rapidly hydrolyzed in simulated intestinal fluid containing 
pancreatic enzymes. Furthermore, the molecules are faster hydrolyzed by the carboxylesterase 
CES1, which is highly expressed in hepatocytes, compared to CES2. CES2 is expressed in 
enterocytes and could lead to hydrolysis during the absorption, limiting the oral bioavailability 
of ester prodrugs (30). 
 
Figure 1 A Aliphatic ester prodrugs of 2a-m screened in B, C and D. Prodrugs with linear aliphatic promoieties (2a-
g) are indicated as circle, branched (2h-i) as rectangle and cyclic (2k-m) as triangle. B The parallel artificial 
membrane permeation assay (PAMPA) was performed at pH 7.4 in quadruplicate. Thresholds were used according 
to Avdeef et al.(24) C Caco-2 cell permeation assay was performed 21 days after seeding of the cells in absorptive 
(a-b, full dots) and efflux (b-a, hollow dots) direction in triplicate. Thresholds for absorptive direction were used 
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according to Hou et al.(27) D The hydrolysis of ester prodrugs was assessed in human liver microsomes, 0.125 
mg/ml at 37°C in triplicate. E The hydrolysis of cyclic ester prodrugs 2k, 2l and 2m were measured in different 
environments in triplicate. (All error bars and ranges are given as the standard deviation. Synthesis and assay 
procedures are described in the suppl. data.) 
 
A problem inherent to all produgs 2a-m is their instability in intestinal fluid, hydrolyzing the 
molecules before absorption. Independent of the promoiety, they showed fast and complete 
hydrolysis with a half-life below 10 minutes in intestinal fluid containing pancreatic enzymes 
(suppl. data). It can therefore be assumed that the structure of the active principle and not the 
promoiety is responsible for the recognition by pancreatic enzymes. Therefore, ethyl ester 
prodrugs of a series of carbohydrate mimetics with different lactic acid derivatives in the 3-
position of the galactose moiety were synthesized and tested (Table 1). Apparently, already 
minor changes of the cyclohexyl lactic acid substituent such as replacing the cyclohexyl moiety 
by a phenyl (® 3) or isopropyl (® 5) group improves pancreatic stability. When cyclohexyl 
lactic acid (® 2b) is replaced by 1-hydroxy-cyclohexaneacetic acid (® 7), stability is further 
enhanced. Finally, with the glycolic acid (® 9), almost complete pancreatic stability could be 
achieved, however, for the price of a substantial reduction of affinity of the active principle. On 
the contrary, an additional methyl group at the cycloheyl moiety replacing GlcNAc (® 5, 7 & 9) 
improves not only the lipophilicity of the prodrug but also the affinity of the corresponding 
active principle (19). Thus, considering both affinity and stability, the prodrugs 7 perfomed best. 
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Table 1 Prodrug; The intestinal fluid stability of ethyl ester prodrugs was determined in 2.5 mg/ml pancreatin at 
pH 6.5 in triplicate. After 30 minutes, samples were quenched and analyzed by LC-MS and the concentration of 
prodrug and active principle was calculated. The error indicates the standard deviation. Active principle; The 
affinity towards E-selectin of the active principle was assessed by micro scale thermophoresis measurements. 
Synthesis and assay procedures are described in the supplementary information. 
 
Prodrug 
 
Intestinal fluid stability 
Active principle 
 
Affinity 
R
1 R2 Promoiety 
R
3
 = CH
2
CH
3
 
Pancreatic 
stability [%]  
R
3
 = H  KD [µM]  
 
H 2b 9.0 ± 5.9 1 60.7 
 
H 3 48.0 ± 4.2 4 329  
 
CH3 5 38.0 ± 3.5 6 14.9 
 
CH3 7 74.8 ± 7.9 8 33.2  
H CH3 9 93.7 ± 5.7 10 133.4 
 
Next, the preferred promoiety and lactic acid moiety were combined and the metabolic 
pathway in liver microsomes of 11 was explored in liver microsomes (Figure 2A). To answer the 
question regarding the influence of the lipophilicity of the promoiety on the metabolism, the 
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phase I metabolism determined in rat liver microsomes (RLM) by adding the co-factor NADPH 
to activate cytochrome P450s and the unspecific carboxylesterases inhibitor bis(4-
nitrophenyl)phosphate (BNPP) to inhibit hydrolysis (31, 32). For the ester prodrug 11, oxidation 
in RLM with a half-life of around 10 minutes was observed (Table 2). Two major metabolites 
showing an increase of the molecular weight by 16 compared to the parent ester were detected 
by mass spectrometry, indicating one oxidation of the compound. When this RLM reaction 
mixture containing the metabolites was treated with sodium hydroxide to hydrolyze the ester 
moiety under basic conditions, unchanged active principle 8 was regained, indicating that the 
oxidation took place on the promoiety. Furthermore, incubating the mixture of oxidized 
metabolites in fresh RLM the metabolites can no longer be hydrolyzed by carboxylesterases to 
yield the active principle 8. Finally, with RLM/NADPH containing active carboxylesterases, i.e. 
without BNPP addition, both metabolic steps occur simultaneously, although with different 
kinetics, leading to 20% of the deprotected active principle 8 and to 80% to the metabolite 12. 
Therefore, only 20% of the prodrug is transformed to the active principle in RLM and 80% is 
lost due to oxidation by CYP450s. Furthermore the prodrug as well as the active principle were 
tested for their susceptibility for the most frequently occurring phase II metabolism, namely 
glucoronidation by UDP-glucuronyltransferases (UGTs) and sulfation by sulfotransferases (STs), 
in RLM and rat liver cytosol (33, 34).Both, prodrug 11 and active principle 8, did not show any 
conjugation by UGTs and STs. Furthermore, the active principle is not oxidized by CYP450. 
The 20/80 oxidation/hydrolysis ratio of 11 was improved with prodrug 13 or 2j, yielding a 50/50 
and 65/35 ratio in favor for the hydrolysis into the active principles 6 and 1, respectively (Figure 
2B). The complete pharmacokinetic analysis of the ester prodrugs 11, 13 and 2j and the affinity 
of their respectively active principle are listed in Table 2. All three compounds showed high 
absorption potential in PAMPA, but not sufficient permeability in Caco-2 cell based assay and 
active efflux, similar to the primary test series 2a-m.  
Next, the ester prodrug 14 was synthesized to have an improved hydrolysis/oxidation ratio and 
affinity of the active principle. Therefore, the cyclobutyl methyl promoiety of 2j and the 1-
hydroxy-cyclohexaneacetic acid of 13 were combined. Furthermore, other modifications 
improving the affinity of the active principle are additionally implemented (Manuscript 3, 4 and 
5). The C-6 of fucose is fluorinated, C-2 hydroxyl group of the galactose is replaced by chlorine 
and the side chain of the GlcNAc is elongated. A comparison of its physicochemical and in vitro 
PK/PD properties with the prodrugs discussed above is summarized in Table 2.  Those changes 
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led to an enhanced lipophilicity of the molecule, sufficient stability against pancreatic enzymes 
and high absorption potential in PAMPA. Unfortunately, the observed efflux ratio was further 
enhanced. But compared to the initial lead prodrug 11, the hydrolysis/oxidation ratio of 14 
improved to 40/60 and the affinity of the active principle improved by factor 10. 
 
Figure 2 A The metabolic pathway of prodrug 11 in rat liver microsomes. Cytochrome P450s oxidize the promoiety, 
leading to a metabolite no longer susceptible to hydrolysis by carboxylesterases. B Structures of prodrugs 13, 2j 
and 14, and their active principles 6, 1 and 15, respectively. A synthesis of the prodrugs is described in the 
Supplementary Information.  
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Table 2 Summary of the physicochemical and PK/PD data of ester prodrugs 11, 13, 2j and 14. Errors are indicated 
as the standard deviation. 
Cpd logD7.4 Stability  
t
1/2 
[min] 
intestinal 
Fluid 
PAMPA 
logP
e 
Caco- cell permeation assay 
logPapp 
Stability  
t
1/2 
[min] 
RLM  
Oxidation 
Stability  
t
1/2 
[min] 
RLM 
Hydrolysis 
Affinity  
K
D
 [µM] 
Active 
principle uptake  
a-b 
efflux  
b-a 
efflux  
ratio  
b-a/a-b 
11 3.1 ±0.1  > 120  -4.9±0.1 -6.4 ±0.1 -5.2 ±0.1 19 
10.7 ±0.3 23.5 ±1.1 
33.2  
80 ±2% 20 ±2%  
13 2.4±0.1 25 ± 1 -5.5 ±0.1 -6.2 ±0.1 -5.2 ±0.1 11 
27 ±2 30 ±2 
14.9 
48 ±2% 52 ±2% 
2j 2.5 ±0.1 < 10 -5.4 ±0.1 -6.1±0.1 -5.3 ±0.1 5.8 
50 ±20  8.1 ±0.2 
60.7 
35 ±5% 65 ±5% 
14 4.0 ±0.2 77 ± 4 -4.6 ±0.2 -6.3 ±0.1 -4.6 ±0.1 48 
62 ±3 72 ±6 
3.3 
58 ±4% 42 ±4% 
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Animal Studies 
For a further evaluation of the pharmacokinetic properties, in vivo bioavailability studies in mice 
were conducted with the prodrugs 11 and 14. To reach their target on the endothelial surface 
of blood vessels adjacent to an inflammatory stimulus, the prodrugs have to fulfill three 
prerequisites. They have to pass the intestinal membrane to reach the blood circulation, the 
bioconversion to the active principle has to be complete and slowly over time to elongate the 
therapeutic window and finally the active principle has to be available at the therapeutic 
concentrations at the target. Unfortunately, both prodrugs 11 and 14 did not show any oral 
bioavailability, with a concentration in blood plasma below the detection limit of the prodrug 
and the corresponding active principle 8 and 15, respectively (Figure 3C and D). Therefore, the 
passive permeation observed in PAMPA was not sufficient to reach oral bioavailability. In the 
case of prodrug 11, the formation of the prodrug led to an elongation of the blood plasma half-
life of the active principle 8 by factor 5 (Figure 3A). After direct injection of the active principle 
a blood plasma half-life of 6.2 min was observed, whereas after the prodrug injection, the active 
principle had a half-life of 34.4 min. Furthermore, the bioconversion of the prodrug to the 
active principle was higher than predicted in liver microsomes. The total exposure (Area under 
the curve, AUC) of the active principle after injection of the prodrug was adjusted to the 
molecular weight (MW) only 20% less compared to the direct injection of the active principle. 
The final prodrug 14 did not show this improvement of the pharmacokinetic properties in vivo 
(Figure 3B. The half-life of the active principle was for both IV administration as prodrug (t1/2 = 
6.8 min) and active principle (t1/2 = 4.2 min) similar and the AUC of the active principle was 
strongly reduced by formation of a prodrug (33% compared to the direct injection of the active 
principle).  
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Figure 3 A and B: Plasma concentration of the active principle 8 (A) and 15 (B) after intravenous injection 20 mg/kg 
of the prodrug (continuous line) or active principle (dotted line). Each point represents the mean and standard 
error of the mean (SEM) of three individual experiments. The half-life and area under the curve was calculated 
using PKSolver (35). A: The half-life of the active principle 8 in plasma was after direct injection 6.2 min (4.5-10.1 
min 95% confidence interval; AUC 0-t = 835213 min*ng*ml-1) and prodrug 11 injection 34.4 min (16.6 – 52.4 min 
95% confidence interval; AUC 0-t = 573121 min*ng*ml-1, 79% of direct injection adjusted to the molecular weight 
(MW)). B: The half-life of the active principle 15 in plasma was after direct injection 4.6 min (3.1-9.1 min 95% 
confidence interval; AUC 0-t = 448121 min*ng*ml-1) and prodrug 14 injection 6.8 min (7.2 – 15.5 min 95% 
confidence interval; AUC 0-t = 134773 min*ng*ml-1, 33% of direct injection adjusted to the MW). C and D: After 
oral gavage of 50 mg/kg, the blood plasma concentration of the active principle and prodrug was followed for a 
period of 180 min in three individual mice. There was no active principle or prodrug detectable over this period of 
time. 
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Conclusion and outlook 
The in vitro pharmacokinetic properties of E-selectin antagonists, especially the passive 
permeation measured in PAMPA, were improved by forming ester prodrugs. But the observed 
permeability was not translatable to an in vivo situation in mice. Apparently, the efflux ratio 
observed in Caco-2 cell permeation assay had a strong impact on the oral bioavailability of the 
prodrugs. The major efflux pump P-glycoprotein (P-gp) preferably recognizes lipophilic 
xenobiotics bound to the membrane (36).The large lipophilic promoieties of the ester prodrugs 
are therefore a potent target for P-gp. Over all, a simple addition of lipophilic moieties to 
improve passive permeation is not sufficient to get oral bioavailable E-selectin antagonists.  
Furthermore, the metabolic pathway of ester prodrugs was studied in liver microsomes. 
Carboxylesterases prefer a lipophilic environment around the ester bond, making ester 
prodrugs with aliphatic promoieties susceptible for hydrolysis (22). As observed in compound 
11, an oxidation of the promoiety by CYP450 leads to a more hydrophilic promoiety and 
therefore reduces drastically the hydrolysis rate of the ester bond by carboxylesterases. The 
reduced bioconversion was however to a lesser extend observable in vivo compared to rat liver 
microsomes. Ester prodrug 11 showed sufficient bioconversion in vivo with a prolonged half-
life of the active principle. Including modification to improve the hydrolysis/oxidation ratio and 
affinity of the active principle led to compound 14. Unfortunately, the in vitro predictions were 
not translatable to in vivo studies in mice, leading to a fast elimination of the active principle. 
Therefore, other approaches to develop an orally bioavailable E-selectin antagonist with high 
affinity have to be followed.  
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Supplementary Data 
Table S1 Physicochemical and in vitro pharmacokinetic properties of ester prodrugs tested. Measurements were conducted in sexduplicate (logD7.4), quadruplicate (logPe) or 
triplicate. 
Compound Molecular 
weight [Da] 
logD7.4 PAMPA 
logPe 
Caco-2 cell permeation assay 
Papp [10-6 cm/s] 
Stability 
Intestinal 
fluid 
Pancreatin 
[min] 
Stability 
HLM 
 
Hydrolysis 
[min] 
Stability RLM 
 
Oxidation 
[min] 
Stability 
RLM 
 
Hydrolysis 
[min] 
Absorption 
a-b 
Efflux 
b-a 
Efflux 
ratio 
b-a/a-b 
1 600.63 < -1.5 < -10        
2a 592.67 1.3 ± 0.1 -7.3 ± 0.0    < 10 153   
2b 606.33 1.4 ± 0.1 -8.1 ± 1.4    < 10 162   
2c 620.34 1.8 ± 0.1 -6.4 ± 0.4     51.5   
2d 634.36 2.2 ± 0.1 -6.1 ± 0.2 0.8 ± 0.1 4.6 ± 1.5 5.7 < 10 42.3   
2e 648.37 2.4 ± 0.1 -5.3 ± 0.3 0.3 ± 0.4 11.5 ± 0.5 36 < 10 52.6   
2f 662.86 2.6 ± 0.1 -5.1 ± 0.2 0.25 ± 0.1 23.7 ± 2.9 94 < 10 45.2   
2g 690.86 > 2.5 -5.0 ± 0.4 0.89 ± 0.51 6.7 ± 2.3 7.5 < 10 36.3   
2h 648.37 2.4 ± 0.1 -5.7 ± 0.2 0.7 ± 0.2 6.6 ± 1.3 9 < 10 60.9   
2i 648.37 2.5 ± 0.1 -5.7 ± 0.1    < 10 41.9   
2j 690.42 > 2.5 -4.8 ± 0.1 0.8 ± 0.7 35.7 ± 1.3 44 < 10    
2k 646.77 2.5 ± 0.1 -5.4 ± 0.1 0.84 ± 0.02 4.8 ± 0.4 5.8 < 10 52.1 50 ± 20 8.1 ± 0.1 
2l 660.80 2.6 ± 0.1 -5.1 ± 0.1 0.76 ± 0.03 11.1 ± 0.3 15 < 10 30.7   
2m 674.83 2.3 ± 0.1 -4.8 ± 0.2 1.0 ± 0.2 19.0 ± 0.5 19 < 10 96.3   
3 600.66 0.6 ± 0.1 -8.8 ± 0.2    29    
7 606.71 1.2 ± 0.1 -7.8 ± 0.0    > 120    
11 674.82 3.7 ± 0.1 -4.9 ± 0.1 0.4 ± 0.1 6.9 ± 0.1 19 119  10.7 ± 0.3 23.5 ± 1.1 
5 538.60 -1.2 ± 0.1 < -10    > 120    
13 648.37 2.4 ± 0.1 -5.5 ± 0.1 0.59 ± 0.05 6.5 ± 0.7 11 25  27 ± 2 30 ± 2 
14 707.17 4.0 ± 0.2 -4.6 ± 0.2 0.49 ± 0.06 23.5 ± 1.3 48 77  62 ± 3 72 ± 6 
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Synthesis 
 
Scheme S1 Reactions and reaction conditions: a) KHCO3, DMF, 4°C – 15°C, 4 h - 6 d, 15 – 80%. The Synthesis of 1 
was described by Kolb et al. (1). 
General procedure: 
2a) To a mixture of 1 (8.0 mg, 0.0133 mmol) and KHCO3 (2.7 mg, 0.0266 mmol in dry DMF (150 µL) at 
4°C, Methyliodide (1.24 µL, 0.020 mmol) was added. After 4 h at this temperature the reaction mixture 
was purified by column chromatography on silica gel (DCM, MeOH 6:1). The obtained product was 
diluted in dioxane, filtered through an Acrodisc filter (0.45 µm) and lyophilized to afford 2a (4.0 mg, 
50%); [a]D20 -84.74 (c 0.40, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 1.19 (d, J = 6.6 Hz, 3H, H-6F), 0.80 – 1.03, 1.21 – 1.44, 1.46 – 1.79, 
1.83 – 1.97, 1.98 – 2.13 (m, 21H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc), 3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 
3.41 (ddd, J = 6.6, 5.3, 1.3 Hz, 1H, H-5G), 3.54 (ddd, J = 9.9, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 
Hz, 1H, H-2G), 3.64 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.73 (s, 3 H, OMe), 3.86 (dd, J = 10.1, 3.4 Hz, 
1H, H-3F), 3.91 (dd, J = 3.4, 1.1 Hz, 1H, H-4G), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.44 (dd, J = 9.1, 4.0 Hz, 1H, 
H-2L), 4.52 – 4.65 (m, 1H, H-5F), 4.80 – 4.91 (m, 1H, H-1F); 13C NMR (126 MHz, MeOD) δ 16.60 (C-6F), 
24.44, 27.19, 27.44, 27.67, 30.09, 30.76, 30.88, 33.54, 34.67, 35.09, 42.33 (C7H13L, C-3cyc, C-4cyc, C-5cyc, 
C-6cyc), 52.55 (OMe), 62.75 (C-6G), 67.44 (C-5F), 68.65 (C-4G), 70.04 (C-2F), 71.57 (C-3F), 72.56 (C-2G), 
73.82 (C-4F), 76.07 (C-5G), 77.48 (C-2cyc), 78.56 (C-2L), 79.24 (C-1cyc), 83.90 (C-3G), 97.38 (C-1F), 102.63 
(C-1G), 177.20 (C=O);  
ESI-MS m/z calcd for C28H48NaO13 [M+Na]+: 615.30; found: 615.37. 
2b) According to general procedure, 1 (9.8 mg, 0.0163 mmol), KHCO3 (3.2 mg, 0.0326 mmol) and 
iodoethane (2 µL, 0.0245 mmol), 4°C, 4 d, gave 2b (7.5 mg, 75%). [a]D20 -94.48 (c 0.75, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.83 – 1.03, 1.20 – 1.44, 1.51 – 1.59, 1.62 – 1.75, 1.84 – 1.96, 1.96 – 
2.13 (m, 24H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, CH3), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 3.25 (dd, J = 9.5, 3.3 
Hz, 1H, H-3G), 3.41 (ddd, J = 6.7, 5.2, 1.2 Hz, 1H, H-5G), 3.54 (ddd, J = 9.9, 8.2, 4.4 Hz, 1H, H-2cyc), 3.59 
(dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.64 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, 
H-3F), 3.91 (dd, J = 3.3, 1.2 Hz, 1H, H-4G), 4.15 – 4.25 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.41 
(dd, J = 9.1, 4.1 Hz, 1H, H-2L), 4.58 – 4.63 (m, 1H, H-5F), 4.76 – 5.02 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 14.50 (CH3), 16.61 (C-6F), 24.45, 27.22, 27.45, 27.67, 30.10, 30.89, 33.58, 
34.70, 35.09, 42.36 (11C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc), 62.26 (OCH2), 62.73 (C-6G), 67.44 (C-5F), 
68.65 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.54 (C-2G), 73.82 (C-4F), 76.04 (C-5G), 77.50 (C-2cyc), 78.66 (C-
2L), 79.26 (C-1cyc), 83.96 (C-3G), 97.38 (C-1F), 102.62 (C-1G), 176.80 (C=O);  
ESI-MS m/z calcd for C29H50NaO13 [M+Na]+: 629.31; found: 629.39. 
2c) According to general procedure, 1 (10.1 mg, 0.0168 mmol), KHCO3 (3.4 mg, 0.0336 mmol) and 
iodopropane (2.5 µL, 0.0252 mmol), 4°C, 3 d, gave 2c (7.0 mg, 70%). [a]D20 -87.19 (c 0.68, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.82 – 0.94, 1.21 – 1.43, 1.49 – 1.76, 1.87 – 1.96, 1.99 – 2.10 (m, 
23H, C7H13L, CH2, H-3cyc, H-4cyc, H-5cyc, H-6cyc), 0.96 (t, J = 7.5 Hz, 3H, CH3), 1.19 (d, J = 6.7 Hz, 3H, H-6F), 
O
OO
COONa
HO
HO
O
O
HO OH
OH
OH
O
OO
COOR
HO
HO
O
O
HO OH
OH
OH
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R= CH32a
2b
2c
2d
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1 2a-j
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3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.39 – 3.43 (m, 1H, H-5G), 3.51 – 3.57 (m, 1H, H-2cyc), 3.59 (dd, J = 
9.5, 7.7 Hz, 1H, H-2G), 3.64 – 3.77 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 
3.91 (d, J = 3.2 Hz, 1H, H-4G), 4.05 – 4.17 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.43 (dd, J = 9.0, 
4.2 Hz, 1H, H-2L), 4.60 (q, J = 6.6 Hz, 1H, H-5F), 4.78 – 4.90 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 10.74 (CH3), 16.60 (C-6F), 23.04, 24.44, 27.22, 27.44, 27.67, 30.09, 30.89, 
33.63, 34.72, 35.08, 42.45 (12C, C7H13L, CH2, C-3cyc, C-4cyc, C-5cyc, C-6cyc), 62.73 (C-6G), 67.44 (C-5F), 67.82 
(OCH2), 68.66 (C-4G), 70.04 (C-2F), 71.57 (C-3F), 72.55 (C-2G), 73.83 (C-4F), 76.06 (C-5G), 77.49 (C-2cyc), 
78.67 (C-2L), 79.25 (C-1cyc), 83.94 (C-3G), 97.38 (C-1F), 102.64 (C-1G), 176.87 (C=O); ESI-MS m/z calcd for 
C30H52NaO13 [M+Na]+: 643.33; found: 643.47. 
2d) According to general procedure, 1 (9.9 mg, 0.0165 mmol), KHCO3 (3.3 mg, 0.0330 mmol) and 
iodobutane (2.8 µL, 0.0248 mmol), 4°C, 3 d, gave 2d (6.0 mg, 60%). [a]D20 -95.80 (c 0.61, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.82 – 0.94, 1.21 - 1.48, 1.50 – 1.77, 1.87 – 1.96, 1.98 – 2.13 (m, 25H, 
C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 2 x CH2), 0.96 (t, J = 7.4 Hz, 3H, CH3), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 
3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.41 (ddd, J = 6.6, 5.1, 1.2 Hz, 1H, H-5G), 3.54 (ddd, J = 9.9, 8.2, 4.5 
Hz, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.64 – 3.77 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, 
J = 10.1, 3.4 Hz, 1H, H-3F), 3.91 (dd, J = 3.4, 1.1 Hz, 1H, H-4G), 4.10 – 4.22 (m, 2H, OCH2), 4.27 (d, J = 7.7 
Hz, 1H, H-1G), 4.42 (dd, J = 8.9, 4.2 Hz, 1H, H-2L), 4.56 – 4.64 (m, 1H, H-5F), 4.82 – 4.88 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 14.00 (CH3), 16.60 (C-6F), 20.21, 24.44, 27.23, 27.44, 27.67, 30.09, 30.89, 
31.79, 33.65, 34.73, 35.06, 42.42 (13C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 2 x CH2), 62.74 (C-6G), 66.02 
(OCH2), 67.43 (C-5F), 68.66 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.55 (C-2G), 73.82 (C-4F), 76.06 (C-5G), 
77.49 (C-2cyc), 78.68 (C-2L), 79.25 (C-1cyc), 83.93 (C-3G), 97.38 (C-1F), 102.64 (C-1G), 176.85 (C=O);  
ESI-MS m/z calcd for C31H54NaO13 [M+Na]+: 657.35; found: 657.43. 
2e) According to general procedure, 1 (9.0 mg, 0.0150 mmol), KHCO3 (3.0 mg, 0.0300 mmol) and 
iodopentane (2.9 µL, 0.0225 mmol), 4°C, 3 d, gave 2e (7.9 mg, 80%). [a]D20 -86.93 (c 0.79, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.81 – 1.03, 1.21 – 1.45, 1.47 – 1.78, 1.85 – 1.97, 1.99 – 2.11 (m, 
30H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 3 x CH2, CH3), 1.19 (d, J = 6.7 Hz, 3H, H-6F), 3.25 (dd, J = 9.5, 3.3 
Hz, 1H, H-3G), 3.41 (ddd, J = 6.8, 5.3, 1.2 Hz, 1H, H-5G), 3.54 (ddd, J = 9.8, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 
(dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.62 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, 
H-3F), 3.91 (dd, J = 3.1, 1.1 Hz, 1H, H-4G), 4.09 – 4.22 (m, 2H, OCH3), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.42 
(dd, J = 8.7, 4.3 Hz, 1H, H-2L), 4.60 (q, J = 6.6 Hz, 1H, H-5F), 4.79 – 4.92 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 14.33 (CH3), 16.61 (C-6F), 23.35, 24.44, 24.47, 27.23, 27.44, 27.67, 29.27, 
29.42, 30.09, 30.89, 33.67, 34.74, 35.05, 42.42 (C7H13L,C-3cyc, C-4cyc, C-5cyc, C-6cyc, 3 x CH2), 62.76 (C-6G), 
66.30 (OCH2), 67.43 (C-5F), 68.68 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.54 (C-2G), 73.82 (C-4F), 76.07 (C-
5G), 77.48 (C-2cyc), 78.69 (C-2L), 79.25 (C-1cyc), 83.92 (C-3G), 97.37 (C-1F), 102.64 (C-1G), 176.84 (C=O);  
ESI-MS m/z calcd for C32H56NaO13 [M+Na]+: 671.36; found: 671.42. 
2f) According to general procedure, 1 (9.9 mg, 0.0165 mmol), KHCO3 (3.3 mg, 0.0330 mmol) and 
iodohexane (3.6 µL, 0.0248 mmol), 4°C, 4 d, gave 2f (5.0 mg, 48%). [a]D20 -73.51 (c 0.80, MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.83 – 1.02, 1.21 – 1.42, 1.50 – 1.77, 1.88 – 1.95, 1.99 – 2.10 (m, 
32H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 4 x CH2, CH3), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 3.25 (dd, J = 9.5, 3.3 
Hz, 1H, H-3G), 3.41 (ddd, J = 6.7, 5.2, 1.2 Hz, 1H, H-5G), 3.54 (ddd, J = 9.8, 8.2, 4.4 Hz, 1H, H-2cyc), 3.59 
(dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.63 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, 
H-3F), 3.91 (dd, J = 3.4, 1.1 Hz, 1H, H-4G), 4.08 – 4.22 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.42 
(dd, J = 8.8, 4.3 Hz, 1H, H-2L), 4.60 (q, J = 6.6 Hz, 1H, H-5F), 4.81 – 4.89 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 14.36 (CH3), 16.60 (C-6F), 23.64, 24.44, 26.76, 27.22, 27.44, 27.67, 29.68, 
30.09, 30.89, 32.56, 33.67, 34.73, 35.05, 42.43 (15C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 4 x CH2), 62.77 
(C-6G), 66.30 (OCH2), 67.43 (C-5F), 68.68 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.54 (C-2G), 73.82 (C-4F), 
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76.08 (C-5G), 77.48 (C-2cyc), 78.68 (C-2L), 79.25 (C-1cyc), 83.92 (C-3G), 97.38 (C-1F), 102.64 (C-1G), 176.84 
(C=O);  
ESI-MS m/z calcd for C33H58NaO13 [M+Na]+: 685.38; found: 685.45. 
2g) According to general procedure, 1 (9.8 mg, 0.0163 mmol), KHCO3 (3.2 mg, 0.0326 mmol) and 
iodooctane (4.4 µL, 0.0245 mmol), 4 - 15°C, 4 h, gave 2g (8.0 mg, 70%). %). [a]D20 -136.14 (c 0.53, 
MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.85 – 1.03, 1.21 – 1.42, 1.50 – 1.76, 1.86 – 1.95, 1.97 – 2.10 (m, 
36H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 6 x CH2, CH3), 1.19 (d, J = 6.7 Hz, 3H, H-6F), 3.25 (dd, J = 9.5, 3.3 
Hz, 1H, H-3G), 3.41 (ddd, J = 6.7, 5.2, 1.3 Hz, 1H, H-5G), 3.54 (ddd, J = 9.8, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 
(dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.64 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, 
H-3F), 3.91 (dd, J = 3.3, 1.1 Hz, 1H, H-4G), 4.08 – 4.22 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.43 
(dd, J = 8.7, 4.3 Hz, 1H, H-2L), 4.57 – 4.63 (m, 1H, H-5F), 4.77 – 4.96 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 14.45 (CH3), 16.60 (H-6F), 23.72, 24.44, 27.09, 27.22, 27.44, 27.67, 29.71, 
30.09, 30.29, 30.36, 30.90, 32.96, 33.68, 34.74, 35.05, 42.44 (17C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 6 x 
CH2), 62.77 (C-6G), 66.30 (OCH2), 67.44 (C-5F), 68.69 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.54 (C-2G), 73.82 
(C-4F), 76.08 (C-5G), 77.48 (C-2cyc), 78.69 (C-2L), 79.26 (C-1cyc), 83.91 (C-3G), 97.37 (C-1F), 102.64 (C-1G), 
176.84 (C=O);  
ESI-MS m/z calcd for C35H62NaO13 [M+Na]+: 713.41; found: 713.45. 
2h) According to general procedure, 1 (9.8 mg, 0.0163 mmol), KHCO3 (3.3 mg, 0.0326 mmol) and  (S)-
(+)-1-Iodo-2-methylbutane (3.2 µL, 0.0245  mmol), 4°C, 6 d, gave 2h (1.5 mg, 15%). [a]D20 -45.07 (c 0.16, 
MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.77 – 1.04, 1.19, 1.20 – 1.51, 1.51 – 1.78, 1.87 – 1.96, 1.98 – 2.11 
(m, 30H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, CH, CH2, 2 x CH3), (d, J = 6.6 Hz, 3H, H-6F), 3.26 (dd, J = 9.5, 
3.3 Hz, 1H, H-3G), 3.40 (ddd, J = 6.5, 5.1, 1.1 Hz, 1H, H-5G), 3.50 – 3.56 (m, 1H, H-2cyc), 3.59 (dd, J = 9.5, 
7.7 Hz, 1H, H-2G), 3.63 – 3.77 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 3.90 
– 3.92 (m, 1H, H-4G), 3.97 – 4.05 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.44 (dd, J = 8.7, 4.3 Hz, 
1H, H-2L), 4.58 – 4.63 (m, 1H, H-5F), 4.75 – 5.02 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 11.56, 16.59 (CH3), 16.78 (C-6F), 24.43, 27.06, 27.22, 27.42, 27.65, 30.08, 
30.67, 33.69, 34.74, 35.04, 35.53, 38.05, 42.47 (C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, CH, CH2), 62.74 (C-6G), 
67.43 (C-5F), 68.67 (C-4G), 70.03 (C-2F), 70.67 (OCH2), 71.56 (C-3F), 72.56 (C-2G), 73.82 (C-4F), 76.07 (C-
5G), 77.50 (C-2cyc), 78.67 (C-2L), 79.26 (C-1cyc), 83.88 (C-3G), 97.37 (C-1F), 102.63 (C-1G);  
ESI-MS m/z calcd for C32H56NaO13 [M+Na]+: 671.36; found: 671.47.  
2i) According to general procedure, 1 (11.0 mg, 0.0183 mmol), KHCO3 (3.7 mg, 0.0366 mmol) and 1-
iodo-3-methylbutane (3.63 µL, 0.0275 mmol), 4°C, 6 d, gave 2i (8.2 mg, 69%). [a]D20 -78.88 (c 0.82, 
MeOH).  
1H NMR (500 MHz, Methanol-d4) δ 0.84 – 1.02, 1.21 – 1.42, 1.51 – 1.59, 1.61 – 1.77, 1.87 – 1.95, 1.99 – 
2.12 (m, 24H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc), 0.96 (d, J = 6.6 Hz, 3H, CH3), 0.97 (d, J = 6.6 Hz, 3H, 
CH3), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.41 (ddd, J = 6.6, 5.2, 1.3 Hz, 1H, 
H-5G), 3.54 (ddd, J = 9.8, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.62 – 3.78 (m, 5H, 
H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 3.91 (dd, J = 3.4, 1.1 Hz, 1H, H-4G), 4.12 – 
4.25 (m, 2H, OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.42 (dd, J = 8.8, 4.3 Hz, 1H, H-2L), 4.60 (q, J = 6.4 Hz, 
1H, H-5F), 4.78 – 4.89 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 16.61(H-6F), 22.73, 22.82 (CH3), 24.44, 24.47, 26.23, 27.23, 27.44, 27.66, 
30.09, 30.90, 33.67, 34.74, 35.05, 38.49, 42.40 (C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, CH, CH2), 62.75 (C-6G), 
64.76 (OCH2), 67.44 (C-5F), 68.67 (C-4G), 70.03 (C-2F), 71.57 (C-3F), 72.55 (C-2G), 73.82 (C-4F), 76.07 (C-
5G), 77.49 (C-2cyc), 78.70 (C-2L), 79.26 (C-1cyc), 83.92 (C-3G), 97.38 (C-1F), 102.63 (C-1G), 176.82 (C=O);  
ESI-MS m/z calcd for C32H56NaO13 [M+Na]+: 671.36; found: 671.44. 
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2j) According to general procedure, 1 (9.9 mg, 0.0165 mmol), KHCO3 (3.3 mg, 0.0330 mmol) and 2-ethyl 
hexyl iodide (4.4 µL, 0.0247 mmol), 4°C, 6 d, gave 2j (2.5 mg, 21%). [a]D20 -40.76 (c 0.32, MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.82 – 1.00, 1.20 – 1.44, 1.52 – 1.77, 1.87 – 1.95, 1.99 – 2.10, 2.31 – 
2.38 (m, 36H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, CH, 4 x CH2, 2 x CH3), 1.19 (d, J = 6.7 Hz, 3H, H-6F), 3.25 
(dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.38 – 3.43 (m, 1H, H-5G), 3.51 – 3.57 (m, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 
Hz, 1H, H-2G), 3.62 – 3.78 (m, 5H, H-1cyc, H-2F, H-4F, H-6G), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 3.91 (dd, 
J = 3.4, 1.1 Hz, 1H, H-4G), 4.06 (ddd, J = 11.0, 5.5, 2.3 Hz, 1H, OCH2), 4.13 (ddd, J = 10.1, 5.6, 4.3 Hz, 1H, 
OCH2), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.44 (dd, J = 8.5, 4.4 Hz, 1H, H-2L), 4.58 – 4.63 (m, 1H, H-5F), 4.80 – 
4.91 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 11.37, 14.41 (CH3), 16.60 (C-6F), 24.05, 24.45, 24.93, 27.20, 27.40, 27.66, 
30.09, 30.77, 31.62, 33.74, 34.76, 35.03, 40.28, 42.48, 43.88 (16C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, CH, 
4 x CH2), 62.79 (C-6G), 67.44 (C-5F), 68.25 (OCH2), 68.71 (C-4G), 70.03 (C-2F), 71.55 (C-3F), 72.56 (C-2G), 
73.83 (C-4F), 76.11 (C-5G), 77.49 (C-2cyc), 78.70 (C-2L), 79.28 (C-1cyc), 83.89 (C-3G), 97.38 (C-1F), 102.65 
(C-1G), 176.90 (C=O);  
ESI-MS m/z calcd for C35H62NaO13 [M+Na]+: 713.41; found: 713.53.  
 
 
Scheme S2 Reactions and reaction conditions: a) DCM, 1-chloro-N,N-2-trimethylpropenylamin, rt, 2 h, 46 -73%; b) 
Pd(OH)2, dioxane, water, H2, rt, 1 -2 h, 62-93%. The synthesis of 16 was described by Norman et. al (2). 
17k) To a mixture of 16 (21.3 mg, 0.019 mmol) in dry DCM (1 mL) under an argon atmosphere at rt, 1-
chloro-N,N-2-trimethylpropenylamin (3.2 µL, 0.022 mmol) was added. After stirring for 2 h 
triethylamine (13 µL, 0.094 mmol) and cyclobutanemethanol (17.6 µL, 0.187 mmol) were added and 
the mixture was stirred for another hour. Concentration in vacuo and column chromatography on silica 
gel (petroleum ether/ethyl acetate 6:1) of the remains gave 17k (14.0 mg, 63%).  [a]D20 -80.61 (c 0.70, 
DCM);  
1H NMR (500 MHz, Chloroform-d) δ 0.77 – 0.98, , 1.12 – 1.40, 1.51 – 1.79, 1.79 – 1.91, 1.91 – 2.10 (m, 
27H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 3 x CH2 (C5H9)), 1.10 (d, J = 6.5 Hz, 3H, H-6F), 2.59 (hept, J = 7.5 
Hz, 1H, CH (C5H9)), 3.34 (m, 1H, H-4F), 3.40 (dd, J = 9.6, 3.1 Hz, 1H, H-3G), 3.47 – 3.57 (m, 2H, H-5G, H-
2cyc), 3.59 (dd, J = 8.9, 5.2 Hz, 1H, H-6aG), 3.62 – 3.73 (m, 3H, H-6bG, H-1cyc, H-2G), 3.91 – 3.94 (m, 2H, H-
2F, H-3F), 4.02 (dd, J = 10.9, 6.9 Hz, 1H, OCH2 (C5H9)), 4.09 – 4.16 (m, 2H, H-4G, OCH2 (C5H9), 4.19 (d, J = 
11.5 Hz, 1H, A of AB, CH2Ph), 4.34 (d, J = 11.9 Hz, 1H, A of AB, CH2Ph), 4.40 (d, J = 7.7 Hz, 1H, H-1G), 4.43 
(d, J = 11.9 Hz, 1H, B of AB, CH2Ph), 4.49 (t, J = 6.4 Hz, 1H, H-2L), 4.53 – 4.75 (m, 8H, H-5F, CH2Ph), 4.84 
(m, 1H, H-1F), 5.04 (d, J = 10.9 Hz, 1H, B of AB, CH2Ph), 5.08 (d, J = 11.0 Hz, 1H, B of AB, CH2Ph), 7.10 – 
7.48 (m, 30H, 6 x C6H5);  
13C NMR (126 MHz, CDCl3) δ 16.58 (C-6F), 18.31, 23.43, 24.71, 24.80, 26.21, 26.24, 26.34, 29.41, 29.69, 
30.05, 33.49, 33.60, 33.91, 34.20, 41.25 (C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 4C C5H9), 65.94 (C-5F), 68.58, 
68.63 (C-6G, OCH2 C5H9), 72.55, 72.89, 72.93, 73.46, 74.61, 75.01, 75.19 (C-5G, CH2Ph), 75.71, 75.87, 
76.10 (C-4G, C-2F, C-2cyc), 77.69 (C-1cyc), 78.78 (C-4F), 79.22 (C-2L), 79.84 (C-3F), 80.72 (C-2G), 81.49 (C-
3G), 94.73 (C-1F), 101.16 (C-1G), 127.15, 127.20, 127.25, 127.30, 127.35, 127.59, 127.83, 127.88, 128.01, 
128.15, 128.18, 128.25, 128.36, 128.45, 138.10, 138.80, 138.98, 139.29, 139.36, 139.61 (36C, 6 x C6H5), 
174.22 (C=O);  
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ESI-MS m/z calcd for C74H90NaO13 [M+Na]+: 1209.63; found: 1209.86. 
17l) To a mixture of 16 (11.5 mg, 0.010 mmol) in dry DCM (500 µL) under a argon atmosphere at rt, 1-
chloro-N,N-2-trimethylpropenylamin (1.7 µL, 0.012 mmol) was added. After stirring for 2 h 
triethylamine (7 µL, 0.051 mmol) and cyclopentanemethanol (11 µL, 0.101 mmol) were added and the 
mixture was stirred for another hour. Concentration in vacuo and column chromatography on silica gel 
(petroleum ether/ethyl acetate 6:1) of the remains gave 17l (9.0 mg, 75%). [a]D20 -69.18 (c 0.90, DCM);  
1H NMR (500 MHz, Chloroform-d) δ 0.77 – 0.95, 1.12 – 1.40, 1.40 – 1.82, 1.92 – 2.05 (m, 29H, C7H13L, H-
3cyc, H-4cyc, H-5cyc, H-6cyc, 4 x CH2 C6H11), 1.10 (d, J = 6.5 Hz, 3H, H-6F), 2.18 (hept, J = 7.5 Hz, 1H, CH C6H11), 
3.34 (m, 1H, H-4F), 3.41 (dd, J = 9.6, 3.1 Hz, 1H, H-3G), 3.47 – 3.57 (m, 2H, H-5G, H-2cyc), 3.59 (dd, J = 8.9, 
5.2 Hz, 1H, H-6aG), 3.61 – 3.73 (m, 3H, H-6bG, H-2G, H-1cyc), 3.91 – 3.96 (m, 3H, H-2F, H-3F, OCH2 C6H11), 
4.02 (dd, J = 10.7, 7.3 Hz, 1H, OCH2 C6H11), 4.13 (d, J = 3.0 Hz, 1H, H-4G), 4.19 (d, J = 11.4 Hz, 1H, A of AB, 
CH2Ph), 4.33 (d, J = 12.0 Hz, 1H, A of AB, CH2Ph), 4.38 – 4.45 (m, 2H, H-1G, CH2Ph), 4.49 (t, J = 6.4 Hz, 1H, 
H-2L), 4.52 – 4.75 (m, 8H, H-5F, CH2Ph), 4.84 (m, 1H, H-1F), 5.05 (d, J = 10.9 Hz, 1H, B of AB, CH2Ph), 5.08 
(d, J = 11.1 Hz, 1H, B of AB, CH2Ph), 7.11 – 7.54 (m, 30H, 6 x C6H5);  
13C NMR (126 MHz, CDCl3) δ 16.59 (C-6F), 23.43, 25.31, 25.44, 26.21, 26.24, 26.35, 29.06, 29.37, 29.44, 
29.69, 30.05, 33.52, 33.59, 34.21, 38.42, 42.16 (C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 5C C6H11), 65.95 (C-
5F), 68.63, 68.74 (C-6G, OCH2 C6H11), 72.55, 72.89, 72.94, 73.45, 74.60, 75.01, 75.20 (C-5G, CH2Ph), 75.72 
, 75.90, 76.11 (C-2F, C4G, C-2cyc), 77.68 (C-1cyc), 78.77 (C-4F), 79.16 (C-2L), 79.84 (C-3F), 80.73 (C-2G), 81.46 
(C-3G), 94.74 (C-1F), 101.16 (C-1G), 127.15, 127.21, 127.25, 127.29, 127.35, 127.58, 127.84, 127.88, 
128.02, 128.15, 128.18, 128.25, 128.36, 128.45, 138.10, 138.81, 138.98, 139.29, 139.37, 139.62 (36C, 
6 x C6H5), 174.21 (C=O);  
ESI-MS m/z calcd for C75H92NaO13 [M+Na]+: 1223.64; found: 1223.84. 
17m) To a mixture of 16 (26.0 mg, 0.023 mmol) in dry DCM (1 mL) under a argon atmosphere at rt, 1-
chloro-N,N-2-trimethylpropenylamin (3.9 µL, 0.027 mmol) was added. After stirring for 2 h 
triethylamine (16 µL, 0.114 mmol) and cyclohexanemethanol (28 µL, 0.228 mmol) were added and the 
mixture was stirred for another 3 hours. Concentration in vacuo and column chromatography on silica 
gel (petroleum ether/ethyl acetate 6:1) of the remains gave 17m (12.7 mg, 46%).[a]D20 -77.28 (c 0.60, 
DCM);  
1H NMR (500 MHz, Chloroform-d) δ 0.79 – 1.01, 1.12 – 1.39, 1.39 – 1.51, 1.52 – 1.77, 1.91 – 2.06 (m, 
32H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 5 x CH2, CH C7H13), 1.10 (d, J = 6.4 Hz, 3H, H-6F), 3.35 (m, 1H, H-
4F), 3.41 (dd, J = 9.6, 3.0 Hz, 1H, H-3G), 3.49 (dd, J = 7.6, 5.4 Hz, 1H, H-5G), 3.51 – 3.56 (m, 1H, H-2cyc), 
3.58 (dd, J = 9.0, 5.2 Hz, 1H, H-6aG), 3.61 – 3.72 (m, 3H, H-6bG, H-2G, H-1cyc), 3.87 (dd, J = 10.7, 6.6 Hz, 
1H, OCH2 C7H13), 3.91 – 3.96 (m, 3H, H-2F, H-3F, OCH2 C7H13), 4.12 (d, J = 3.0 Hz, 1H, H-4G), 4.20 (d, J = 
11.4 Hz, 1H, A of AB, CH2Ph), 4.34 (d, J = 11.9 Hz, 1H, B of AB, CH2Ph), 4.40 (d, J = 7.8 Hz, 1H, H-1G), 4.42 
(d, J = 12.0 Hz, 1H, A of AB, CH2Ph), 4.49 (t, J = 6.4 Hz, 1H, H-2L), 4.52 – 4.75 (m, 8H, H-5F, CH2Ph), 4.84 
(m, 1H, H-1F), 5.05 (d, J = 10.9 Hz, 1H, A of AB, CH2Ph), 5.08 (d, J = 11.0 Hz, 1H, A of AB, CH2Ph), 7.15 – 
7.43 (m, 30H, 6 x C6H5);  
13C NMR (126 MHz, CDCl3) δ 16.59 (C-6F), 23.43, 25.56, 25.57, 26.22, 26.24, 26.29, 26.35, 29.68, 33.52, 
33.61, 34.19, 37.03, 41.22 (17C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 6C C7H13), 65.94 (C-5F), 68.65 (C-6G), 
69.84 (OCH2 C7H13), 72.54, 72.88, 72.97, 73.45, 74.61, 75.01, 75.18 (C-5G, CH2Ph), 75.71, 75.90, 76.10 
(C-4G, C-2F, C-2cyc), 77.66 (C-1cyc), 78.76 (C-4F), 79.12 (C-2L), 79.83 (C-3F), 80.72 (C-2G), 81.44 (C-3G), 94.74 
(H-1F), 101.13 (H-1G), 127.14, 127.22, 127.25, 127.31, 127.34, 127.36, 127.58, 127.59, 127.84, 127.87, 
128.01, 128.14, 128.18, 128.25, 128.36, 128.44, 138.09, 138.80, 138.98, 139.27, 139.36, 139.60 (36C, 
6 x C6H5), 174.15 (C=O);  
ESI-MS m/z calcd for C76H94NaO13 [M+Na]+: 1237.66; found: 1237.89. 
2k) A mixture of 17k (14.0 mg, 0.012 mmol) and Pd(OH)2 (12.9 mg) in dioxane/water (1.0 mL, 4:1) was 
stirred under a hydrogen atmosphere. After 1 h the mixture was filtered through a pad of celite and 
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evaporated to dryness. Column chromatography on silica gel (DCM/Methanol 6:1) gave 2k (7.0 mg, 
92%). [a]D20 -93.80 (c 0.70, MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.83 – 1.03, 1.21 – 1.43, 1.51 – 1.60, 1.61 – 1.76, 1.76 – 1.85, 1.86 – 
2.00, 2.00 – 2.13 (m, 27H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 3 x CH2 C5H9), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 
2.66 (hept, J = 7.4 Hz, 1H, CH C5H9), 3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.40 (ddd, J = 6.6, 5.1, 1.1 Hz, 1H, 
H-5G), 3.54 (ddd, J = 9.8, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.63 – 3.78 (m, 5H, 
H-2F, H-4F, H-6G, H-1cyc), 3.86 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 3.91 (dd, J = 3.3, 1.1 Hz, 1H, H-4G), 4.08 (dd, 
J = 10.9, 6.6 Hz, 1H, OCH2 C5H9), 4.17 (dd, J = 10.9, 6.8 Hz, 1H, OCH2 C5H9), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 
4.43 (dd, J = 8.7, 4.4 Hz, 1H, H-2L), 4.60 (q, J = 6.7 Hz, 1H, H-5F), 4.87 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 16.59 (C-6F), 19.16, 24.45, 25.62, 25.68, 27.21, 27.42, 27.65, 30.07, 30.88, 
33.68, 34.74, 35.02, 35.47, 42.49 (15C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 4C C5H9), 62.72 (C-6G), 67.42 
(C-5F), 68.65 (C-4G), 69.89 (OCH2 C5H9), 70.02 (C-2F), 71.55 (C-3F), 72.55 (C-2G), 73.81 (C-4F), 76.06 (C-
5G), 77.47 (C-2cyc), 78.71 (C-2L), 79.24 (C-1cyc), 83.88 (C-3G), 97.36 (C-1F), 102.63 (C-1G), 176.87 (C=O);  
ESI-MS m/z calcd for C32H54NaO13 [M+Na]+: 669.35; found: 669.41. 
2l) A mixture of 17l (9.0 mg, 0.008 mmol) and Pd(OH)2 (9.0 mg) in dioxane/water (1.0 mL, 4:1) was 
stirred under a hydrogen atmosphere. After 2 h the mixture was filtered through a pad of celite and 
evaporated to dryness. Column chromatography on silica gel (DCM/Methanol 6:1) gave 2l (3.2 mg, 64%). 
[a]D20 -126.74 (c 0.32, MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.82 – 1.04, 1.20 – 1.43, 1.49 – 1.84, 1.86 – 1.96, 1.99 – 2.11 (m, 
29H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 4 x CH2 C6H11)), 1.19 (d, J = 6.6 Hz, 3H, H-6F), 2.24 (hept, J = 7.5 
Hz, 1H, CH C6H11), 3.25 (dd, J = 9.5, 3.3 Hz, 1H, H-3G), 3.41 (ddd, J = 6.6, 5.1, 1.1 Hz, 1H, H-5G), 3.54 (ddd, 
J = 9.8, 8.1, 4.4 Hz, 1H, H-2cyc), 3.59 (dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.63 – 3.78 (m, 5H, H-6G, H-2F, H-4F, 
H-1cyc), 3.86 (dd, J = 10.1, 3.3 Hz, 1H, H-3F), 3.91 (dd, J = 3.3, 1.1 Hz, 1H, H-4G), 4.03 (dd, J = 10.5, 7.1 Hz, 
1H, OCH2 C6H11), 4.08 (dd, J = 10.7, 7.1 Hz, 1H, OCH2 C6H11), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.43 (dd, J = 
8.7, 4.3 Hz, 1H, H-2L), 4.60 (q, J = 8.5, 7.5 Hz, 1H, H-5F), 4.85 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 16.59 (C-6F), 24.43, 26.32, 27.22, 27.43, 27.66, 30.08, 30.29, 30.37, 33.68, 
34.74, 35.04, 39.89, 42.46 (16C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 5C C6H11), 62.72 (C-6G), 67.42 (C-5F), 
68.65 (C-4G), 70.02, 70.06 (C-2F, OCH2 C6H11), 71.55 (C-3F), 72.55 (C-2G), 73.81 (C-4F), 76.06 (C-5G), 77.48 
(C-2cyc), 78.69 (C-2L), 79.25 (C-1cyc), 83.90 (C-3G), 97.37 (C-1F), 102.63 (C-1G), 176.85 (C=O);  
ESI-MS m/z calcd for C33H56NaO13 [M+Na]+: 683.36; found: 683.46. 
2m) A mixture of 17m (12.0 mg, 0.010 mmol) and Pd(OH)2 (10.0 mg) in dioxane/water (1.0 mL, 4:1) was 
stirred under a hydrogen atmosphere. After 2 h the mixture was filtered through a pad of celite and 
evaporated to dryness. Column chromatography on silica gel (DCM/Methanol 6:1) gave 2m (6.2 mg, 
92%). [a]D20 -81.79 (c 0.36, MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.82 – 1.09, 1.20 – 1.43, 1.52 – 1.61, 1.60 – 1.80, 1.88 – 1.95, 1.99 – 
2.10 (32H, C7H13L, H-3cyc, H-4cyc, H-5cyc, H-6cyc, 5 x CH2, CH C7H13), 1.19 (d, J = 6.7 Hz, 3H, H-6F), 3.25 (dd, 
J = 9.5, 3.3 Hz, 1H, H-3G), 3.40 (ddd, J = 6.6, 5.2, 1.1 Hz, 1H, H-5G), 3.54 (ddd, J = 9.8, 8.1, 4.4 Hz, 1H, H-
2cyc), 3.59 (dd, J = 9.5, 7.7 Hz, 1H, H-2G), 3.63 – 3.77 (m, 5H, H-6G, H-2F, H-4F, H-1cyc), 3.86 (dd, J = 10.1, 
3.4 Hz, 1H, H-3F), 3.91 (dd, J = 3.3, 1.1 Hz, 1H, H-4G), 3.94 (dd, J = 10.7, 6.4 Hz, 1H, OCH2 C7H13), 3.99 (dd, 
J = 10.7, 6.5 Hz, 1H, OCH2 C7H13), 4.27 (d, J = 7.7 Hz, 1H, H-1G), 4.43 (dd, J = 8.6, 4.4 Hz, 1H, H-2L), 4.60 
(m, 1H, H-5F), 4.85 (m, 1H, H-1F);  
13C NMR (126 MHz, MeOD) δ 16.59 (C-6F), 24.43, 24.45, 26.77, 26.78, 27.23, 27.43, 27.65, 30.10, 30.74, 
30.76, 30.89, 33.70, 34.74, 35.03, 38.53, 42.47 (17C, C7H13L, C-3cyc, C-4cyc, C-5cyc, C-6cyc, 6C C7H13), 62.73 
(C-6G), 67.42 (C-5F), 68.65 (C-4G), 70.02 (C-2F), 71.25 (OCH2 C7H13), 71.55 (C-3F), 72.54 (C-2G), 73.81 (C-
4F), 76.06 (C-5G), 77.47 (C-2cyc), 78.67 (C-2L), 79.24 (C-1cyc), 83.88 (C-3G), 97.36 (C-1F), 102.62 (C-1G), 
176.81 (C=O);  
ESI-MS m/z calcd for C34H58NaO13 [M+Na]+: 697.38; found: 697.55. 
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Scheme S3 Reactions and reaction conditions: a) KHCO3, DMF, 4°C – 15°C, 4 h - 6 d, 15 – 80%. The synthesis of 4 
was described by Kolb et al. (3). 
3) According to general procedure (described for compound 2a), 4 (14.1 mg, 0.0237 mmol), KHCO3 (4.7 
mg, 0.0474 mmol) and iodoethane (2.85 µL, 0.0356 mmol), 4°C, 1 d, gave 3 (10.9mg mg, 77%). [a]D20 -
60.70 (c 1.09, MeOH);  
1H NMR (500 MHz, Methanol-d4) δ 0.84 – 0.95, 1.20 – 1.43, 1.67 – 1.76, 2.00 – 2.08 (m, 8H, H-3cyc, H-
4cyc, H-5cyc, H-6cyc), 1.15 – 1.19 (m, 6H, H-6F, CH3), 3.12 (d, J = 6.3 Hz, 2H, CH2Ph), 3.34 – 3.37 (m, 1H, H-
3G), 3.40 (dd, J = 6.8, 5.4 Hz, 1H, H-5G), 3.49 – 3.60 (m, 2H, H-2G, H-2cyc), 3.62 – 3.77 (m, 5H, H-6G, H-2F, 
H-4F, H-1cyc), 3.85 (dd, J = 10.1, 3.4 Hz, 1H, H-3F), 3.90 (d, J = 3.2 Hz, 1H, H-4G), 4.11 (q, J = 7.1 Hz, 2H, 
CH2), 4.26 (d, J = 7.6 Hz, 1H, H-1G), 4.53 – 4.64 (m, 2H, H-5F, H-2L), 4.82 – 4.87 (m, 1H, H-1F), 7.15 – 7.32 
(m, 5H, C6H5);  
13C NMR (126 MHz, MeOD) δ 14.36 (CH3), 16.60 (C-6F), 24.44, 30.06, 30.92, 40.34 (C-3cyc, C-4cyc, C-5cyc, 
C-6cyc), 62.25 (OCH3), 62.68 (C-6G), 67.41 (C-5F), 68.48 (C-4G), 70.03 (C-2F), 71.56 (C-3F), 72.36 (C-2G), 
73.82 (C-4F), 76.05 (C-5G), 77.40 (C-2cyc), 79.28 (C-1cyc), 81.33 (C-2L), 83.97 (C-3G), 97.32 (C-1F), 102.54 (C-
1G), 127.65, 129.24, 130.76, 138.17 (6C, C6H5), 175.06 (C=O);  
ESI-MS m/z calcd for C29H44NaO13 [M+Na]+: 623.27; found: 623.37. 
 
Scheme S4 Reagents and reaction conditions: (i) i. nBu2SnO, MeOH, reflux, 3 h, ii. CsF, DME, rt, 18 h, 25%; (ii) 
DMAP/cyclohexylmethanol, 82°C, overnight (79%); (iii) Pd(OH)2/C, THF, H2 balloon, JXH-VIII-018 (91%), JXH-VIII-
005 (87%); (iv) ) KHCO3/EtI/DMF, 0-4°C, 24 h, (54%). The synthesis of 18 was described by Norman et al. (2). 
19 and 20) A suspension of 18 (95.6 mg, 0.12 mmol) and Bu2SnO (34.35 mg, 0.138 mmol) in dry MeOH 
(5 mL) was refluxed for 3 h. The solvent was removed under reduced pressure and the resulting foam 
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dried in vacuo 4 h. CsF (42 mg, 0.24 mmol) was dried in vacuo at 100°C for 30 min and flushed with 
argon. Then benzyl (R)-4-Methyl-2-(((trifluoromethyl)sulfonyl)oxy)pentanoate (85 mg, 0.24 mmol), CsF 
(36 mg) and DME (3.0 mL) were added to the tin acetal at rt. The reaction mixture was stirred at rt 
overnight. The solvent was removed under reduced pressure. The residue was purified by silica gel 
chromatography (petroleum ether/ethyl acetate, 6:4 - 3:1) to afford 20 (85 mg, 70%) as white foam and 
19 (20 mg) as white foam. [a]D20 -108.3 (c 0.77, DCM);  
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.2 Hz, 2H), 7.40 – 7.12 (m, 23H), 5.48 (s, 1H, OCHPh), 5.16 (d, J 
= 12.2 Hz, 1H, OCH2Ph), 5.08 (d, J = 12.2 Hz, 1H, OCH2Ph), 4.97 (d, J = 3.0 Hz, 1H, Fuc-H1), 4.85 (d, J = 
6.6 Hz, 1H, Fuc-H5), 4.82 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.71 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.66 – 4.55 (m, 
3H, Lactic-H2, OCH2Ph), 4.32 – 4.24 (m, 2H, Gal-H6a, OCH2Ph, Gal-H1), 4.20 (d, J = 3.3 Hz, 1H, Gal-H4), 
4.01 – 3.88 (m, 4H, Gal-H6b, Fuc-H2, Fuc-H3, Gal-H2), 3.65 – 3.60 (m, 1H, MeCy-H1), 3.61 (d, J = 11.2 
Hz, 1H, OCH2Ph), 3.47 (dd, J = 9.7, 3.4 Hz, 1H, Gal-H3), 3.25 (s, 1H, Gal-H5), 3.22 (s, 1H, Fuc-H4), 3.19 (t, 
J = 9.5 Hz, 1H, MeCy-H2), 2.38 (d, J = 1.5 Hz, 1H, 2-OH), 2.10 – 2.03 (m, 1H), 1.96 (dt, J = 13.5, 6.7 Hz, 
1H), 1.80 (ddd, J = 14.5, 9.6, 5.2 Hz, 1H), 1.69 – 1.53 (m, 4H), 1.38 – 1.16 (m, 2H), 1.09 (d, J = 6.4 Hz, 3H, 
MeCy), 1.04 (d, J = 6.5 Hz, 3H, Fuc-H6), 1.02 – 0.98 (m, 1H), 1.00 (d, J = 1.8 Hz, 3H, CH3), 0.99 (d, J = 1.9 
Hz3H, CH3);  
13C NMR (126 MHz, CDCl3) δ 173.71 (C=O), 139.62, 139.43, 138.61, 138.32, 135.63, 128.59, 128.54, 
128.51, 128.35, 128.33, 128.11, 128.03, 127.92, 127.82, 127.42, 127.34, 127.03, 126.81, 125.90, 101.14 
(Gal-C1), 99.52 (CHPh), 98.49 (Fuc-C1), 82.26 (MeCy-C2), 79.89 (MeCy-C1), 79.56 (Fuc-C2), 79.02 (Gal-
C3), 78.61 (Fuc-C4), 78.02 (Lac-C2), 75.45 (Fuc-C3), 75.05 (Gal-C4), 74.72 (OCH2Ph), 74.42 (OCH2Ph), 
71.25 (OCH2Ph), 71.08 (Gal-C2), 69.27 (Gal-C6), 66.56 (Gal-C5), 66.46 (OCH2Ph), 66.09 (Fuc-C5), 41.92, 
39.44, 33.64, 31.41, 24.65, 23.28, 23.17, 21.80 (8C), 18.74 (MeCy), 16.46 (Fuc-C6);  
MS (ESI) m/z: calcd for C60H72NaO13 [M+Na]+: 1023.49; found: 1023.56. 
21) A mixture of 19 (19.0 mg, 0.019 mmol) and DMAP (catalytic amount) in Cyclohexylmethanol (0.5 
mL) was stirred at 82°C overnight. The solvent was removed under high vacuum with heating and the 
residue was purified by silica gel chromatography (petroleum ether/ethyl acetate, 6:4 - 3:1) to afford 
21 (16.7 mg, 79%) as white foam. [a]D20 -96.7 (c 0.7, DCM);  
1H NMR (500 MHz, CDCl3) δ 7.58 (d, J = 7.3 Hz, 2H), 7.39 – 7.11 (m, 18H), 5.62 (s, 1H, OCHPh), 4.97 (d, J 
= 3.4 Hz, 1H, Fuc-H1), 4.87 (q, J = 6.4 Hz, 1H, Fuc-H5), 4.82 (d, J = 11.6 Hz, 1H, OCH2Ph), 4.71 (d, J = 11.7 
Hz, 1H, OCH2Ph), 4.65 – 4.58 (m, 2H, OCH2Ph), 4.57 (dd, J = 9.5, 4.0 Hz, 1H, Lactic-H2), 4.38 (d, J = 3.3 
Hz, 1H, Gal-H4), 4.32 – 4.29 (m, 1H, Gal-H6a), 4.28 (d, J = 7.7 Hz, 1H, Gal-H1), 4.27 (d, J = 11.3 Hz, 1H, 
OCH2Ph), 4.08 (dd, J = 11.9, 1.1 Hz, 1H, Gal-H6b), 3.98 – 3.92 (m, 3H, Fuc-H3, Fuc-H2, Gal-H2), 3.91 – 
3.82 (m, 2H, OCH2Cyclohexyl), 3.66 – 3.61 (m, 1H, MeCy-H1), 3.61 (d, J = 11.3 Hz, 1H, OCH2Ph), 3.51 (dd, 
J = 9.7, 3.4 Hz, 1H, Gal-H3), 3.36 (s, 1H, Gal-H5), 3.23 (s, 1H, Fuc-H4), 3.19 (t, J = 9.5 Hz, 1H, MeCy-H2), 
2.41 (d, J = 1.3 Hz, 1H, 2-OH), 2.06 (m, 1H), 2.02 – 1.91 (m, 1H), 1.81 – 1.56 (m, 11H), 1.39 – 1.13 (m, 
6H), 1.09 (d, J = 6.4 Hz, 3H, Fuc-H6), 1.05 (d, J = 6.5 Hz, 3H, MeCy), 1.01 (d, J = 2.5 Hz, 3H), 1.00 (d, J = 
2.7 Hz, 3H), 1.11 – 0.85 (m, 2H);  
13C NMR (126 MHz, MeOD) δ 13C NMR (126 MHz, CDCl3) δ 174.14 (C=O), 139.65, 139.45, 138.64, 138.35, 
128.62, 128.55, 128.13, 128.05, 127.93, 127.84, 127.44, 127.36, 127.04, 126.84, 125.95 (Ar-C), 101.18 
(Gal-C1), 99.62 (CHPh), 98.53 (Fuc-C1), 82.29 (MeCy-C2), 79.92 (MeCy-C1), 79.59 (Fuc-C3), 78.99 (Gal-
C3), 78.64 (Fuc-C4), 77.97 (Lac-C2), 75.47 (Fuc-C2), 75.17 (Gal-C4), 74.75 (OCH2Ph), 74.45 (OCH2Ph), 
71.26 (OCH2Ph), 71.12 (Gal-C2), 69.96 (CO2CH2Cy), 69.37 (Gal-C6), 66.65 (Gal-C5), 66.12 (Fuc-C5), 42.07, 
39.46, 36.99, 33.66, 31.43, 29.64, 29.59, 26.29, 25.58, 24.72, 23.30, 23.22, 21.87 (14C), 18.77 (MeCy), 
16.50 (Fuc-C6);  
MS (ESI) m/z: calcd for C60H78NaO13 [M+Na]+: 1029.53; found: 1029.77. 
13) A suspension of 21 (16.0 mg, 0.0145 mmol) and Pd(OH)2/C (5.0 mg, 10% Pd) in THF (4.0 mL) was 
hydrogenated with H2 balloon at rt for 2hr. The reaction mixture was filtered through celite, the solvent 
was removed under reduced pressure. The residue was purified by silica gel chromatography 
(DCM/MeOH, 19:1 – 9:1) to afford JXH-VIII-018 as white solid.  The solid was redissolved in H2O/CH3CN 
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(4:1), filtered through Acrodisc® syringe filter with 0.45 μm PTFE member and the filtrate was lyophilized 
to provide 13 (8.6 mg, 91%) as white solid. 
1H NMR (500 MHz, MeOD) δ 4.99 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.89 (q, J = 6.3 Hz, 1H, Fuc-H5), 4.42 (dd, J 
= 9.4, 4.0 Hz, 1H, Lactic-H2), 4.25 (d, J = 7.8 Hz, 1H, Gal-H1), 4.03 – 3.93 (m, 2H, OCO2CH2Cy), 3.91 (d, J 
= 2.6 Hz, 1H, Gal-H4), 3.83 (dd, J = 10.2, 3.3 Hz, 1H, Fuc-H3), 3.77 – 3.70 (m, 2H, Fuc-H2, Gal-H6a), 3.69 
(d, J = 2.6 Hz, 1H, Fuc-H4), 3.67 – 3.61 (m, 3H, Gal-H6b, Gal-H2, MeCy-H1), 3.39 (t, J = 6.3 Hz, 1H, Gal-
H5), 3.25 (dd, J = 9.5, 3.2 Hz, 1H, Gal-H3), 3.19 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.11 (m, 1H), 2.04 – 1.93 (m, 
1H), 1.81 – 1.58 (m, 10H), 1.56 – 1.47 (m, 1H), 1.35 – 1.21 (m, 6H), 1.18 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.13 
(d, J = 6.3 Hz, 3H, MeCy), 1.09 – 1.00 (m, 2H), 0.98 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.7 Hz, 3H). 
13C NMR (126 MHz, MeOD) δ 176.69 (C=O), 102.43 (Gal-C1), 100.48 (Fuc-C1), 84.68 (MeCy-C2), 83.80 
(Gal-C3), 79.96 (MeCy-C1), 79.21 (Lac-C2), 75.95 (Gal-C5), 73.83 (Fuc-C4), 72.20 (Gal-C2), 71.38 (Fuc-
C3), 71.26 (CO2CH2Cy), 70.34 (Fuc-C2), 68.67 (Gal-C4), 67.55 (Fuc-C5), 62.84 (Gal-C6), 43.91, 40.42, 
38.52, 34.95, 31.92, 30.75, 30.73, 27.43, 26.77, 25.42, 24.23, 23.67, 22.25, 19.57, 16.73. MS (ESI) m/z: 
calcd for C32H56NaO13 [M+Na]+: 671.36; found: 671.45. 
6) A suspension of 20 (68 mg, 0.0679 mmol) and Pd(OH)2/C (17 mg, 10% Pd) in THF (5.0 mL) was 
hydrogenated with H2 balloon at rt for 2.5h. The reaction mixture was filtered through celite, the solvent 
was removed under reduced pressure. The residue was purified by silica gel chromatography 
(DCM/(MeOH:H2O, 10:1), 7:3 - 6:4), ion-exchanged with Dowex® Marathon™ C sodium form, then 
purified with reversed-phase column chromatography (RP-18, MeOH/H2O) to afford 6 (34 mg, 87%) as 
white solid. 
1H NMR (500 MHz, D2O) δ 5.11 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.87 (q, J = 6.6 Hz, 1H, Fuc-H5), 4.50 (d, J = 
8.0 Hz, 1H, Gal-H1), 3.96 (dd, J = 9.8, 3.7 Hz, 1H, Lactic-H2), 3.95 – 3.87 (m, 2H, Gal-H4, Fuc-H3), 3.87 – 
3.79 (m, 2H, Fuc-H4, Fuc-H2), 3.79 – 3.70 (m, 3H, Gal-H6a, Gal-H6b, MeCy-H1), 3.65 – 3.61 (m, 2H, Gal-
H2, Gal-H5), 3.43 (dd, J = 9.6, 3.1 Hz, 1H, Gal-H3), 3.24 (t, J = 9.6 Hz, 1H, MeCy-H2), 2.15 (m, 1H), 1.88 – 
1.84  (m, 1H), 1.75 – 1.56 (m, 4H), 1.55 – 1.43 (m, 1H), 1.37 – 1.25 (m, 2H), 1.21 (d, J = 6.6 Hz, 3H), 1.10 
(t, J = 6.4 Hz, 3H), 1.15 – 1.06 (m, 1H), 0.95 (d, J = 2.8 Hz, 3H), 0.94 (d, J = 2.9 Hz, 3H);  
13C NMR (126 MHz, D2O) δ 182.62 (C=O), 99.77 (Gal-C1), 98.92 (Fuc-C1), 84.24 (MeCy-C2), 82.75 (Gal-
C3), 79.75 (Lac-C2), 78.68 (MeCy-C1), 74.17 (Gal-C5), 71.99 (Fuc-C4), 69.82 (Gal-C2), 69.27 (Fuc-C3), 
68.20 (Fuc-C2), 66.50 (Fuc-C5), 66.34 (Gal-C4), 61.73 (Gal-C6), 42.74, 38.75, 33.17, 30.31, 23.87, 22.67, 
22.58, 20.92 (8xC), 18.12 (MeCy), 15.55 (Fuc-C6);   
MS (ESI) m/z: calcd for C25H44NaO13 [M+H]+: 575.27; found: 575.28 
5) Compound 6 (9.6 mg, 0.016 mmol) in dry DMF (100 μL) was added KHCO3 (3.36 mg, 0.032 mmol) and 
EtI (2.68 μL) at 0°C. The reaction mixture was stirred at 4 °C for 24 hrs. The solvent was removed under 
high vacuum and the residue was purified by silica gel chromatography (DCM/MeOH, 9:1 - 6:1), the 
desired product was dissolved in acetonitrile/H2O and then filtered through 0.45 um filter, the filtrate 
was lyophilized to afford 5 (5.2 mg, 54%) as white foam. 
1H NMR (500 MHz, MeOD) δ 4.99 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.88 (q, J = 6.5 Hz, 1H, Fuc-H5), 4.39 (dd, J 
= 9.6, 3.9 Hz, 1H, Lactic-H2), 4.25 (d, J = 7.8 Hz, 1H, Gal-H1), 4.24 – 4.14 (m, 2H, CO2CH2CH3), 3.92 (d, J 
= 2.6 Hz, 1H, Gal-H4), 3.83 (dd, J = 10.3, 3.3 Hz, 1H, Fuc-H3), 3.75 – 3.61 (m, 6H, Fuc-H2, Gal-H6a, Fuc-
H4, Gal-H6b, Gal-H2, MeCy-H1), 3.39 (t, J = 6.0 Hz, 1H, Gal-H5), 3.25 (dd, J = 9.5, 3.2 Hz, 1H, Gal-H3), 
3.19 (t, J = 9.3 Hz, 1H, MeCy-H2), 2.12 – 2.09 (m, 1H, CHCH3CH3), 2.04 – 1.95 (m, 1H), 1.74 – 1.58 (m, 
4H), 1.54 – 1.46 (m, 1H), 1.34 – 1.21 (m, 3H), 1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.18 (d, J = 6.6 Hz, 3H, 
Fuc-H6), 1.13 (d, J = 6.3 Hz, 3H, MeCy), 1.38 – 1.23 (m, 1H),  0.97 (d, J = 6.6 Hz, 3H, CHCH3CH3), 0.95 (d, 
J = 6.7 Hz, 3H, CHCH3CH3);  
13C NMR (126 MHz, MeOD) δ 176.64 (C=O), 102.43 (Gal-C1), 100.48 (Fuc-C1), 84.67 (MeCy-C2), 83.86 
(Gal-C3), 79.96 (MeCy-C1), 79.20 (Lac-C2), 75.92 (Gal-C5), 73.83 (Fuc-C4), 72.17 (Gal-C2), 71.38 (Fuc-
C3), 70.34 (Fuc-C2), 68.65 (Gal-C4), 67.55 (Fuc-C5), 62.82 (Gal-C6), 62.24 (OCH2CH3), 43.79 
(CH3CH3CHCH2), 40.42 (Cy-C3), 34.94 (Cy-C4), 31.92 (Cy-C6), 25.37 (CH3CH3CHCH2), 24.22 (Cy-C5), 
23.68, 22.18 (CH3CH3CHCH2), 19.57 (CH3Cy), 16.72 (Fuc-C6), 14.47 (OCH2CH3);  
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MS (ESI) m/z: calcd for C27H48NaO13 [M+Na]+: 603.30; found: 603.32. 
 
 
 
Scheme S5 Reactions and reaction conditions: (i) i. Bu2SnO, MeOH, reflux, 3 h, ii. CsF, DME, r.t., 1 h, (90%); (ii) 
Pd(OH)2/MeOH, H2 balloon, rt, (87%); (iii) KHCO3/EtI/DMF, 0°C, 24 h, (70%). The synthesis of 18 was described by 
Norman et al. (2). 
22) A suspension of 18 (258 mg, 0.323 mmol) and Bu2SnO (96.73 mg, 0.388 mmol) in dry MeOH (5 mL) 
was refluxed for 3 h. The solvent was removed under reduced pressure and the resulting foam dried in 
vacuo 4 h. CsF (98 mg, 0.647 mmol) was dried in vacuo at 100°C for 30 min and flushed with argon. Then 
benzyl (R)-2-(((trifluoromethyl)sulfonyl)oxy)propanoate (152 mg, 0.485 mmol), CsF (98 mg) and DME 
(4.0 mL) were added to the tin acetal at rt. The reaction mixture was stirred at rt for 1 h. The solvent 
was removed under reduced pressure. The residue was purified by silica gel chromatography 
(petroleum ether/ethyl acetate, 6:4 - 1:1) to afford 22 (289 mg, 90%) as white foam.  
1H NMR (500 MHz, CDCl3) δ 7.57 (d, J = 7.4 Hz, 2H), 7.44 – 7.10 (m, 24H), 5.49 (s, 1H, PhCH), 5.19 (d, J = 
12.2 Hz, 1H, OCH2Ph), 5.10 (d, J = 12.2 Hz, 1H, OCH2Ph), 4.97 (d, J = 2.8 Hz, 1H, Fuc-H1), 4.85 (d, J = 6.5 
Hz, 1H, Fuc-H5), 4.82 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.71 (d, J = 11.7 Hz, 1H, OCH2Ph), 4.66 – 4.55 (m, 3H, 
Lactic-H2, OCH2Ph), 4.29 (d, J = 11.3 Hz, 1H, OCH2Ph), 4.27 – 4.24 (m, 3H, Gal-H6a, Gal-H1, Gal-H4), 3.97 
– 3.90 (m, 4H, Gal-H6b, Fuc-H3, Fuc-H2, Gal-H2), 3.65 (d, J = 11.2 Hz, 1H, OCH2Ph), 3.62 (m, 1H, Cy-H1), 
3.46 (dd, J = 9.8, 3.3 Hz, 1H, Gal-H3), 3.25 (m, 2H, Fuc-H4, Gal-H5), 3.20 (t, J = 9.5 Hz, 1H, Cy-H2), 2.44 
(s, 1H, 2-OH), 2.06 (m, 1H, Cy-H6a), 1.71 – 1.56 (m, 3H, Cy-H5a, Cy-H4a, Cy-H3), 1.53 (d, J = 6.9 Hz, 3H, 
Me-Lactic), 1.35 – 1.17 (m, 2H, Cy-H6b, Cy-H5b), 1.09 (d, J = 6.4 Hz, 3H, Me-Cy), 1.05 (d, J = 6.5 Hz, 3H, 
Fuc-H6), 1.07 – 0.98 (m, 1H, Cy-H4b); 
13C NMR (126 MHz, CDCl3) δ 173.62 (C=O), 139.62, 139.43, 138.64, 138.27, 135.60, 128.60, 128.42, 
128.32, 128.14, 128.06, 127.95, 127.86, 127.47, 127.38, 127.06, 126.86, 125.98 (Ar-C), 101.41 (Gal-C1), 
99.67 (PhCH), 98.46 (Fuc-C1), 82.20 (Cy-C2), 80.16 (Cy-C1), 79.60 (Fuc-C3, Gal-C3), 78.64 (Fuc-C4), 75.91 
(Lactic-C2), 75.53 (Fuc-C2), 75.20 (Gal-C4), 74.77 (OCH2Ph), 74.44 (OCH2Ph), 71.30 (OCH2Ph), 70.88 (Gal-
C2), 69.31 (Gal-C6), 66.60 (Gal-C5), 66.59 (OCH2Ph), 66.13 (Fuc-C5), 39.47 (Cy-C3), 33.67 (Cy-C4), 31.47 
(Cy-C6), 23.32 (Cy-C5), 18.78, 18.66 (Lactic-Me, Cy-CH3), 16.61 (Fuc-C6);   
MS (ESI) m/z: calcd for C57H66NaO13 [M+Na]+: 981.44; found: 981.61.  
10) A suspension of 22 (28.8 mg, 0.03 mmol) and Pd(OH)2/C (10 mg, 10% Pd) in MeOH (2.0 mL) was 
hydrogenated with H2 balloon at rt overnight. The reaction mixture was filtered through celite, the 
solvent was removed under reduced pressure. The residue was purified by silica gel chromatography 
(DCM/(MeOH:H2O, 10:1), 7:3 - 6:4), ion-exchanged with Dowex® Marathon™ C sodium form, then 
purified with reversed-phase column chromatography (RP-18, MeOH/H2O) to afford  10 (14 mg, 87%) 
as white solid.  
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1H NMR (500 MHz, MeOD) δ 5.00 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.86 (m, 1H, Fuc-H5), 4.31 (d, J = 7.8 Hz, 
1H, Gal-H1), 4.11 (q, J = 6.8 Hz, 1H, Lactic-H2), 3.93 (d, J = 2.6 Hz, 1H, Gal-H4), 3.85 (dd, J = 10.3, 3.3 Hz, 
1H, Fuc-H3), 3.78 – 3.58 (m, 6H, Gal-H6a, Fuc-H2, Fuc-H4, Gal-H6b, Cy-H1, Gal-H2), 3.43 (t, J = 5.8 Hz, 
1H, Gal-H5), 3.26 – 3.12 (m, 1H, Gal-H3), 3.21 (t, J = 9.3 Hz, 1H, Cy-H2), 2.12 (m, 1H, Cy-H6a), 1.74 – 1.56 
(m, 3H, Cy-H5a, Cy-H4a, Cy-H3), 1.43 (d, J = 6.9 Hz, 3H Me-Lactic), 1.40 – 1.22 (m, 2H, Cy-H6b, Cy-H5b), 
1.19 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.13 (d, J = 6.3 Hz, 3H, Me-Cy), 1.12 – 1.04 (m, 1H, Cy-H4b);  
13C NMR (126 MHz, MeOD) δ 181.17 (C=O), 102.25 (Gal-C1), 100.25 (Fuc-C1), 84.47 (Cy-C2),  83.97 (Gal-
C3),  79.93 (Cy-C1),  77.56 (Lactic-C2), 75.82 (Gal-C5),  73.82 (Fuc-C4),  71.38 (Fuc-C3),  71.23 (Gal-C2), 
70.32 (Fuc-C2),  67.78 (Gal-C4), 67.52 (Fuc-C5),   63.04 (Gal-C6), 40.34 (Cy-C3), 34.93 (Cy-C4), 31.87 (Cy-
C6), 24.20 (Cy-C5), 19.59 (CH3-Lactic, Cy-CH3), 16.76 (Fuc-C6);  
MS (ESI) m/z: calcd for C22H38NaO13 [M+H]+: 533.22; found: 533.22.  
9) Compound 10 (12 mg, 0.022 mmol) in dry DMF (225 μL) was added KHCO3 (3.6 mg, 0.044 mmol) and 
EtI (6.6 μL) at 0°C. The reaction mixture was stirred at 4 °C for 24 hrs. The solvent was removed under 
high vacuum and the residue was purified by silica gel chromatography (DCM/MeOH, 9:1 - 6:1) to afford 
9 (8.5 mg, 70%) as white foam.  
1H NMR (500 MHz, MeOD) δ 4.99 (d, J = 4.0 Hz, 1H, Fuc-H1), 4.88 (q, J = 6.5 Hz, 1H, Fuc-H5), 4.39 (q, J = 
6.9 Hz, 1H, Lactic-H2), 4.27 (d, J = 7.8 Hz, 1H, Gal-H1), 4.26 – 4.14 (m, 2H, CO2CH2CH3), 3.94 (d, J = 2.9 
Hz, 1H, Gal-H4), 3.84 (dd, J = 10.2, 3.3 Hz, 1H, Fuc-H3), 3.80 – 3.52 (m, 6H, Gal-H6a, Fuc-H2, Fuc-H4, 
Gal-H6b, MeCy-H1, Gal-H2), 3.40 (t, J = 6.0 Hz, 1H, Gal-H5), 3.31 – 3.27 (m, 1H, Gal-H3), 3.19 (t, J = 9.3 
Hz, 1H, MeCy-H2), 2.16 – 2.06 (m, 1H), 1.70 – 1.57 (m, 3H), 1.43 (d, J = 6.9 Hz, 3H, CH3CH), 1.38 – 1.23 
(m, 3H), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.18 (d, J = 6.6 Hz, 3H, Fuc-H6), 1.13 (d, J = 6.3 Hz, 3H, MeCy), 
1.07 – 1.03  (m, 1H);  
13C NMR (126 MHz, MeOD) δ 176.34 (C=O), 102.37 (Gal-C1), 100.43 (Fuc-C1), 84.56 (MeCy-C2), 83.95 
(Gal-C3), 80.02 (MeCy-C1), 76.65 (Lac-C2), 75.97 (Gal-C5), 73.83 (Fuc-C4), 71.87 (Gal-C2), 71.39 (Fuc-
C3), 70.34 (Fuc-C2), 68.44 (Gal-C4), 67.51 (Fuc-C5), 62.82 (Gal-C6), 62.31 (OCH2CH3), 40.41 (Cy-C3), 
34.93 (Cy-C4), 31.94 (Cy-C6), 24.22 (Cy-C5), 19.57 (CH3Cy), 19.13 (CHCH3), 16.74 (Fuc-C6), 14.44 
(OCH2CH3);  
MS (ESI) m/z: calcd for C24H42NaO13 [M+Na]+: 561.25; found: 561.45 
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Scheme S6 Reactions and reaction conditions: a) i. Bu2SnO, MeOH, reflux, 4 h; ii. 13, CsF, DME, rt, 18 h, benzylester 
14 = 58%, lactone 15 = 18%; b) NaOEt, MeOH, DCM, 0°C, 1h, 94%; after 2 steps; c) H2 (1 bar), Pd(OH)2/C, THF, rt., 
2 h, 69%; d) NaOH, H2O, rt, 2h, 85%. e) cyclohexylmethanol, DMAP, 80°C, 18h, 62%; f) H2 (1 bar), Pd(OH)2/C, THF, 
rt., 2 h, 78%; The synthesis of 18 was described by Norman et al. (2). 
 
Scheme S7 Reagent and conditions: a) i. Cl2, DCM, 0 °C, 0.5 h; ii. Ag2CO3, MeOH, rt, 2.5 h, 80% (2 steps); b) Ac2O, 
H2SO4, rt, 18 h, 81-90%; c) NH4OAc, DMF, rt, 18 h, 64% or 7N NH3 in MeOH, 0 °C 5 h, 60%; d) DBU, Cl3CCN, DCM, 
rt, 1.5 h, 81%; e) i. 4Å MS, TMSOTf, DCM, -18 °C to rt, 4 h; ii.  CH3ONa, CH3OH, rt, 1 h, 34% (2 steps); f) i. nBu2SnO, 
MeOH, reflux, 3 h, ii. CsF, DME, rt, 18 h, 25% (2 steps); g) cyclobutylmethanol/DMAP, 85 °C, 48 h, 70%; h) 
Pd(OH)2/C, THF, H2 balloon 14 (87%), 15 (92%). 
36) Compound 35 (16.0 mg, 0.016 mmol) and DMAP (2.1 mg) was dissolved in cyclobutylmethanol (0.2 
mL). The reaction mixture was stirred at 85°C for 48 hrs. The solvent was removed under high vaccum 
and the residue (11.6 mg) was used for next step without further purification. 
14) A suspension of 36 (11.0 mg, 0.011 mmol) and Pd(OH)2/C (3.2 mg, 10% Pd) in THF (3.0 mL) was 
hydrogenated with H2 balloon at rt for 2h. The reaction mixture was filtered through celite, the solvent 
was removed under reduced pressure. The residue was purified by silica gel chromatography 
(DCM/MeOH 19:1 - 9:1), the desired product was dissolved in acetonitrile/H2O and then filtered through 
0.45 um filter, the filtrate was lyophilized to provide 14(6.9 mg, 87%) as white fluffy solid. [a]D20 -32.0 
(c 0.18, MeOH);  
1H NMR (500 MHz, CD3OD) δ 5.24 (q, J = 6.5 Hz, 1H, Fuc-H5), 5.14 (d, J = 3.0 Hz, 1H, Fuc-H1), 4.47 (d, J 
= 8.4 Hz, 1H, Gal-H1), 4.29 (dd, J = 9.1, 3.4 Hz, 1H, Lactic-H2), 4.21 – 4.14 (m, 2H, OCH2cBu, Fuc-H4), 4.11 
(dd, J = 10.7, 6.8 Hz, 1H, OCH2CBu), 3.90 (m, 2H, Gal-H4, Fuc-H3), 3.86 – 3.79 (m, 2H, Fuc-H2, Gal-H2), 
3.76 (dd, J = 11.3, 6.9 Hz, 1H, Gal-H6a), 3.68 (dd, J = 11.3, 5.0 Hz, 1H, Gal-H6b), 3.66 – 3.57 (m, 1H, Cy-
H1), 3.48 (m, 2H, Gal-H5, Gal-H3), 3.39 (t, J = 9.3 Hz, 1H, Cy-H2), 2.66 (dt, J = 14.8, 7.4 Hz, 1H), 2.06 (m, 
4H), 2.00 – 1.86 (m, 3H), 1.78 (m, 5H), 1.53 (m, 2H), 1.42 – 1.17 (m, 3H), 1.06 – 0.95 (m, 7H), 0.91 (t, J = 
7.3 Hz, 3H); 13C NMR (126 MHz, CD3OD) δ 176.59 (C=O), 102.39 (Gal-C1), 100.06 (Fuc-C1), 85.52 (Gal-
C3), 81.64 (Cy-C1), 80.75 (Cy-C2), 79.50 (Lactic-C2), 76.00 (Gal-C5), 70.19, 69.95, 69.77, 69.25 (Fuc-C2, 
Fuc-C4, Fuc-C3, Fuc-C5), 68.37 (O OCH2cBu), 62.58 (Gal-C6), 61.25 (Gal-C2), 46.45, 44.03, 35.41, 32.01, 
29.81, 25.67, 25.62, 25.23, 24.77, 24.01, 23.66, 22.21, 19.16, 10.86 (14xC);  
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MS (ESI) m/z: calcd for C31H50ClF3NaO12 [M+Na]+: 729.28; found: 729.42. 
15) A suspension of 35 (2.7 mg, 0.0027 mmol) and Pd(OH)2/C (2.0 mg, 10% Pd) in THF (2.0 mL) was 
hydrogenated with H2 balloon at rt for 3 hrs. The reaction mixture was filtered through celite, the solvent 
was removed under reduced pressure. To the residue was added a drop of 1N NaOH aqueous solution 
and then purified with reversed-phase column chromatography (RP-18, MeOH/H2O) to afford 15 (1.65 
mg, 92%) as white solid.  
1H NMR (500 MHz, D2O) δ 5.29 (q, J = 6.4 Hz, 1H, Fuc-H5), 5.27 (d, J = 3.3 Hz, 1H, Fuc-H1), 4.69 (d, J = 
8.6 Hz, 1H, Gal-H1), 4.29 (d, J = 1.3 Hz, 1H), 4.00 (dd, J = 10.4, 3.4 Hz, 1H), 3.96 – 3.89 (m, 3H), 3.83 (dd, 
J = 10.0, 8.7 Hz, 1H), 3.79 – 3.71 (m, 3H), 3.71 – 3.68 (m, 1H), 3.66 (dd, J = 10.1, 3.1 Hz, 1H), 3.45 (t, J = 
9.6 Hz, 1H), 2.24 – 2.16 (m, 1H), 2.05 – 1.95 (m, 1H), 1.85 (m, 1H), 1.81 – 1.66 (m, 3H), 1.60 – 1.44 (m, 
2H), 1.42 – 1.30 (m, 2H), 1.24 (q, J = 13.1 Hz, 2H), 1.07 – 1.00 (m, 1H), 0.95 (d, J = 6.6 Hz, 3H), 0.94 (d, J 
= 6.7 Hz, 3H), 0.90 (t, J = 7.4 Hz, 3H); 
MS (ESI) m/z: calcd for C26H41ClF3NaO12 [M-Na]-: 637.22; found: 637.44. 
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Methods 
LogD7.4 determination (shake-flask method) 
 Equal amounts of TRIS-HCl buffer (0.1 M, pH 7.4) and 1-octanol were mixed and vigorously shaken for 
5 minutes to saturate the phases. The mixture was left until complete separation of the phases occurred 
and the buffer was retrieved. The stock solutions of test compounds (DMSO, 10 mM) were diluted to 
10 µM in saturated buffer (Final DMSO concentration; 0.1 %). The buffer was transferred to a 96-well 
plate and saturated 1-octanol was added, resulting in a 3/180 and 4/180 1-octanol to water ratio, 
respectively. Each ratio was measured in triplicate and simultaneous measurements were conducted 
with propranolol as control. The plate was sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) on 
a Heidolph Titramax 1000 plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Germany) 
and centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). The 
aqueous phase was transferred to a 96-well plate for analysis by liquid chromatography-mass 
spectrometry (LC-MS, see below). 
The logD7.4 coefficients were calculated from the 1-octanol:buffer ratio (o:b), the initial concentration 
of the analyte in buffer (10 µM), and the concentration of the analyte in buffer with Equation 1: !"#$%.' 	= !"#*+,	-./	01	01 ×	 +3:56   (eq. 1) 
Parallel artificial membrane permeation assay (PAMPA): 
Effective permeability (logPe) was determined in a 96-well format with PAMPA. For each compound, 
measurements were performed at pH7.4 in quadruplicate. Four wells of a deep well plate were filled 
with 500 µL PRISMA HT buffer (pH 7.4, pION P/N 110 151). Then, analyte dissolved in DMSO (10 mM) 
was added to the buffer to yield 50 µM solutions (Containing 0.5 % DMSO). To exclude precipitation, 
the optical density (OD) was measured at 650 nm, and solutions exceeding OD 0.01 were filtrated. 
Afterwards, 200 µL was transferred to each well of the donor plate of the PAMPA sandwich (pIon 
Billerica, USA, P/N 110 163). The filter membranes at the bottom of the acceptor plate were infused 
with 5 µL of GIT-0 Lipid Solution (pIon, P/N 110 669) and 200 µL of Acceptor buffer (pION, P/N 110 139) 
was filled into each acceptor well. The sandwich was assembled, placed in the GutBoxTM (pION), and 
left undisturbed for 16 h. Then, it was disassembled and the compound concentration of donor, 
acceptor and reference compartment was measured by LC-MS (see below). Effective permeability 
(logPe) was calculated from the compound flux deduced from the concentration in the donor and 
acceptor compartment as well as the retention in the filter area with the aid of the PAMPA Explorer 
Software (pIon, version 3.5) (4, 5). 
Caco-2 cell permeation assay 
Caco-2 cells were cultivated in tissue culture flasks (BD Biosciences, Franklin Lakes, NJ, USA) with DMEM 
high glucose medium, containing L-glutamine (2 mM), nonessential amino acids (0.1 mM), Penicillin 
(100 U/ml), Streptomycin (100 µg/ml), and fetal bovine serum (10%). The cells were kept at 37°C in 
humidified air containing 5% CO2, and the medium was changed every second day. When approximately 
90% confluence was reached, the cells were split in a 1:10 ratio and distributed to new tissue culture 
flasks. At passage numbers between 60 and 65, they were seeded at a density of 5.3 ´ 105 cells per well 
to Transwell 6-well plates (Corning Inc., Corning, NY, USA) with 2.5 ml of culture medium in the 
basolateral and 1.5 ml in the apical compartment. The medium was renewed on alternate days. 
Permeation experiments were performed between days 19 and 21 post seeding. Previous to the 
experiment, the integrity of the Caco-2 monolayers was evaluated by measuring the transepithelial 
electrical resistance (TEER) with an Endohm tissue resistance instrument (World Precision Instruments 
Inc., Sarasota, FL, USA). Experiments were performed in the apical-to-basolateral (absorptive) and 
basolateral-to-apical (secretory) directions in triplicates. Transport medium (DMEM without sodium 
pyruvate and phenol red) was withdrawn from the donor compartments of three wells and replaced by 
the same volume of compound stock solutions to reach an initial sample concentration of 62.5 µM. The 
transwell plate was then shaken (250 rpm) in the incubator. Samples (40 µl) were withdrawn after 15, 
30, and 60 min from the donor and acceptor compartments and the concentrations were determined 
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by LC-MS. Apparent permeability coefficients (Papp) were calculated according to Equation 2, where 
dQ/dt is the permeability rate, A the surface area of the monolayer, and c0 the initial compound 
concentration in the donor compartment. 
 7899 = :;:< ∗ +>∗0? (eq. 2) 
At the end of the experiment, TEER values were assessed again for each well and results from wells with 
values below 300 Ωcm2 were discarded (6). 
Simulated intestinal fluid stability assay 
Incubations were performed in triplicate in a 96-well format on an Eppendorf Thermomixer Comfort. 
The reaction mixture (270 µl) consisting of porcine pancreatin in TRIS-HCl buffer (0.1 M, pH 6.5) was 
preheated (37°C, 500 rpm, 10 min), and the incubation was initiated by adding 30 µl of compound 
solution (200 µM) in TRIS-HCl buffer. The final concentration of the compound was 20 µM, and the 
pancreatin concentration was 2.5 mg/ml. At the beginning of the experiment (t = 0 min) and after an 
incubation time of 5, 10, 20, 30, and 60 min, samples (40 µl) were transferred to 120 µl of ice-cooled 
MeOH and centrifuged (3600 rpm, 4 °C, 10 min). The supernatant was transferred to a 96-well plate for 
LC-MS analysis. The metabolic degradation was assessed as percentage remaining compound versus 
incubation time. The concentration of the free acid was measured by LC-MS as well. Negative control 
experiments were performed in parallel by incubating the compound in assay buffer. Positive control 
experiments were conducted simultaneously with 2b. 
Human liver microsomal stability assay 
Incubations were performed in triplicate in a 96-well format on an Eppendorf Thermomixer Comfort. 
The reaction mixture (270 µl) consisting of human liver microsomes, TRIS-HCl buffer (0.1 M, pH 7.4) and 
MgCl2 (2 mM) was preheated (37°C, 500 rpm, 10 min), and the incubation was initiated by adding 30 µl 
of compound solution (20 µM) in TRIS-HCl buffer. The final concentration of the compound was 2 µM, 
and the microsomal concentration was 0.125 mg/ml. At the beginning of the experiment (t = 0 min) and 
after an incubation time of 5, 10, 20, 40, and 60 min, samples (40 µl) were transferred to 120 µl of ice-
cooled MeOH and centrifuged (3600 rpm, 4 °C, 10 min). The supernatant was transferred to a 96-well 
plate for LC-MS analysis. The metabolic degradation was assessed as percentage remaining compound 
versus incubation time. The concentration of the free acid was measured by LC-MS as well. Negative 
control experiments were performed in parallel by preincubating the microsomes with the specific 
carboxylesterase inhibitor Bis(4-nitrophenyl)phosphate (1 mM) for 5 min before addition of the 
compound solution. Positive control experiments were conducted simultaneously with FimH ester 
prodrugs (7). 
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Recombinant carboxylesterases hydrolysis study 
Incubations were performed in a 96-deepwell on an eppendorf Thermomixer comfort. The reaction 
mixture (180 μl) consisting of human carboxylesterase 1b or human carboxylesterase 2 (Sigma Aldrich), 
TRIS-HCl buffer (0.1 M, pH 7.4), test compound and reference compounds was preheated (40°C, 500 
rpm, 10 min). Concurrently, controls experiments were performed with buffer. The incubation was 
initiated by adding 30 μl of the compound solution (200 μM) to TRIS buffer and human carboxylesterase 
1 or 2. The final concentration of the compound was 20 μM and the concentration of the 
carboxylesterase was 100 μg/ml. At time points 0, 10, 30, 60, 90 and 120 min 25 μl of samples was 
transferred to 75 μl of icecooled MeOH. After the last time point, the quenching plate was put in the 
freezer (10 min) and later centrifuged (4 °C, 3600 rpm, 10 min). On an agilent 96-well plate the 
supernatant was transferred for LC-MS analysis. The metabolic release was calculated as percentage 
remaining compound versus incubation time. 
Oxidation in rat liver microsomes assay 
Incubations were performed in triplicate in a 96-well format on an Eppendorf Thermomixer Comfort. 
The reaction mixture (240 µl) consisting of rat liver microsomes, TRIS-HCl buffer (0.1 M, pH 7.4), MgCl2 
(2 mM), Compound and Bis(4-nitrophenyl)phosphate (0.1 mM) was preheated (37°C, 500 rpm, 10 min), 
and the incubation was initiated by first adding 30 µl of compound solution (200 µM) in TRIS-HCl buffer 
and then adding 30 µl of nicotinamide adenine dinucleotide phosphate (NADPH, 10 mM). The final 
concentration of the compound was 20 µM, 1 mM NADPH and the microsomal concentration was 0.5 
mg/ml. At the beginning of the experiment (t = 0 min) and after an incubation time of 5, 10, 20, 40, and 
60 min, samples (40 µl) were transferred to 120 µl of ice-cooled MeOH and centrifuged (3600 rpm, 4 
°C, 10 min). The supernatant was transferred to a 96-well plate for LC-MS analysis. The metabolic 
degradation was assessed as percentage remaining compound versus incubation time. Control 
experiments were performed in parallel by preincubating the microsomes by not adding NADPH. 
Positive control experiments were conducted simultaneously with Midazolam. 
Hydrolysis in rat liver microsomes assay 
Assays were conducted according to human liver microsomal stability assay with 0.5 mg/ml rat liver 
microsomes and 20 µM compound concentration in the reaction mixture. 
Simultaneous oxidation and hydrolysis in rat liver microsomes assay 
Assays were conducted according to oxidation in rat liver microsomes assay in triplicate without adding 
BNPP to the reaction mixture. After 60 minutes the percentage of hydrolyzed molecule compared to 
the initial incubated prodrug was calculated.  
Glucoronidation in rat liver microsomes assay 
Incubations and sample taking were performed according to oxidations in rat liver microsomes. 15 
minutes prior measurements, Alamethicin and Saccharolactone was added. The incubation was initiated 
by first adding 30 µl of compound solution (200 µM) in TRIS-HCl buffer and then adding 30 µl of UDP-α-
D-glucuronic acid (UDPGA, 50 mM). The final concentrations were of the compound 20 µM, 5 mM 
UDPGA, 0.25 mg/ml Alamethicin, 1 mM Saccharolactone and the microsomal concentration was 0.5 
mg/ml. Control experiments were performed in parallel by preincubating the microsomes by not adding 
UDPGA. Positive control experiments were conducted simultaneously with Testosterone. 
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Sulfation in rat liver microsomes assay 
Incubations and sample taking were performed according to oxidations , butin rat liver cytosol. The 
incubation was initiated by first adding 30 µl of compound solution (200 µM) in TRIS-HCl buffer and then 
adding 30 µl of 3'-phosphoadenosine-5'-phosphosulfate (PAPS, 2 mM). The final concentrations were 
of the compound 20 µM, 0.2 mM PAPS. Control experiments were performed in parallel by 
preincubating the microsomes by not adding PAPS. Positive control experiments were conducted 
simultaneously with Hespericine. 
Metabolite screening and hydrolysis susceptibility  
A primary assay was conducted according to the oxidation in rat liver microsomes assay with 40 µM 
prodrug concentration and 2 mM NADPH. After 60 minutes, the complete reaction mixture was 
quenched in cold methanol in a 3 to 1 methanol to reaction mixture ratio. The mixture was concentrated 
in vacuo and resuspended in TRIS-HCl, to obtain a theoretical concentration of 100 µM of metabolite, 
assuming 100% oxidation occurred. Samples of this mixture were taken for metabolite analysis by LC-
MS. Additional samples were added to 0.5 M sodium hydroxide in a 1 to 1 ratio, and after 30 minutes, 
the reaction was neutralized to verify the place of oxidation by measuring the concentration of active 
principle.  Finally, the susceptibility of the metabolite was measured by incubating the mixture according 
to hydrolysis in rat liver microsomes assay with 0.5 mg/ml rat liver microsomes and a theoretical 
concentration of 10 µM metabolite. Over a time of 60 minutes, samples were taken analyzed for the 
active principle by LC-MS.  
Micro scale thermophoresis  
Reagents, devices and compounds. MonolithTM NT.115, Protein Labeling Kit BLUE-NHS (Amine Reactive), 
and Standard Treated Capillaries were purchased from Nanotemper Technologies GmbH (Munich, 
Germany). HEPES, NaOH, NaCl, CaCl2· 2H2O, and Tween 20 were purchased from Sigma-Aldrich Chemie 
GmbH (Steinheim, Germany). Slide-A-Lyzer cassettes (10 kDa MWCO) and bovine serum albumin (BSA) 
standard ampules were obtained from Thermo Fisher Scientific (Rockford, IL, USA): 
E-selectin production. Cloning, transfection, expression and purification were previously described for 
the E-selectinLEC2 construct by Preston et al. (8). 
Labeling. E-selectinLEC2 was labeled using the amine reactive protein labeling kit BLUE-NHS. Buffer 
exchange and labeling were performed according to the manufacturer’s protocol. To protect the 1ysines 
in the binding site from being labeled, the protein was saturated with 600 µM of compound 1. The 
labeled protein was dialyzed over night against assay buffer (10mM HEPES pH 7.4, 150 mM NaCl, 1 mM 
CaCl2) using Slide-A-Lyzer dialysis cassettes (10 kDa MWCO). Protein concentration was determined by 
HPLC-UV against a BSA standard.(9, 10) 
Microscale Thermophoresis. MST experiments were carried out at 25° C with 50% LED power, 30% MST 
power, a laser on time of 30 sec, and a laser off time of 5 sec using standard treated capillaries. Ligands 
were dissolved in assay buffer containing 0.05% v/v Tween 20. A 16-point dilution series of ligand 
starting at 0.5 mM for compound 1 and 3b at 2.5 mM, 4b at 5 mM, 5b at 20 mM and 6b at 0.25 mM 
was prepared and subsequently mixed 1:1 with a solution of 0.1 μM E-SelectinLEC2 and incubated for 10 
mins at room temperature. Datapoints were normalized using the bound and unbound borders 
achieved by NanoTemper Analysis 1.5.41 software (NanoTemper Technologies GmbH, Munich, 
Germany) and analyzed/illustrated with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). The 
measurements were globally fitted using Equation 3 for single site binding (11). 
 
 [PL]= (CP+ CL+KD) - B(CP+CL+KD) - 4CPCL
2CP
 (eq. 3) 
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Where [PL] is the protein-ligand complex concentration and KD is the dissociation constant. CP 
represents the total concentration of protein and CL the total concentration of ligand. 
In vivo pharmacokinetic studies 
Male and female Balb/c mice weighting between 19 and 25 g were obtained from Janvier (Labs Le 
Genest-Saint-Isle, France) and were housed 3 per cage. The mice were kept under specific pathogen-
free conditions in the Animal House of the Biozentrum, University of Basel, and animal experimentation 
guidelines according to the regulations of the Swiss veterinary law were followed. After 7 days of 
acclimatization, 8- to 14-week-old mice were used for the studies. Animals had free access to chow and 
water at any time except 2 hours prior dosage and were kept in a 12 h/12 h light/dark cycle. For 
administration volumes and sampling the good practice guidelines were followed. 
The pharmacokinetic studies were performed by intravenous (IV) administration of the active principle 
or ester prodrugs at a dosage of 20 mg/kg or oral dosage of 50 mg/kg of the ester prodrugs by oral 
gavage. The compounds were diluted in 0.9 % NaCl Solution and injected into the tail vein. Tween 80 
and DMSO was added to maximal 2%, respectively 5% if solubility problems occurred. Blood samples 
were obtained from the tail veins 7, 15, 30, 60, 90, min and 2 h after injection. Blood samples 
(approximately 20 µL) were transformed into tubes containing 1 µL 1 M EDTA solution and centrifuged 
at 2000 rpm for 10 minutes to obtain blood plasma. 5 µL of blood plasma was diluted in 50 µL cold 
MeOH containing 1 µM internal standarts to precipitate proteins. The supernatants were analyzed by 
LC-MS (See below). 
Liquid chromatography-mass spectrometry measurements (LC-MS)  
Analyses were performed using a 1100/1200 Series HPLC System coupled to a 6410 Triple Quadrupole 
mass detector (Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with electrospray ionization. 
The system was controlled with the Agilent MassHunter Workstation Data Acquisition software (version 
B.03.01). The column used was an Atlantis® T3 C18 column (2.1 x 50 mm) with a 3 µm-particle size 
(Waters Corp., Milford, MA, USA). The mobile phase consisted of eluent A: 10 mM ammonium acetate, 
pH 5.0 in 95:5, H2O: ACN; and eluent B: ACN containing 0.1% formic acid. The flow rate was maintained 
at 0.6 mL/min. The gradient was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 
5% A/95% B for 0.1 min. The system was then brought back to 95% A/5% B, resulting in a total duration 
of 4 min. Fragmentor voltage and collision energy were optimized for the analysis of compounds in 
multiple reaction monitoring mode in positive mode for ester prodrugs or negative mode for active 
principles. 
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3.8 Manuscript 2: Amidic E-selectin antagonists 
The bioisosteric replacement of the carboxylic acid of previously designed E-selectin 
antagonists is a promising approach. Not only the affinity, but also the pharmacokinetic 
properties of the compounds is enhanced. In this manuscript, the physicochemical and 
pharmacokinetic properties of amidic E-selectin antagonists is evaluated in vitro and in vivo 
with a focus on the observed active transport of the molecule. 
Contribution to the Project: 
Philipp Dätwyler designed and performed the assays of the pharmacokinetic evaluation in vitro 
and in vivo of the E-selectin antagonists. He further performed some affinity measurements by 
microscale thermophoresis and wrote the manuscript. 
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Abstract 
E-selectin is a C-type lectin expressed on endothelial cells of blood vessels adjacent to 
inflammatory stimuli. It interacts with structures containing the tetrasaccharide sialyl Lewisx 
(sLex) expressed on leukocytes, initiating the inflammatory adhesion cascade and the 
extravasation of the leukocytes to the side of inflammation. This process is highly regulated 
under physiological conditions, but alterations of the inflammatory adhesion cascade can lead 
to chronic inflammatory diseases. Previous developments of E-selectin antagonists starting 
from the natural ligand sLex led to non-orally bioavailable antagonists due to their hydrophilic 
core structure and a carboxylic acid. Herein, we present a lead development study with the 
goal to improve the pharmacokinetic properties of E-selectin antagonist by replacing the 
carboxylic acid with more lipophilic amides. Due to observed active uptake transport in 
enterocytes, the first orally bioavailable E-selectin antagonist with high affinity was 
developed. 
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Introduction 
Cell-cell adhesion mediated by C-type lectins plays a crucial role in the inflammation cascade 
(1). In prolonged inflammation E-selectin is the main mediator between the site of 
inflammation and leucocytes (2). E-selectin is expressed on the vascular endothelium at sites 
of inflammation and binds cell surface glycoproteins of leukocytes, inducing their rolling which 
leads to the arrest and extravasation on the side of inflammation (3). This recognition is 
necessary for the initiation of the inflammatory cascade and therefore for host defense. 
However, excessive amplification of this process is associated with various diseases with an 
inflammatory component (4, 5). Therefore, blocking E-selectin and hence, inhibiting the initial 
step of leucocyte extravasation is a potential treatment of various acute and chronic 
inflammatory diseases (6). 
The main motive recognized by E-selectin is the tetrasaccharide sialyl Lewisx (sLex), present on 
glycoproteins located on leukocytes (7). Several E-selectin antagonists with improved affinities 
and pharmacokinetic properties have been developed. Recent studies showed a positive 
effect of the intravenously applied pan-selectin antagonist Rivipansel for the treatment of 
vaso-occlusive crisis (VOC) in sickle cell anemia patients in a phase II study and GMI1271 in 
resistance multiple myeloma (MM) in mice (8, 9). VOC and MM are severe and acute 
conditions requiring intensive care therefore therefore intravenous (IV) administrations are 
tolerated. However, for chronic inflammatory diseases, an orally bioavailable treatment 
would be more convenient. Many different chronic diseases with a strong correlation to E-
selectin overexpression, such as arthrosclerosis, rheumatoid arthritis and psoriasis, still 
constitute an urgent unmet medical need (10-13).  
Carbohydrates as lead structures for oral bioavailable drug candidates have the inherent 
problems of a large polar surface area leading to high hydrophilicity (14). A consequent 
reduction of the polar motives not required for binding in sLex and replacing them by lipophilic 
residues led to the antagonist 1 (15). Compound 1 is still a highly hydrophilic and large 
molecule, containing two carbohydrate moieties. Additionally, the carboxylic acid leads to a 
charged molecule, which is not fulfilling the criteria for oral bioavailability. Since further 
reduction of the polarity or size of the molecule induces a loss in affinity, alternative 
approaches to reach sufficient lipophilicity and permeability are needed (16, 17). Replacing 
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the carboxylic acid by an uncharged bioisostere offers the opportunity to improve the 
pharmacokinetic profile of E-selectin antagonists. 
Methods 
A detailed description of methods and procedures, as well as the synthesis of compounds 2a-
p and 3 is presented in the supplementary data. 
Microscale thermophoresis: Cloning, transfection, expression and purification were 
previously described for the E-selectinLEC2 construct by Preston et al. (17). Microscale 
thermophoresis (MST) experiments were carried out at 25° C with 50% LED power, 30% MST 
power, an initial delay of 5 sec, a laser on time of 30 sec, and a laser off time of 5 sec using 
standard treated capillaries and a 16 point dilution series. 
LogD7.4: The lipophilicity of molecules was assessed in sexduplicate at two different octanol-
buffer ratios at pH 7.4. The octanol-buffer ratio and reference compound were chosen 
individually to minimize the inherent error of the assay. 
Parallel artificial membrane permeation assay (PAMPA): Passive permeability of the 
molecules was measured at room temperature and pH 7.4 in quadruplicate. The starting 
incubation concentration was 25 µM and the incubation time was 16 h (unstirred). The 
evaluation was done according to Avdeef et al. (18).  
Caco-2 cell based permeation assay: Experiments were run 21 days after seeding the Caco-2 
cells on transwell plates in triplicate for the absorptive (Uptake) and secretory (Efflux) 
direction. The initial concentration of the incubation was 62.5 µM and samples were taken 
after 30 min incubations. The evaluation was done according to Hubatsch et al. (19) and Hou 
et al. (20). 
Solubility: The thermodynamic solubility of the molecules was determined in aqueous Tris-
HCl buffer (0.1 M pH 7.4) in triplicate. After adding the solution to solids, the mixture was put 
on ultrasonification for 30 minutes and after 24 h, the mixture was filtered. 
Metabolic stability: The metabolic stability of compound 2l was assessed in rat liver 
microsomes at a concentration of 0.5 mg/ml and compound concentration of 20 µM in 
triplicate. The reaction was initiated by adding the co-factor β-nicotinamide adenine 
dinucleotide phosphate (NADPH) to a final concentration of 1 mM. After 60 minutes, the 
incubation was stopped by adding ice-cold methanol. 
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Animal oral bioavailability studies: The oral bioavailability of compounds was assessed in 
male and female 8 to 12 week Balb/C mice. The formulation of the compound was done 
according to Thackaberry et al. to minimize acute toxic effects (21). The formulated compound 
was given either by an oral gavage and or by intravenous injection in triplicate and 
concentrations in the blood plasma was measured over a period of 3 h. The evaluation was 
done with PKSolver, using a one compartment model (22). The studies were permitted by the 
Swiss government (Animal study Nr. A 2865) and guidelines according to the regulations of 
the Swiss veterinary law were followed. 
Results and discussion 
By a consequent reduction of the polar surface area of sLex, compound 1 was obtained by 
Norman et al. (15). Compound 1 is still a highly hydrophilic and large molecule, containing two 
carbohydrate moieties and a carboxylic acid. Accordingly, the measured logD7.4 is below -1.5 
leading to insufficient passive permeation. Forming amidic bioisosteres allows the 
replacement of the charged carboxylic acid with a neutral moiety and furthermore to 
introduce larger lipophilic residues. Figure 1 summarizes different amidic derivatives 2a-p, 
which were screened for their affinity towards E-selectin and permeability properties (Table 
1).  
 
Figure 1 E-selectin antagonist 1 and different amidic bioisosteres thereof (2a-p). 
Replacement of carboxylate in 1 by an amide (®2a) induces a 3-fold decrease of affinity 
towards E-selectin, but an increase of logD7.4 close to zero. A further aliphatic elongation does 
not only improve the lipophilicity of the compounds, but also the affinity. Especially the 
cyclobutylamine 2e and further lipophilic derivatives thereof at position 2’ of the ring improve 
the affinity to E-selectin to the range of 15 to 25 µM. Only the flexible elongations in 
compound 2m led to a reduced affinity. Furthermore, these lipophilic residues increased the 
logD7.4 to measured values above 2.0. A logD7.4 value between 2 and 3 is considered to be 
optimal for membrane permeability of small molecules (23). Therefore, the passive 
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permeation properties of the molecules were tested in a PAMPA (24). Although the 
lipophilicity increases with the size of the amidic residue, none of the molecules were 
sufficiently permeating the artificial membrane to predict a moderate to high absorption 
potential and no correlation between the lipophilicity and permeability was observed (Figure 
2A, A) (18). Selected molecules showing good affinity or high lipophilicity were furthermore 
tested in a Caco-2 cell based permeation assay in the absorptive (uptake) or secretory (efflux) 
direction in order to assess their absorption potential and active transport. Surprisingly, 2h, 
2k and 2m showed sufficient uptake indicating a moderate absorption potential. Furthermore, 
compound 2h and 2l are actively taken up with an uptake ratio above 2.0. Both molecules 
consist of a terminal isopropyl moiety, similar to the terminal position of the amino acid L-
valine. Di- and tripeptides including L-valine, as well as L-valin ester prodrugs are known to be 
actively taken up by enterocytes over the Pept1-transporter (25, 26). To verify the active 
transport, the Caco-2 transport assay was performed with 2h and co-incubation of 2 mM 
enalapril, a known inhibitor of Pept1 (27). This led to a reduction of the uptake ratio to 1.9 ± 
0.5, which is below the threshold for a predicted active transportation. Therefore, we assume 
that Pept1 is major contributor for the observed active transport of 2h and 2l in the Caco-2 
cell based transport assay.  
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Table 1 Pharmacodynamic and pharmacokinetic properties of E-selectin antagonists. The affinities of the E-
selectin antagonists were measured by microscale thermopheresis. Octanol-water distribution coefficients 
(logD7.4) were determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. The effective 
permeability (logPe) through an artificial membrane was determined by the PAMPA in quadruplicate at pH 
7.4.The thresholds for moderate and high absorption potential are -6.3 and -5.7, respectively (18). The apparent 
permeation (Papp) through a cell monolayer was assessed by a Caco-2 cell assay in the absorptive (apical to 
basolateral, Uptake) and secretory (basolateral to apical, Efflux) directions in triplicates and the uptake ratio was 
determined by dividing uptake by efflux. Thresholds for moderate and high absorption potential for the 
absorptive direction are 2 and 20 *10-6 cm/s (20). Uptake ratio was calculated by dividing uptake AB by efflux BA 
Compound showing an uptake ratio of 2.0 or more are considered to show active uptake (19). The given ranges 
are standard deviation.  
Cpd. Affinity KD MST 
[µM] 
(95% CI) 
logD7.4 PAMPA 
logPe 
 
Caco-2, Papp [10-6 cm/s] 
uptake AB efflux BA uptake ratio 
AB/BA 
1 60.7 (52.2-70.6) < -1.5 < -10    
2a 166 (145-189) -0.3 ± 0.1 -8.5 ± 0.3    
2b 112 (98.6-128) -0.2 ± 0.1 -8.5 ± 0.3    
2c 107 (93.5 -127) 0.4 ± 0.0 -7.6 ± 0.1    
2d 32.6 (30.2-39.5) 0.3 ± 0.0 -8.4 ± 0.3    
2e 18.2 (14.9-19.3) 0.1 ± 0.1 -7.5 ± 0.3    
2f 20.5 (17.7-25.8) 0.7 ± 0.1 -7.5 ± 0.1    
2g 21.5 (16.7-27.7) 1.3 ± 0.1 -8.6 ± 0.4 0.08 ± 0.01 0.14 ± 0.03 0.6 ± 0.2 
2h 23.4 (15.4-35.6) 1.4 ± 0.1 -8.2 ± 0.2 5.6 ± 0.7 1.15 ± 0.33 4.8 ± 1.9 
2i 38.2 (32.4-45.7) 1.4 ± 0.1 -9.3 ± 0.5    
2j 15.3 (13.1-17.9) 0.8 ± 0.0 < -10.0    
2k 23.6 (16.7-33.5) 1.1 ± 0.1 -8.5 ± 0.2 8.9 ± 1.6 4.8 ± 4.4 1.9 ± 2.1 
2l 15.0 (13.1-17.4) 1.2 ± 0.1 -9.3 ± 0.5 0.8 ± 0.2 0.25 ± 0.05 3.3 ± 0.7 
2m 45.9 (34.13-61.8) 1.9 ± 0.1 -8.5 ± 0.2 6.6 ± 1.4 7.3 ± 7.8 0.9 ± 1.2 
2n 16.2 (12.9-20.3) 2.3 ± 0.1 -8.5 ± 0.3 1.0 ± 0.3 1.18 ± 0.08 0.8 ± 0.4 
2o 22.4 (17.2-29.0) 2.3 ± 0.1 -8.4 ± 0.3 0.09 ± 0.03 0.50 ± 0.07 0.2 ± 0.1 
2p  2.5 ± 0.1 -7.0 ± 0.1 0.31 ± 0.02 1.10 ± 0.10 0.3 ± 0.1 
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Figure 2 A The logD7.4 of amidic E-selectin antagonists 2a-p versus the effective permeation logPe measured in 
PAMPA. Thresholds for moderate and high absorption potential are indicated as dotted lines and the range is 
given as standard deviation. B The apparent permeation logPapp is measured in a Caco-2 cell based permeation 
assay. Thresholds for moderate and high absorption potential are indicated as dotted lines and the range is given 
as standard deviation. 
To verify the observed permeability predicting either an active uptake or a moderate passive 
absorption potential, the oral bioavailability of E-selectin antagonists was tested in a mouse 
model (Table 2). Compound 2n was used as reference, since it was not sufficiently permeable 
even though its high lipophilicity. Besides the reference compound 2n, the oral bioavailability 
of 2k was below the detection limit. Overall, none of the compounds predicted to have 
moderate absorption potential in the Caco-2 cell based assay showed oral bioavailability 
above 3%. Only compound 2l has an oral bioavailability of 7.7 %, although it did not show 
sufficient permeability in both permeation assays.  
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Table 2 Oral bioavailability and plasma half life (t1/2, after IV injection) of amidic E-selectin antagonists in mice. It 
was assessed by comparing the area under curve (AUC) of the blood plasma concentration in mice after 
intravenous injection (IV) and oral gavage (PO) in triplicate. Errors given are the standard deviation. 
Cpd. t1/2 
[min] 
Oral bioavailability (F) 
[%] 
2h 7.5 ± 2.1 1.6 ± 0.8 
2k 8.2 ± 0.4 < 0.5 
2l 10.3 ± 2.0 7.7 ± 0.3 
2m 5.0 ± 1.4 2.0 ± 1.5 
2n 8.4 ± 1.7 < 0.5 
 
Based on these data, the terminal cyclobutylamine-2-isoproxy moiety was chosen as preferred 
amidic replacement of the carboxylic acid. Furthermore, the stability against oxidation by 
cytochrome P450 metabolic enzymes in rat liver microsomes as well as the solubility in 
aqueous solution of 2l was assessed. With a solubility of 1.5 ± 0.1 mg/ml and a stability of 88 
± 3 % of starting concentration remaining after 60 minutes incubating in liver microsomes, 
compound 2l met the required pharmacokinetic properties for further investigations. 
Furthermore, other structural modifications known to enhance the affinity of E-selectin 
antagonists were implemented to form compound 3 (Figure 3A). The hydroxyl group at 2- 
position of galactose was replaced by chloride (manuscript 5), the cyclohexyl linker between 
the galactose and the fucose moiety was stabilized by adding an ethyl moiety (16), and the 
fucose was trifluorinated at the 6-position to improve the internal no-conventional hydrogen 
bond (manuscript 3). All three structural changes are enhancing the lipophilic character of the 
molecule, leading to a measured logD7.4 of 3.6 and improved passive permeation in PAMPA 
(Table 3). Unfortunatelly, those changes lead also to a dramatically reduced solubility and an 
active efflux in the Caco-2 cells assay. However, despite the active efflux, an oral bioavailability 
of 4.3 ± 0.3 % was reached.  
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Figure 3 A Compound 3 with implemented modification to improve affinity. B Oral bioavailability of amidic E-
selectin antagonist 3 in mice. Intravenous injection (IV) and oral gavage (PO) were given in triplicate. Error bars 
are given as standard deviation. 
Table 3 Pharmacodynamic and pharmacokinetic properties of E-selectin antagonist 3. The E-selectin affinity was 
measured by isothermal titration calorimetry (ITC). Octanol-water distribution coefficients (logD7.4) were 
determined at pH 7.4 by a miniaturized shake flask procedure in sextuplicate. The effective permeability (Pe) 
through an artificial membrane was determined by the PAMPA in quadruplicate at pH 7.4. The apparent 
permeation (Papp) through a cell monolayer was assessed by a Caco-2 cell assay in the absorptive (apical to 
basolateral, Uptake) and secretory (basolateral to apical, Efflux) directions in triplicates and the uptake ratio was 
determined by dividing Uptake by Efflux. The oral bioavailability was assessed by comparing the AUC of the 
concentration in blood plasma in mice after intravenous injection (IV) and oral gavage (PO) in triplicate. All ranges 
given are as standard deviation. 
Cpd Affinity 
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Conclusions  
By replacing the carboxylic acid moiety of E-selectin antagonists by more lipophilic amides, 
not only the pharmacodynamic, but also the pharmacokinetic properties were enhanced. A 
simple addition of lipophilic moieties was not sufficient to improve the permeability of the 
antagonists, since the core structure fails the established the rules of Lipinski et al. (28) and 
Veber et al. (29) to predict oral bioavailability. Even though the antagonists showed 
insufficient passive permeability, specific amidic replacements lead according to the Caco-2 
cell assay to active uptake. In the case of the cyclobutylamine-2-isoproxy moiety (® 2l), the 
active uptake resulted in a 7 % oral bioavailability in mice. When additional structural 
modifications were implemented to improve the affinity (2l ® 3), oral bioavailability although 
to a slightly reduced proportion was observed. To our knowledge, this is the first reported 
highly affine and oral bioavailable E-selectin antagonist. 
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3.9 Manuscript 3: Non-conventional hydrogen bond  
The core of sialyl Lewisx is stabilized by an intramolecular non-conventional hydrogen bond 
formed between H-C5 of the L-fucose moiety and O5 of D-galactose. By replacing the methyl 
group in the 5-position of L-Fuc by the electron-withdrawing CF3-group, the polarization of the 
neighboring H-C is increased and thus leading to an increased quality of the non-conventional 
hydrogen bond. This is expected to have an impact on the affinity and physicochemical 
properties of newly synthesized E-selectin antagonists.  
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Introduction 
Hydrogen bonding is important in many chemical processes. It is responsible for water's unique 
solvent capabilities, for holding complementary strands of DNA together, and for determining 
the three-dimensional structure of folded proteins including enzymes and antibodies (1-3). 
Principally, a hydrogen bond is formed between a proton donor AH containing an 
electronegative donor atom A and an acceptor B exhibiting at least one lone pair of electrons. 
Although the electronegativity of carbon and hydrogen are almost identical, there were some 
early suggestions that C-H groups can form weak, so-called non-classical or non-conventional 
hydrogen bonds when sufficiently activated by adjacent electronegative substituents (4-6). 
Some years ago, we discovery by NMR experiments that the trisaccharide core of Lewisx (1, Lex, 
Figure 1A) is stabilized by an intramolecular non-conventional hydrogen bond formed between 
H-C5 of the L-fucose moiety and O5 of D-galactose. Quantum mechanical calculations exhibited 
that the C−H···O hydrogen bond represents approx. 40% of the total energy stabilizing the Lex 
core (7). The remaining stabilizing energy is contributed by the exo-anomeric effects reducing 
the conformational flexibility of the glycosidic bonds, a repulsion exerted by the N-acetate 
group of D-GlcNAc pushing the L-Fuc moiety underneath D-Gal and finally a strong stacking 
interaction between L-Fuc and the D-Gal (Figure 1A) (8, 9). These findings were later confirmed 
by Battistel et al. based on long range HSQC NMR experiments (10). Recently, we reported that 
non-conventional hydrogen bonds are not limited to the Lewis core but stabilize a wide range 
of fucosylated glycoepitopes and thereby constitute a general secondary structural element 
stabilizing carbohydrate conformations (11). 
Intrigued by this observation, we planned to further enhance the strength of the non-
conventional hydrogen bonds donated by H-C5 by appropriate substitution of L-fucose. We 
selected sialyl Lewisx (2, sLex, Figure 1B) as model compound because of its important role as 
ligands of E- and P-selectin in inflammatory diseases, e.g. ischemia-reperfusion injuries, asthma, 
or psoriasis (12-14). Blocking the selectin-leukocyte interaction with selectin antagonists was 
shown to have a significant therapeutic impact (15-17). 
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Figure 1 A Trisaccharide Lewisx (1) stabilized by exoanomeric effects, repulsion between the NAc-group of D-
GlcNAc and L-fucose, a strong stacking interaction between the L-Fuc and the D-Gal moiety and the non-
conventional H-bond C5Fuc-H···O5Gal, (7-9). B Sialyl Lewisx (2), the tetrasaccharide epitope recognized by selectins; 
pharmacophores are highlighted in red. C E-selectin antagonists with an electron-withdrawing CF3-group in the 5-
position of L-Fuc moiety (3 - 7) exhibiting improved non-conventional H-bonds between H-C5Fuc  and O-5Gal. 
However, due to the shallow binding site of E- and P-selectin and the considerable distances 
between the pharmacophores (Figure 1B, highlighted in red), their pre-organization in the 
bioactive form turned out to be a prerequisite for high binding affinity (9, 18-21). In order to 
further stabilize the Lex core and therewith the degree of pre-organization, we replaced in the 
current study the methyl group in the 5-position of L-Fuc by the electron-withdrawing CF3-
group. This is expected to increase the polarization of the neighboring H−C(5) bond, and thus 
the quality of the non-conventional hydrogen bond (Figure 1C). 
Results 
For the chemical syntheses of the sLex mimetics 3 - 7 we primarily used a 2+2 strategy, i.e. 
Fucα1-3GlcNAc mimetics were glycosylated with a D-galactosyl donor carrying (1S)-carboxy-2-
cyclohexylethyl in its 3-position (22). Only for antagonist 5 a linear approach was applied, i.e. 
starting from a GlcNAc mimic the subunits were introduced one by one. For comparison 
purposes, analogs equipped L-fucose instead of 6,6,6-trifluoro-L-fucose were prepared as well 
(23). 
Synthesis of 6,6,6-trifluoro-L-fucose. A previous reported preparation of 6,6,6-trifluoro-L-
fucose afforded a mixture of furanose and pyranose derivatives (24). To prevent the undesired 
formation of the furanose form, a strategy used for the synthesis of the trifluoromethyl analog 
of L-rhamnopyranose was applied, yielding 2,3,4-tribenzyl-6,6,6-trifluoro-L-fucose (9) starting 
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from D-lyxose (8) in an overall yield of 12% (Scheme 1, see also Supplementary Information) 
(25).  
Synthesis of trifluorinated sLex mimetics. For the synthesis of disaccharide mimics 13a-c and 
15a,b (Scheme 1), 2,3,4-tribenzyl-6,6,6-trifluoro-L-fucose (9) was transformed into an α/β-
mixture of the glycosyl donor 10 using Cl3CCN in the presence of K2CO3 at 0 °C. Fucosylation of 
the non-cyclic acceptors 11a-c and cyclic acceptors 12a,b promoted with TBSOTf in DCM/1,4-
dioxane yielded mainly the α-fucosides 13a-c, 15a and, via the TBS-protected 14b, the 
pseudodisaccharide 15b.  
 
Scheme 1 a) Cl3CCN, K2CO3, DCM, 0 °C, 18 h, (90%, α/β = 1:4); b) i. 11a-c, TBSOTf, DCM/1,4-dioxane (1:2), 4 Å mol. 
sieves, 0 °C to rt, 18 h; ii. NaOMe, MeOH/DCM (1:1), rt, 3 h, (13a: 42%, 13b: 50%, 13c: 41%, 2 steps); c) 12a 
(excess), TBSOTf, DCM, 4 Å mol. sieves, 0 °C to rt, 18 h, (15a: 56%) or 12b, TBSOTf, DCM/1,4-dioxane (1:2), 4 Å 
mol. sieves, 0 °C to rt, 18 h (14b), d. HF-py, MeCN, 0 °C, 48 h, (15b: 50%, 2 steps). 
For the synthesis of the test compounds 3 - 5 (Scheme 2), two different strategies were applied. 
In the first strategy, the pseudodisaccharides 13a,b were galactosylated with donor 16 using 
DMTST as promotor (17a,b) (26). Deprotection yielded the test compounds 3 and 4. In a second 
approach, pseudodisaccharide 13c was first galactosylated with donor 18 followed by alkylation 
of the 3’-position with triflate 20 (27, 28). Final deprotection by catalytic hydrogenation yielded 
the test compound 5.  
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Scheme 2 a) DMTST, DCM, 4 Å mol. sieves, rt, 24 h, (17a: 75%, 17b: 87%); b) i. H2 (1 bar), Pd(OH)2/C, THF, rt, 2 h, 
ii. LiOH/MeOH (1:1), H2O, 60 °C microwave, 10 h, (3: 45%, 4: 55%,); c) i. DMTST, DCM, 4 Å mol. sieves, rt, 18 h; ii. 
NaOMe, MeOH/DCM (1:1), rt, 18 h, (82%, 2 steps); d) Bu2SnO, MeOH, reflux, 4 h; 20, CsF, DME, rt, 18 h (45%); e) 
H2 (1 bar), Pd(OH)2/C, THF, rt, 2 h, (5: 33%). 
Finally, the synthesis of sLex mimetics containing cyclohexane-1,2-diol or 1-methyl-
cyclohexane-2,3-diol instead of GlcNAc is described in scheme 3.  
 
Scheme 3 a) DMTST, DCM, 4 Å mol. sieves, rt, 24 h, (22a: 68%, 22b: 46%); b) i. H2 (1 bar), Pd(OH)2/C, THF, rt, 2 h, 
ii. LiOH/MeOH (1:1), H2O, 60 °C microwave, 10 h, (6: 69%, 7: 40%); c) i. H2 (1 bar), Pd(OH)2/C, THF, rt, 2 h, ii. 
NaOMe, MeOH, 3 h, rt, (23: 40%, 24: 34%). 
Affinity determination by microscale thermophoresis. With the microscale thermophoresis 
assay (MST) dissociation constant (KD) can be determined based on the thermophoretic 
behavior of E-selectin in the presence of different amounts of antagonist (29). For better 
comparison purposes, the analogues 25 - 30 containing natural L-fucose were tested alongside 
with the new antagonists 3 - 7 (Table 1). In both series, 3 - 7 (containing 6,6,6-trifluoro-L-fucose) 
and 25 - 30 (containing L-fucose), the apparent affinity gains clearly demonstrate the beneficial 
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contribution of the pre-organization of the Lex core mimics to affinity (9, 26). However, MST 
measurements revealed that selectin antagonists with a CF3-group performed better compared 
to their counterparts without the modification on the L-fucose moiety. Finally, a benzoyl group 
in 2’-position led to a 3-fold improvement of affinity (see e.g. Table 1, entry 7 vs. entry 9), most 
probably because of an improved pre-organization of the acid pharmacophore (see 
Supplementary Information, Figure SQ). The beneficial effects from the individual SAR 
observations, i.e. a constrained linker, an improved non-conventional hydrogen bond and an 
improved pre-organization of the acid moiety proved to be additive and surmount to a gain of 
affinity by a factor of 2000 when realized in one molecule (see 25 vs. 24).  
Table 1 Affinities for E-selectin (Lec-EGF-SCR2) were determined by a microscale thermophoresis (MST) assay (30); 
25 & 27-31 have been published earlier; a)for the synthesis of 26 see supplementary information. 
 
Entry Ligand Spacer R1 R2 KD [μM] Improvement 
1 3 
 
CF3 H 879 5.6-fold 
2 25(31) CH3 H 4922 
3 4 
 
CF3 H 161 3.1-fold 
4 26a) CH3 H 499 
5 5 
 
CF3 H 55.6 2.7-fold 
6 27(26) CH3 H 150 
7 6 
 
CF3 H 21.5 2.8-fold 
8 28(20) CH3 H 60.7 
9 23 CF3 Bz 7.2 2.6-fold 
10 29(31) CH3 Bz 19.1 
11 7 
 
CF3 H 5.2 2.6-fold 
12 30(9) CH3 H 13.7 
13 24 CF3 Bz 2.4 1.8-fold 
14 31(9) CH3 Bz 4.3 
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Chemical shift as an indicator for proximity (Table 2). The 1H chemical shift of H5 of the fucose 
moiety containing either CH3 or CF3 at the 5-position was monitored as a reporter for the 
strength of the non-conventional H-bond between H-C5Fuc and O5Gal as this values is highly 
sensitive to the distance of the investigated H-bond interaction and represents a population-
weighted average of all conformations present in solution (9, 31).  
Table 2 Comparison of the H5 chemical shifts of the 6,6,6-trifluoro-L-fucosyl moiety (3-7) and the fucosyl moiety 
(25-28, 30). For the full chemical shift assignments see Supplementary Information and Ref 41 (for methyl α-L-
fucoside 32).  
Entry Linker Compound 
δ [ppm] of 
H5Fuc 
Δδ [ppm] 
rel. to 32  
Compound 
δ [ppm] of 
H5trifluorFuc 
Δδ [ppm] 
rel. to 33 
1 - 
 
3.93   - 
 
4.19 - 
2 
 
25 4.12(31) 0.19 3 4.57 0.38 
3 
 
26 4.16 0.23 4 4.58 0.39 
4 
 
27 4.35(26) 0.42 5 4.87 0.68 
5 
 
28 4.50(26) 0.57 6 5.10 0.91 
6 
 
30 4.84(9) 0.91 7 5.32-5.38 1.13-1.19 
 
In the L-Fuc series, the chemical shift of H5Fuc for both antagonists with the non-cyclic linkers, 
i.e. with 1,2-ethandiol (25) and (2R)-1,2-propandiol (26) (entry 2 and 3), exhibits values almost 
identical to methyl L-fucoside (32) (entry 1), indicating that the fraction of conformations 
exhibiting a close proximity between H-C5Fuc and O5Gal is low. In contrast, in the trifluoro-L-Fuc 
series, a powerful downfield shift of almost 0.5 ppm compared to 6,6,6-trifluoro-α-L-fucoside 
(33) indicates that the fraction of conformations stabilized by the non-conventional H-bond is 
substantially increased (3 & 4), or in other words the average H-bond distance substantially 
decreased. An additional restriction of the conformational flexibility by introducing the (2R,3R)-
2,3-butanediol linker (entry 4) and to an even larger extent, by cyclic D-GlcNAc replacements 
(entry 5 and 6) induced substantial downfield shifts of the H5Fuc signal in both series. In these 
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cases, the spatial proximity of H5Fuc and O5Gal is further pronounced, indicating an increased 
pre-organization of the antagonists in the bioactive conformation. Thus, the polarization of the 
H-C5 bond induced by the electron withdrawing potential of the CF3-group likely leads to a 
strengthening of the non-classical H-bond. In summary, by improving the pre-organization of 
the core of sLex-derived E-selectin mimetics, we achieved an almost 1’000-fold improvement 
of the dissociation constants KD when the flexible L-fucose derivative 25 (Table 1, entry 2) is 
compared with the rigid, CF3-analogue 7 (entry 11).  
Isothermal Titration Calorimetry (ITC, Table 3). The substitution of the methyl group (C6) by an 
electron withdrawing trifluoromethyl group (30 ® 7) polarizes the adjacent hydrogen at 
5-position of L-Fuc and thereby improves the core pre-organization. In ITC experiments, this 
effect is observed as a decreased entropic cost (30 ® 7; -TΔΔS° = -1.6 kJ mol-1) upon binding as 
well as an enthalpic gain (30 ® 7; ΔΔH° = -1.0 kJ mol-1), most likely due to improved protein–
ligand interactions. Furthermore, larger size of the trifluormethyl group might also better shield 
the Ca2+ cavity, lowering the local dielectric constant and therefore strengthening the existing 
electrostatic interactions. 
Table 3 Thermodynamic parameters of E-selectin binding to sLex (2) and glycomimetic antagonists (7 & 30) 
determined by isothermal titration calorimetry (ITC). All measurements were carried out at 298.15 K. Affinities 
measured with microscale thermophoresis (MST) are shown for comparison.  
Cpd. 
 MST: KD 
[μM] 
ITC:  KD 
[μM] 
ΔG° 
[kJ mol-1] 
ΔH° 
[kJ mol-1] 
-TΔS° 
[kJ mol-1] 
2 sLex 739 778 -17.7 4.9 -22.6 
30 
 
13.7 17.8 -27.1 -5.9 -21.2 
7 
 
5.2 6.39 -29.6 -6.9 -22.8 
 
C-H···O non-conventional hydrogen bond confirmed by molecular dynamics (MD) simulations 
and ab initio calculations. The pairwise analysis of preferred conformations of derivatives 3 & 
25, 6 & 28, and 7 & 30 obtained from 0.48 µs MD simulations resulted in a consistent shortening 
of the average FucH5-GalO5 distance when the methyl group of L-Fuc was replaced by a CF3 
group from 5.84 Å in 25 to 5.72 Å in 3, from 2.98 Å in 28 to 2.84 Å in 6, and from 2.84 Å in 30 
OH3C
HO
OH
OH
OF3C
HO
OH
OH
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to 2.69 Å in 7. This correlates well with the trend in measured chemical shifts of FucH5 
(increased deshielding with shorter FucH5-GalO5 distance).  
The quantification of the intramolecular stabilization using our established high-level ab initio 
approach (MP2/aug-cc-pVTZ counterpoise / B3LYP/6-31G(d,p) (7) showed a strong increase of 
the C-H···O hydrogen bond interaction from 1.87 kcal/mol in 28 (N.B. in Lex (1) it is 1.76 
kcal/mol) to 3.55 kcal/mol in the CF3-counterpart 6. The total stacking interaction between the 
Fuc and the Gal moiety is also improved from 4.35 kcal/mol in 28 (N.B. in Lex (1) it is 4.52 
kcal/mol) to 6.65 kcal/mol in 6, clearly demonstrating the key effect of the CF3 group on the 
stabilization of the bioactive core conformation.  
Co-crystallization of E-selectin (Lec-EGF-SCR2) with the antagonists 6 and 7 (30).  
When the CH3-group of L-Fuc was replaced by aromatic and heteroaromatic substituents, only 
a minor influence of affinity was observed (32). This is in accordance with the substituent in the 
5-position of the fucose moiety pointing to the surrounding water. In addition, all substituents 
can still exert a hydrophobic contact with the β-face of the above Gal moiety, essential for the 
pre-organization of the core. Thus, the replacement of CH3 group by the electron-withdrawing 
CF3 group leads mainly to an improved polarization of the C5-H bond leading to a further 
stabilization of the core by an improvement of the non-conventional hydrogen bond formed 
with the ring oxygen of the adjacent D-Gal moiety. When the co-crystal structures of the CF3-
derivatives 6 and 7 were compared with E-selectin co-crystalized with the Fuc derivatives 30 
and 28, a shortening of the C5Fuc-O5Gal distance by 0.10 to 0.13 Å (from 3.42/3.44 Å to 3.32/3.31 
Å) was detected (30). Compared to 3.69 Å for the C-H bond (1.09 Å) and the van der Waals radii 
of H5Fuc and O5Gal on side and an optimal H-bond of 2.8 Å on the other side, this is a substantial 
effect (33).  
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Figure 3 Close-up view of the ligand interaction in co-crystal structures of E-selectin with 28 (A), 6 (B), 30 (C), and 
7 (D). All ligands establish similar interaction pattern with E-selectin (consisting of lectin domain, EGF-like domain 
and two consensus repeats) (30). Ligand interacting amino acids are labeled, the Ca2+ is shown as green sphere, 
oxygen and nitrogen atoms are colored red and blue, respectively. The distance between C5 of L-fucose and the 
O5 of D-galactose are indicated in red. 
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Acid stability assay. Natural polysaccharides containing acidic carbohydrates have been 
reported to be unstable in acidic conditions (34). To examine the stability of glycomimetics and 
their potential to surpass the gastric passage without degradation for a potential oral dosage 
form, stability assays in acidic conditions have been conducted (Table 4). The measured stability 
of all compounds was much higher than required for the gastric passage, since the experiments 
had to be conducted over a duration of 10 days to obtain visual degradation (35). Furthermore, 
the introduction of the electron-withdrawing CF3 group leads to higher acidic stability of 
compound 3 and 6 compared to their corresponding nonfluorinated counterparts. The 
incorporation of the CF3 group therefore not only increases the affinity of the glycomimetics, 
but additionally enhances the stability of the compounds due to the core stabilization.  
Table 4. Stability of glycomimetics counterparts 3, & 25 and 6 & 28 in 1 M HCl aqueous solution (pH approximately 
0) and at physiological pH 7.4 (TRIS-HCl buffer 1.0 M) was measured in triplicate over a period of 10 days at room 
temperature (25 °C). Standard deviation is indicated and stabilities reported over 95% were considered as stable.  
Entry Ligand R1 
Stability 
1 M HCl 
Stability 
pH 7.4 
1 3 CF3 > 95 % > 95 % 
2 25 CH3 79.7 ± 0.1 % > 95 % 
3 6 CF3 83.8 ± 1.4 % > 95 % 
4 28 CH3 54.7 ± 1.9 % > 95 % 
 
Conclusions 
Increasingly, non-conventional hydrogen bonds are considered to play a significant role in 
molecular recognition involved in the binding of small molecules to large ones. In addition, a 
number of investigations were focusing on the question whether these weak interactions are 
also conformationally influential (36). 
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3.10 Manuscript 4: Bridging oligosaccharides and glycomimetics with protein 
receptors  
 
In this manuscript, the development and evaluation of an in silico tool to categorize the quality 
of hydrogen bonds in carbohydrate lectin interaction is described. This tool guides lead 
compound developments by reducing the polarity of carbohydrate mimetics without loosing 
affinity. The poor pharmacokinetic properties of carbohydrates are primarily due to their polar 
surface consisting of hydroxyl groups. The categorization by the in silico tool was evaluated in 
vitro in three different projects. 
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Abstract 
The past failure of carbohydrate-based drug candidates are mostly attributed with low affinity 
but also poor pharmacokinetics. One reason for the low affinity of carbohydrates are the high 
desolvation costs, linked to the numerous hydroxyl groups of carbohydrates. Furthermore, 
common pharmacokinetic parameters including the polar surface area (PSA) as well as the 
number of hydrogen bond acceptors and donors, that are usually above drug-like values. To 
reduce the likeliness of failure, hydroxyl groups making no or only a minimal contribution to 
binding should be replaced. Therefore, we developed the software Acca-Bruca and correlated 
thermodynamic data for 37 monodeoxygenated ligands with the crystal structures of the 
parent compound. The data resulted in a linear-regression model with a good correlation 
(R2 = 0.85) that was further simplified by a categorization system with three classes. Finally, the 
model and the categorization system were integrated in Acca-Bruca. To assess the predicting 
capabilities of Acca-Bruca, we performed two prospective studies on carbohydrate–lectin 
interactions and considered one example retrospectively. In addition, we report on preliminary 
results on non-carbohydrate ligands, analyzed with Acca-Bruca. 
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Introduction 
Carbohydrates play an important role as energy source, as structural element in the form of 
cellulose or chitin, and as key elements in diverse physiological processes such as cell 
recognition and cell adhesion. For these processes carbohydrates bind to lectins, exhibiting 
high selectivity because of the three-dimensional structure of the oligosaccharides and their 
combinatorial complexity (1-6). 
Lectins involved in cell adhesion, such as selectins, siglecs, and galectins, emerged as drug 
targets in the early 1990’s, only to be abandoned shortly afterwards and deemed undruggable 
(7-13). Past and present failures of carbohydrate-based drug candidates are mostly attributed 
to issues like poor pharmacokinetics (PK) and low affinity (14). Carbohydrates contain 
numerous hydroxyls and charged groups, leading to their inherent polarity leading to 
insufficient permeability and oral bioavailability (7, 15). Furthermore, desolvation costs of the 
polar surface of carbohydrates and their binding sites are high and have to be compensated by 
the energy gained from the carbohydrate–lectin interactions (16). Cabani et al. calculated the 
cost of desolvating an isolated hydroxyl group to be 25 kJ/mol (17). The overall cost is scaled 
down for vicinal groups, leading to a total desolvation cost of 34 kJ/mol for two adjacent 
hydroxyl groups. This downscale effect applies to monosaccharides with 3 to 4 hydroxyl groups 
in proximity to each other, though the costs will add up with every additional unit of an 
oligosaccharide. The list of orally bioavailable glycomimetic drugs is therefore short and 
exclusively derived from monosaccharides: Oseltamivir (Tamiflu®) for the prevention of 
influenza infections, miglitol (Glyset®) and sodium–glucose cotransporter 2 (SGLT2) inhibitors 
used in diabetes, miglustat (Zavesca®) to treat Gaucher’s disease, topiramate (Topamax®) for 
the treatment of epilepsy, and nucleosidic reverse transcriptase inhibitors (NRTIs) to treat HIV 
patients (18-23). 
To harness the therapeutic potential of carbohydrate-lectin interactions, it will be necessary to 
address the problems originating from the polar nature of carbohydrates. However, hydrogen 
bonds (H-bonds) formed by hydroxyl groups substantially contribute to specificity and affinity 
of carbohydrate-lectin interactions and basically cannot be removed without careful inspection 
(24). In order for a hydroxyl group to exert a beneficial influence on binding, its desolvation cost 
has to be lower than the energy gained by newly formed protein-ligand interactions. This is 
only achieved by (i) optimal H-bonding distance and geometry, (ii) multiple H-bonds formed 
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to/from a single hydroxyl group, and (iii) their buriedness since the dielectric constant ε is lower 
in buried cavities of the binding site (ε ≈ 5-10) than on protein surface (ε ≈ 20) or in bulk water 
(ε ≈ 80) (25). Therefore, a H-bond is energetically more valuable in buried protein cavities (26). 
Additionally, occluded H-bonds show slower exchange rates when shielded from bulk water 
due to a penalized transition state (27). 
Early pharmacokinetic profiling in lead optimization became an integral part of modern drug 
design reducing preclinical research costs and improving time-to-market efficiency (28).To 
support carbohydrate-based drug design we developed Acca-Bruca, an open source program 
for analyzing crystal structures and subsequently categorizing H-bond interactions to assist 
medicinal chemists in their decision-making process leading from oligosaccharides to 
glycomimetics. 
Results 
Acca-Bruca descriptors. In order to build our H-bonds categorizing tool on a solid basis, we 
analyzed six carbohydrate–lectin interactions with published co-crystal structures (Table 1). 
Thermodynamic data for 37 monodeoxygenated ligands bidning to those proteins were 
available from published literature. Each data point corresponds to the contribution of a single 
hydroxyl group. 
Acca-Bruca scoring algorithm relies on six descriptors available from co-crystal structures. The 
descriptors are defined as follows: 
Atom buriedness as the number of protein heavy atoms within a sphere of a 8 Å radius around 
the ligand’s heavy atoms. 
Average ligand buriedness is defined as the sum of buriedness of all ligand heavy atoms divided 
by the number of ligand heavy atoms. 
Geometry-corrected H-bond energy is calculated with the directional H-bond potential function 
from the Yeti force-field (25). 
Number of interactions is counted from the highest possible sum of H-bond energies. 
Charge type refers to the type of interaction, e.g. a normal H-bond is assigned value 0, a charge-
assisted H-bond is assigned value 1, and a salt-bridge formed between two charged functional 
groups (ligand-protein) is denoted with value 2. 
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BFactDiff is calculated as the difference of B-factors of two interacting atoms. Atoms without a 
B-factor, for example in NMR solution structures, are treated as if there was no difference in 
the B-factor. 
Table 1 Carbohydrate–lectin co-crystals with corresponding thermodynamic data for monodeoxygenated ligands. 
Target 
Data 
Points PDB code Resolution [Å] References 
FimH 3 4XO8 1.7 (29) 
Arabinose 
Binding Protein 
4 5ABP 1.8 (30, 31) 
Lectin IV 7 1LED 2.0 (32, 33) 
Concanavalin A 10 1CVN 2.3  (34, 35) 
Artocarpin 3 1VBO 2.4 (36, 37) 
DGL 10 1DGL 2.4 (38, 39) 
 
Linear-regression model. A linear-regression model was built using Canvas 2.6 (40, 41) to relate 
the experimental differential thermodynamic fingerprint ΔΔGExp of the parent molecule and its 
monodeoxygenated-derivatives with the six descriptors (see above; atom buriedness, average 
ligand buriedness, H-bond geometry, number of interactions, charge type, and B-factor 
difference) calculated by Acca-Bruca. It was not possible to describe carbohydrates satisfactory 
by using only the atom buriedness, as they often bind on the lectin surfaces. Therefore, atoms 
that are deeply buried upon binding but are part of a rather solvent exposed ligand had to be 
penalized as described by Equation 1. Furthermore, the B-factor differences were applied as a 
penalty for the geometric H-bond energies, as dissimilar B-factors would have the most 
pronounced effect on the interaction geometry. The remaining three descriptors Number of 
interactions, ChargeType, and Geometry-corrected H-bond energy were used to build the model 
described by Equation 2. However, to avoid overestimation of an individual descriptor, three 
models relying on a combination of two descriptors (i. Interactions and ChargeType; ii. 
Interactions and Geometry; iii. ChargeType and Geometry) were built. The average of the three 
models has led to the following parameters for Equation 2: a = 2.43, b = 4.02, c = 1.45, and d = -
0.44. 
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DEFGHIJHKK = BLM"NDEFGHIJHKK ∗ LOHFP#HQG#PJIDEFGHIJHKK100  Eq. 1 
 
TU"FH = DEFGHIJHKK ∗ (P ∗ WJMHFPUMG"JK + Y ∗ ZℎPF#H\]^H + U ∗ _H"NHMF] ∗ D`PUM$Gaa) + I Eq. 2 
 
To facilitate the interpretation of the predicted ΔΔG values from the linear-regression model, 
three classes of hydroxyl groups were defined. All hydroxyl groups that were substantial for 
binding and their removal would lead to an affinity loss by a factor of 40 or more, belong to 
class I. These hydroxyl groups should not be removed from a compound, unless they are related 
to toxicity or metabolic instability. 
Class II includes the hydroxyl groups that were scored between a factor of 4 and 40 (3.4 kJ/mol 
and 9.1 kJ/mol, respectively) in terms of loss in affinity. Removing a class II hydroxyl group can 
improve PK properties of a carbohydrate mimetic, however the loss in affinity must be 
considered and weighed against the associated PK benefits. 
Class III includes all groups that were considered worthwhile removing, as they could improve 
PK properties with only a small loss in affinity by a factor of 4 or less, or even a gain through 
reduced desolvation costs. 
 
Figure 1 Linear-regression model. Data points in red are considered substantial and therefore belong to class I. 
Data points in orange belong to the intermediate class II, which can be removed to improve PK properties but will 
lead to a minor affinity loss. Data points in green belong to class III, which are dispensable. Dashed lines show a 
factor of 4 and 40 in change of affinity (3.4 kJ/mol and 9.1 kJ/mol, respectively). Goodness of fit, R2 = 0.85. 
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Although the model was built with carbohydrate hydroxyl groups in mind, support for other 
interactions, e.g. salt bridges between arginine and carboxyl groups frequently occurring in 
sialylated carbohydrates, were implemented as well. The robustness of the resulting model was 
validated by splitting the whole data set ten times randomly into a training- and a test-set (3:1). 
The ten test-sets were predicted with an average Q2 of 0.83, while the models average R2 was 
0.85 (Table S1). Furthermore, ΔΔGExp values were scrambled to show the model’s sensitivity 
towards the experimental data. The scramble test did not yield a predictive model (R2 = 0.04, 
Figure S1). 
Naïve Bayes classification. To cross-validate our approach and anticipate potential over fitting 
of the linear-regression model we also built a conditional probability model. This statistical 
approach is not predicated on training the model beforehand. However, interpretation of data 
which has not been encountered before is difficult. 
The probability model included all previous 37 data points and three Bayes classifiers, which 
span the experimental ΔΔG values and that describe the probability for a data point belonging 
to the classes I-III. Class I was defined as > 9.1 kJ/mol with 9 data points, class II as between 
3.4 kJ/mol and 9.1 kJ/mol with 16 data points, and class III as < 3.4 kJ/mol including 12 data 
points. Four descriptors were included in this model; number of H-bonds, charge type, H-bond 
geometry, and buriedness calculated by the Equation 1. The model predicted 32 out of 37 data 
points correctly with two data points in class I, two data points in class II, and one data point in 
class III incorrectly classified either one class too high or too low. This was caused by the fact 
that the incorrectly predicted data points were untypical representatives for their class, for 
example slightly more buried than others. Therefore, the probability for this descriptor 
combination was lower for the correct class and higher for the incorrect class. 
Acca-Bruca output. The classification generated by Acca-Bruca can be visualized in a molecule 
viewer able to color atoms by b-factor. The b-factor column in the pdb output is used to color 
the assigned atoms in red, yellow and green for the classes I-III, respectively. Unclassified 
atoms, such as carbon atoms are colored in blue (Figure 2). Furthermore, the classification is 
available as a tabular output within the program, referenced by the pdb atom and residue name 
from the used input structure. 
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Figure 2. Exemplary output of compound 1A produced by Acca-Bruca, visualized in PyMol. The ligand is colored 
by b-factor, whereas red, yellow and green atoms stand for the classes I-III, respectively. Unclassified atoms, such 
as carbon atoms are colored in blue. The protein is shown as gray surface, water molecules as spheres. 
 
Prospective PK study – E-selectin antagonists. After successful phase II clinical trials of the pan-
selectin antagonist Rivipansel for the treatment of vaso-occlusive crises in patients with sickle-
cell disease, the interest to develop an orally bioavailable selectin antagonist arose (42). Several 
projects to improve pharmacokinetic properties were conducted, but so far no orally 
bioavailable selectin antagonist has been identified (43-46). E-, P-, and L-selectin are a family 
of Ca2+-dependent C-type lectins mediating cell-cell adhesion that play a role in inflammation 
(47). E-selectin is expressed on the vascular endothelium. The minimal binding epitope is the 
tetrasaccharide sialyl Lewisx (48), which was also the starting point for mimetic lead structures 
such as 1A (Table 2, Figure 2). 
The large and hydrophilic core structure of 1A demands a consequent reduction in size and 
polar surface area (PSA) to increase the drug-likeness of the antagonists. In addition, a recent 
study on E-selectin co-crystallized with sLex revealed a conformational change of E-selectin to 
a high-affinity state upon ligand binding (49). This is important, because the hydroxyl group 
classification directly depends on the input crystal structure, from which Acca-Bruca cannot 
predict such conformational changes. Since we assume that this high-affinity conformation is 
generally adopted upon crystallization with E-selectin antagonists, we docked lead compound 
1A to the high-affinity state co-crystal structure (1.9 Å, PDB ID: 4C16). The three hydroxyls of 
fucose interacting with the calcium ion and the negatively charged surrounding (Glu80, Glu88, 
Glu107) and the 6-hydroxyl group of galactose forming a hydrogen bond with Glu92 were 
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identified as important for the lectin-antagonist interaction and therefore assigned to class I. 
However, the 4-hydroxyl group of galactose forming a single interaction with Tyr48 was 
assigned to class II and the 2-hydroxyl group not involved in any direct interaction with the 
lectin to class III. 
To test our prediction and quantify the influence of a single hydroxyl group on the octanol-
water distribution-coefficient (logD7.4), the polar surface area (PSA), and the passive 
permeability (logPe) measured in a parallel artificial membrane permeation assay (PAMPA) (50), 
we synthesized a series of galactose mono deoxy-derivatives (1B-1D, Table 2, see also Schemes 
1-3, supporting information). The experimental affinities shown in Table 2 confirm the hydroxyl 
group classification of Acca-Bruca. Compared to compound 1A (2.8 μM), compound 1B (Gal-
2H) exhibits a 3-fold (7.8 μM), compound 1C (Gal-4H) a 20-fold (53.8 μM) and compound 1D 
(Gal-6H) complete loss of affinity (1700 μM). The removal of one hydroxyl increases the logD7.4 
values by 0.4 (1C) to 0.5 (1B and 1D). But more importantly, the PSA is reduced below the 
threshold value of 140 Å2 recommended by Veber (51). These improvements of the 
physicochemical properties resulted in better passive permeation, even though all compounds 
are still below the accepted threshold for sufficient permeability (logPe > -6.3) (52). 
Interestingly, the strongest effects regarding the observed permeability are shown by 
compound 1D (Gal-6H), which has a reduced rotatable bond count compared to 
compounds 1B and 1C (Gal-2H and Gal-4H) and the smallest PSA among the tested 
compounds. However, the gain in permeability does not justify the loss of affinity that 
accompanies the removal of the hydroxyl group of compound 1D (Gal-6H). 
Compound 1B (Gal-2H) exhibits a lower molecular weight and improved lipophilicity, PSA and 
permeability (logPe) without a pronounced loss in affinity and is therefore a good starting point 
for further development of orally bioavailable E-selectin antagonists. 
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Table 2 E-selectin antagonist lead structure (1A) and its galactose mono deoxy-derivatives (1B - 1D). Class I 
hydroxyl groups are shown in red, class II in orange, and class III in green. 
Compound Structure Affinity 
[μM] 
logD7.4 PSA [Å2] PAMPA 
(logPe) 
1A 
 
2.8 0.54 ±0.03 149 Below detection limit 
1B 
Gal-2H 
 
7.8 1.01 ±0.03 135 -8.52 ±0.04 
1C 
Gal-4H 
 
53.8 0.92 ±0.02 128 -8.42 ±0.02 
1D 
Gal-6H 
 
1700 1.06 ±0.02 122 -6.85 ±0.02 
 
Prospective lead optimization – Siglec-8 ligands. Kroezen et al. will publish results of their lead 
optimization program regarding pulmonary deliverable Siglec-8 ligands for the treatment of 
asthma (Manuscript ready to publish). Siglec-8 is a CD33-related, human immune-inhibitory 
receptor that down-regulates immune response under inflammatory conditions. Already 
slightly hydrophobic molecules with a logP around 1 are absorbed in the lung within minutes 
and have a higher lung bioavailability compared to oral delivery (53). 
Because the lead structure 6’sulfo-sLex (2A, Neu5Acα2–3[6S]Galβ1–4[Fucα1–3]GlcNAc) is very 
polar (clogP = -9.7) we tried to improve PK properties early on in the lead optimization process 
without sacrificing affinity. Thus, 6’sulfo-sLex (2A) bound to human Siglec-8 (54), was analyzed 
by Acca-Bruca. Because the hydroxyl groups of fucose and N-acetyl-glucosamine of compound 
2A were all assigned to class III, we focused on the partial structure, disaccharide Neu5Ac-α2-
3(6-O-sulfo)GalOMe (2B) and prepared deoxy-derivatives thereof. In a competitive binding 
assay IC50 values were determined and subsequently ligand efficiencies (LE) were calculated. LE 
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is defined as the binding affinity per ligand heavy atom and is routinely used in early stages of 
a lead optimization process to evaluate the effectiveness of structural modifications (55). To 
illustrate change in PK properties we also report the calculated octanol-water partition 
coefficient (clogP) and PSA in Table 3. 
The IC50 of compound 2B decreased by a factor of 2 compared to compound 2A. However, 
compound 2B shows a more than four order of magnitude increase of clogP accompanied by a 
decrease of the PSA by 70 Å2, and an increase of LE by 0.04, overall improvements of PK 
parameters essential for lung bioavailability. 
The hydroxyl group in position 9 of the sialic acid is exposed to solvent. Hence its removal 
(® 2C, Sia-9H) leads to the largest change in clogP (+1.1) and PSA (-22 Å2), while the affinity is 
preserved. Galactose modifications show less distinct changes in PSA because they are 
relatively small compared to the contribution of the sulfate group. The small improvement in 
affinity is most likely due to reduced desolvation costs of compounds 2E and 2F (Gal-1H and 
Gal-4H, both LE = 0.14). In contrast, compound 2D (Gal-2H, LE = 0.12) does not show an affinity 
improvement, likely because the reduced desolvation costs are lost and a stabilizing 
intramolecular H-bond to the sialic acid ring oxygen is no longer possible, leading to higher 
desolvation costs. Additional improvements of LE, clogP, and PSA were achieved by combined 
galactose modifications. While the LE of the dideoxy-derivative 2G (Gal-1,2H) is increased to 
0.15, the LE of trideoxy 2H (Gal-1,2,4H) additionally lacking the ring oxygen, is even further 
increased to 0.17, with a distinct increase in clogP to -2.5 and a decrease of PSA to 187 Å2. 
Removing the hydroxyl group at C8 of sialic acid in compound 2I as well as removing the sulfate 
group in compound 2J, both classed as class I, renders the ligand inactive as predicted. 
Drug-like, rule of five compliant molecules with affinities in the range of 10 nM, and an average 
number of 38 heavy atoms correspond to a LE of 0.29 (56). The observed improvement in LE 
of 0.04 from the tetrasaccharide 2A (LE = 0.08) to the disaccharide 2B (LE = 0.12) and additional 
improvement of 0.05 obtained for compound 2H (Gal-1,2,4H, LE = 0.17) can therefore be 
regarded as a significant step forward in lead optimization. The improvements also emphasizes 
the importance of proper group analysis, as the removal of two hydroxyl groups, a methoxy 
group, and the ring oxygen, all assigned to class III, govern this change. 
 
Table 3 Siglec-8 ligands analyzed by Acca-Bruca. Class I groups are shown in red, class II in orange, and class III in 
green. 
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Name Structure IC50 [μM] LE clogP PSA 
2A 
6’sulfo-sLex 
 
303 0.08 -9.7 308 
2B 
 
681 0.12 -5.2 238 
2C 
Sia-9H 
 
572 0.13 -4.1 216 
2D 
Gal-2H 
 
626 0.12 -4.3 228 
2E 
Gal-1H 
 
354 0.14 -5.4 240 
2F 
Gal-4H 
 
251 0.14 -4.5 234 
2G 
Gal-1,2H 
 
190 0.15 -4.6 216 
2H 
Gal-1,2,4H 
 
109 0.17 -2.5 187 
2I 
Sia-8,9H 
 
> 2000 - -3.9 208 
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2J 
Gal-1,2H-6OH 
 
> 2000 - -4.5 176 
 
Retrospective lead optimization – Galectin-3 antagonists. Overexpression of human galectin-3 
(hGal-3) is related to cancer drug resistance and plays an important role in various stages of 
cancer progression, but is also implicated in inflammatory processes and is therefore regarded 
as a valuable therapeutic target for the treatment of cancer and pharmacological modulation 
of inflammation (10). Human galectin-3 naturally binds to D-galactose and galactose-based 
disaccharides like lactose (3A, Lac) and N-acetyllactosamine (3B, LacNAc) in the milli- to 
micromolar range. A recent patent review by Blanchard et al. summarized the current 
strategies in industry and academia towards a selective hGal-3 inhibitor .62 While most 
modifications were made on C3 of galactose to facilitate an arginine–arene interaction, Lund 
University patented a scaffold that includes a substituted cyclohexanol linked to the galactose 
as shown in compound 3C (57). 
Intrigued by this finding we classified the lactose (3A) hydroxyl groups using a high-resolution 
crystal structure (3ZSJ, 0.86 Å) of lactose binding to hGal-3 and compared them with the 
patented scaffold. Analyzing the crystal structure (1KJL, 1.4 Å) of LacNAc (3B) bound to hGal-3 
yielded the same classification (58). 
Interestingly, the removed groups on the cyclohexanol ring are in a good agreement with our 
predicted classification. The 1- and 6-hydroxyls of glucose as well as the ring oxygen were 
assigned to class III (3A and 3B), which is reflected in the absence of these groups in the 
patented molecules.  
To further increase the binding affinity of galectin-3 antagonists, Gal-3-hydroxyl classified as 
class III interaction was modified to bear an arene moiety (R1 in 3C) that can form a cation-π 
stacking interaction with Arg144 of hGal-3. Glc-2-hydroxyl, assigned to class II, was either 
modified to an amide, like in LacNAc (3B) or a triazole. This allowed to introduce an arene 
substituent (R2 in 3C) that can interact with Arg186, also by cation-π stacking. In this example, 
the two groups were not removed to improve PK properties, but modified to extend the binding 
mode towards other parts of the protein that offered new interactions and therefore higher 
affinity. 
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Table 4 Galectin-3 Antagonists analyzed by Acca-Bruca; class I hydroxyl groups are shown in red, class II in orange, 
and class III in green. 
Name Structure 
3A 
Lactose 
 
3B 
N-Acteyllactosamine 
 
3C 
Forskarpatent I 
Syd Ab 
 
 
Acca-Bruca – scope. Although the linear-regression model was built for carbohydrates, the 
application of Acca-Bruca may not be limited to those only. Instead, a preliminary analysis on 
marketed drugs containing hydroxyl groups suggests that Acca-Bruca can also predict H-bonds 
which are not carbohydrate related. Orally bioavailable molecules therapeutically used, had to 
undergone rigorous cycles of optimization and their hydroxyl groups must be regarded as 
valuable, otherwise they would have been removed. Based on this premise, we analyzed 
molecules from three different drug classes containing at least one hydroxyl group: amprenavir 
(4A), atorvastatin (4B), and alprenolol (4C) (Table 5). 
The analysis with Acca-Bruca categorized the hydroxyl group of amprenavir (4A) only as class 
II. Indeed, this particular hydroxyl group forms only one H-bond with Asp25. However, since it 
mimics the transition state recognized by asparte proteases, it is essential for the HIV protease 
inhibition. The hydroxyl groups of atorvastatin (4B) and alprenolol (4C), however, were assigned 
to class I. Both hydroxyl groups of atorvastatin (4B) participate in three good H-bonds with the 
charged amino acids (O3 with Arg590 and O5 with Asp690, Glu559, Lys691 and Asn755). The 
hydroxyl group of alprenolol (4C) forms two H-bonds, donating one to the charged Asp113 and 
accepting one from Asn312. The hydroxyl groups of 4B and 4C are in good agreement with our 
premise and shows that Acca-Bruca is sensible not only to carbohydrate hydroxyl groups. 
Table 5. Marketed drugs from three different classes analyzed by Acca-Bruca. Class I hydroxyl groups are shown 
in red, class II in orange, and class III in green. 
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Name Structure PDB Code 
4A 
Amprenavir 
 
3S45 
4B 
Atorvastatin 
 
1HWK 
4C 
Alprenolol 
 
3NYA 
 
Conclusions 
Based on thermodynamic data from 37 monodeoxygenated ligands and six descriptors 
calculated from their respective co-crystal structures, a linear-regression model for H-bond 
scoring with a correlation of R2 = 0.85 was built. Randomized training- and test-sets, a scramble-
test confirming the sensitivity towards the selected descriptors, and a conditional probability 
model excluding the risk of potential over-fitting verified the validity of the linear-regression 
model. The resulting score for a specific hydroxyl group was assigned to class I (substantial), 
class II (intermediate) and class III (dispensable) to facilitate the read out. Finally, the linear-
regression model and categorization criteria were implemented into Acca-Bruca for 
convenience. 
Three carbohydrate-lectin interactions were analyzed regarding the potential for improving 
pharmacokinetic properties and for lead optimization.  
With Acca-Bruca, the change in affinity associated with the removal of specific hydroxyl groups 
of E-selectin antagonist 1A could be correctly assessed and correlates well with experimentally 
determined affinities. In addition, when hydroxyl groups were assigned to class III, their 
removal allows pharmacokinetic improvements, e.g. the removal of a single hydroxyl group 
leads to increased logD7.4 and improved passive permeation, compared to the parent 
compound. Thus, antagonist 1B exhibits improved PK properties with only a slight loss in affinity 
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and is therefore a good starting point for further development of orally bioavailable E-selectin 
antagonists. 
Based on prediction by Acca-Bruca, the siglec-8 lead compound 6’sulfo-sLex (2A), a highly polar 
tetrasaccharide (clogP = -9.7), was optimized in regards to ligand efficiency (LE) and 
pharmacokinetic properties. The overall LE improvement of 0.09 is not only based on the 
reduction from the tetrasaccharide to the disaccharide (2A to 2B), but also the removal of four 
polar atoms (2B   2H), most likely due to a reduced cost of desolvation.  
Additionally, current strategies in human galectin-3 drug design could be rationalized using 
Acca-Bruca. A patented scaffold replacing the glucose unit with a cyclohexanol ring overlaps 
with our predicted assignment of hydroxyl groups. 
Furthermore, Acca-Bruca was applied to three different non carbohydrate-based drugs 
containing at least one hydroxyl group. The hydroxyl groups of the two drugs atorvastatin (4B) 
and alprenolol (4C) were predicted as class I hydroxyls, whereas the hydroxyl group of 
amprenavir (4A) was predicted as class II. Although only classified as class II, the hydroxyl group 
of amprenavir (4A) is essential for the inhibition of HIV proteases, since it mimics the transition 
state of the enzymatic hydrolysis. Albeit intriguing, further evaluation is needed before using 
Acca-Bruca for non-carbohydrates. 
The development of Acca-Bruca and the implementation of a classification system for hydroxyl 
groups of carbohydrates allows medicinal chemists to readily assess carbohydrate-lectin 
interactions. Additionally, the open source nature of the program allows for individual 
adaptations. 
The potential to reduce the time spent on early lead optimization cycles is essential for lowering 
investment and risk of failure, both aspects relevant for academia and pharmaceutical industry 
alike. Finally, Acca-Bruca supports the challenge to develop oligosaccharides into oral 
carbohydrate-based drugs. 
Methods 
Crystal structure preparation and model building. Crystal structures with resolution above 2.0 Å 
were preprocessed by the Protein Preparation Wizard. The system was solvated with the TIP3P 
solvent model within an orthorhombic box and minimized using Desmond 4.4 with 2500 
iterations and a convergence threshold of 0.05 kcal/mol/Å (59-61). Otherwise, default 
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parameters were used. After minimization, waters with less than 2 non-water interactions were 
discarded. Crystal structures with resolution below 2.0 Å were directly analyzed by Acca-Bruca. 
NMR solution structure preparation. The structure of Siglec-8 (PDB accession code 2N7B) was 
preprocessed and minimized as described above. Waters with less than 2 non-water 
interactions were again discarded after minimization. Hydroxyl groups were classified by Acca-
Bruca based on the described non-linear regression model. 
Polar surface area calculation. Even simple oligosaccharides can have a rather complex 3D 
structure resulting in variable exposure of the polar functional groups to the surrounding 
environment. For their proper characterization in terms of the surface area available for 
interaction with the solvent molecules (SASA) and particularly the polar fraction of it (PSA), a 
specialized 3D-based algorithm was developed. 
A 3D grid of points (density 0.25 Å) centered at the molecular centroid is created around the 
ligand. Molecular solvent accessible surface is constructed by analyzing overlaps of a solvent 
probe (radius of 1.4 Å) with the molecule (solute) at each of the grid points. The Van der Waals 
radii for atoms recommended by the Cambridge Crystal Data Bank are used (62). Next, the 
accessible surface is adjusted by subtracting the probe radius to obtain the effective Van der 
Waals surface. Each point of the final surface is assigned either to the polar (all O and N, polar 
H atoms, S atom in -SH or -SO2- groups) or the non-polar (remaining atoms) surface depending 
on the nearest atom. 
In order to minimize the bias associated with grid placement, the final result is averaged from 
four distinct calculations using altered spatial orientation (original orientation plus three 
additional orientations obtained by x, y, z rotations). Using the steps and settings described 
above, the algorithm produces reliable PSA values (± 0.5 Å2), which for simple conformational 
(3D) independent molecular species compare well with their standardized contributions (63). 
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The name Acca-Bruca originates from a swiss-italian pharmaceutical sciences student that 
made a statement about the importance of hydrogen bonds during a lecture. In German, H-
bonds are often called H-Brücke and she phrased her sentence using the Italian phonetic sound 
for H /’akka/ and the word Bruca, which doesn’t have a meaning in neither Italian, German nor 
English, but sounds very similar to Brücke. Everybody could follow her statement, although with 
a smile. 
The Acca-Bruca source code is available under an open source license on GitHub. 
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3.11 Manuscript 5: Towards a nanomolar E-selectin antagonist 
 
In this manuscript, the stepwise approach towards highly affine E-selectin antagonists is 
described. By replacing structural group from the natural ligand sLex, the lead development 
process improved the affinity by pre-organization, orientation of functional groups, 
desolvation, and rigidification without having an effect on the entropic properties. 
Furthermore, lower molecular weight, reduced numbers of hydrogen bond acceptors and 
donors, and a more hydrophobic character increased the drug-likeness of the final E-selectin 
antagonist. 
Contribution to the project: 
Philipp Dätwyler was measuring and evaluating in the physicochemical and pharmacokinetic 
properties of compound 9. He further contributed to the writing and arrangement of the 
publication. 
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E-selectin is a cell-adhesion lectin expressed on the surface of vascular endothelial cells 
involved in the recruitment of leukocytes to the site of inflammation. By interacting with the 
tetrasaccharide sialyl Lewisx ([Neu5Ac(α2-3)Galβ(1-4)[Fucα(1-3)]GlcNAc, sLex, 1) in the glycan 
of glycoproteins on leukocytes, E-selectins mediate the initial contact and enable leukocyte-
rolling along the vessel endothelium (1). This process is crucial to defend the body against 
infections, but excessive extravasation of leukocytes can harm the tissue and is associated with 
a broad variety of diseases, such as atherosclerosis (2), rheumatoid arthritis (3), and asthma 
bronchiale (4). Furthermore, selectins are associated with sickle cell disease (5) and carcinoma 
cell metastasis (6, 7). Hence, blocking this interaction is a promising strategy to suppress an 
inflammation at the beginning of the cascade (8-10).  
To develop a potent E-selectin antagonist we are optimizing ligands based on the sLex epitope. 
This approach culminated in the intravenously applied glycomimetic drug rivipansel 
(Glycomimetics, Inc.) that is currently in clinical phase III for the treatment of an acute sickle 
cell crisis (11, 12). In our previous work (13), we discussed the thermodynamics of glycomimetic 
E-selectin antagonists (compounds 1-4). We showed that binding of sLex to E-selectin is entropy 
driven arising from the release of bound water molecules from the binding interface to bulk 
water and a well pre-organized ligand conformation in solution.  
In sLex, the D-GlcNAc moiety interacts only weakly through van der Waals interactions with the 
protein and acts rather as a spacer between L-Fuc and D-Gal to stabilize the bioactive 
conformation of sLex. Its replacement by the more rigid and hydrophobic (1R,2R,3S)-3-
methylcyclohexane-1,2-diol stabilized the core conformation of compounds 3 and 4 and 
improved the affinity 15-18 fold. Core-preorganization turned out to improve both, enthalpy 
and entropy (1→3; ΔΔH° = -4.0 kJ mol-1; -TΔΔS° = -3.2 kJ mol-1), due to a reduced 
conformational entropy loss upon ligand binding, a more stable interaction with E-selectin and 
reduced desolvation costs of the hydrophobic mimic of D-GlcNAc. The replacement of D-
Neu5Ac by a smaller, hydrophobic and unsubstituted (S)-cyclohexyl lactic acid further improved 
affinity by a factor of 2-3, as seen in compounds 2 and 4. The carboxylic acid forming a salt 
bridge to Arg97 gained more flexibility allowing for an optimal orientation resulting in an 
enthalpic gain (1→2; ΔΔH° = -7.2 kJ mol-1), largely compensated by an entropic loss (1→2; -
TΔΔS° = +4.5 kJ mol-1). Progress in the development of E-selectin antagonists, new analysis 
methods allowing for global analyses of multiple ITC experiments (14, 15), and co-crystal 
structures of E-selectin with sLex and glycomimetics antagonists (Figure 1A) (16) require the 
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resumption of this important topic. 
Surprisingly, the hydroxy group in 2-position of L-Fuc was not found to be involved in a direct 
interaction with the E-selectin in a soaked crystal structure with sLex (PDB-code: 1G1T) from 
Somers et al. (2000) (17), but it was found to be crucial for binding in structure-activity 
relationship studies (18, 19). This discrepancy could only recently be explained when Preston 
et al. (2015) published a co-crystal structure of E-selectin in complex with sLex (PDB-code: 4CSY) 
and compound 4 (PDB-code: 4C16) (16), disclosing substantial conformational changes at the 
binding site compared to the soaked crystal structure (Figure 1B). Loop composed of residues 
81-89 in the binding site moves up to 10 Å towards the binding site. Glu88 replaces Asn83, 
coordinates with Ca2+ and forms a hydrogen bond with 2-OH of L-Fuc. Additionally, Gln85 and 
Glu107 shift into hydrogen bonding distance of 2-OH and 3-OH of L-Fuc, respectively. The 
changes are not only limited to the binding site, but the relative position between the lectin 
domain and the EGF-like domain is significantly altered. This induced fit is part of a catch-bond 
mechanism, which was demonstrated for P- and L-selectin as well (20, 21).  
To understand the impact of protein-ligand interactions, we have determined seven E-selectin 
complex structures (Table S1) ranging from 778 µM to 0.34 µM (Table 1). In general, all ligands 
bind in a very similar conformation to E-selectin and establish the same protein-ligand 
interactions (Figure 1A). Thus, the differences in the binding affinity between the ligands does 
not derive from the formation of new or optimized protein-ligand interactions but rather from 
a change in pre-organization of the ligand in solution and optimized desolvation. We found that 
contributions of modifications of E-selectin antagonists with a stabilized core conformation (D-
GlcNAc or its rigid mimetic (1R,2R,3S)-3-methylcyclohexane-1,2-diol) are additive instead of 
cooperative (Figure 2, Table 1). In a previous publication we found modifications of E-selectin 
antagonists containing a (1R,2R)-cyclohexane-1,2-diol, a more flexible mimetic of D-GlcNAc, to 
be non-additive (13). Although the concept of additivity is very popular in medicinal chemistry, 
the separation of energy into individual group contributions is often not applicable. According 
to Williamson et al. the additive approach is not valid, if non-covalent interactions are either 
mutually reinforcing (positively cooperative) or mutually weakening (negatively cooperative) 
(22, 23). Gerhard Klebe and co-workers demonstrated that the local hydration pattern of a 
binding interaction may result in non-additivity (24, 25). However, the high degree of pre-
organization of core-stabilized E-selectin antagonists and their identical binding mode allowed 
for a deconvolution of the binding affinity into individual contributions of distinct functional 
E-selectin antagonists  Manuscript 5 
 151 
groups. In this publication, we present the most successful modifications of each carbohydrate 
subunit of sLex (compound 1) and their respective benefits for the binding interaction with 
E-selectin. 
 
Figure 11 A Close-up view of the co-crystal structures of E-selectin with sLex (1) and E-selectin with its 
glycomimetics 2-9. All ligands form similar interactions with the protein. B Detailed representation of the 
interaction between glycomimetic compound 4 (PDB: 4C16) and E-selectin as observed in the crystal structure. 
Amino acids forming an induced fit upon ligand binding are shown in red. Pharmacophores are highlighted in blue. 
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Figure 2 Thermodynamic contributions of individual groups in E-selectin antagonists. Group contribution of (S)-
cyclohexyl lactic acid (purple); (R,R,)-3-methylcyclohexane-1,2-diol (green); acetylation in 2’-position of galactose 
(brown); ethyl substitution in 3’-position of (R,R,)-3-cyclohexane-1,2-diol (blue); trifluormethyl substitution in 6’-
position of fucose (magenta) and an azetidine amide substitution of the carboxylic acid (red). The black factors 
indicate the affinity improvement of a given ligand modification. The differences in the thermodynamic properties 
are given as ΔΔ-values in kJ mol-1. 
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Table 5 Thermodynamic parameters of E-selectin binding to sLex (1) and glycomimetic antagonists (2-9) 
determined by isothermal titration calorimetry (ITC). All measurements were carried out at 298.15 K. Affinities 
measured with microscale thermophoresis (MST) are shown for comparison. Confidence intervals and 
stoichiometries (N-values) are listed in Table S2. 
 
Cmpd 
MST: KD 
[μM] 
ITC:  KD 
[μM] 
ΔG° 
[kJ mol-1] 
ΔH° 
[kJ mol-1] 
-TΔS° 
[kJ mol-1] 
1 739 778 -17.7 4.9 -22.6 
2 269 269 -20.4 -2.3 -18.1 
3 - 43.4 -24.9 0.9 -25.8 
4 13.7 17.8 -27.1 -5.9 -21.2 
5 5.25 6.39 -29.6 -6.9 -22.8 
6 9.53 8.36 -29.0 -10.7 -18.3 
7 3.41 4.96 -30.3 -7.5 -22.7 
8 2.82 6.56 -29.6 -8.0 -21.6 
9 0.339 
0.282 
(0.310*) 
-37.4 
-(-37.2*) 
-15.1 
(-15.4*) 
-22.3 
(-21.8*) 
*The values in brackets of 9 are calculated from the single group contributions of compounds 5-8 and 
demonstrate the additivity of the individual modifications on the rigid sLex core structure 
L-Fuc modification for core pre-organization (compound 5). While all hydroxyl groups of L-Fuc 
form essential interactions with the protein and/or the structural Ca2+ ion in the E-selectin 
binding site, a nonconventional intramolecular C-H···O hydrogen bond between H-C(5) of L-Fuc 
and O(5) of D-Gal helps by locking the core in a bioactive conformation (26). The substitution 
of the methyl group (C6) by a strongly electron withdrawing trifluormethyl group (4→5) 
strongly polarizes the adjacent hydrogen at 5-position of L-Fuc and thereby improves the core 
pre-organization. This leads to decreased entropic costs (4→5; -TΔΔS° = -1.6 kJ mol-1) upon 
binding as well as an enthalpic gain (4→5; ΔΔH° = -1.0 kJ mol-1), most likely due to improved 
protein-ligand interactions (Table 1). Enthalpy is additionally favoured by decreased 
desolvation costs of a trifluormethyl group compared to the original methyl group. 
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Furthermore, higher hydrophobicity and size of the trifluormethyl group might also better 
shield the Ca2+ cavity, lowering the local dielectric constant in the cavity and therefore 
strengthening the existing electrostatic interactions. 
GlcNAc modification to reduce the desolvation penalty and enhance the rigidity (compound 6). 
Replacing the GlcNAc moiety by a cyclohexan-1,2-diol preserves the sLex-like conformation 
while improving the affinity due to a lower desolvation penalty. An additional methyl 
substitution in 3-position further rigidifies the core structure (13). Elongating the alkyl 
substituent to an ethyl group (4→6) is found to improve affinity by 2-fold (27). The ethyl group 
does not further rigidify the cyclohexane, but it forms enthalpically beneficial hydrophobic 
contacts (4→6; ΔΔH° = -4.8 kJ mol-1) with Gln85 largely compensated by an entropic loss 
(4→6; -TΔΔS° = +2.9 kJ mol-1) due to conformational restrictions upon binding. However, the 
low electron density of this ethyl group (PDB-code: XXXX) suggests some residual flexibility even 
in the bound state. 
D-Gal modification for acid orientation (compound 7). The hydroxyl group in 2-position of D-Gal 
does not interact with the protein in the bound state. Any hydrophobic substituent in this 
position, e.g. an acetate (compound 7) or a benzoate,(27) was found to be favourable for the 
affinity compared to the hydroxyl group (Table 1). These substituents do not directly interact 
with the protein but prevent the ligand from forming an unfavourable intramolecular hydrogen 
bond with the acid in solution. This allows for a more bound-like conformation being present 
in solution (4→7; -TΔΔS° = -1.5 kJ mol-1) having an optimal lactic acid orientation (4→7; ΔΔH° = 
-1.6 kJ mol-1) for the salt bride formation with the positively charged Arg97.  
Neu5Ac substitution to lower desolvation costs (compound 8). The carboxylic acid of 
compounds 1 - 7 can form an intramolecular hydrogen bond with one of the hydroxy groups in 
2 and 4 position of the D-Gal. These hydrogen bonds have to be broken upon binding which 
results in an enthalpic penalty. This penalty can be circumvent by substituting the carboxylic 
acid with an azetidine amide, which furthermore lowers the desolvation enthalpy (4→8; ΔΔH° 
= -2.1 kJ mol-1). Likely, the amide most likely has a slightly weaker interaction with Arg97 which 
leads to an enthalpic loss but an entropic gain due to retained flexibility of both protein and 
ligand (4→8; -TΔΔS° = -0.4 kJ mol-1). 
Combining all beneficial modifications to derive a drug-like molecule (compound 9). Any single 
modification of compounds 5-8 improves the affinity by a factor of only 2.1 - 3.6-fold compared 
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to compound 4. But, due to the rigid core structure and the consequent additivity the minor 
improvements combined in one derivative result in an affinity improvement of a factor of more 
than 63-fold (4→9). The summed up individual thermodynamic contributions of modifications 
5-8 to calculate the theoretical thermodynamics of compound 9 (Table 1) differ by less than 
0.5 kJ mol-1 from the experimentally determined thermodynamics demonstrating high 
additivity effects. Comparing our final compound 9 with the natural binding motif sLex 
(compound 1) we were able to improve the originally unfavourable enthalpy by -20.0 kJ mol-1 
(1→9), whereas the favorably entropy could be maintained (-TΔΔS° = +0.3 kJ mol-1) (Figure 3). 
Furthermore, according to Lipinski’s rule of 5 for oral bioavailability (MW ≤ 500 Da; H-bond 
acceptors ≤ 5; H-bond acceptors ≤ 10; logP ≤ 5) the drug-likeness of glycomimetic 9 is greatly 
improved compared to sLex (28). Compound 9 fulfils the requirements for H-bond donation 
(reduced from 14 to 5 H-bond donors) and lipophilicity (logP of  -7.4 increased to 2.0). 
Lipophilicity is increased mainly due to the replacement of the charged carboxylic acid by a 
neutral amide and the introduction of the trifluormethyl group. Moreover, the number of H-
bond acceptors (reduced from 25 to 14) and the molecular weight (reduced from 821 Da to 
742 Da) were consequently improved. In addition, compound 9 is stable in rat liver microsomes 
against hydrolysis of the ester bond by esterases as well as oxidation by cytochrome P450s. 
However, low solubility (44 ± 8 µM) and low permeation of compound 9 over a colorectal 
adenocarcinoma cell (Caco-2) (29) membrane still leave room for further optimization.  
 
Figure 3. Thermodynamic fingerprints of the natural binding motif sialyl Lewisx (compound 1) and the 
glycomimetic compound 9 derived from ITC measurements. Ligand pre-organization, desolvation, 
rigidification and pharmacophore orientation improved binding enthalpy by 20 kJ/mol, while the 
beneficial entropy could be maintained. Without the formation of a new interaction affinity could be 
improved by almost 3000-fold. 
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In summary, in 20 years of optimizing E-selectin antagonists we were able to improve the 
affinity almost 3000-fold compared to the lead structure sLex and it is probably the first example 
in carbohydrate-based drug discovery of an oligosaccharide being rationally improved to a sub-
micromolar binder. Biophysical analysis and X-ray crystallography guided the enthalpic 
optimization process where we did not alter pharmacophores of the glycomimetic ligands, but 
improved the affinity only by pre-organization, orientation of functional groups, desolvation, 
and rigidification. Furthermore, lower molecular weight, reduced numbers of hydrogen bond 
acceptors and donors, and a more hydrophobic character increased the drug-likeness of our E-
selectin antagonists. Our approach presents a general approach to improve carbohydrate-
based lead structures in drug discovery.  
Acknowledgements. The authors thank the staff of the Swiss Light Source, Paul Scherrer 
Institute, Villigen, Switzerland. 
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4 FimH antagonists 
4.1  Urinary tract infection 
Urinary tract infection (UTI) is defined as bacterial infection of the otherwise sterile urinary 
tract. The infection either takes places in the lower urinary tract, i.e. in the bladder and urethra 
(Cystitis) or in the upper urinary tract, i.e. in the kidneys (Pyelonephritis) (1,2). Clinically, a 
distinction between uncomplicated and complicated UTIs is made. In the case of an 
uncomplicated UTI, no structural or neurological abnormalities of the urinary tract arise, 
whereas complicated UTIs are accompanied by factors compromising the urinary tract or host 
defense, such as neurological diseases, immunosuppression, renal failure, renal 
transplantation, pregnancy and the presence of foreign bodies such as catheters (3). The vast 
majority of complicated UTIs are related to catheter induced UTIs (CAUTI) (4,5). 
UTIs are one of the most common infections, affecting approximately 150 million peoples every 
year (6,7). Bacteria can colonize the urethra in both men and woman, but compared to men, 
the short urethra of women makes it easier for bacteria to reach the bladder before removal 
by micturition. Therefore, women are affected by UTI up to 5 times more often compared to 
men (8,9). The incidence rate of UTI in women for one year is 11% and the risk of suffering from 
UTI once during lifetime is approximately 50% (10). Other risk factors are sexual activity, vaginal 
infections, prior UTIs, diabetes and genetic susceptibility (8,9,11-14). The primary symptoms of 
UTIs are strangury, burning micturition and bacteriuria or pyuria. If untreated, UTI can lead to 
hematuria, fever and even to a potentially life-threating sepsis (15-17). 
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4.1.1 Current treatment options  
In most cases, an antibiotic treatment is prescribed to erase the symptoms of an acute cystitis 
and to prevent the infection of the kidneys (18). Due to the inherent problems of bacteria 
resistance to antibiotics, the recommendations for the treatment changes over time. For a long 
time, treatment with trimethoprim-sulfomethoxazol or fluoroquinolone-derivatives like 
ofloxacine and norfloxacine were first-line therapies (10). Latest recommendations advise 
against the use of these antibiotics. Currently, fosfomycin-trometamole in a single dose 
treatment or nitrofurantione over a period of three days are considered as first line 
therapeutics for the treatment of UTI (19, 20). For peoples suffering from recurrent UTIs, 
preventive antibiotics are indicated either dosed daily or post coitus (21, 22).  
Other preventions besides antibiotics are heavily discussed. Whereas probiotics have been 
shown to be ineffective, the use of cranberry juice showed varying effectivity in meta analyses 
(23-25). Pure D-mannose was recently marketed as medical product to prevent UTIs and 
showed effectiveness in one study, but crucial data about pharmacodynamics and –kinetics 
(PK/PD) are not available and the study suffers from a low number of recruitments (26). Future 
treatment possibilities might include vaccinations (27, 28). Another approach is presented 
below. 
4.2  Uropathogenic Escherichia coli (UPEC) 
In approximately 75% of all ambulatory UTI cases, uropathogenic Escherichia coli (UPEC) are 
the causing pathogens. Besides UPEC, Klebsiella, Enterecoccus and Staphylococcus bacterial 
strains are the major pathogen groups (6, 10, 29). E. coli are gram-negative bacteria, which are 
part of the common intestinal flora of humans (30). Mutated E. coli strains can become 
pathogenic; thus intestinal pathogenic E. coli mainly cause diarrhea and extraintestinal 
pathogenic E. coli (ExPEC) are not harmful in the intestines but colonize and harm parts of the 
body outside the gut. UPEC as shown in Figure 4.1 are part of ExPEC(31).  
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Figure 4.1. Electron micrograph of an uropathogenic E. coli expressing type 1 pili used from Capitani et al. (32). 
UPEC have developed the ability to colonize bladder and kidney cells. As a first step of the 
pathogenesis, UPEC attach to the luminal surface of the bladder (33, 34). This binding is 
mediated by type 1 pili interacting with oligomannosides on the urinary bladder mucosa (35). 
Once adhered to the cell surface, UPEC invade the host cell and replicate inside the cell to form 
a biofilm-like intracellular bacterial community (IBC), in which UPEC are in a quiescent mode, 
resistant to the innate immune response and antibiotic treatment (36, 37). An IBC can persist 
for months until quiescent bacteria reactivate, exit the cell, and infect new bladder cells. The 
formation of IBC can be a source for recurrent urinary-tract infections (38). 
4.2.1 Type 1 Pili 
Type 1 pili are the primary virulence factor of UPEC to promote cystitis by binding to uroplakin 
Ia on the mucosal surface of the human urinary bladder (39). This initial step of adhesion 
prevents the rapid clearance of UPEC from the urinary tract by the bulk flow of urine and at the 
same time enables the invasion of the host cells (35). Type 1 pili are filamentous protein 
complexes consisting of a helical structure (500-3000 FimA subunits) and on the tip the three 
subunits FimF, FimG, and FimH (Figure 4.2) (40-42). The pilus rod is assembled through the 
chaperon-usher pathway (43), i.e. the chaperon protein FimC in the periplasm binds pilus 
subunits, folds them to FimA, and delivers them to the transmembrane assembly platform 
FimD, where FimA is released to be incorporated into the pilus (32). 
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Figure 4.2 The type 1 pilus is consisting of a helical structure formed by FimA subunits and a terminal tip consisting 
of FimF, FimG and the lectin domain FimH with the terminal carbohydrate recognition domain (CRD). Upon binding 
of mannosides, FimH is undertaking a conformational change into a medium affinity state. Once shear stress is 
applied by urinary flow, a high affinity conformation is formed. 
4.2.2 Lectin FimH 
FimH on the distal tip of the type 1 pili consists of the carbohydrate recognition domain (CRD) 
which recognizes the mannosides on the luminal surface of the bladder cells. FimH is a 
polypeptide of 279 amino acids, folding into two domains containing only β-strands. The C-
terminal domain (pili domain) anchors FimH to FimG and the N-terminal domain (lectin domain) 
contains the CRD (44). The lectin domain is an elongated, 11 β-stranded domain with a jelly 
roll-like topology. On the tip, the mannose-binding pocket is located (45). FimH binds to 
mannosides in a so-called catch bond mechanism (46). Under shear stress, the FimH domains 
are separated and the affinity towards mannose residues increase up to 100-fold (47). Due to 
this effect, UPEC is able to prevent its clearance from the bladder by urinary flow. When the 
flow ceases, the bacteria can transmigrate again over the urothelial surface (48, 49). 
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Figure 4.3. Crystal structure of FimH lectin domain binding α-D-methyl-manno-pyranoside (1) (44). The lipophilic 
residues Tyr47, Ile52 and Tyr137 play a crucial role in the development of highly affine FimH antagonists 
(PDB: 5JCQ). 
4.3 FimH Antagonists 
Increasing resistance against antibiotics require new approaches for the treatment of UTI (50-
53). The bacterial lectin FimH interacting with oligomannosides on the bladder surface is a 
potential therapeutic target. The adherence of the UPEC to the cell surface followed by the cell 
invasion can be prevented by α-D-manno-pyranosides, blocking the CRD and thus preventing 
the interaction with the urothelial surface (54, 55). More than three decades ago, proof of 
concept studies to treat UTIs with α-D-methyl-manno-pyranoside (1)(Figure 4.3) have been 
conducted in mice (56). Over the last decades, FimH antagonists have been further improved 
regarding their affinity as well as their pharmacokinetic properties (Figure 4.4.) (57-70). First 
systematic studies to improve the affinity of FimH antagonists have been conducted with 
aliphatic aglycones, e.g. to obtain n-heptyl-α-D-manno-pyranoside 2 (59). Starting from the p-
nitrophenyl α-D-manno-pyranoside (3a), highly affine FimH antagonists could be obtained by a 
further aromatic elongation of the aglycone with a squaric acid (® 4a & 4b) (60, 64), phenyl 
(®5a - 5f) (61, 63, 66) or indolinyl (®6a & 6b) (65). The binding mode of monovalent FimH 
Tyr48	
Tyr137	
Ile52	
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antagonists can be rationalized on the basis of the structure of the CRD. In the binding pocket 
α-D-mannose establishes an extended network of hydrogen bonds or hydrophobic interactions 
(71). Furthermore, the entrance to the mannose binding pocket is formed by three 
hydrophobic amino acids (Tyr48, Ile52 and Tyr137; Figure 4.3) and can host the aliphatic and 
aromatic aglycones. The high affinity of biphenyl-α-D-manno-pyranosides could be achieved 
due to π-π stacking interactions of the outer aromatic ring with Tyr48 and/or Tyr137. An 
electron withdrawing substituent on the outer aromatic ring additionally improves these 
interactions (61,70). Further strategies to achieve high-affinity FimH antagonists are based on 
combinatorial chemistry (® 7) or C-mannosides (® 8) (68,69). To overcome permeability or 
solubility problems, ester prodrugs (® 9) or phosphate prodrugs (® 10) were synthesized (61, 
67). 
 
Figure 4.4. Monovalent FimH antagonists showing nanomolar affinities.   
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4.5 Manuscript 6: Tyrosin-perfluoroarene interactions of FimH antagonists 
 
Previous work showed the potential for high affinity of biphenyl-α-D-manno-pyranosides , due 
to π-π stacking interactions with a tyrosine gate. An bioisosteric replacement of the carboxylic 
acid improved the pharmacokinetic properties as well as affinity. In this Manuscript, a further 
improvement of the affinity was achieved by forming perfluorinated aglycones. The molecule 
furthermore showed promising physicochemical properties.  
Contribution to the project: 
Philipp Dätwyler was measuring and evaluating in the physicochemical properties of 
perfluorinated FimH antagonists. He further contributed to the writing and arrangement of the 
publication. 
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Tyrosine-perfluoroarene interactions lead to picomolar FimH antagonists  
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Abstract  
Antimicrobial resistance arising from a frequent use of antibiotics as a first-line treatment in 
urinary tract infections (UTI) has become a serious concern demanding for alternative 
treatment strategies. In this context, an anti-adhesive approach targeting FimH, a bacterial 
lectin used by uropathogenic E. coli (UPEC) to attach to urothelial cells of the host and thus 
initiate the infective process, attracted considerable interest. FimH can adopt different 
conformations, i.e. a low/medium-affinity state in the absence and a high-affinity state in the 
presence of shear forces. Until recently, however, only the high-affinity state has been 
thoroughly investigated, despite the fact that a therapeutically successful FimH antagonist 
should bind efficaciously to the low-affinity conformation as well. Entry to the mannose 
binding site of FimH is controlled by two tyrosines. In this communication we show that π−π 
stacking interactions between the aglycone of mannosidic FimH antagonists and the so-called 
tyrosine gate can be enhanced by electron poor substituents, which increases affinity for both 
affinity states. For biphenyl mannosides equipped with polyfluorinated outer aromatic rings, 
low nanomolar KD values for the low-affinity state and picomolar KD values for the high-affinity 
state were identified. Crystal structures of the lectin domain of FimH co-crystallized with 
polyfluorinated antagonists show a perfect face-to-face alignment of the two aromatic rings. 
Substantial effects on the binding thermodynamics suggest that improved stacking 
interactions have a considerable impact on the dynamics and conformation of the low affinity 
construct. Moreover, fluorination improves pharmacokinetic parameters as predictive 
indicators for oral availability. 
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Introduction 
Urinary tract infections (UTI) caused by uropathogenic E. coli (UPEC) are among the most 
common infections. Particularly often affected are women, who have a 40 – 50% risk to 
experience at least one symptomatic UTI episode during their life (1, 2). Because of the high 
morbidity and the resulting associated costs, UTI pose a serious burden on healthcare systems 
(3, 4). Uropathogenic E. coli (UPEC) account for approx. 70% of the reported UTI cases (5). To 
date, patients with acute uncomplicated lower UTI are mainly treated with antibiotics to 
relieve them of associated symptoms and to prevent the infection from exacerbating into a 
pyelonephritis or urosepsis, which can be life threatening (6, 7). However, the repeated use 
of antibiotics as the first-line treatment for UTI led to increased antibiotic-resistance,8,9 
highlighting the need for new strategies for the prevention and treatment of UTI with oral 
therapeutics (8-10).  
The adhesin FimH, located on the tip of type 1 pili of UPEC, is a bacterial virulence factor (11-
13). Its adherence to the highly mannosylated glycoprotein uroplakin 1a (UP1a) on urothelial 
cells of the host is the first step of the infection but also enables UPEC to evade clearance by 
the bulk flow of urine (14, 15). FimH consists of two domains; an N-terminal lectin domain 
(FimHLD), being implicated as a mannose-specific carbohydrate recognition domain (CRD), and 
a C-terminal pilin domain (FimHPD) anchoring the adhesion FimH to the pilus (16-18). For an 
efficient colonization of urothelial cells, bacteria only weakly interact with the cell surface, 
allowing exploration for optimal nutrition supply. However, to avoid clearance from the 
bladder when shear forces arise, strong adherence is required. To fulfill these two opposing 
tasks, FimH relies on a sophisticated allosteric mechanism, allowing a fine-tuning of its 
mannose binding affinity through conformational adaption. In the low-affinity state, there is 
a close interaction between FimHPD and FimHLD, allosterically attenuating the mannose 
binding capacity. Shear forces induced by urination, provoke the separation of the two 
domains, which induces the high affinity state. This conformational switch of FimH is by no 
means a one-step process. Intermediate states and a high variability of the conformational 
ensemble have been described (19, 20). Although all conformational states of FimH are 
relevant for the pathogenicity of UPEC, efforts for the development of therapeutic FimH 
antagonists have mainly been focused on the high affinity conformation of the protein (21).  
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Within the last three decades, a large number of monovalent a-D-mannosides containing 
lipophilic aglycones, such as alkyl, phenyl, , diarylamides, dioxocyclo-butenylaminophenyl, 
umbelliferyl, biphenyl, indol(in)ylphenyl, triazolyl, and thiazolylamino have been synthesized 
(22-33). Moreover, a wide range of multivalent ligands has been described (34-40). Generally, 
FimH antagonists consist of a mannose moiety establishing an extended hydrogen bond 
network within the CRD and with alpha configuration a lipophilic aglycone interacting with the 
hydrophobic amino acids Tyr48, Tyr137 and Ile52 lining the entrance to the CRD (41).  
In order to optimize complementary electrostatic properties to the electron rich tyrosine side 
chain, a series of electron deficient biphenyl aglycones were attached to mannose. To avoid 
unfavorable steric clashes, the substitution with fluorine atoms exhibiting a van der Waals 
radius comparable to hydrogen was explored (42). In case of hexafluorobenzene, the high 
electronegativity of fluorine induces an inductive polarization that leads to a positive potential 
above and below the ring plane resulting in a quadrupole moment of 31.7 x 10-40 C.m2. Because 
of the inverse electron density distribution, the quadrupole moment of benzene exhibits the 
same magnitude but with opposite sign (−29.0 x 10-40 C.m2). Such a complementary charge 
distribution results in a particularly strong electrostatic attraction (43-47). 
The attractive interaction between electron-poor and electron-rich phenyl rings was 
demonstrated in experimental studies on the rotational barrier in 1,8-diarylnaphthalenes. 
Fluorine substitution lead to an increase of the energy barrier of approximately 2.1 kJ mol-1 
per fluorine atom (48-50). Furthermore, studies on arene-arene interactions also indicated 
the beneficial influence of fluorine substitutions on favoring T-shaped or parallel displaced 
orientations rather than a sandwich conformation (51-53). The influence of fluoroarenes on 
protein binding affinity was demonstrated for different targets, including carbonic anhydrase 
II and the cysteine protease cathepsin L (54-59).  
Based on a series of biphenyl a-D-mannosides (1–3, Figure 1), we aimed to improve affinity 
for all relevant conformational states of FimH by introducing different fluorination patterns 
on the terminal aromatic ring. In addition to perfluorination, as in 4 and 5, a cyano substituent 
was introduced in the para position (® 6). This modification is marked by an increase in the 
Hammett constant, further increasing the electrostatic attraction to the Tyr48 side chain. The 
difluorinated compound 7 was designed to enable favorable σ–π interactions in an edge-to-
face arrangement with the tyrosine gate residues. 
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Figure 1 A Electrostatic potential visualized on the interaction of perfluorinated aglycone of mannoside 5 and 
Tyr48 of FimH. Regions of negative potential (red) of the perfluorinated aglycone overlap with regions of positive 
potential (blue) of the Tyr48 side chain and vice versa. B Four biphenyl a-D-mannosides with different 
fluorination patterns were synthesized. 
Results and Discussion 
For the exploitation of π–π stacking interactions between the outer aromatic ring of biphenyl 
α-D-mannopyranosides and Tyr48 four representatives with different fluorination patterns 
were synthesized.  
Synthesis. The synthesis of the biphenyl mannoside derivatives 4 and 5 is depicted in Scheme 
1. Pentafluorinated biphenyls 13 and 14 were synthesized starting from anisole derivatives 8 
and 9 in a copper-catalyzed arylation of pentafluorobenzene (10) followed by demethylation 
using boron tribromide (60). 13 and 14 were reacted in a BF3×Et2O-promoted mannosylation 
(® 16 & 17) followed by deacetylation under Zemplén conditions affording mannosides 
4 and 5. 
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Scheme 1 a) CuI, 1,10-phenantroline, K3PO4, DMF/p-xylene, 130 °C, 2-10 h, 36% for 11, 46% for 12; b) BBr3, DCM, 
-78 °C → rt, 5-19 h, 88% for 13, 90% for 14; c) BF3×Et2O, DCM, 40 °C, 3-24 h, 40% for 16, 42% for 17; d) 
MeONa/MeOH, rt, 2 h, 74% for 4, 89% for 5. 
For the synthesis of the tetrafluorinated derivative 6 (Scheme 2), the previously described 
mannoside 18 (31) was coupled in a microwave-assisted arylation reaction in the presence of 
CuI and 1,10-phenantroline with commercially available 2,3,5,6-tetrafluorobenzonitrile (19) 
to give intermediate 20 in 66% yield. As a result of the high electrophilicity of the cyano group, 
by-products were formed almost exclusively under Zemplén conditions (NaOMe, MeOH) . 
When milder deacetylation conditions (aq. NH3 in isopropanol/THF) were applied, by-product 
formation could not be completely avoided, but the test compound 6 was obtained in 
reasonable yield  
 
Scheme 2 a) CuI, 1,10-phenantroline, K3PO4, p-xylene, microwave, 150 → 160 °C, 13 h, 66%; b) 2.0 M NH3(aq), i-
PrOH, THF, rt, 24 h, 39%; c) bis(pinacolato)diborone, PdCl2(dppf)×CH2Cl2, KOAc, DMF, microwave, 120 °C, 2 h, 
61%; d) PdCl2(dppf)×CH2Cl2, K3PO4, DMF, 90 °C, 2.5 h, 58%; e) 1.3 M NH3(aq), i-PrOH, THF, rt, 4.5 d, 73%. 
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For the synthesis of the difluorinated derivative 7 (Scheme 2), mannoside 18 was transformed 
into the boronic acid pinacol ester 21 followed by Suzuki coupling (® 23) (61). By mild 
deprotection with aq. NH3 compound 7 in good yield without formation of by-products. 
FimH constructs. For the determination of binding affinities, two different recombinant FimH 
constructs were used. The isolated lectin domain of FimH (FimHLD), which is locked in the high 
affinity conformation, was expressed as previously described (25). The full-length FimH variant 
(FimHFL), representing the low-affinity conformational state, consists of the tethered lectin 
and pilin (FimHPD) domains stabilized by a synthetic oligopeptide corresponding to residues 1-
14 of the natural FimG donor strand (19).  
Competitive fluorescence polarization assay. In this assay, the antagonist of interest displaces 
a fluorescently labeled competitor from the binding site, thereby causing a reduction in 
fluorescence polarization (27).  
Full-length FimH. All fluorinated antagonists exhibited higher affinities to full-length FimH 
compared to their non-fluorinated counterparts (Table 1). While the introduction of a 
pentafluorophenyl ring led roughly to a 3-fold improvement of affinity compared to biphenyl 
α-D-mannoside (1 ® 5, KD 1100 nM vs. 346 nM), antagonist 4 exhibiting an additional o-chloro 
substituent on the phenyl ring adjacent to the anomeric position showed an even 4.5-fold 
improved affinity (2 ® 4, KD 458 nM vs. 103 nM). Apart from the electron-withdrawing effect 
of fluorine, which enhances π−π stacking interactions to Tyr48, the new antagonists can also 
benefit from a slightly increased surface area leading to improved van der Waals contacts. The 
Hammett constant (σpara) reveals that the introduction of a cyano group in the para-position 
of the terminal phenyl ring results in a significantly higher electron-withdrawing potential than 
for a para-fluoro substituent (σpara 0.660 vs. 0.062). Therefore, not surprisingly, the 
replacement of the para-fluoro with a para-cyano group led to a further substantial increase 
in the binding affinity (4 ® 6, KD 103 nM vs. 22 nM). Finally, the difluorinated cyano derivative 
7 exhibits an activity almost identical to 6. This compound was designed to capitalize on σ−π 
interactions resulting from an edge-to-face orientation to Tyr48, which has been shown to be 
energetically more favorable than the face-to-face conformation in the benzene homodimer 
(44), However, the strong polarization of the aromatic ring in 7 might create a larger dipole 
moment, resulting in a stronger interaction with the solvent compared to 6 and, thus, in a 
higher desolvation penalty. Therefore, the observed similarity of the affinity values between 
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6 and 7 can be a result of different factors compensating each other. In any case, the 
mannosides 6 & 7 are the best antagonists of the full-length FimH variant reported to date. 
Lectin domain. The fluorination of the terminal phenyl moiety in biphenyl α-D-mannoside (1), 
results in an almost 4-fold affinity gain for antagonist 5. An additional chloro-substituent 
(2 ® 4), however, surprisingly remained without an impact on binding affinity in the FP assay. 
However, for the corresponding p-cyano substituted inhibitors 3 and 6, a 3-fold gain in 
potency can be observed. This results in a highly potent inhibitor with picomolar affinity. A 
similar effect was for the difluorinated derivative 7. The gain in binding affinity for fluorinated 
compounds can most likely be attributed to enhanced π–π interactions to the tyrosine gate. 
It is not clear, however, why this trend is not observed for fluorination of 2.  
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Table 1 Affinity of FimH antagonists to FimHFL and FimHLD, physicochemical and pharmacokinetic parameters, 
and quantum mechanical calculation of the π–π stacking energies of Tyr48 with different biphenyl derivatives in 
the gas phase. 
Cpd. 
 
FimHFL KD 
[nM]a 
FimHLD 
KD [nM]a 
Solubility 
[µg/mL] 
logD7.4 d 
 
PAMPA  
logPee 
DEgas 
[kJ mol-1]  
128 
 
1’100 15.1 21 ± 1 b 2.1 ± 0.1 −4.7 ± 0.1 −19.8 
264 
 
458 2.8 5.5 ± 0.2 b 2.6 ± 0.1 n.d. −19.6 
328 
 
59.1 1.06 
195 ± 5 
192 ± 5 b 
2.1 ± 0.0 −5.2 ± 0.0 −34.3 
4 
 
103 4.48 47 ± 7 c 2.7 ± 0.2 −4.7 ± 0.2 −35.2 
5 
 
346 4.01 131 ± 10 c 2.3 ± 0.1 −4.7 ± 0.2 −34.4 
6 
 
22.1 0.349 111 ± 7 c 2.2 ± 0.1 −4.8 ± 0.1 −42.9 
7 
 
22.7 0.577 97 ± 15 c 2.2 ± 0.1 −5.0 ± 0.1 
−39.8[f]/ 
−30.7[g] 
[a] Dissociation constants (KD) were determined in competitive fluorescence polarization assay towards FimHFL 
and FimHLD using fluorencent 3ʹ-chloro-N-(2-(3-(3ʹ,6ʹ-dihydroxy-3-oxo-3H-spiro- [isobenzofuran-1,9ʹ-xanthen]-5-
yl)thioureido)ethyl)-4ʹ-(α-D-mannopyranosyloxy)biphenyl-4-carboxamide as reference compound (27). 
Experimental errors for measurements with new compounds are given in Table S1. [b] Kinetic solubility was 
measured in a 96-well format using the μSOL Explorer solubility analyzer at the indicated pH in triplicate. [c] 
Thermodynamic solubility was measured in Tris-HCl buffer (pH 7.4, 0.1 M) in duplicate, unless otherwise stated. 
[d] Octanol-water distribution coefficients (logD7.4) were determined at pH 7.4 by a miniaturized shake flask 
procedure in sextuplicate. [e] Pe = effective permeability: diffusion through an artificial membrane was 
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determined by the parallel artificial membrane permeability assay (PAMPA) in quadruplicate at pH 7.4. [f] ΔEgas 
obtained with fluorine atoms on the same side as the chlorine atom. [g] ΔEgas obtained with fluorine atoms on 
opposing side of chlorine. 
Isothermal Titration Calorimetry (ITC). In order to reveal the influence of fluorination of the 
aglycone on the thermodynamic signature of binding, ITC experiments were performed (Table 
2). In case of antagonists exhibiting an affinity in the low nanomolar or picomolar range 
(® 6 & 7), a competitive format described previously had to be applied (27).  
Interaction of antagonists with the lectin domain. Dissociation constants for all antagonists 
follow the same trend observed in the competitive fluorescence polarization assay. The 
introduction of an ortho-chloro substituent on the phenyl ring adjacent to the anomeric 
position (1 ® 2) improved the enthalpy ΔΔH° by −13.1 kJ mol-1. Due to unoptimized π–π 
stacking of the unsubstituted biphenyl in mannoside 1, any adjustment of the aglycone has a 
strong impact on enthalpy. However, the enthalpy gain observed for 2 versus 1 is partially 
compensated by an unfavorable entropy (−TΔΔS° = 5.3 kJ mol-1) resulting from a reduced 
flexibility of the protein–ligand complex (23). The introduction of the cyano group on the 
terminal aromatic ring (2 ® 3) leads to a further enthalpy boost of ΔΔH° by −7.8 kJ mol-1 by a 
strengthened π–π interaction to Tyr48. The enthalpy gain ΔΔH° can be further enhanced by 
the addition of four fluorine substituents (3 ® 6), by −6.7 kJ mol-1). Nevertheless, this enthalpy 
gain is again partly compensated by entropy costs related to a decreased mobility of the ligand 
and Tyr48. By contrast, the difluorinated cyano derivative 7 shows an enthalpic penalty ΔΔH° 
of 3.7 kJ mol-1 compared to 6. This could be a consequence of the aforementioned polarization 
within the phenyl ring leading to a stronger attraction between aglycone and solvent, and thus 
to higher desolvation costs. 
Interaction of antagonists with full-length FimH (FimHFL). As observed for FimHLD, the KDs of 
ITC measurements are in good agreement with the results from the fluorescent polarization 
assay. As earlier reported, the affinity of antagonists to FimHFL is again reduced by 
approximately two orders of magnitude (62). In contrast to measurements with FimHLD, an 
astonishing compensation of enthalpic and entropic contributions is observed. In general, the 
enthalpy of binding is highly negative, while an entropic penalty mitigates the strength of the 
interaction. While effects like these are commonly observed for carbohydrate–lectin binding 
events, the magnitude of the recorded thermodynamic contributions exceeds well beyond the 
range that is usually reported for such interactions (63). A possible explanation is that the 
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binding site of the inhibitor has a profound impact on the global conformational dynamics of 
the receptor, an assessment supported by large difference of thermodynamic parameters 
between measurements with the FimHFL and FimHLD constructs. These significant alterations 
(e.g. ΔΔH°FL-6/LD-6 = −27.4 kJ mol-1; −TΔΔS°FL-6/LD-6 = 39.1 kJ mol-1) have to be attributed to 
changes distal from the binding site, which is structurally identical in the X-ray model of both 
constructs (19).  
In general, FimH can exist in a flexible low- and a medium-affinity state, characterized by 
interdomain interactions between lectin and pilin domain. Upon separation of the two 
domains, the high-affinity state is formed (18-20). It has been reported recently, that binding 
to FimH is able to alter the equilibrium between the preexisting low- and medium-affinity 
conformational states and that this transition is likely associated with enthalpy–entropy 
compensation (20). As documented for inhibitor 6, the thermodynamic signature of this 
binding event reveals a significant entropic penalty of −TΔS°FL-4b = 53.9 kJ mol-1, originating 
from a restriction in the mobility of the lectin domain as a whole and especially from a fixation 
of the clamp loop (residues 1–16) forming the mannose binding site. Only when shear forces 
separate lectin and pilin domains the high-affinity state is formed. The thermodynamic 
signature of binding to the high-affinity state can be studied with the FimHLD construct, which 
is locked in the high-affinity state. As expected, the entropy penalty is much smaller (−TΔΔS° 
LD-6 /FL-6 = −39.1 kJ mol-1) because conformational changes are no longer necessary. However, 
the enthalpy gain (ΔΔH°LD-6 /FL-6= −27.1 kJ mol-1) associated with the conformational changes 
is much smaller as well.  
As a result, the optimized π–π stacking to Tyr48 of fluorinated aglycones in combination with 
improved interactions of the clamp loop residues culminate in a highly favorable enthalpy 
term of ΔH°FL-6 = −95.0 kJ mol-1. While the effect of the tetrafluorcyano-substitution of the 
terminal aromatic ring can be rationalized by enhanced π–π stacking interactions for the high-
affinity state (ΔΔH°LD-6/LD-3 = −6.7 kJ mol-1; −TΔΔS°LD-6/LD-3 = 4.2 kJ mol-1), the observed 
thermodynamic fingerprint is much more pronounced for the full length construct (ΔΔH°FL-6/FL-
3 = −19.1 kJ mol-1; −TΔΔS°FL-6/FL-3 = 17.3 kJ mol-1). For the inhibitors 4 and 6, the magnitude of 
enthalpy–entropy compensation correlates well with the electrostatic properties of the 
terminal aromatic ring (σpara 0.062 vs. 0.660; ΔΔH°FL-4/FL-6 = 25.1 kJ mol-1; −TΔΔS°FL-4/FL-6 = −23.8 
kJ mol-1). In summary, this observation emphasizes that the improved stacking interactions 
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with Tyr48 translate to variations in the global arrangement of the protein by an allosteric 
mechanism. 
Table 2. Thermodynamic profile of selected FimH antagonists binding to FimHLD and FimHFL. The measurements 
were performed at 25 °C and pH 7.4. 
Cpd. 
 
KD 
[nM]a 
ΔG° 
[kJ mol-1] 
ΔH° 
[kJ mol-1] 
−TΔS° 
[kJ mol-1] 
LD-128 
 
17.7 
(14.0 – 22.3) 
−44.2 
−45.0 
(−45.6 – −44.5) 
0.8 
LD-2 
 
5.8 
(4.7 – 7.1) 
−47.0 
−53.1 
(−53.5 – −52.7) 
6.1 
LD-328, b 
 
1.3 
(1.1 – 1.6) 
−50.7 
−60.9 
(−61.4 – −60.4) 
10.1 
LD-4b 
 
3.1 
(0.8 – 10.1 
−48.6 
−55.3 
(−57.6 – −53.5) 
6.8 
LD-6b 
 
0.5 
(0.3 – 0.8) 
−53.3 
-67.6 
(−67.1 – −66.0) 
14.3 
LD-7b 
 
1.0 
(0.6 – 1.7) 
−51.3 
−63.9 
(−64.6 – −63.2) 
12.7 
FL-364 
 
130 
(110 – 150) 
−39.3 
−75.9 
(−77.0 – −74.9) 
36.6 
FL-4 
 
98 
(66 – 141) 
−40.0 
−69.6 
(−73.7 – −65.9) 
29.6 
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FL-6 
 
64 
(37 – 102) 
−41.2 
−97.7 
(−100.2 - −90.5) 
53.4 
[a] 95% confidence interval from fitting in parentheses; [b] ΔH° obtained from direct titration; KD obtained from 
competitive titration against n-heptyl 2-deoxy-α-D-mannoside.  
X-ray Crystallography. To gain insight into the binding mode of the fluorinated FimH 
antagonists regarding the orientation of the aglycones towards the tyrosine gate motif, we 
co-crystallized the tetrafluorinated cyanide 6 and the pentafluorinated derivative 5 with 
FimHLD (Figure 2). Both structures were obtained at a resolution of 2.1 Å. The binding mode 
of the mannose moieties in 5 & 6 is identical to previously reported non-fluorinated analogues 
1 (PDB 4X50) (23) & 3 (PDB 4CST) (27). In all crystal structures, the biphenyl aglycone is 
interacting with Tyr48 and Tyr137. While the orientation of the side chain of Tyr137 is not 
affected by different modifications of the biphenyl aglycone, substantial effects can be seen 
for the orientation of Tyr48. In the structure of 1 (Figure 2B), the Tyr48 side chain adopts a 
slightly tilted orientation, resulting in a suboptimal arrangement for π–π stacking interactions 
to the aglycone. Although the introduction of the electron-withdrawing cyano group (® 3, 
Figure 2D) is supposed to improve π–π stacking, a face-to-face conformation with Tyr48 is not 
observed. Instead, the Tyr48 side chain displays a certain flexibility implicated from the 
observation of two distinct rotamers (27). By contrast, the terminal tetrafluorocyano phenyl 
ring in analogue 6 (Figure 2C) is in an optimal parallel alignment with Tyr48, most likely due to 
a markedly enhanced π–π stacking resulting from the electron deficiency of the fluorinated 
ring. A similar orientation is found for the pentafluorinated derivative 5 (Figure 2C). It is 
noteworthy that the aglycones of the co-crystallized antagonists 5 and 6 are involved in crystal 
packing contacts potentially influencing the binding modes. Therefore the binding poses in 
the crystal structures have to be validated by solution NMR spectroscopy. 
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Figure 2 Comparison of the crystal structures of FimHLD co-crystallized with fluorinated antagonists. (A) Binding 
mode of non-fluorinated analogue 1 (green sticks, PDB 4X50). (B) Binding mode of non-fluorinated analogue 3 
(cyan sticks, PDB 4CST). (C) Binding mode of 5 (yellow sticks). (D) Binding mode of 6 (magenta sticks).  
NMR chemical shift perturbation (CSP). The structural information obtained from X-ray 
crystallography was complemented with data from NMR CSP experiments of FimHLD in 
solution. 1H,15N-HSQC spectra of 15N-labeled FimHLD were measured upon addition of the 
fluorinated compounds 4, 5 and 6 and their non-fluorinated counterparts 1 and 3 (23). 
Residues in the mannose binding pocket exhibit nearly identical chemical shifts for all five 
antagonists (Figure 3A) confirming the similar orientation and hydrogen bond network of their 
mannosyl moieties as observed in the X-ray structure shown in Figure 2. In contrast, chemical 
shift differences were observed for residues in the binding loop around Tyr48. Previously, the 
residues Glu50 and Thr51 have been identified as sensitive reporters for the conformation of 
the Tyr48 residue (23). The formation of a T-shaped NH-π interaction of Thr51 HN with the 
Tyr48 ring in complex with most other mannoside antagonists (e.g. with biphenyl mannoside 
1), thereby leads to a strong upfield shift of Thr51 HN while Glu50 is shifted downfield, 
corresponding to shielding and deshielding effects by the aromatic ring current from Tyr48, 
respectively (Figure 3B). The 1H,15N-HSQC spectra of FimHLD with 4, 5 and 6 revealed the 
presence of this Tyr48 conformation in agreement with the X-ray structural data (Figure 2, C 
and D). A comparable signal shift in the 1H,15N-HSQC spectrum has been observed for a 
previously published FimH ligand, which also showed strong π–π interactions with Tyr48 in 
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the X-ray structure (23). It is tempting to speculate that the observed conformation of the 
tyrosine gate and the aglycone in the X-ray structures of these three compounds represents 
the optimal stacking arrangement of Tyr48 and aglycone. 
 
Figure 3 1H,15N-HSQC spectral regions of FimHLD with fluorinated compounds 4, 5 and 6 and with their non-
fluorinated counterparts 1 and 3. A) Signal shift of four representative amino acids in the mannose binding site. 
B) Signal shift of Glu50 and Thr51. 
Ab initio calculation of π-π stacking interactions.  The available X-ray structural data was used 
as input for the quantum mechanical calculation of π–π stacking interaction energies of 
different aglycones and Tyr48. Analysis of the interaction energies in Table 1 suggest that the 
π–π stacking is strongest between Tyr48 and the tetrafluorinated cyanide 6 
(DEgas = −42.9 kJ mol-1) and weakest compounds 1 and 2 exhibiting unsubstituted terminal 
aromatic rings (DEgas = −19.8 and −19.6 kJ mol-1, respectively). Introduction of the o-chloro 
substituent to the biphenyl derivatives 1 (® 2) and 5 (® 4) does not influence the π–π 
stacking. The addition of the p-cyano group or the perfluorinated phenyl ring equally improve 
the π–π stacking energies as seen for compound 3, 4 and 5 (DEgas between −34.3 and 
−35.2 kJ mol-1). However, the substitution of the p-fluoro with the p-cyano group 4a (® 6) and 
thereby the increase of the Hammett constant of the para substituent, further increases the 
π–π stacking energy (DEgas = −42.9 kJ mol-1). Interestingly, the difluorinated cyanide 7 shows a 
comparable interaction energy when the two fluorine atoms are on the solvent exposed, 
coinciding side with the chlorine atom (DEgas = −39.8 kJ mol-1). 
Physicochemical and in vitro pharmacokinetic characterization. To study the influence of 
polyfluorination of the aglycone on the physicochemical and pharmacokinetic parameters of 
FimH antagonists, the aqueous solubility and lipophilicity of the new antagonists were 
determined (64, 65). Furthermore, the permeability through an artificial membrane (PAMPA) 
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was determined as an estimate for oral bioavailability (66). The results are summarized in 
Table 1. 
Within the non-fluorinated series, introduction of an o-chloro substituent (® 2) followed by 
addition of a p-cyano group (® 3) led to a 4-fold decrease and 9-fold increase, respectively, 
of the aqueous solubility compared to 1. While the same o-chloro substitution within the 
fluorinated series (® 4) led to a similar 3-fold reduction of the aqueous solubility, no change 
in this parameter was observed compared to 5 upon replacing the p-fluoro by a p-cyano group 
(® 6). Since the aqueous solubility of 1 and 2 was determined in a kinetic solubility assay, this 
parameter cannot be directly compared with the thermodynamic solubility measured for their 
fluorinated analogues 4 and 5. By contrast, the thermodynamic solubility was measured for 
all cyanides (3, 6 and 7) allowing for a detailed comparison. Tetrafluorination of cyanide 3 
(® 6) had a negative impact on the solubility reducing it 2-fold to 111 µg/mL. Interestingly, 
the difluorinated analogue 7, despite a higher predicted polarization of the terminal phenyl 
ring, had essentially the same solubility as 6. Nevertheless, the solubility of antagonists 6 and 
7 lies above the minimal acceptable value for complete absorption of a 1 mg/kg dose of 
moderately permeable compounds, estimated by Lipinski et al. to be 52 µg/mL (67).  
All fluorinated antagonists showed slightly higher lipophilicity than their non-fluorinated 
equivalents. Interestingly, difluorinated cyanide 7 had the same logD7.4 value as the 
tetrafluorinated 6. With a lipophilicity between 2.2 and 2.7, these molecules are expected to 
be well absorbed by means of passive diffusion upon oral administration (68). Moreover, a 
high lipophilicity supports tubular reabsorption from the glomerular filtrate favoring slower 
renal clearance and thus a prolonged therapeutic effect in the bladder upon a single dose (69). 
The increased lipophilicity of the fluorinated antagonists is also reflected in higher effective 
permeabilities (log Pe) determined in PAMPA. Since a logPe values above -5.7 indicates a high 
potential for intestinal absorption, all tested compounds are envisaged to easily permeate the 
membranes lining the small intestine (70). 
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Conclusions 
Over the years, the high-affinity conformation of FimH present in the isolated FimHLD was the 
main target in the development of anti-adhesive medicine for UTI neglecting the equally 
relevant low-affinity state observed in the full-length FimH. A recently published study 
addressed that issue and showed that even the most potent FimH antagonists bind with 
around two orders of magnitude lower affinity to FimHFL than to FimHLD (62). With such a need 
for improvement of efficacy against the low-affinity conformation of FimH (71), we designed 
and synthesized a series of new FimH antagonists bearing fluorinated aromatic aglycone with 
the goal to enhance the π−π stacking with Tyr48 located at the entrance of the binding site. 
The pentafluorinated analogue of biphenyl a-D-mannoside (® 5) shows improved binding to 
full-length FimH. An additional introduction of a p-cyano group (® 6) results in a dissociation 
constant of 22.1 nM, the highest reported affinity of an FimH antagonist for FimHFL to date. In 
case of FimHLD, a similar improvement was observed in almost all fluorinated antagonists, with 
6 & 7 even reaching subnanomolar affinities. ITC measurements of fluorinated antagonists 
with FimHLD reveal a marked increase in enthalpy with the highest gain observed for the 
tetrafluorinated derivative 6. The thermodynamic signature of the interaction of 6 with the 
full-length construct reveals important details about the global protein dynamics upon ligand 
binding. Given that FimHFL is predicted to exist in an equilibrium of low- and high-affinity state 
in solution (20), the distinct loss of entropy of 6 may indicate a stabilization of a conformation 
that is characterized by extensive interactions between the lectin and pilin domains and hence 
fewer degrees of conformational freedom. Furthermore, the strong stacking interaction of the 
aglycone with Tyr48 leads to a restriction of the mobility of the clamp loop of FimH. Finally, 
the crystal structures of FimHLD with 5 and 6 reveal a parallel alignment of the aromatic rings 
of Tyr48 and the aglycone, suggesting particularly strong π−π stacking. This orientation was 
confirmed by chemical shift perturbation NMR experiments of FimHLD with 4, 5 and 6 in 
solution monitoring the backbone signals of the loop residues Glu50 and Thr51 as reporters 
for the tyrosine gate conformation. This allowed for the quantum mechanical calculation of 
π−π stacking energies that clearly separate the different substitutions on the terminal ring and 
revealed its importance for the stacking interaction energies. 
The physicochemical and pharmacokinetic parameters solubility, lipophilicity, and 
permeability were determined to estimate the oral bioavailability of the new FimH 
antagonists. While the fluorination of the terminal phenyl group had a negative effect on the 
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aqueous solubility, most inhibitors are still soluble enough (> 52 µg/mL) for oral 
administration. By contrast, lipophilic modifications introduced on the aglycone were 
advantageous for permeability indicating high intestinal absorption of all new antagonists. 
Based on the experimentally determined logD7.4 values, a slow renal elimination due to tubular 
reabsorption and thus, a longer lasting therapeutic effect of a single dose of FimH antagonist, 
can be expected.  
In summary, the introduction of multiple fluorine substituents to the terminal phenyl rings of 
biphenyl mannoside-type inhibitors of FimH results in improved π−π stacking interactions to 
Tyr48. Antagonists 6 & 7 display the best pharmacodynamic profile towards full-length FimH 
as well as FimHLD and nearly optimal pharmacokinetic parameters for oral bioavailability. In 
future work, we aim to evaluate in vivo pharmacological parameters of these promising drug 
candidates in a mouse model of UTI. 
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Experimental Part 
Synthesis 
General methods: NMR spectra were recorded on a Bruker Avance III 500 MHz NMR spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, HMBC). Chemical 
shifts are referenced to residual CHCl3, CHD2OD or HDO. Optical rotations were measured using Perkin-
Elmer Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were obtained on a Waters 
micromass ZQ Mass Spectrometer. The LC-HRMS analysis were carried out using a Agilent 1100 LC 
equipped with a photodiode array detector and a Micromass QTOF I equipped with a 4 GHz digital-
time converter. Microwave-assisted reactions were carried out with CEM Discover and Explorer. 
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) and visualized 
by using UV light and/or by charring with a molybdate solution (a 0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). MPLC separations 
were carried out on a CombiFlash Companion or Rf from Teledyne Isco equipped with RediSep normal-
phase or RP-18 reversed-phase flash columns. LC–MS separations were carried out on a Waters system 
equipped with sample manager 2767, pump 2525, PDA 2996, column SunFireTM Prep C18 OBDTM (5 
µm, 19 x 150 mm), and Micromass ZQ. All compounds used for biological assays are of 100% purity 
based on HPLC analytical results. Commercially available reagents were purchased from Sigma-Aldrich, 
Alfa Aesar and Acros Organics. Dry DMF was purchased from Acros Organics. All the other solvents 
were dried prior to use where indicated. Methanol (MeOH) was dried by storing over activated 
molecular sieves 3Å for at least one day. Dichloromethane (DCM) was dried by filtration over Al2O3 
(Fluka, type 5016 A basic) and stored over activated molecular sieves 4Å. Molecular sieves 3Å and 4Å 
were activated in vacuo at 200 °C for 30 min immediately before use. 
3-Chloro-2',3',4',5',6'-pentafluoro-4-methoxy-biphenyl (11). To a solution of 8 (320 mg, 1.192 mmol) 
and 10 (200 µL, 1.788 mmol, 1.5 eq) in dry p-xylene/DMF (4 mL, 1:1) was added 1,10-phenanthroline 
(71 mg, 0.358 mmol, 0.3 eq) followed by CuI (68 mg, 0.358 mmol, 0.3 eq) and dry K3PO4 (506 mg, 2.334 
mmol, 2.0 eq). The mixture was degassed in an ultrasonic bath and flushed with argon. After stirring 
for 10 h at 130 °C, the mixture was diluted with EtOAc (50 mL), washed with H2O (2 x 20 mL) and brine 
(20 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by MPLC on silica gel (petroleum ether) to yield 11 (132 mg, 36%) as a white solid. 1H NMR (500 MHz, 
CDCl3): δ = 7.46 (m, 1H, Ar-H), 7.31 (m, 1H, Ar-H), 7.04 (d, J = 8.6 Hz, 1H, Ar-H), 3.96 ppm (s, 3H, OCH3); 
13C NMR (125 MHz, CDCl3): δ = 155.89 (Ar-C), 144.15, 140.69, 137.79 (m, 5C, 5 Ar-CF), 131.92, 129.89, 
123.04, 119.30 (4 Ar-C), 114.64 (dt, J = 3.9, 16.8 Hz, Ar-C), 56.37 ppm (OCH3). 
2',3',4',5',6'-Pentafluoro-4-methoxy-biphenyl (12). To a solution of 9 (187 mg, 0.799 mmol) and 10 
(133 µL, 1.199 mmol, 1.5 eq) in dry DMF (0.5 mL) under argon was added 1,10-phenanthroline (16 mg, 
0.080 mmol, 0.1 eq) followed by CuI (15 mg, 0.080 mmol, 0.1 eq) and dry K3PO4 (339 mg, 1.598 mmol, 
2.0 eq). After stirring for 2 h at 130 °C, DMF was co-evaporated with xylene to dryness in vacuo. The 
residue was purified by MPLC on silica gel (petroleum ether) to yield 12 (100 mg, 46%) as a white solid. 
Analytical data are with accordance with the literature data (72).  
3-Chloro-2',3',4',5',6'-pentafluoro-4-hydroxy-biphenyl (13). To a solution of 11 (132 mg, 0.427 mmol) 
in CH2Cl2 (6 mL) was added dropwise a 1.0 M solution of BBr3 in CH2Cl2 (1.00 mL, 1.0 mmol, 2.3 eq) at -
78 °C under argon. The content of the flask was slowly warmed to ambient temperature and stirred 
for 19 h. Then, the mixture was cooled to 0 °C  and carefully quenched by slow addition of H2O. The 
mixture was diluted with EtOAc (50 mL), washed with H2O (2 x 20 mL) and brine (20 mL). The organic 
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layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by MPLC on silica gel 
(petroleum ether/EtOAc, 1:0-9:1) to yield 13 (110 mg, 88%) as a white solid. 1H NMR (500 MHz, CDCl3): 
δ = 7.42 (s, 1H, Ar-H), 7.27 (m, 1H, Ar-H), 7.14 (d, J = 8.5 Hz, 1H, Ar-H), 5.76 ppm (s, 1H, OH); 13C NMR 
(125 MHz, CDCl3): δ = 152.35 (Ar-C), 144.08, 140.69, 137.85 (m, 5C, 5 Ar-CF), 130.78, 130.58, 120.43, 
119.54, 116.72 (5 Ar-C), 114.57 ppm (dt, J = 4.1, 17.0 Hz, Ar-C); ESI-MS: m/z: Calcd for C12H3ClF5O [M-
H]-: 293.0, found: 293.0. 
2',3',4',5',6'-Pentafluoro-4-hydroxy-biphenyl (14). To a solution of 12 (100 mg, 0.365 mmol) in CH2Cl2 
(3 mL) was added dropwise a 1.0 M solution of BBr3 in CH2Cl2 (0.910 mL, 0.910 mmol, 2.5 eq) at -78 °C 
under argon. The content of the flask was slowly warmed to ambient temperature and stirred for 5 h. 
Then, the mixture was cooled to 0 °C  and carefully quenched by slow addition of H2O. The mixture 
was extracted with CH2Cl2 (3 x 20 mL). The organic layer was dried over Na2SO4 and concentrated in 
vacuo. The residue was purified by MPLC on silica gel (hexane/EtOAc, 1:0-9:1) to yield 14 (85 mg, 90%) 
as a white solid. Analytical data are with accordance with the literature data (73).  
3-Chloro-2',3',4',5',6'-pentafluoro-biphenyl-4-yl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside (16). 
To a suspension of 15 (83 mg, 0.212 mmol) and 13 (0.149 mmol, 0.7 eq) in dry CH2Cl2 (4 mL), BF3·Et2O 
(80 µL, 0.636 mmol, 3.0 eq) was added dropwise under argon. After stirring for 3 h at 40 °C, the reaction 
mixture was diluted with EtOAc (50 mL), washed with satd aq NaHCO3 (20 mL), H2O (20 mL) and brine 
(20 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by MPLC on silica gel (petroleum ether/EtOAc, 1:0-3:2) to yield 16 (37 mg, 40%) as colorless oil. [α]  
+57.3 (c 0.74, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.49 (br s, 1H, Ar-H), 7.31-7.28 (m, 2H, Ar-H), 5.64-
5.61 (m, 2H, H-1, H-3), 5.54 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.39 (t, J = 10.1 Hz, 1H, H-4), 4.28 (dd, J = 5.5, 
12.2 Hz, 1H, H-6a), 4.15 (ddd, J = 2.2, 5.5, 10.1 Hz, 1H, H-5), 4.11 (dd, J = 2.2, 12.2 Hz, 1H, H-6b), 2.21, 
2.07, 2.04, 2.02 ppm (4 s, 12H, 4 COCH3); 13C NMR (125 MHz, CDCl3): δ = 170.57, 170.07, 169.89 (4C, 4 
CO), 151.96 (Ar-C), 144.15, 140.67, 137.65 (m, 5C, 5 Ar-CF), 132.32, 129.76, 124.77, 122.09, 116.78 (5 
Ar-C), 114.19 (dt, J = 4.1, 17.0 Hz, Ar-C), 96.53 (C-1), 70.07 (C-5), 69.36 (C-2), 68.82 (C-3), 65.90 (C-4), 
62.20 (C-6), 20.97, 20.82, 20.79, 20.72 ppm (4 COCH3); ESI-MS: m/z: Calcd for C26H22ClF5NaO10 [M+Na]+: 
647.1, found: 647.2. 
2',3',4',5',6'-Pentafluoro-biphenyl-4-yl 2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside (17). To a 
suspension of 15 (30 mg, 0.077 mmol) and 14 (0.077 mmol, 1.0 eq) in dry CH2Cl2 (1 mL), BF3·Et2O (10 
µL, 0.077 mmol, 1.0 eq) was added dropwise under argon. After stirring for 1 h at 40 °C, another 
portion of BF3·Et2O (10 µL, 0.077 mmol, 1.0 eq) was added followed by another 2 h later (1.0 eq). After 
stirring for 3 h, the reaction mixture was diluted with EtOAc (50 mL), washed with satd aq NaHCO3 (20 
mL) and H2O (20 mL). The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue 
was purified by MPLC on silica gel (petroleum ether/EtOAc, 1:0-7:3) to yield 17 (19 mg, 42%) as 
colorless oil. [α]  +68.6 (c 0.95, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.38 (d, J = 8.6 Hz, 2H, Ar-H), 
7.21 (d, J = 8.8 Hz, 2H, Ar-H), 5.60 (d, J = 1.2 Hz, 1H, H-1), 5.57 (dd, J = 3.5, 10.1 Hz, 1H, H-3), 5.46 (dd, 
J = 1.7, 3.3 Hz, 1H, H-2), 5.38 (t, J = 10.0 Hz, 1H, H-4), 4.28 (dd, J = 6.1, 12.7 Hz, 1H, H-6a), 4.10 (m, 2H, 
H-5, H-6b), 2.21, 2.06, 2.05, 2.02 ppm (4 s, 12H, 4 COCH3); 13C NMR (125 MHz, CDCl3): δ = 170.64, 
170.10, 170.09, 169.87 (4 CO), 156.28 (Ar-C), 145.25-136.85 (m, 5C, 5 Ar-CF), 131.74, 121.03, 116.85 
(6C, 6 Ar-C), 95.80 (C-1), 69.55 (C-5), 69.44 (C-2), 68.94 (C-3), 66.05 (C-4), 62.24 (C-6), 21.00, 20.83, 
20.82, 20.73 ppm (4 COCH3); ESI-MS: m/z: Calcd for C26H23F5NaO10 [M+Na]+: 613.1, found: 613.1. 
3-Chloro-2',3',4',5',6'-pentafluoro-biphenyl-4-yl a-D-mannopyranoside (4). To a solution of 16 (37 
mg, 0.059 mmol) in dry MeOH (6 mL) was added 0.3 M MeONa/MeOH (500 µL, 2.5 eq) at rt under 
argon. The mixture was stirred for 2 h and then neutralized with AcOH (20 µL) and evaporated to 
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dryness in vacuo. The crude product was purified by MPLC on silica gel (DCM/MeOH, 1:0-9:1) to afford 
4 (20 mg, 74%) as a white solid. [α]  +79.1 (c 1.00, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.54-7.52 
(m, 2H, Ar-H), 7.39 (m, 1H, Ar-H), 5.65 (d, J = 1.7 Hz, 1H, H-1), 4.12 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 4.00 
(dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.81-3.70 (m, 3H, H-4, H-6a, H-6b), 3.63 ppm (ddd, J = 2.3, 5.6, 9.7 Hz, 1H, 
H-5); 13C NMR (125 MHz, CD3OD): δ = 154.04 (Ar-C), 145.44, 142.03, 139.09 (m, 5C, 5 Ar-CF), 132.87, 
131.19, 124.96, 122.26, 118.09 (5 Ar-C), 115.86 (dt, J = 3.8, 17.4 Hz, Ar-C), 100.64 (C-1), 76.13 (C-5), 
72.37 (C-3), 71.76 (C-2), 68.20 (C-4), 62.66 ppm (C-6) 
2',3',4',5',6'-Pentafluoro-biphenyl-4-yl a-D-mannopyranoside (5). To a solution of 17 (19 mg, 0.032 
mmol) in dry MeOH (2 mL) was added 1.0 M MeONa/MeOH (50 µL, 1.6 eq) at rt under argon. The 
mixture was stirred for 2 h and then neutralized with AcOH (10 µL) and evaporated to dryness in vacuo. 
The crude product was purified by MPLC on silica gel (DCM/MeOH, 1:0-9:3) to afford 5 (12 mg, 89%) 
as a white solid. [α]  +97.3 (c 0.60, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.41 (d, J = 8.5 Hz, 2H, Ar-
H), 7.27 (d, J = 8.8 Hz, 2H, Ar-H), 5.57 (d, J = 1.2 Hz, 1H, H-1), 4.04 (dd, J = 1.7, 3.2 Hz, 1H, H-2), 3.92 (dd, 
J = 3.4, 9.4 Hz, 1H, H-3), 3.80-3.71 (m, 3H, H-4, H-6a, H-6b), 3.61 ppm (ddd, J = 2.2, 5.2, 9.5 Hz, 1H, H-
5); 13C NMR (125 MHz, CD3OD): δ = 158.71 (Ar-C), 146.48-138.12 (m, 5C, 5 Ar-CF), 132.66, 121.23, 
117.92 (5C, 5 Ar-C), 117.19 (m, Ar-C), 100.10 (C-1), 75.61 (C-5), 72.38 (C-3), 71.90 (C-2), 68.33 (C-4), 
62.70 ppm (C-6);  
4'-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyloxy)-3'-chloro-2,3,5,6-tetrafluoro-biphenyl-4-
carbonitrile (20). To a microwave tube with 18 (300 mg, 0.513 mmol) and 19 (135 mg, 0.770 mmol, 
1.5 eq), dry p-xylene (4 mL) was added under argon followed by the addition of 1,10-phenanthroline 
(51 mg, 0.257 mmol, 0.5 eq), CuI (49 mg, 0.257 mmol, 0.5 eq) and dry K3PO4 (218 mg, 1.027 mmol, 2.0 
eq). The tube was sealed with a Teflon septum, evacuated through a needle, and flushed with argon. 
Then, the mixture was degassed in an ultrasonic bath for 10 min, flushed again with argon and exposed 
to microwave irradiation at 150 °C for 8 h. Then, additional potions of 19 (45 mg, 0.257 mmol, 0.5 eq), 
1,10-phenanthroline (17 mg, 0.086 mmol, 0.2 eq), CuI (16 mg, 0.084 mmol, 0.2 eq) and dry K3PO4 (72 
mg, 1.027 mmol, 0.3 eq) were added. Microwave irradiation was continued for another 5 h at 160 °C. 
The mixture was diluted with EtOAc (50 mL), washed with H2O (2 x 30 mL) and brine (20 mL). The 
organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by MPLC on 
silica gel (petroleum ether/EtOAc, 1:0-7:3) to yield 20 (215 mg, 66%) as colorless oil. [α]  +76.6 (c 
1.05, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.53 (br s, 1H, Ar-H), 7.33 (s, 2H, Ar-H), 5.64 (d, J = 1.6 Hz, 
1H, H-1), 5.59 (dd, J = 3.5, 10.0 Hz, 1H, H-3), 5.51 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 5.38 (t, J = 10.0 Hz, 1H, 
H-4), 4.25 (dd, J = 5.2, 12.0 Hz, 1H, H-6a), 4.13-4.07 (m, 2H, H-5, H-6b), 2.19, 2.05, 2.03, 2.00 ppm (4 s, 
12H, 4 COCH3); 13C NMR (125 MHz, CDCl3): δ = 170.45, 169.99, 169.82, 169.78 (4 CO), 152.69 (Ar-C), 
147.21 (m, 2C, 2 Ar-CF), 144.01 (m, 2C, 2 Ar-CF), 132.10, 129.65 (2 Ar-C), 125.20 (t, J = 16.1 Hz, Ar-C), 
124.93, 121.16, 116.68 (3 Ar-C), 107.40 (t, J = 3.3 Hz, CN), 96.40 (C-1), 93.39 (t, J = 17.1 Hz, Ar-C), 70.09 
(C-5), 69.19 (C-2), 68.69 (C-3), 65.74 (C-4), 62.08 (C-6), 20.87, 20.73, 20.71, 20.63 ppm (4 COCH3); IR 
(neat): n = 2247 (CºN) cm-1; ESI-MS: m/z: Calcd for C27H22ClF4NNaO10 [M+Na]+: 654.1, found: 654.2. 
3'-Chloro-2,3,5,6-tetrafluoro-4'-(a-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (6). To a 
suspension of 20 in i-PrOH (3.0 mL) was added 2.0 M NH3(aq) (3.0 mL) and THF (1.5 mL). After 24 h of 
stirring at rt, the solvent was evaporated in vacuo. The residue was purified by MPLC on silica gel 
(DCM/MeOH, 1:0-19:1) followed by MPLC on RP-18 (H2O/MeOH, 1:0-0:1) to yield 6 (10,8 mg, 39%) as 
a white solid. [α]  +77.0 (c 1.08, MeOH); 1H NMR (500 MHz, CD3OD): δ = 7.63 (br s, 1H, Ar-H), 7.56 (d, 
J = 8.7 Hz, 1H, Ar-H), 7.47 (br d, J = 8.6 Hz, 1H, Ar-H), 5.68 (d, J = 1.6 Hz, 1H, H-1), 4.12 (dd, J = 1.9, 3.4 
Hz, 1H, H-2), 4.00 (dd, J = 3.4, 9.5 Hz, 1H, H-3), 3.80-3.70 (m, 3H, H-4, H-6a, H-6b), 3.61 ppm (ddd, J = 
€ 
D
20
€ 
D
20
€ 
D
20
€ 
D
20
FimH antagonists  Manuscript 6 
 191 
2.3, 5.6, 9.7 Hz, 1H, H-5); 13C NMR (125 MHz, CD3OD): δ = 154.67 (Ar-C), 148.95 (m, 2C, 2 Ar-CF), 145.31 
(m, 2C, 2 Ar-CF), 132.79, 131.17 (2 Ar-C), 126.69 (m, Ar-C), 125.07, 121.75, 118.00 (3 Ar-C), 108.53 (m, 
CN), 100.58 (C-1), 94.12 (m, Ar-C), 76.21 (C-5), 72.36 (C-3), 71.71 (C-2), 68.18 (C-4), 62.65 ppm (C-6); 
IR (KBr): n = 2247 (CºN) cm-1. 
2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl 2,3,4,6-tetra-O-acetyl-a-D-
mannopyranosyloxy (21). A microwave tube was charged with 18 (100 mg, 0.171 mmol), 
bis(pinacolato)diborone (52 mg, 0.205 mmol, 1.2 eq) and KOAc (68 mg, 0.688 mmol, 3.0 eq). The tube 
was sealed with a Teflon septum, evacuated through a needle, and flushed with argon. Then anhydrous 
DMF (2 mL) was added and the mixture was degassed in an ultrasonic bath for 10 min and flushed 
again with argon. Then, PdCl2(dppf)×CH2Cl2 (5.6 mg, 6.9 µmol, 0,07 eq) was added and the mixture was 
exposed to microwave irradiation at 120 °C for 2 h. The mixture was diluted with EtOAc (50 mL), 
washed with H2O (2 x 20 mL) and brine (20 mL). The organic layer was dried over Na2SO4 and 
concentrated in vacuo. The residue was purified by MPLC on silica gel (petroleum ether/EtOAc, 1:0-
2:3) to yield 21 (61 mg, 61%) as colorless oil. [α]  +63.4 (c 0.56, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 
7.83 (d, J = 1.5 Hz, 1H, Ar-H), 7.63 (dd, J = 1.5, 8.2 Hz, 1H, Ar-H), 7.15 (d, J = 8.2 Hz, 1H, Ar-H), 5.63-5.59 
(m, 2H, H-1, H-3), 5.53 (dd, J = 1.9, 3.4 Hz, 1H, H-2), 5.38 (t, J = 10.1 Hz, 1H, H-4), 4.27 (dd, J = 5.3, 12.3 
Hz, 1H, H-6a), 4.13 (ddd, J = 2.3, 5.3, 10.2 Hz, 1H, H-5), 4.04 (dd, J = 2.3, 12.3 Hz, 1H, H-6b), 2.20, 2.06, 
2.03 (4 s, 12H, 4 COCH3), 1.33 ppm (s, 12H, 4 CCH3); 13C NMR (125 MHz, CDCl3): δ = 170.63, 170.06, 
169.92, 169.86 (4C, 4 CO), 153.48, 137.11, 134.52, 124.02, 116.09 (6C, Ar-C), 96.34 (C-1), 84.26 (2C, 2 
C(CH3)2), 69.87 (C-5), 69.44 (C-2), 68.92 (C-3), 65.93 (C-4), 62.17 (C-6), 24.99, 24.97 (4C, 2 C(CH3)2), 
21.00, 20.85, 20.81, 20.80 ppm (4 COCH3); ESI-MS: m/z: Calcd for C26H34BClNaO12 [M+Na]+: 607.2, 
found: 607.2. 
4'-(2,3,4,6-Tetra-O-acetyl-a-D-mannopyranosyloxy)-3'-chloro-2,3-difluoro-biphenyl-4-carbonitrile 
(23). A round-bottom flask was charged with 22 (61 mg, 0.104 mmol), boronate 21 (30 mg, 0.136 mmol, 
1.3 eq) and K3PO4 (66 mg, 0.312 mmol, 3.0 eq), then evacuated and flushed with argon. Anhydrous 
DMF (4 mL) was added and the mixture was degassed in an ultrasonic bath for 10 min and flushed with 
argon followed by the addition of PdCl2(dppf)×CH2Cl2 (4 mg, 5.2 µmol, 0.03 eq). After stirring for 2.5 h 
at 90 °C, the mixture was diluted with EtOAc (50 mL) and washed with H2O (20 mL) and brine (20 mL). 
The organic layer was dried over Na2SO4 and concentrated in vacuo. The residue was purified by MPLC 
on silica gel (petroleum ether/EtOAc, 1:0-1:1) to yield 23 (36 mg, 58%) as colorless oil. [α]  +70.8 (c 
0.90, CHCl3); 1H NMR (500 MHz, CDCl3): δ = 7.60 (br s, 1H, Ar-H), 7.45 (m, 1H, Ar-H), 7.41 (br d, J = 8.6 
Hz, 1H, Ar-H), 7.30-7.28 (m, 2H, Ar-H), 5.63-5.60 (m, 2H, H-1, H-3), 5.53 (m, 1H, H-2), 5.40 (t, J = 10.1 
Hz, 1H, H-4), 4.28 (dd, J = 5.2, 12.2 Hz, 1H, H-6a), 4.14 (ddd, J = 2.0, 5.2, 10.0 Hz, 1H, H-5), 4.10 (dd, J = 
2.0, 12.2 Hz, 1H, H-6b), 2.21, 2.07, 2.04, 2.03 ppm (4 s, 12H, 4 COCH3); 13C NMR (125 MHz, CDCl3): δ = 
170.54, 170.08, 169.90, 169.84 (4 CO), 152.39 (dd, J = 15.7, 262.2 Hz, Ar-CF), 152.17 (Ar-C), 147.92 (dd, 
J = 11.8, 253.6 Hz, Ar-CF), 134.60 (d, J = 10.0 Hz, Ar-C), 131.06 (d, J = 3.1 Hz, Ar-C), 128.71 (m, Ar-C), 
128.49 (d, J = 3.7 Hz, Ar-C), 127.99 (d, J = 4.7 Hz, Ar-C), 125.61 (m, Ar-C), 125.02, 116.94 (2 Ar-C), 112.86 
(d, J = 3.6 Hz, CN), 102.27 (d, J = 11.4 Hz, Ar-C), 96.58 (C-1), 70.08 (C-5), 69.33 (C-2), 68.79 (C-3), 65.84 
(C-4), 62.15 (C-6), 20.97, 20.81, 20.79, 20.75 ppm (4 COCH3); IR (neat): n = 2234 (CºN) cm-1; ESI-MS: 
m/z: Calcd for C27H24ClF2NNaO10 [M+Na]+: 618.1, found: 618.1. 
3'-Chloro-2,3-difluoro-4'-(a-D-mannopyranosyloxy)-biphenyl-4-carbonitrile (4c). To a suspension of 
21c in i-PrOH (0.5 mL) was added 1.3 M NH3(aq) (2 mL) and THF (1.0 mL). After 4.5 d of stirring at rt, the 
solvent was evaporated in vacuo. The residue was purified by MPLC on silica gel (DCM/MeOH, 1:0-9:1) 
to yield 7 (19 mg, 73%) as a white solid. [α]  +87.4 (c 0.95, MeOH); 1H NMR (500 MHz, CD3OD): δ = 
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7.69 (m, 1H, Ar-H), 7.61 (ddd, J = 1.7, 5.9, 7.8 Hz, 1H, Ar-H), 7.55-7.51 (m, 2H, Ar-H), 7.47 (ddd, J = 1.7, 
6.8, 8.3 Hz, 1H, Ar-H), 5.65 (d, J = 1.6 Hz, 1H, H-1), 4.12 (dd, J = 1.8, 3.4 Hz, 1H, H-2), 4.00 (dd, J = 3.4, 
9.5 Hz, 1H, H-3), 3.79-3.70 (m, 3H, H-4, H-6a, H-6b), 3.61 ppm (ddd, J = 2.3, 5.6, 9.7 Hz, 1H, H-5); 13C 
NMR (125 MHz, CD3OD): δ = 154.13 (Ar-C), 153.42 (dd, J = 15.8, 258.7 Hz, Ar-CF), 148.95 (dd, J = 11.8, 
251.2 Hz, Ar-CF), 136.13 (d, J = 9.9 Hz, Ar-C), 131.68 (d, J = 3.6 Hz, Ar-C), 129.91 (d, J = 3.4 Hz, Ar-C), 
129.40 (d, J = 4.7 Hz, Ar-C), 129.07 (Ar-C), 127.28 (m, Ar-C), 125.14, 118.20 (2 Ar-C), 113.73 (d, J = 3.6 
Hz, CN), 102.73 (d, J = 12.5 Hz, Ar-C), 100.59 (C-1), 76.14 (C-5), 72.37 (C-3), 71.75 (C-2), 68.18 (C-4), 
62.65 ppm (C-6); IR (KBr): n = 2236 (CºN) cm-1;  
Protein production and purification 
FimHLD and FimHFL were produced and purified as reported earlier (19, 74).  
Fluorescence polarization (FP) assay 
FP assays were essentially performed as previously described (27). A detailed experimental protocol is 
given in the Supporting Information. 
Isothermal Titration Calorimetry (ITC)  
All ITC experiments with FimHLD were performed using a VP-ITC instrument from MicroCal, Inc. 
(Malvern Instruments, Worcestershire, U.K.) with a sample cell volume of 1.4523 mL. For experiments 
with FimHFL, an ITC200 device from MicroCal, Inc. (Malvern Instruments, Worcestershire, U.K.) with a 
sample cell volume of 203.7 µL was used. The measurements were performed with 2% DMSO at 25 °C, 
a stirring speed of 307 rpm (VP-ITC) or 750 rpm (ITC200), and 10 μcal s−1 (VP-ITC) / 6 μcal s−1 (ITC200) 
reference power. The protein samples were dialyzed in assay buffer (10 mM HEPES, 150 mM NaCl, 
pH 7.4) prior to all experiments. For experiments with FimHLD, the c-values [c = Mt(0) KD-1, where Mt(0) 
is the initial protein concentration] for compounds 1 and 2 were in a reliable range between 5 and 
1000. For compounds 3, 4, 6, and 7, the c-values of the direct titrations were above 1000, so additional 
competitive ITC experiments were performed (75). The ligands were titrated into protein preincubated 
with a nine- to 70-fold excess of n-heptyl 2-deoxy-α-D-mannoside, resulting in sigmoidal titration 
curves. For measurements with FimHFL, all compounds were analyzed by direct titration. Baseline 
correction and peak integration was performed with Origin 7.0 (OriginLab, USA) or NITPIC version 1.2.0 
(76). Baseline subtraction and curve fitting with the three variables N (stoichiometry), KD (dissociation 
constant), and ΔH° (change in enthalpy) were performed with SEDPHAT versions 10.40 and 12.1b 
(National Institutes of Health) (77). Global fitting analyses were performed for the competitive 
titrations (3, 4, 6, and 7 competing for the binding site) and for the direct titration of the competitor 
to obtain KD values. The ΔH° and N values were then obtained by fitting of the direct titrations of 3, 4, 
6, and 7. For compounds 1 and 2, as well as for all experiments with FimHFL, all variables could be 
determined from a global analysis of two independent direct titrations. The 95% confidence intervals 
of KD and ΔH° were calculated with the 1-dimensional error surface projection. The ΔG° (Gibb’s free 
energy of binding) and -TΔS° (change in entropy) values were calculated from Eq. (1) 
 ΔG° = ΔH° − TΔS° = −RT lnKA (Eq. 1) 
with T being the absolute temperature and R the universal gas constant (8.314 Jmol-1 K-1).  
FimH complex crystallization and structure refinement 
For crystallization, FimHLD (residues 1–158) at a final concentration of 15 mg/mL (ca. 0.9 mM) with a 
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3-fold molar excess of ligand 5 (ligand dissolved in DMSO) in 20 mM HEPES pH 7.4, 2% DMSO was used. 
FimHLD/5 crystals were grown in sitting-drop vapor diffusion at 19 °C in 0.1 M BisTrisPropane, propionic 
acid, cacodylate (PCPT buffer) pH 8.0 and 25 % PEG1500. Crystals appeared after 2 months and grow 
up to their final size within 3 months. They were cryopreserved by addition of 20% ethylene glycol 
(v/v) and flash-cooled with liquid nitrogen. FimHLD/6 was crystallized in 0.1 M Na acetate pH 5.0, 1.5 M 
(NH4)2SO4 at 19 °C and flash-cooled after a quick soak in 2.5 M Li2SO4 (78). Data was collected at the 
X06SA beamline of the Swiss Light Source (Paul Scherrer Institute, Switzerland) and indexed, integrated 
and scaled with XDS (79, 80). The structures were solved by molecular replacement with PHASER (81) 
using the FimHLD / biphenyl α-mannopyranoside complex (PDB code 4X50)(23) as search model. The 
structures were built using the COOT software85 and periodically refined with the PHENIX software 
(82). Geometric restraints for the ligands were generated with PRODRG (83). The final protein models 
were validated with Molprobity  and deposited in the Protein Data Bank with the PDB codes 5MCA and 
(To be announced). Data collection and refinement statistics are given in the Supporting Information. 
NMR chemical shift perturbation (CSP) 
NMR samples for backbone CSP experiments contained 250 µM uniformly 15N-labeled FimHLD and an 
excess (1.3 – 1.7 mM nominal due to solubility limitations) of fluorinated compounds 4, 5 and 6, 
respectively, in 20 mM sodium phosphate buffer pH 7.0 with 7% D2O. 0.1 mM TSP-d4 (3-
(trimethylsilyl)-2,2’,3,3’-tetradeuteropropionic acid, Armar Chemicals, Switzerland) was added as an 
internal reference. All spectra were acquired on a 500 MHz Bruker Avance III NMR spectrometer 
equipped with a 5 mm TXI RT probe head at a temperature of 298 K. All spectra were acquired and 
processed with Topspin 3.2 (Bruker BioSpin, Switzerland) and analysed with CcpNmr Analysis 2.4 (84). 
The backbone resonance assignment as well as CSP data with the non-fluorinated reference 
compounds 1 and 3 were available from a previous study (23). As all tested mannoside ligands bound 
in the slow exchange regime, peak assignment was performed based on chemical shift proximity. 
Ab initio calculations 
Input structures were prepared from the co-crystal structures of 5 and 6 and from the available 
structures in the Protein Data Bank for 1 (PDB 4X50) & 3 (PDB 4CST). The input structure for compound 
2 was generated from 1, by replacing the appropriate hydrogen with a chlorine substituent. Compound 
4 and 7 were equally prepared, starting from 5 and 6, respectively. The aglycone–Tyr48 complexes 
were optimized by Jaguar (85) DFT calculations using the B3LYP-MM functional in combination with 
the cc-pVDZ++ basis-set in the gas phase. The same level of theory was used to compute the π-π 
stacking interaction energies from the optimized complexes. 
Physicochemical and in Vitro Pharmacokinetic Studies 
Materials. Tris-HCl, 1-octanol, NaOH, formic acid, and 1-propranolol were purchased from Sigma-
Aldrich Chemie GmbH (Steinheim, Germany), PRISMA HT universal buffer, GIT-0 Lipid Solution, and 
Acceptor Sink Buffer were purchased from pIon (Billerica, USA). ACN and MeOH were ordered from 
Acros Organics (Geel, Belgium). 
The solubility, permeability and lipophilicity of 3 was reported previously (27).  
LogD7.4 determination (shake-flask method). Equal amounts of Tris-HCl buffer (0.1 M, pH 7.4) and 1-
octanol were mixed and vigorously shaken for 5 minutes to saturate the phases. The mixture was left 
until complete separation of the phases occurred and the buffer was retrieved. The test compound 
was diluted with buffer to a concentration of 10 µM. The buffer was transferred to a 96-well plate and 
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saturated 1-octanol was added, resulting in a 3/180 and 4/180 1-octanol to water ratio, respectively. 
Each ratio was measured in triplicate and simultaneous measurements were conducted with 1-
propanolol as positive control. The plate was sealed with aluminium foil, shaken (1350 rpm, 25 °C, 2 h) 
on a Heidolph Titramax 1000 plate-shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, 
Germany) and centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge, Hamburg, Germany). 
The aqueous phase was transferred to a 96-well plate for analysis by liquid chromatography-mass 
spectrometry (LC-MS, see below). 
The logD7.4 coefficients were calculated from the 1-octanol:buffer ratio (o:b), the initial concentration 
of the analyte in buffer (10 µM), and the concentration of the analyte in buffer (cb) with equation 2: !"#$%.' 	= !"#*+,	-./	01	01 ×	 +3:56   (Eq. 2) 
 
Aqueous Solubility. Lyophilized compound was added to 200 µL Tris-HCl buffer (pH 7.4, 0.1 M) in 
duplicate until a precipitation was formed. The vials were put into super-sonic bath (Branson 2510, 
Danbury, USA) for 30 min at 25 °C and then left at 25 °C for 24 h to equilibrate. The dispersion was 
filtrated (0.2 µm), diluted in Tris-HCl buffer and analyzed by LC-MS (see below). 
Parallel artificial membrane permeability assay (PAMPA). Effective permeability (logPe) was 
determined in a 96-well format with PAMPA (66, 70).For each compound, measurements were 
performed at pH 7.4 in quadruplicate. Four wells of a deep well plate were filled with 650 µL of PRISMA 
HT universal buffer (pIon, Billerica, USA), adjusted to pH 7.4 by adding the requested amount of NaOH 
(0.5 M). Samples (150 µL) were withdrawn from each well to determine the blank spectra by UV/Vis-
spectroscopy (190 to 500 nm, SpectraMax 190, Molecular Devices, Silicon Valley, CA, USA). Then, 
analyte dissolved in DMSO (10 mM) was added to the remaining buffer to yield 50 µM solutions. 
Afterwards, samples (150 µL) were withdrawn to determine the reference spectra. Further 200 µL was 
transferred to each well of the donor plate of the PAMPA sandwich (pIon, P/N 110 163). The filter 
membranes at the bottom of the acceptor plate were infused with 5 µL of GIT-0 Lipid Solution and 
200 µL of Acceptor Sink Buffer was filled into each acceptor well. The sandwich was assembled, placed 
in the GutBoxTM (pION), and left undisturbed for 16 h. Then, it was disassembled and samples (150 µL) 
were transferred from each donor and acceptor well to UV-plates for determination of the UV/Vis 
spectra. Effective permeability (logPe) was calculated from the compound flux deduced from the 
spectra, the filter area, and the initial sample concentration in the donor well with the aid of the 
PAMPA Explorer Software (pIon, version 3.5). 
Liquid chromatography-mass spectrometry measurements (LC-MS). Analyses were performed using 
a 1100/1200 Series HPLC System coupled to a 6410 Triple Quadrupole mass detector (Agilent 
Technologies, Inc., Santa Clara, CA, USA) equipped with electrospray ionization. The system was 
controlled with the Agilent MassHunter Workstation Data Acquisition software (version B.03.01). The 
column used was an Atlantis® T3 C18 column (2.1 x 50 mm) with a 3 µm-particle size (Waters Corp., 
Milford, MA, USA). The mobile phase consisted of eluent A: H2O containing 0.1% formic acid; and 
eluent B: ACN containing 0.1% formic acid. The flow rate was maintained at 0.6 mL/min. The gradient 
was ramped from 95% A/5% B to 5% A/95% B over 1 min, and then hold at 5% A/95% B for 0.1 min. 
The system was then brought back to 95% A/5% B, resulting in a total duration of 4 min. Fragmentor 
voltage and collision energy were optimized for the analysis of compounds in multiple reaction 
monitoring mode in negative mode. The concentration of the analytes was quantified by the Agilent 
Mass Hunter Quantitative Analysis software (version B.04.00). 
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4.6 Publication 1: FimH ester prodrug approach  
This publication describes the synthesis and experimental determination of physicochemical 
and pharmacokinetic properties of ester prodrugs starting from the bioisostere 5e.  
 
Figure 1 Proposed mode of action of ester prodrugs. 
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ARTICLE
Prodruggability of carbohydrates— oral FimH antagonists
Wojciech Schönemann, Simon Kleeb, Philipp Dätwyler, Oliver Schwardt, and Beat Ernst
Abstract: The bacterial lectin FimH is a promising therapeutic target for the nonantibiotic prevention and treatment of urinary
tract infections. In this communication, an ester prodrug approach is described to achieve oral bioavailability for FimH antag-
onists. By introducing short-chain acyl promoieties at the C-6 position of a biphenyl !-D-mannopyranoside, prodrugs with an
excellent absorption potential were obtained. The human carboxylesterase 2 was identified as a main enzyme mediating rapid
bioconversion to the active principle. Despite their propensity to hydrolysis within the enterocytes during absorption, these
ester prodrugs present a considerable progress in the development of orally available FimH antagonists.
Key words: FimH antagonists, oral bioavailability, ester prodrugs, enzyme-mediated bioconversion, renal excretion.
Résumé : La lectine bactérienne FimHest une cible thérapeutiqueprometteuse pour la prévention et le traitement sans antibiotiques
des infections des voies urinaires. Dans la présente communication, nous décrivons une approche faisant appel a` un promédicament
a` base d’ester pour permettre l’obtention d’une biodisponibilité orale a` l’administration d’antagonistes de la protéine FimH. En
ajoutant des groupements labiles acylés a` courtes chaînes enpositionC-6 d’unbiphényl-!-D-mannopyranoside, nous avons obtenudes
promédicaments dotés d’un excellent potentiel d’absorption. Nous avons établi que la carboxylestérase 2 humaine était la principale
enzyme assurant une bioconversion rapide de ces promédicaments en leur principe actif. Malgré leur propension a` l’hydrolyse a`
l’intérieur des entérocytes au cours de l’absorption, ces promédicaments a` base d’ester représentent unprogrès considérable sur le plandu
développement d’antagonistes de la protéine FimH biodisponibles après administration par voie orale. [Traduit par la Rédaction]
Mots-clés : antagonistes de la protéine FimH, biodisponibilité orale, promédicaments a` base d’ester, bioconversion enzymatique,
excrétion rénale.
Introduction
Urinary tract infections (UTIs) primarily caused by uropatho-
genic Escherichia coli (UPEC) are among the most prevalent infec-
tious diseases worldwide and are treated with antibiotics as first
line therapy.1 However, frequent and repeated use of antibiotics
can lead to antimicrobial resistance and treatment failure, corrob-
orating the need for alternative therapeutic strategies.2 Bacterial
adhesion to urothelial cells is a crucial first step of the infection
cycle, preventing UPEC from being washed out by urine flow and
enabling the bacteria to infect urothelial cells.3 This initial adhe-
sion is mediated by the mannose-specific lectin FimH localized at
the tip of bacterial type 1 pili.4 FimH consists of a lectin domain
hosting the carbohydrate recognition domain (CRD) and a pilin
domain regulating the switch between the low- and high-affinity
states of the CRD.5 The CRD interacts with the mannosylated
glycoprotein uroplakin 1a on the surface of urothelial cells and
thereby initiates the bacterial infection.
More than three decades ago, Firon et al. introduced FimH antag-
onists as a novel class of therapeutics for prevention and treatment
of UTI.6 Since then, several alkyl and aryl !-D-mannopyranosides
with nanomolar affinities towards the FimH-CRDwere reported.7 In
vivo pharmacokinetic studies with orally bioavailable biphenyl !-D-
mannopyranosides in amousemodelwerefirst performed in2010,7d
and since then, additional reports describing orally active FimH an-
tagonists have been published.7f,7g In either case, high oral dosages
(≥50mg/kg) were necessary to achieve theminimal effective concen-
trations required for anti-adhesive effects in the bladder. The antag-
onists were furthermore rapidly eliminated from circulation, such
that the therapeutic effect— upon a single dose— could be main-
tained only for a few hours.
When despite high oral dosages only low antagonist concentra-
tion can be detected in the urine, the reasons are either low intes-
tinal absorption (i.e., due to low aqueous solubility or low
membrane permeability) or extensive nonrenal elimination.8
Moreover, undesirably fast renal excretion of the systemically
available fraction is due to high glomerular filtration, i.e., low
plasma protein binding (PPB), or poor reabsorption in the renal
tubules.9 We recently reported ester prodrugs of antagonist 1
(Fig. 1) where the carboxylic acid moiety on the terminal ring of
the biphenyl aglycone is masked as ester, leading to increased
intestinal absorption.7d In a second approach, we replaced the
carboxylic acid moiety by bioisosteres to raise lipophilicity and
PPB and, consequently, to slow down excretion of the systemically
available antagonist into the bladder.10 In the case of the cyanide
3, the physicochemical profile allowed for excellent oral absorp-
tion and sustained renal excretion, whereas other bioisosteres,
e.g., the p-methylsulfonyl-biphenyl mannoside 4a, were too polar
for absorption.
A common feature of carbohydrate derivatives is their high
polarity, resulting from their many hydroxyl groups. By peracyla-
tion the hydrophilic character can be markedly reduced, leading
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to an increased cellular uptake.11a,11b However, polyacylated car-
bohydrate derivatives may also exhibit disadvantages, like low
solubility and complex in vivo pharmacokinetic profiles due to
different rates for deacylation leading to numerous metabolic
intermediates, whereof eachmetabolite could be renally excreted
individually.
In the present communication, we describe an ester prodrug
strategy applied for the optimization of the pharmacokinetic pa-
rameters relevant for oral absorption of methylsulfonyl bio-
isostere 4a. As opposed to peracylation, only one of the hydroxyl
groups was acylated. For the adjustment of lipophilicity and met-
abolic hydrolysis, the aliphatic esters were elongated or branched,
thereby paving the way for orally available prodrugs with sus-
tained excretion of the pharmacologically active principle 4a into
the bladder (Scheme 1).
Results and discussion
Synthesis of prodrugs 5a–5h
For the acylation, we selected the C-6 hydroxyl group of the
mannose moiety of antagonist 4a because the steric accessibility
of the 6-position guarantees successful enzymatic hydrolysis. In
the prodrugs 5a–5g, the C-6 hydroxyl group is directly acylated,
whereas in prodrug 5h, an additional acetal linkerwas introduced
to further improve the accessibility of themetabolic cleavage site.
Upon hydrolysis of the ester, the resulting hemiacetal intermedi-
ate is expected to collapse spontaneously, releasing the active
principal as well as formaldehyde.
The synthetic route applied for the synthesis of the prodrugs
5a–5g is depicted in Scheme 2. BF3·Et2O-promoted mannosyla-
tion of p-iodophenol 7 (¡ 8) followed by deacetylation under
standard Zemplén conditions yielded mannoside 9. Selective
protection of the primary alcohol in 9 with tert-butyldimeth-
ylsilyl chloride followed by benzylation of the remaining three
hydroxyl groups and, finally, removal of the TBDMS group un-
der acidic conditions was performed according to one of the
representative procedures to give intermediate 10.12 Suzuki
cross-coupling with 4-(methanesulfonyl)phenylboronic acid
pinacol ester (11) afforded mannoside 12.13 Then the promoiety
in the 6-position was introduced with acetic anhydrate (¡ 13a)
or corresponding acid chlorides (¡ 13b–13g). The prodrugs
5a–5g were finally obtained after hydrogenolysis in the pres-
ence of palladium hydroxide on carbon.
For the synthesis of 5h (Scheme 3), a modified final acylation
strategy was necessary, since a methylene linker had to be intro-
duced between the 6-OH of the mannose moiety and the acyl
group. A convenient approach involves methylthiomethyl ether
Fig. 1. Pharmacokinetics of biphenyl !-D-mannopyranosides improved by (a) an ester prodrug approach7d and (b) bioisosteric modifications.10
Compared to the parent carboxylates 1a and 1b, the ester prodrugs 2a–2c exhibit oral availability; with bioisosteres of the carboxylates 1a and
1b, a prolonged renal excretion (¡ 4a–4c) and improved oral bioavailablity (¡ 3) could be achieved.
Scheme 1. Proposed mode of action. Ester prodrugs of the biphenyl !-D-mannopyranoside 4a are hydrolyzed upon absorption by esterases.
The active principle 4a is excreted renally and binds to FimH lectins located at the tip of type 1 pili of UPECs in the bladder, resulting in a
therapeutic effect.7d
910 Can. J. Chem. Vol. 94, 2016
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for a subsequent introduction of diverse acyl groups. Starting
from 12, the methylthiomethyl ether 14 was obtained according
to a previously described procedure.14 After removal of the main
impurities by flash chromatography, this intermediate was cou-
pled with pivalic acid in presence of N-iodosuccinimide yielding
the pivaloyloxymethyl ester 15.15 Finally, debenzylation by hy-
drogenolysis gave prodrug 5h.
Physicochemical and pharmacokinetic properties
Table 1 summarizes the physicochemical and pharmacokinetic
properties of the ester prodrugs 5a–5h, i.e., their aqueous solubil-
ity,16 lipophilicity as quantified by the octanol–water partition
coefficient (log P),17 and permeability determined with the paral-
lel artificial membrane permeability assay (PAMPA)18 as well as
with colorectal adenocarcinoma cells (Caco-2).19 Table 1 also in-
cludesmetabolic stability data, describing the susceptibility of the
ester prodrugs to hydrolysis by rat and human liver associated
esterases.20
Lipophilicity and permeability
Our primary goal, namely to increase lipophilicity and perme-
ability of the biphenyl mannoside 4a, could clearly be achieved.
The log P coefficients increased in parallel with the number of
carbons of the acyl promoiety. Whereas acetate 5a was only
Scheme 2. (a) BF3·Et2O, CH2Cl2, 4 Å MS, 40 °C, 30 h, 67%; (b) MeONa–MeOH, rt, 27 h, 61%; (c) (i) TBDMSCl, imidazole, DMF, 0 °C¡ rt, 18 h;
(ii) BnBr, NaH, TBAI, DMF, 0 °C¡ rt, 5 h. (iii) H2SO4 (1 M), MeOH, 0 °C, 18 h, 58% (for three steps); (d) PdCl2(dppf)·CH2Cl2, K3PO4, DMF, 80 °C,
19 h, 86%; (e) Ac2O or R2-Cl, DMAP, pyridine, 0 °C¡ 60 °C, 3–24 h, 58%–91%; (f) Pd(OH)2/C, H2 (1 bar), EtOH, rt.
Scheme 3. (a) Ac2O, AcOH, DMSO, 4 Å MS, rt, 23 h; (b) PivOH, NIS, 0 °C¡ rt, 15 h, 33%; (c) Pd(OH)2/C, H2 (1 bar), EtOH, rt.
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slightly more lipophilic than the parent compound 4a, propi-
onate 5b, isobutyrate 5c, and butyrate 5d exhibited markedly
elevated lipophilicity. The aspired log P values above 2 could be
reached in the case of pivaloate 5e, pivaloyloxymethyl 5h,
isovalerate 5f, and valerate 5g. Furthermore, the effective perme-
ability (log Pe) deduced from PAMPA rose proportionally to log P.
Log Pe values above −5.7 are a strong indication for intestinal
absorption, whereas those above −6.3 propose only a moderate
potential. The PAMPA values for prodrugs 5a and 5b (log Pe −5.4
and −5.0) indicate a relevant improvement in membrane perme-
ability compared to parent compound 4a (log Pe −7.2) and optimal
permeability for the more lipophilic esters 5c–5h (log Pe −4.7 to
−4.4).21
In addition to PAMPA, bi-directional permeation studies
through a monolayer of Caco-2 cells were performed to reveal
passive permeation as well as carrier-mediated transport through
the cell membranes lining the small intestines.19 By treatment
with bis(4-nitrophenyl) phosphate (BNPP), the esterases expressed
by Caco-2 cells were inhibited,20 enabling the study of membrane
permeation independent of enzyme-mediated hydrolysis.22 Ap-
parent permeability (Papp) derived from the experiments in the
absorptive direction (apical ¡ basal) paralleled the trends ob-
served in lipophilicity (log P) and PAMPA (log Pe). Whereas 5a and
5b exhibited low permeability (Papp < 5 × 10−6 cm/s), high perme-
ability (Papp > 9 × 10−6 cm/s) was detected for the remaining pro-
drugs. For the most polar prodrugs 5a and 5b, high Papp in the
secretory direction (basal ¡ apical) is leading to unfavorable ef-
flux ratios (b ¡ a/a ¡ b). In these cases, efflux carrier activity
probably outbalanced the slow diffusion in the absorptive direc-
tion.23 Otherwise, the more lipophilic prodrugs 5c–5g diffused
more rapidly and therefore appeared only as weak efflux trans-
porter substrates. Finally, the performance of 5h remains in the
high-permeability range. However, its overall evaluation is wors-
ened when the efflux ratio of 3.2 is taken into account.
Solubility
For achieving oral bioavailability, quantitative dissolution of
the orally administered prodrug in the intestine is an additional
requirement.24 Regarding aqueous solubility, the prodrugs listed
in Table 1 can be divided into two categories: esters with branched
acyl promoieties (isobutyrate 5c, pivaloate 5e, and isovalerate 5f)
were sparsely soluble in aqueous medium (around 60 !g/mL),
whereas the linear esters (acetate 5a, propionate 5b, butyrate 5d,
and valerate 5g) and the extended pivaloyloxymethyl ester in 5h
showed solubility values of at least 145 !g/mL. Provided that the
prodrugs are applied at a therapeutic dose of atmost 1mg/kg body
weight, aqueous solubility of 52!g/mL should be aspired,24 which
could barely be achieved with the branched-chain derivatives. By
contrast, the prodrugs 5a, 5b, 5d, 5g, and 5h markedly exceeded
this minimum solubility criterion for quantitative intestinal ab-
sorption.
Considering the twopivotal criteria for oral absorption— aqueous
solubility and membrane permeability — the prodrug 5b (high
solubility, moderate permeability) as well as the derivatives 5d
and 5g (moderate solubility, high permeability) showed the most
promising profiles for a successful absorption.
Gastrointestinal stability
Other prerequisites for developing orally bioavailable prodrugs
are chemical stability under the conditions encountered in the
gastrointestinal tract as well as resistance to hydrolysis during the
absorption phase.25 To assess the stability of the esters against
hydrolysis under acidic and physiological conditions, the butyrate
5dwas dissolved in phosphate buffer (20 mM, pH 2.5 and 7.4) and
acetate buffer (20 mM, pH 5.0) at 37 °C and stirred for 3 h.26 At
physiological or acidic pH, 5d proved to be stable. We therefore
expect only marginal prodrug loss in the strongly acidic environ-
ment of the stomach and the slightly acidic environment of the
proximal small bowel.27
Enzymatic hydrolysis
Whereas the prodrug has to fulfill stability requirements prior
to absorption, it should be rapidly cleaved once in circulation.25
Enzymatic ester hydrolysis is undesirable during absorption but
necessary once the prodrug has reached circulation. It ismediated
by plasma-borne esterases or, as in case ofmany ester prodrugs, by
the carboxylesterase (CES) localized in the endoplasmic reticulum
of different tissues.28 The CES superfamily encloses various
isozymes classified into five subfamilies. The isozymes human
carboxylesterase isotype 1 (hCE1), highly expressed in the liver but
scarcely observed in the gastrointestinal tract, and human carbox-
ylesterase isotype 2 (hCE2), present in both liver and small intes-
tine, have been identified as major human CES.20,29 To estimate
the prodrugs’ propensity to CES-mediated hydrolysis irrespective
of the type of isozyme involved, we incubated the prodrugs 5a–5h
(initial concentration = 2 !M) with rat liver microsomes (RLM)
Table 1. Physicochemical and pharmacokinetic parameters of different ester prodrugs 5a−5h.
Caco-2 Papp (10−6 cm/s)d
Compound log Pa
Solubility
(!g/mL)b
PAMPA
log Pe (cm/s)c
a¡ b
(absorptive)
b¡ a
(secretory) b¡ a/a¡ b
RLM
t1/2 (min)e
HLM
t1/2 (min)
4a10 0.4±0.0 246±17 −7.2±0.0 0.4±0.0 1.8±0.1 5.0
5a 0.9±0.1 146±6 −5.4±0.1 1.8±0.7 17.7±1.1 10 33 nd
5b 1.5±0.1 253±10 −5.0±0.0 4.0±0.6 15.2±0.7 3.8 6.5 3.0
5c 1.8±0.1 61±1 −4.6±0.0 10.5±0.9 19.5±0.1 1.9 3.7 nd
5d 1.8±0.0 145±9 −4.7±0.1 17.3±1.9 23.5±1.2 1.4 1.8 1.1
5e 2.3±0.1 58±7 −4.6±0.1 14.1±1.2 19.8±3.3 1.4 15 nd
5f 2.1±0.1 65±4 −4.4±0.0 17.8±2.4 24.3±3.0 1.4 2.0 nd
5g 2.2±0.1 149±5 −4.5±0.1 18.1±0.2 29.4±4.0 1.6 <1 <1
5h 2.1±0.1 154±12 −4.5±0.1 9.4±1.3 30.3±3.2 3.2 44 nd
Note: The indicated values represent the mean ± SD of replicate determinations.
aOctanol−water partition coefficients (log P) were determined by a miniaturized shake-flask procedure in sextuplicate.17
bKinetic aqueous solubility was measured in triplicate.16
cPe = effective permeability: diffusion through an artificial membrane was determined by the parallel artificial membrane perme-
ability assay (PAMPA) in quadruplicate.18
dPapp = apparent permeability: permeation through a Caco-2 cell monolayer was assessed in the absorptive (a¡ b) and secretory (b¡ a)
direction in triplicate. The initial compound concentration (c0) in the donor chamber was 62.5 !M.19
eMicrosomal stability was determined with pooled male rat liver microsomes (RLM) (0.125 mg/mL) and pooled human liver micro-
somes (HLM) (0.125mg/mL) at pH 7.4 and 37 °C. The initial compound concentration was 2 !M. The concentration of the prodrug in the
incubation was monitored by LC-MS and t1/2 was calculated from the slope of the linear regression from the log percentage compound
remaining versus incubation time relationship.20
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(0.125 mg/mL in TRIS–HCl 0.1 M, pH 7.4 at 37 °C). In a further step,
we assessed the most promising esters 5b, 5d, and 5g using hu-
man liver microsomes (HLM) (0.125 mg/mL). The metabolic half-
lives (t1/2) derived from the microsomal incubations revealed two
major trends: first, an increasing susceptibility to hydrolysis along
with increased lipophilicity of the linear esters and, second, steri-
cally hindered branched acyl moieties, such as present in piv-
aloate 5e and pivaloyloxymethyl 5h, hampering the enzymatic
turnover. Moreover, exposing the pivaloate ester by an acetal
linker (¡ 5h) actually did not increase the rate of enzyme-
mediated hydrolysis.
Rapid hydrolysis as detected for the propionate, butyrate, and
valerate esters (5b, 5d, and 5g) is essential for the release of the
pharmacologically active principle. However, the prodrug ap-
proach might only be successful when the cleavage takes place in
liver and plasma and not in the small intestines during absorption
or, more precisely, when the hydrolysis is mediated by the
isozyme hCE1 rather than by hCE2.25 Since liver microsomes pre-
pared by differential centrifugation from a crude liver homoge-
nate contain both CES, selective inhibition of only one reveals
which isozyme is mainly involved. Therefore, loperamide (a spe-
cific inhibitor of hCE2) was added during the incubation of 5b, 5d,
and 5gwith HLM.30 Figure 2 summarizes the hydrolytic activity in
presence of the hCE2 specific inhibitor at ascending concentra-
tions (1, 10, and 100 !M). The metabolic turnover of the esters 5b,
5d, and 5g was in fact inhibited by loperamide, which attributes
the hydrolysis to the hCE2 isozyme.30 Recognition of the em-
ployed promoieties by isotype 2 correlates with the reported sub-
strate specificity of the two isozymes. Accordingly, hCE2 prefers
esters with a relatively small acyl moiety and a large alcohol
group, whereas hCE1 primarily catalyzes the hydrolysis of esters
with a large acyl but small alcohol moiety.20 Bioconversion medi-
ated by isotype 2 might interfere with the intestinal absorption,
even in the case of the well-soluble and permeable prodrugs 5b,
5d, and 5g. By hydrolysis within the enterocytes, the polar active
principle 4a is formed and likely effluxed back into the gut lumen
instead into the portal blood.25
Conclusions
Several short-chain fatty acids (propionic acid, butyric acid, and
valeric acid) were identified as useful acyl promoieties for opti-
mizing the intestinal absorption potential of the biphenyl man-
noside 4a. We showed that acylation of only one hydroxyl group
on the sugar moiety was sufficient to improve lipophilicity into
the range required for membrane permeability, whilst sufficient
solubility could be sustained. Moreover, the introduced ester pro-
moieties are stable in acidic conditions of the gastrointestinal
tract; however, they are fast hydrolyzed by esterases upon absorp-
tion.
The downside of acylation of a hydroxyl group of the sugar
moiety could be premature cleavage of the promoiety by hCE2
located in the enterocytes. Therefore, choosing the appropriate
prodrug moiety should be guided by enzymatic stability studies.
Furthermore, the half-life of the prodrug should allow that the
majority of the prodrug is absorbed unchanged.
For proving the benefits of the prodrug approach on oral bio-
availability and for assessing whether the intestinal uptake is
affected by concomitant hydrolysis, in vivo pharmacokinetic stud-
ies in a mouse model are currently performed.
Experimental section
Synthesis
General methods
NMR spectra were recorded on a Bruker Avance DMX-500
(500 MHz) spectrometer. Assignment of 1H and 13C NMR spectra
was achieved using 2Dmethods (COSY, HSQC, and HMBC). Chem-
ical shifts are expressed in ppm using residual CHCl3, CHD2OD, or
HDO as references. Optical rotations were measured using a
Perkin-Elmer Polarimeter 341. Electron spray ionization mass
spectra (ESI-MS) were obtained on a Waters micromass ZQ mass
spectrometer. The LC-HRMS analyses were carried out using an
Agilent 1100 LC equipped with a photodiode array detector and a
Micromass QTOF I equipped with a 4 GHz digital-time converter.
Reactions were monitored by TLC using glass plates coated with
silica gel 60 F254 (Merck) and visualized by using UV light and (or)
by charring with a molybdate solution (a 0.02 M solution of am-
monium cerium sulfate dihydrate and ammoniummolybdate tet-
rahydrate in aqueous 10% H2SO4). MPLC separations were carried
out on a CombiFlash Companion or Rf from Teledyne Isco
equipped with RediSep normal-phase columns. All compounds
used for biological assays are at least of 97% purity based on HPLC
analytical results. Commercially available reagents were pur-
chased from Aldrich, Alfa Aesar, ABCR, or Acros Organics. Sol-
ventswere purchased fromSigma-Aldrich or Acros andwere dried
prior to use where indicated. Methanol (MeOH), pyridine, and
dimethyl sulfoxide (DMSO) were dried by storing with activated
molecular sieves of 3 or 4 Å for at least 1 day. Dichloromethane
(DCM) was dried by filtration over Al2O3 (Fluka, type 5016 A basic).
Molecular sieves of 3 and 4 Å were activated in vacuo at 500 °C for
1 h immediately before use.
General procedure A for esterification
To a solution of 12 in dry pyridine (2mL) were added Ac2O or the
corresponding acyl chloride and a catalytic amount of dimeth-
ylaminopyridine (DMAP). The mixture was stirred at rt under ar-
gon until the reaction was complete (monitored by TLC) and then
diluted with ethyl acetate (EtOAc) and washed with H2O and
brine. The organic layer was dried over Na2SO4, concentrated in
vacuo, and co-evaporatedwith xylene. The residuewas purified by
MPLC on silica gel (petroleum ether – EtOAc, 7:3) to afford 13a–
13g.
General procedure B for hydrogenolysis
A solution of 13a–13g or 15 in EtOHwas stirred under hydrogen
(1 bar) in the presence of Pd(OH)2/C (E101 NE/W, 20% Pd) at rt until
the reaction was complete (monitored by TLC) and then filtered
through Celite, washed with methanol (MeOH), and concentrated
in vacuo. The residue was purified by MPLC on silica gel (DCM–
MeOH) to give 5a–5h.
4-Iodophenyl 2,3,4,6-tetra-O-acetyl-!-D-mannopyranoside (8)
Penta-O-acetyl-D-mannopyranose (15.0 g, 45.4mmol), 4-iodophenol
(11.2 g, 50.0 mmol, 1.1 equiv.), and activated molecular sieves of 4 Å
(2.00 g) were stirred in dry DCM (60mL) under argon. After 1 h, a first
Fig. 2. Human liver microsome mediated hydrolysis of ester
prodrugs 5b, 5d, and 5g in presence of loperamide (1, 10, and
100 !M), a specific inhibitor of the human carboxylesterase isotype 2.
The bars represent the metabolic release of the parent compound 4a
in the presence of different concentrations of inhibitor (1, 10, and
100 !M) relative to the accumulation in the control experiment
without loperamide.
Schönemann et al. 913
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portion of BF3·Et2O (10 mL, 81 mmol, 1.8 equiv.) was added dropwise
followed by the addition of a second portion (6.8 mL, 55.2 mmol,
1.2 equiv.) 4 h later. The reaction was stirred at 40 °C for 30 h. The
reaction mixture was filtered through Celite and the filtrate was
diluted with EtOAc (250 mL), washed with satd aq NaHCO3 (3 ×
100mL) and brine (100mL). The organic layer was dried over Na2SO4
and concentrated in vacuo. The residue was crystallized from Et2O–
hexane (1:1) to give 8. Themother liquorwas concentrated and 8was
crystallized again from Et2O–hexane (2:1). The filtrate was concen-
trated and purified by MPLC on silica gel (petroleum ether – EtOAc,
9:1). Compound 8 was obtained in an overall yield of 67% (16.8 g).
Analytical data were in accordance with literature data.31
4-Iodophenyl !-D-mannopyranoside (9)
To a solution of 8 (16.8 g, 30.5 mmol) in dry MeOH (100 mL) was
added freshly prepared 1 M MeONa–MeOH (2 mL) under argon.
The reactionmixture was stirred overnight at rt and then neutral-
ized with Amberlyst-15 (H+) ion-exchange resin, filtered, and con-
centrated in vacuo. Recrystallization from ethanol (250 mL)
afforded white crystals of 9. The mother liquor was concentrated
and purified by MPLC on silica gel (DCM–MeOH, 9:1). Compound 9
was obtained in an overall yield of 61% (7.10 g). !!"D
20" 106.5 (c 1.00,
MeOH). 1H NMR (500MHz, CD3OD): # = 7.61 (d, J = 8.9 Hz, 2H, Ar-H),
6.96 (d, J = 8.9 Hz, 2H, Ar-H), 5.48 (d, J = 1.4 Hz, 1H, H-1), 4.01 (dd, J =
1.8, 3.2 Hz, 1H, H-2), 3.89 (dd, J = 3.4, 9.4 Hz, 1H, H-3), 3.80–3.69 (m,
3H, H-4, H-6a, H-6b), 3.57 ppm (ddd, J = 2.4, 5.4, 9.7 Hz, 1H, H-5).
13C NMR (125 MHz, CD3OD): # = 157.84, 139.52, 120.15 (5C, Ar-C),
100.13 (C-1), 85.31 (Ar-C), 75.52 (C-5), 72.32 (C-3), 71.84 (C-2), 68.28
(C-4), 62.65 ppm (C-6). HRMS: m/z: calcd. for C12H15INaO6 [M+Na]+:
404.9811; found: 404.9808.
4-Iodophenyl 2,3,4-tri-O-benzyl-!-D-mannopyranoside (10)
To a stirred solution of 9 (6.61 g, 17.3 mmol) in dry DMF (17 mL)
were added TBDMSCl (2.61 g, 17.3 mmol, 1.0 equiv.) and imidazole
(2.35 g, 34.6 mmol, 2.0 equiv.) under argon at 0 °C. After 1 h, the
reaction mixture was removed from the ice bath and allowed to
reach rt. Another portion of TBDMSCl (0.26 g, 1.73 mmol,
0.1 equiv.) was added after 15 h. The reaction was stirred for 3 h
until 9 was completely consumed. The reaction mixture was di-
luted with DCM (200 mL) and washed with satd aq NaHCO3 (2 ×
150 mL) and brine (150 mL). The organic layer was dried over
Na2SO4, concentrated in vacuo, and co-evaporated with toluene
(2 × 100 mL) to afford 9.60 g of crude product. The obtained com-
pound (6.01 g) was dissolved in dry DMF (28 mL) under argon.
Sodium hydride (1.75 g, 43.6 mmol, 60% in mineral oil) was added
to the stirred solution together with an additional portion of DMF
(16 mL) at 0 °C followed by the addition of BnBr (6.47 mL,
54.5 mmol). The reaction mixture was removed from the ice bath
and allowed to reach rt. Bu4NI (0.88 g, 2.42 mmol) was added after
2 h. When the reaction was complete after another 2 h, the mix-
ture was diluted with EtOAc (250 mL) and washed with satd aq
NaHCO3 (150 mL), H2O (150 mL), and brine (100 mL). The organic
layer was dried over Na2SO4, concentrated in vacuo, and co-
evaporated with toluene (75 mL) to afford 10.8 g of a yellowish
product. The crude compound (10.8 g) was then dissolved inMeOH
(70mL) under argon and a solution of H2SO4 inMeOH (1M, 560$L)
was added dropwise. The reaction was stirred at 0 °C until com-
pletion (18 h, monitored by TLC) and then themixture was diluted
with EtOAc (100 mL) and washed with satd aq NaHCO3 (100 mL),
H2O (100mL), and brine (100mL). The aqueous layer was extracted
with EtOAc (100mL). The combined organic layers were dried over
Na2SO4, concentrated in vacuo, and the major impurities were
removed by MPLC on silica gel (petroleum ether – EtOAc, 85:15).
The crude 10 was crystallized from petroleum ether – EtOAc (3:1).
The mother liquor was concentrated and the residue was recrys-
tallized from MeOH (20 mL). Compound 10 was obtained in an
overall yield of 58% (4.32 g) over three steps. !!"D
20 " 55.9 (c 1.00,
EtOAc). 1H NMR (500 MHz, CDCl3): # = 7.48 (d, J = 8.7 Hz, 2H, Ar-H),
7.35–7.24 (m, 15H, Ar-H), 6.67 (d, J = 8.7 Hz, 2H, Ar-H), 5.49 (d, J =
1.7 Hz, 1H, H-1), 4.90 (d, J = 10.9 Hz, 1H, PhCH2O), 4.78 (d, J = 12.2 Hz,
1H, PhCH2O), 4.70–4.62 (m, 4H, PhCH2O), 4.07–4.02 (m, 2H, H-4,
H-3), 3.89 (br s, 1H, H-2), 3.70–3.69 (m, 2H, H-6a, H-6b), 3.62 (m, 1H,
H-5), 1.81 ppm (s, 1H, OH). 13C NMR (125 MHz, CDCl3): # = 155.93,
138.53, 138.42, 138.35, 138.09, 128.61, 128.58, 128.19, 128.03, 127.95,
127.86, 127.80, 118.73 (23C, Ar-C), 96.66 (C-1), 85.12 (Ar-C), 79.88 (C-3
or C-4), 75.40 (PhCH2O), 74.74 (C-2), 74.43 (C-3 or C-4), 73.38
(PhCH2O), 73.28 (C-5), 72.69 (PhCH2O), 62.06 ppm (C-6). ESI-MS:m/z:
calcd. for C33H33INaO6 [M+Na]+: 675.12, found: 675.18.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-
!-D-mannopyranoside (12)
Compounds 10 (2.50 g, 3.83 mmol) and 11 (843 mg, 4.21 mmol)
were dissolved in dry DMF (20 mL) under argon. The mixture was
degassed in an ultrasonic bath and flushed with argon for 5 min
followed by the addition of K3PO4 (2.44 g, 11.5 mmol, 3.0 equiv.)
and Pd(dppf)Cl2·CH2Cl2 (156 mg, 0.19 mmol, 0.05 equiv.). The mix-
ture was stirred at 80 °C for 19 h. The reactionmixture was diluted
with EtOAc (200 mL), washed with H2O (2 × 120 mL) and brine
(120 mL), dried over Na2SO4, and concentrated in vacuo. The resi-
due was purified by MPLC on silica gel (petroleum ether – EtOAc,
1:1) to give 12 (2.24 g, 86%) as a white solid. !!"D
20 " 70.8 (c 1.01,
EtOAc). 1H NMR (500 MHz, CDCl3): # = 7.99–7.97 (m, 2H, Ar-H),
7.72–7.70 (m, 2H, Ar-H), 7.53–7.52 (m, 2H, Ar-H), 7.42–7.29 (m, 15H,
Ar-H), 7.08–7.06 (m, 2H, Ar-H), 5.58 (d, J = 1.9 Hz, 1H, H-1), 4.97 (d, J =
10.9 Hz, 1H, PhCH2O), 4.87 (d, J = 12.3 Hz, 1H, PhCH2O), 4.78–4.69
(m, 4H, PhCH2O), 4.16–4.09 (m, 2H, H-3, H-4), 4.00 (d, J = 2.2 Hz, 1H,
H-2), 3.79–3.73 (m, 3H, H-5, H-6a, H-6b,), 3.09 ppm (s, 3H, SO2CH3).
13C NMR (125MHz, CDCl3): # = 156.68, 146.14, 138.87, 138.46, 138.35,
138.15, 133.34, 128.78, 128.65, 128.63, 128.24, 128.09, 128.06, 128.02,
127.91, 127.84, 127.67, 116.99 (30C, Ar-C), 96.67 (C-1), 80.00 (C-3 or
C-4), 75.46 (PhCH2O), 74.79 (C-2), 74.59 (C-3 or C-4), 73.41 (PhCH2O),
73.31 (C-5), 72.74 (PhCH2O), 62.25 (C-6), 44.79 ppm (SO2CH3). ESI-
MS: m/z: calcd. for C40H40NaO8S [M+Na]+: 703.23, found: 703.26.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-acetyl-2,3,4-tri-O-benzyl-
!-D-mannopyranoside (13a)
Prepared according to the general procedure A from 12 (100mg,
0.147 mmol), Ac2O (27 $L, 0.294 mmol, 2.0 equiv.), and DMAP
(1 mg, 0.008 mmol, 0.05 eq). The reaction was started at 0 °C and
allowed to warm up to rt. Yield: 104 mg (96%) as a colorless oil.
!!"D
20" 70.0 (c 1.00, CHCl3). 1H NMR (500MHz, CDCl3): # = 7.90 (d, J =
8.5 Hz, 2H, Ar-H), 7.63 (d, J = 8.4 Hz, 2H, Ar-H), 7.46 (d, J = 8.8 Hz, 2H,
Ar-H), 7.33–7.17 (m, 15H, Ar-H), 7.03 (d, J = 8.7 Hz, 2H, Ar-H), 5.52 (d,
J = 1.7 Hz, 1H, H-1), 4.88 (d, J = 10.8 Hz, 1H, PhCH2O), 4.77–4.63 (m,
4H, PhCH2O), 4.54 (d, J = 10.8 Hz, 1H, PhCH2O), 4.26–4.18 (m, 2H,
H-6a, H-6b), 4.07 (dd, J = 3.0, 9.2 Hz, 1H, H-3), 3.98–3.92 (m, 2H, H-2,
H-4), 3.81 (m, 1H, H-5), 2.99 (s, 3H, SO2CH3), 1.92 ppm (s, 3H,
COCH3). 13C NMR (125 MHz, CDCl3): # = 170.83 (CO), 156.71, 146.07,
138.84, 138.29, 138.10, 138.09, 133.31, 128.64, 128.59, 128.57, 128.55,
128.24, 128.05, 127.99, 127.95, 127.93, 127.90, 127.84, 127.61, 117.12
(30C, Ar-C), 96.43 (C-1), 79.97 (C-3), 75.34 (PhCH2O), 74.48 (C-2),
74.32 (C-4), 73.05, 72.56 (2 PhCH2O), 71.01 (C-5), 63.21 (C-6), 44.74
(SO2CH3), 20.95 ppm (COCH3). ESI-MS:m/z: calcd. for C42H42NaO9S
[M+Na]+: 745.24, found: 745.31.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl–6-O-
propionyl-!-D-mannopyranoside (13b)
Prepared according to the general procedure A from 12 (70 mg,
0.103 mmol), propionyl chloride (33 $L, 0.309 mmol, 3.0 equiv.),
and DMAP (1 mg, 0.008 mmol, 0.08 equiv.). The reaction was
started at rt and then warmed up to 60 °C. Yield: 38 mg (58%) as a
colorless oil. !!"D
20" 63.0 (c 1.84, CHCl3). 1H NMR (500 MHz, CDCl3):
# = 7.97 (d, J = 8.4 Hz, 2H, Ar-H), 7.70 (d, J = 8.4 Hz, 2H, Ar-H), 7.51 (d,
J = 8.7 Hz, 2H, Ar-H), 7.41–7.27 (m, 15H, Ar-H), 7.10 (d, J = 8.7 Hz, 2H,
Ar-H), 5.58 (d, J = 1.5 Hz, 1H, H-1), 4.95 (d, J = 10.7 Hz, 1H, PhCH2O),
4.83 (d, J = 12.3Hz, 1H, PhCH2O), 4.77–4.72 (m, 3H, PhCH2O), 4.60 (d,
914 Can. J. Chem. Vol. 94, 2016
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J = 10.7 Hz, 1H, PhCH2O), 4.34–4.28 (m, 2H, H-6a, H-6b), 4.14 (dd, J =
3.0, 9.2 Hz, 1H, H-3), 4.03 (t, J = 9.5 Hz, 1H, H-4), 3.99 (m, 1H, H-2),
3.88 (ddd, J = 2.4, 4.4, 9.8 Hz, 1H, H-5), 3.08 (s, 3H, SO2CH3), 2.27 (q,
J = 7.5 Hz, 2H, CH2COO), 1.07 ppm (t, J = 7.6 Hz, 3H, CH3). 13C NMR
(125 MHz, CDCl3): ! = 174.29 (CO), 156.77, 146.18, 138.89, 138.36,
138.17, 138.15, 137.46, 137.16, 133.37, 128.70, 128.65, 128.63, 128.61,
128.29, 128.12, 128.01, 127.99, 127.97, 127.92, 127.68, 118.42, 117.18
(30C, Ar-C), 96.44 (C-1), 80.02 (C-3), 75.44 (PhCH2O), 74.61 (C-2),
74.50 (C-4), 73.15, 72.65 (2 PhCH2O), 71.19 (C-5), 63.14 (C-6), 44.80
(SO2CH3), 27.66 (CH2COO), 9.21 ppm (CH3). ESI-MS: m/z: calcd. for
C43H44NaO9S [M+Na]+: 759.26, found: 759.13.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-isobutyryl-
!-D-mannopyranoside (13c)
Prepared according to the general procedure A from 12 (70 mg,
0.103 mmol), isobutyryl chloride (33 "L, 0.309 mmol, 3.0 equiv.),
and DMAP (2 mg, 0.016 mmol, 0.16 equiv.). The reaction was
started at rt and then warmed up to 60 °C. Yield: 63 mg (82%) as a
colorless oil. !#"D
20$ 60.0 (c 3.17, CHCl3). 1H NMR (500 MHz, CDCl3):
! = 7.96 (d, J = 8.4 Hz, 2H, Ar-H), 7.68 (d, J = 8.4 Hz, 2H, Ar-H), 7.49
(d, J = 8.7 Hz, 2H, Ar-H), 7.39–7.26 (m, 15H, Ar-H), 7.09 (d, J = 8.7 Hz,
2H, Ar-H), 5.57 (d, J = 1.6 Hz, 1H, H-1), 4.94 (d, J = 10.6 Hz, 1H,
PhCH2O), 4.81 (d, J = 12.2 Hz, 1H, PhCH2O), 4.74–4.71 (m, 3H,
PhCH2O), 4.58 (d, J = 10.6 Hz, 1H, PhCH2O), 4.35 (dd, J = 1.7, 11.9 Hz,
1H, H-6a), 4.25 (dd, J = 5.2, 11.9 Hz, 1H, H-6b), 4.12 (dd, J = 3.0, 9.2 Hz,
1H, H-3), 4.00 (t, J = 9.5 Hz, 1H, H-4), 3.97 (m, 1H, H-2), 3.86 (ddd, J =
1.6, 5.0, 9.8 Hz, 1H, H-5), 3.06 (s, 3H, SO2CH3), 2.49 (hept, J = 7.0 Hz,
1H, CH(CH3)2), 1.09 (d, J = 7.0 Hz, 3H, CH3), 1.06 ppm (d, J = 7.0 Hz,
3H, CH3). 13C NMR (125 MHz, CDCl3): ! = 176.85 (CO), 156.73, 146.17,
138.85, 138.33, 138.14, 133.31, 128.67, 128.62, 128.56, 128.22, 128.06,
128.01, 127.95, 127.90, 127.64, 117.14 (30C, Ar-C), 96.34 (C-1), 79.96
(C-3), 75.48 (PhCH2O), 74.67 (C-2), 74.61 (C-4), 73.16, 72.63 (2
PhCH2O), 71.32 (C-5), 62.98 (C-6), 44.77 (SO2CH3), 34.10 (CH), 19.12,
18.92 ppm (2 CH3). ESI-MS: m/z: calcd. for C44H46NaO9S [M+Na]+:
773.28, found: 773.28.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-butyryl-
!-D-mannopyranoside (13d)
Prepared according to the general procedure A from 12 (54 mg,
0.080 mmol), butyryl chloride (10 "L, 0.094 mmol, 1.2 equiv.), and
DMAP (1 mg, 0.008 mmol, 0.1 equiv.). The reaction mixture was
stirred at rt. Yield: 45 mg (75%) as a colorless oil. !#"D
20 $
68.6 (c 1.13, CHCl3). 1H NMR (500MHz, CDCl3): ! = 8.02 (d, J = 8.4 Hz,
2H, Ar-H), 7.75 (d, J = 8.5 Hz, 2H, Ar-H), 7.56 (d, J = 8.8 Hz, 2H, Ar-H),
7.45–7.32 (m, 15H, Ar-H), 7.15 (d, J = 8.8 Hz, 2H, Ar-H), 5.64 (d, J =
1.7 Hz, 1H, H-1), 5.00 (d, J = 10.7 Hz, 1H, PhCH2O), 4.87 (d, J = 12.3 Hz,
1H, PhCH2O), 4.81–4.77 (m, 3H, PhCH2O), 4.65 (d, J = 10.7 Hz, 1H,
PhCH2O), 4.40–4.33 (m, 2H, H-6a, H-6b), 4.19 (dd, J = 3.0, 9.2 Hz, 1H,
H-3), 4.07 (t, J = 9.5 Hz, 1H, H-4), 4.04 (m, 1H, H-2), 3.92 (ddd, J = 2.2,
4.6, 9.8 Hz, 1H, H-5), 3.12 (s, 3H, SO2CH3), 2.29 (t, J = 7.5 Hz, 2H,
CH2COO), 1.67–1.59 (m, 2H, CH2), 0.91 ppm (t, J = 7.4 Hz, 3H, CH3).
13C NMR (125 MHz, CDCl3): ! = 173.42 (CO), 156.72, 146.10, 138.83,
138.31, 138.12, 138.10, 133.27, 128.64, 128.59, 128.57, 128.55, 128.21,
128.05, 127.98, 127.95, 127.93, 127.91, 127.86, 127.60, 117.10 (30C,
Ar-C), 96.37 (C-1), 79.95 (C-3), 75.40 (PhCH2O), 74.58, 74.49 (C-2, C-4),
73.10, 72.59 (2 PhCH2O), 71.17 (C-5), 62.94 (C-6), 44.73 (SO2CH3),
36.23 (CH2COO), 18.47 (CH2), 13.80 ppm (CH3). ESI-MS: m/z: calcd.
for C44H46NaO9S [M+Na]+: 773.28, found: 773.44.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-pivaloyl-
!-D-mannopyranoside (13e)
Prepared according to the general procedure A from 12 (100mg,
0.147mmol), pivaloyl chloride (36 "L, 0.294mmol, 2.0 equiv.), and
DMAP (1 mg, 0.008 mmol, 0.05 equiv.). The reaction was started at
rt and then warmed up to 60 °C. Yield: 101 mg (90%) as a colorless
oil. !#"D
20 $ 88.7 (c 1.02, CHCl3). 1H NMR (500 MHz, CDCl3): ! = 7.90
(d, J = 8.4 Hz, 2H, Ar-H), 7.62 (d, J = 8.4 Hz, 2H, Ar-H), 7.44 (d, J =
8.7 Hz, 2H, Ar-H), 7.35–7.20 (m, 15H, Ar-H), 7.05 (d, J = 8.7 Hz, 2H,
Ar-H), 5.53 (d, J = 1.6 Hz, 1H, H-1), 4.90 (d, J = 10.6 Hz, 1H, PhCH2O),
4.77 (d, J = 12.2 Hz, 1H, PhCH2O), 4.68–4.65 (m, 3H, PhCH2O), 4.55
(d, J = 10.7 Hz, 1H, PhCH2O), 4.36 (dd, J = 1.5, 11.8 Hz, 1H, H-6a),
4.15–4.08 (m, 2H, H-3, H-6b), 3.98–3.93 (m, 2H, H-2, H-4), 3.82 (ddd,
J = 1.3, 5.3, 9.8 Hz, 1H, H-5), 2.99 (s, 3H, SO2CH3), 1.05 ppm (s, 9H,
C(CH3)3). 13C NMR (125 MHz, CDCl3): ! = 178.19 (CO), 156.61, 146.05,
138.75, 138.25, 138.07, 133.16, 128.59, 128.52, 128.46, 128.11, 127.97,
127.91, 127.84, 127.83, 127.52, 127.59, 117.08 (30C, Ar-C), 96.13 (C-1),
79.84 (C-3), 75.40 (PhCH2O), 74.71, 74.64 (C-2, C-4), 73.11, 72.50 (2
PhCH2O), 71.33 (C-5), 63.07 (C-6), 44.62 (SO2CH3), 38.82 (C(CH3)3),
27.17 ppm (C(CH3)3). ESI-MS: m/z: calcd. for C45H48NaO9S [M+Na]+:
787.29, found: 787.36.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-isovaleryl-
!-D-mannopyranoside (13f)
Prepared according to the general procedure A from 12 (38 mg,
0.056 mmol), isovaleryl chloride (27 "L, 0.223 mmol, 4.0 equiv.),
and DMAP (1 mg, 0.008 mmol, 0.14 equiv.). The reaction mixture
was stirred at rt. Yield: 35 mg (81%) as a colorless oil. !#"D
20 $
59.0 (c 0.93, CHCl3). 1HNMR (500MHz, CDCl3): ! = 7.99 (d, J = 8.4 Hz,
2H, Ar-H), 7.72 (d, J = 8.4 Hz, 2H, Ar-H), 7.53 (d, J = 8.7 Hz, 2H, Ar-H),
7.42–7.29 (m, 15H, Ar-H), 7.11 (d, J = 8.7 Hz, 2H, Ar-H), 5.59 (d, J =
1.6 Hz, 1H, H-1), 4.97 (d, J = 10.7 Hz, 1H, PhCH2O), 4.84 (d, J = 12.3 Hz,
1H, PhCH2O), 4.77–4.74 (m, 3H, PhCH2O), 4.62 (d, J = 10.7 Hz, 1H,
PhCH2O), 4.38 (dd, J = 1.9, 11.9 Hz, 1H, H-6a), 4.29 (dd, J = 4.9, 12.0 Hz,
1H, H-6b), 4.15 (dd, J = 3.0, 9.2 Hz, 1H, H-3), 4.04 (t, J = 9.5 Hz, 1H,
H-4), 4.00 (m, 1H, H-2), 3.88 (ddd, J = 1.8, 4.8, 9.8 Hz, 1H, H-5), 3.09 (s,
3H, SO2CH3), 2.16 (d, J = 7.1 Hz, 2H, CH2COO), 2.04 (m, 1H,
CH(CH3)2), 0.89 (d, J = 3.0 Hz, 3H, CH3), 0.88 ppm (d, J = 3.0 Hz, 3H,
CH3). 13C NMR (125 MHz, CDCl3): ! = 172.93 (CO), 156.76, 146.14,
138.85, 138.33, 138.15, 138.13, 133.29, 128.66, 128.62, 128.60, 128.58,
128.22, 128.09, 127.98, 127.96, 127.94, 127.89, 127.62, 117.11 (30C,
Ar-C), 96.39 (C-1), 79.97 (C-3), 75.45 (PhCH2O), 74.61, 74.57 (C-2, C-4),
73.13, 72.62 (2 PhCH2O), 71.22 (C-5), 62.89 (C-6), 44.77 (SO2CH3),
43.48 (CH2COO), 25.70 (CH(CH3)2), 22.56 ppm (2 CH3). ESI-MS: m/z:
calcd. for C45H48NaO9S [M+Na]+: 787.29, found: 787.46.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-valeryl-
!-D-mannopyranoside (13g)
Prepared according to the general procedure A from 12 (69 mg,
0.101 mmol), valeryl chloride (49 "L, 0.404 mmol, 4.0 equiv.), and
DMAP (1 mg, 0.008 mmol, 0.08 equiv.). The reaction was started at
rt and then warmed up 60 °C. Yield: 70 mg (91%) as a yellowish oil.
!#"D
20$ 63.9 (c 1.00, CHCl3). 1H NMR (500MHz, CDCl3): ! = 7.90 (d, J =
8.4 Hz, 2H, Ar-H), 7.64 (d, J = 8.4 Hz, 2H, Ar-H), 7.45 (d, J = 8.7 Hz, 2H,
Ar-H), 7.33–7.20 (m, 15H, Ar-H), 7.03 (d, J = 8.7 Hz, 2H, Ar-H), 5.52 (d,
J = 1.5 Hz, 1H, H-1), 4.88 (d, J = 10.7 Hz, 1H, PhCH2O), 4.76 (d, J =
12.3 Hz, 1H, PhCH2O), 4.70–4.63 (m, 3H, PhCH2O), 4.53 (d, J =
10.7 Hz, 1H, PhCH2O), 4.28–4.21 (m, 2H, H-6a, H-6b), 4.07 (dd, J = 3.0,
9.2 Hz, 1H, H-3), 3.95 (t, J = 9.5 Hz, 1H, H-4), 3.92 (m, 1H, H-2), 3.81
(ddd, J = 2.3, 4.4, 9.8 Hz, 1H, H-5), 3.01 (s, 3H, SO2CH3), 2.19 (t, J =
9.5 Hz, 2H, CH2COO), 1.50–1.44 (m, 2H, CH2), 1.24–1.17 (m, 2H, CH2),
0.77 ppm (t, J = 7.4 Hz, 3H, CH3). 13C NMR (125 MHz, CDCl3): ! =
173.63 (CO), 156.76, 146.12, 138.84, 138.32, 138.14, 138.12, 133.29,
128.65, 128.60, 128.59, 128.57, 128.22, 128.06, 127.99, 127.97, 127.94,
127.92, 127.88, 127.61, 117.12 (30C, Ar-C), 96.43 (C-1), 79.97 (C-3),
75.21 (PhCH2O), 74.59, 74.52 (C-2, C-4), 73.11, 72.60 (2 PhCH2O), 71.17
(C-5), 63.01 (C-6), 44.75 (SO2CH3), 34.04 (CH2COO), 27.00, 22.35 (2
CH2), 13.78 ppm (CH3). ESI-MS: m/z: calcd. for C45H48NaO9S
[M+Na]+: 787.29, found: 787.56.
4=-(Methylsulfonyl)-biphenyl-4-yl 2,3,4-tri-O-benzyl-6-O-
pivaloyloxymethyl-!-D-mannopyranoside (15)
Compound 12 (250 mg, 0.367 mmol) was dissolved in dry DMSO
under argon followed by the addition of Ac2O (2 mL) and AcOH
(0.2 mL). The reaction was stirred at rt for 19 h. The mixture was
diluted with EtOAc (50 mL) and washed with satd aq NaHCO3 (2 ×
50mL) and brine (50mL). The organic layer was dried over Na2SO4,
Schönemann et al. 915
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concentrated in vacuo, and purified by MPLC on silica gel (petro-
leum ether – EtOAc, 7:3) to afford 153 mg of 14. The intermediate
14 (113 mg) was dissolved in dry DMF (2 mL) under argon and
PivOH (47 mg, 0.460 mmol) and NIS (52 mg, 0.230 mmol) were
added. The reaction was quenched after 17 h with Et3N (0.100 mL).
Then, the mixture was diluted with EtOAc (50 mL) and washed
with satd aq NaHCO3 (50 mL), H2O (50 mL) and brine (50 mL). The
organic layer was dried over Na2SO4, concentrated in vacuo and
purified by MPLC on silica gel (petroleum ether – EtOAc, 7:3).
Compound 15was obtained in an overall yield of 33% (72 mg) over
two steps. !!"D
20" 64.3 (c 0.58, CHCl3). 1HNMR (500MHz, CDCl3): # =
7.84 (d, J = 8.4 Hz, 2H, Ar-H), 7.63 (d, J = 8.4 Hz, 2H, Ar-H), 7.45 (d, J =
8.7 Hz, 2H, Ar-H), 7.32–7.21 (m, 15H, Ar-H), 7.02 (d, J = 8.7 Hz, 2H,
Ar-H), 5.50 (d, J = 1.6 Hz, 1H, H-1), 5.22 (s, 2H, OCH2O), 4.88 (d, J =
10.9 Hz, 1H, PhCH2O), 4.75 (d, J = 12.4 Hz, 1H, PhCH2O), 4.70 (d,
J = 12.4 Hz, 1H, PhCH2O), 4.65–4.62 (m, 2H, PhCH2O), 4.59 (d, J =
11.0 Hz, 1H, PhCH2O), 4.05–3.97 (m, 2H, H-3, H-4), 3.90 (m, 1H, H-2),
3.83 (dd, J = 4.4, 10.7 Hz, 1H, H-6a), 3.78–3.72 (m, 2H, H-5, H-6b), 2.99
(s, 3H, SO2CH3), 1.08 ppm (s, 9H, C(CH3)3). 13C NMR (125 MHz,
CDCl3): # = 178.10 (CO), 156.90, 146.19, 138.83, 138.47, 138.19, 133.28,
128.74, 128.60, 128.59, 128.55, 128.08, 128.00, 127.98, 127.86, 127.83,
127.67, 117.16 (30C, Ar-C), 96.74 (C-1), 89.94 (OCH2O), 80.00 (C-3),
75.25 (PhCH2O), 74.55, 74.50 (C-2, C-4), 73.16, 72.62 (2 PhCH2O),
72.38 (C-5), 69.04 (C-6), 44.78 (SO2CH3), 39.04 (C(CH3)3), 27.17 ppm
(C(CH3)3). ESI-MS: m/z: calcd. for C46H50NaO10S [M+Na]+: 817.30,
found: 817.39.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-acetyl-!-D-mannopyranoside
(5a)
Prepared according to the general procedure B from 13a (50mg,
0.069 mmol) with 15 mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(5 mL). Purified by MPLC on silica gel (DCM–MeOH, 9:1). Yield:
24 mg (75%) as a white solid. !!"D
20 " 101.2 (c 0.19, MeOH). 1H NMR
(500 MHz, CD3OD): # = 8.02 (d, J = 8.5 Hz, 2H, Ar-H), 7.88 (d, J =
8.5 Hz, 2H, Ar-H), 7.71 (d, J = 8.8 Hz, 2H, Ar-H), 7.26 (d, J = 8.6 Hz, 2H,
Ar-H), 5.57 (d, J = 1.5 Hz, 1H, H-1), 4.39 (dd, J = 1.9, 11.8 Hz, 1H, H-6a),
4.24 (dd, J = 6.4, 11.8 Hz, 1H, H-6b), 4.08 (dd, J = 1.8, 3.4 Hz, 1H, H-2),
3.94 (dd, J = 3.4, 9.0 Hz, 1H, H-3), 3.82–3.73 (m, 2H, H-4, H-5), 3.18 (s,
3H, SO2CH3), 1.93 ppm (s, 3H, CH3). 13C NMR (125 MHz, CD3OD): # =
172.68 (CO), 158.24, 147.29, 140.20, 134.42, 129.59, 129.03, 128.47,
118.37 (12C, Ar-C), 99.90 (C-1), 73.02 (C-5), 72.39 (C-3), 71.77 (C-2),
68.52 (C-4), 64.81 (C-6), 44.48 (SO2CH3), 20.69 ppm (CH3). HRMS:
m/z: calcd. for C21H24NaO9S [M+Na]+: 475.1039, found: 475.1037.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-propionyl-
!-D-mannopyranoside (5b)
Prepared according to the general procedure B from 13b (28mg,
0.038mmol) with 20mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(5 mL). Purified by MPLC on silica gel (DCM–MeOH, 1:0 to 9:1).
Yield: 11mg (59%) as awhite oil. !!"D
20" 93.8 (c 0.50,MeOH). 1HNMR
(500 MHz, CD3OD): # = 8.02 (d, J = 8.4 Hz, 2H, Ar-H), 7.87 (d, J =
8.4 Hz, 2H, Ar-H), 7.70 (d, J = 8.7 Hz, 2H, Ar-H), 7.25 (d, J = 8.7 Hz, 2H,
Ar-H), 5.58 (d, J = 1.0 Hz, 1H, H-1), 4.42 (dd, J = 1.6, 11.7 Hz, 1H, H-6a),
4.23 (dd, J = 6.7, 11.7 Hz, 1H, H-6b), 4.09 (d, J = 1.6 Hz, 1H, H-2), 3.95
(dd, J = 3.4, 9.1 Hz, 1H, H-3), 3.82–3.73 (m, 2H, H-4, H-5), 3.18 (s, 3H,
SO2CH3), 2.25 (dq, J = 2.8, 7.6 Hz, 2H, CH2COO), 1.02 ppm (t, J =
7.6Hz, 3H, CH3). 13CNMR (125MHz, CD3OD): # = 175.92 (CO), 158.18,
147.26, 140.19, 134.37, 129.57, 129.03, 128.45, 118.34 (12C, Ar-C),
99.75 (C-1), 73.11 (C-5), 72.39 (C-3), 71.74 (C-2), 68.57 (C-4), 64.75 (C-6),
44.48 (SO2CH3), 28.20 (CH2COO), 9.31 ppm (CH3). HRMS:m/z: calcd.
for C22H26NaO9S [M+Na]+: 489.1195, found: 489.1192.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-isobutyryl-
!-D-mannopyranoside (5c)
Prepared according to the general procedure B from 13c (40mg,
0.053 mmol) with 25mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(4 mL). Purified by MPLC on silica gel (DCM–MeOH, 1:0 to 9:1).
Yield: 18 mg (70%) as a white oil. !!"D
20 " 109.8 (c 0.85, MeOH).
1H NMR (500MHz, CD3OD): # = 8.02 (d, J = 8.4 Hz, 2H, Ar-H), 7.86 (d,
J = 8.5 Hz, 2H, Ar-H), 7.68 (d, J = 8.7 Hz, 2H, Ar-H), 7.25 (d, J = 8.7 Hz,
2H, Ar-H), 5.60 (d, J = 1.1 Hz, 1H, H-1), 4.45 (dd, J = 1.6, 11.7 Hz, 1H,
H-6a), 4.20 (dd, J = 7.0, 11.7 Hz, 1H, H-6b), 4.09 (dd, J = 1.7, 3.2 Hz, 1H,
H-2), 3.95 (dd, J = 3.4, 9.1 Hz, 1H, H-3), 3.82–3.72 (m, 2H, H-4, H-5),
3.18 (s, 3H, SO2CH3), 2.45 (hept, J = 7.0 Hz, 1H, CH(CH3)2), 1.06 (d, J =
7.0 Hz, 3H, CH3), 1.02 ppm (d, J = 7.0 Hz, 3H, CH3). 13C NMR
(125 MHz, CD3OD): # = 178.50 (CO), 158.14, 147.26, 140.17, 134.34,
129.60, 129.02, 128.43, 118.29 (12C, Ar-C), 99.61 (C-1), 73.27 (C-5),
72.37 (C-3), 71.71 (C-2), 68.57 (C-4), 64.84 (C-6), 44.48 (SO2CH3), 35.12
(CH), 19.23, 19.14 ppm (2 CH3). HRMS: m/z: calcd. for C23H28NaO9S
[M+Na]+: 503.1352, found: 503.1353.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-butyryl-
!-D-mannopyranoside (5d)
Prepared according to the general procedure B from 13d (45mg,
0.060mmol) with 40mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(5 mL). Purified by MPLC on silica gel (DCM–MeOH, 9:1). Yield:
21 mg (72%) as a colorless oil. !!"D
20 " 97.3 (c 1.05, MeOH). 1H NMR
(500 MHz, CD3OD): # = 8.01 (d, J = 8.5 Hz, 2H, Ar-H), 7.87 (d, J =
8.5 Hz, 2H, Ar-H), 7.69 (d, J = 8.8 Hz, 2H, Ar-H), 7.24 (d, J = 8.8 Hz, 2H,
Ar-H), 5.58 (d, J = 1.4 Hz, 1H, H-1), 4.43 (dd, J = 1.8, 11.7 Hz, 1H, H-6a),
4.20 (dd, J = 6.9, 11.7 Hz, 1H, H-6b), 4.08 (dd, J = 1.7, 3.3 Hz, 1H, H-2),
3.93 (dd, J = 3.4, 9.1 Hz, 1H, H-3), 3.79 (m, 1H, H-5), 3.73 (m, 1H, H-4),
3.17 (s, 3H, SO2CH3), 2.21–2.17 (m, 2H, CH2COO), 1.55–1.47 (m, 2H,
CH2), 0.83 ppm (t, J = 7.4 Hz, 3H, CH3). 13C NMR (125 MHz, CD3OD):
# = 175.09 (CO), 158.18, 147.24, 140.19, 134.31, 129.56, 129.03, 128.43,
118.31 (12C, Ar-C), 99.70 (C-1), 73.17 (C-5), 72.39 (C-3), 71.74 (C-2),
68.59 (C-4), 64.72 (C-6), 44.47 (SO2CH3), 36.88 (CH2COO), 19.29
(CH2), 13.92 ppm (CH3). HRMS: m/z: calcd. for C23H28NaO9S
[M+Na]+: 503.1352, found: 503.1350.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-pivaloyl-
!-D-mannopyranoside (5e)
Prepared according to the general procedure B from 13e (50mg,
0.065 mmol) with 15 mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(5 mL). Purified by MPLC on silica gel (DCM–MeOH, 9:1). Yield:
24 mg (73%) as a white oil. !!"D
20 " 96.0 (c 1.18, MeOH). 1H NMR
(500 MHz, CD3OD): # = 8.02 (d, J = 8.5 Hz, 2H, Ar-H), 7.85 (d, J =
8.6 Hz, 2H, Ar-H), 7.68 (d, J = 8.7 Hz, 2H, Ar-H), 7.26 (d, J = 8.9 Hz, 2H,
Ar-H), 5.62 (d, J = 1.5 Hz, 1H, H-1), 4.45 (dd, J = 1.7, 11.7 Hz, 1H. H-6a),
4.15 (dd, J = 7.4, 11.7 Hz, 1H, H-6b), 4.09 (dd, J = 1.8, 3.4 Hz, 1H, H-2),
3.96 (dd, J = 3.4, 9.2 Hz, 1H, H-3), 3.81 (ddd, J = 1.6, 7.4, 9.2 Hz, 1H,
H-5), 3.73 (t, J = 9.6 Hz, 1H, H-4), 3.18 (s, 3H, SO2CH3), 1.07 ppm (s,
9H, C(CH3)3). 13C NMR (125 MHz, CD3OD): # = 179.92 (CO), 158.09,
147.28, 140.16, 134.31, 129.65, 129.03, 128.43, 118.26 (12C, Ar-C),
99.43 (C-1), 73.38 (C-5), 72.35 (C-3), 71.68 (C-2), 68.59 (C-4), 65.14
(C-6), 44.48 (SO2CH3), 39.72 (C(CH3)3), 27.43 ppm (C(CH3)3). HRMS:
m/z: calcd. for C24H30NaO9S [M+Na]+: 517.1508, found: 517.1507.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-isovaleryl-
!-D-mannopyranoside (5f)
Prepared according to the general procedure B from 13f (34 mg,
0.044mmol) with 40mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(7 mL). Purified by MPLC on silica gel (DCM–MeOH, 9:1). Yield:
12 mg (55%) as a colorless oil. !!"D
20" 120.3 (c 0.60, MeOH). 1H NMR
(500 MHz, CD3OD): # = 8.02 (d, J = 8.5 Hz, 2H, Ar-H), 7.88 (d, J =
8.5 Hz, 2H, Ar-H), 7.70 (d, J = 8.8 Hz, 2H, Ar-H), 7.25 (d, J = 8.8 Hz, 2H,
Ar-H), 5.58 (d, J = 1.3 Hz, 1H, H-1), 4.45 (dd, J = 1.6, 11.7 Hz, 1H, H-6a),
4.18 (dd, J = 7.0, 11.7 Hz, 1H, H-6b), 4.07 (dd, J = 1.7, 3.3 Hz, 1H, H-2),
3.94 (dd, J = 3.4, 9.2 Hz, 1H, H-3), 3.79 (m, 1H, H-5), 3.72 (m, 1H, H-4),
3.17 (s, 3H, SO2CH3), 2.09 (dd, J = 3.0, 7.2 Hz, 2H, CH2COO), 1.95 (m,
1H, CH(CH3)2), 0.83 ppm (app-t, J = 6.3 Hz, 6H, 2 CH3). 13C NMR
(125 MHz, CD3OD): # = 174.55 (CO), 158.20, 147.24, 140.19, 134.28,
129.57, 129.03, 128.42, 118.30 (12C, Ar-C), 99.69 (C-1), 73.25 (C-5),
72.39 (C-3), 71.74 (C-2), 68.60 (C-4), 64.72 (C-6), 44.47 (SO2CH3), 44.16
(CH2COO), 26.67 (CH(CH3)2), 22.68, 22.66 ppm (2 CH3). HRMS: m/z:
calcd. for C24H30NaO9S [M+Na]+: 517.1508, found: 517.1499.
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4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-valeryl-
!-D-mannopyranoside (5g)
Prepared according to the general procedure B from 13g (51 mg,
0.067mmol) with 40mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(15 mL). Purified by MPLC on silica gel (DCM–MeOH, 95:5). Yield:
25 mg (76%) as a white solid. !!"D
20 " 111.4 (c 1.00, MeOH). 1H NMR
(500 MHz, CD3OD): # = 7.99 (d, J = 8.5 Hz, 2H, Ar-H), 7.85 (d, J =
8.5 Hz, 2H, Ar-H), 7.68 (d, J = 8.8 Hz, 2H, Ar-H), 7.23 (d, J = 8.8 Hz, 2H,
Ar-H), 5.56 (d, J = 1.4 Hz, 1H, H-1), 4.41 (dd, J = 1.8, 11.7 Hz, 1H, H-6a),
4.18 (dd, J = 7.0, 11.7 Hz, 1H, H-6b), 4.05 (dd, J = 1.7, 3.3 Hz, 1H, H-2),
3.91 (dd, J = 3.4, 9.1 Hz, 1H, H-3), 3.77 (m, 1H, H-5), 3.70 (t, J = 9.6 Hz,
1H, H-4), 3.15 (s, 3H, SO2CH3), 2.21–2.17 (m, 2H, CH2COO), 1.48–1.42
(m, 2H, CH2), 1.24–1.17 (m, 2H, CH2), 0.79 ppm (t, J = 7.4 Hz, 3H,
CH3). 13C NMR (125 MHz, CD3OD): # = 175.26 (CO), 163.63, 158.20,
147.22, 140.20, 134.28, 129.56, 129.02, 128.41, 118.31 (12C, Ar-C),
99.73 (C-1), 73.18 (C-5), 72.40 (C-3), 71.74 (C-2), 68.60 (C-4), 64.75 (C-6),
44.48 (SO2CH3), 34.71 (CH2COO), 27.96, 23.20 (2 CH2), 13.99 ppm
(CH3). HRMS:m/z: calcd. for C24H30NaO9S [M+Na]+: 517.1508, found:
517.1499.
4=-(Methylsulfonyl)-biphenyl-4-yl 6-O-pivaloyloxymethyl-
!-D-mannopyranoside (5h)
Prepared according to the general procedure B from 15 (36 mg,
0.045mmol) with 30mg of Pd(OH)2/C (E101 NE/W, 20% Pd) in EtOH
(5 mL). Purified by MPLC on silica gel (DCM–MeOH, 95:5). Yield:
10 mg (24%) as a white solid. !!"D
20 " 111.4 (c 1.00, MeOH). 1H. NMR
(500 MHz, CD3OD): # = 7.99 (d, J = 8.5 Hz, 2H, Ar-H), 7.86 (d, J =
8.5 Hz, 2H, Ar-H), 7.67 (d, J = 8.8 Hz, 2H, Ar-H), 7.23 (d, J = 8.8 Hz, 2H,
Ar-H), 5.52 (d, J = 1.6 Hz, 1H, H-1), 5.26 (s, 2H, OCH2O), 4.03 (dd, J =
1.8, 3.3 Hz, 1H, H-2), 3.91–3.90 (m, 2H, H-3, H-6a), 3.85 (m, 1H, H-6b),
3.75–3.71 (m, 2H, H-4, H-5), 3.15 (s, 3H, SO2CH3), 1.19 ppm (s, 9H,
C(CH3)3). 13C. NMR (125 MHz, CD3OD): # = 179.44 (CO), 158.49,
147.36, 140.16, 134.45, 129.65, 129.01, 128.50, 118.44 (12C, Ar-C),
100.20 (C-1), 90.45 (OCH2O), 74.36 (C-5), 72.42 (C-2), 71.83 (C-3), 70.53
(C-6), 68.32 (C-4), 44.48 (SO2CH3), 39.92 (C(CH3)3), 27.39 ppm
(C(CH3)3). HRMS: m/z: calcd. for C25H32NaO10S [M + Na]+: 547.1614,
found: 547.1607.
Pharmacokinetic assays
Materials
DMSO, 1-propanol, 1-octanol, Dulbecco’smodifiedEagle’smedium
(DMEM) high glucose, penicillin–streptomycin (solution stabilized,
with 10 000 units of penicillin/mL and 10 mg of streptomycin/mL),
L-glutamine solution (200 mM), magnesium chloride, ammonium
acetate, BNPP, and loperamide hydrochloride were purchased from
Sigma-Aldrich (St. Louis, Missouri). PRISMA HT universal buffer,
GIT-0 Lipid Solution, and Acceptor Sink Buffer were ordered from
pIon (Woburn, Massachusetts). MEM nonessential amino acids solu-
tion 10 mM (100×), fetal bovine serum (FBS), and DMEM without
sodium pyruvate and phenol red were bought from Invitrogen
(Carlsbad, California). Acetonitrile (MeCN) and MeOH were ordered
from Acros Organics (Geel, Belgium). Pooled male RLM (Sprague–
Dawley) and pooledHLMwere ordered fromBDBioscience (Franklin
Lakes, New Jersey). The Caco-2 cells were kindly provided by Prof G.
Imanidis, FHNW, Muttenz, Switzerland, and originated from the
American Type Culture Collection (Rockville, Maryland).
Log P determination
The in silico prediction tool ALOGPS32 was used to estimate the
octanol–water partition coefficients (log P) of the compounds. De-
pending on these values, the compounds were classified into
three categories: hydrophilic compounds (log P below zero), mod-
erately lipophilic compounds (log P between zero and one) and
lipophilic compounds (log P above 1). For each category, two dif-
ferent ratios (volume of 1-octanol to volume of buffer) were de-
fined as experimental parameters (Table 2).
Equal amounts of phosphate buffer (0.1 M, pH 7.4) and 1-octanol
were mixed and shaken vigorously for 5 min to saturate the
phases. The mixture was left until separation of the two phases
occurred, and the buffer was retrieved. Stock solutions of the test
compounds were diluted with buffer to a concentration of 1 $M.
For each compound, three determinations per 1-octanol:buffer
ratio were performed in different wells of a 96-well plate. The
respective volumes of buffer containing analyte (1$M)were pipetted
to the wells and covered by saturated 1-octanol according to the
chosen volume ratio. The plate was sealed with aluminum foil,
shaken (1350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 plate-
shaker (Heidolph Instruments GmbH & Co. KG, Schwabach, Ger-
many), and centrifuged (2000 rpm, 25 °C, 5 min) (5804 R Eppendorf
centrifuge, Hamburg, Germany). The aqueous phasewas transferred
to a 96-well plate for analysis by liquid chromatography –mass spec-
trometry (LC-MS) (see below).
The log P coefficients were calculated from the 1-octanol:buffer
ratio (o:b), the initial concentration of the analyte in buffer (1 $M),
and the concentration of the analyte in buffer (cB) with eq. 1:
(1) log P % log#1 $M & cBcB × 1o:b$
The average of the three log P values per 1-octanol:buffer ratio was
calculated. If the two means obtained for a compound did not
differ by more than 0.1 unit, the results were accepted.
PAMPA
Effective permeability (log Pe)was determined in a 96-well for-
mat with PAMPA.18 For each compound, measurements were per-
formed at pH 7.4 in quadruplicate. Four wells of a deep well plate
were filled with 650$L of PRISMAHT universal buffer, adjusted to
pH 7.4 by adding the requested amount of NaOH (0.5 M). Samples
(150 $L) were withdrawn from each well to determine the blank
spectra by UV/Vis-spectroscopy (190–500 nm) (SpectraMax 190,
Molecular Devices, Silicon Valley, California). Then, analyte dis-
solved in DMSO (10 mM) was added to the remaining buffer to
yield 50 $M solutions. To exclude precipitation, the optical den-
sity (OD) was measured at 650 nm, and solutions exceeding OD
0.01 were filtrated. Afterwards, samples (150 $L) were withdrawn
to determine the reference spectra. A further 200 $L was trans-
ferred to each well of the donor plate of the PAMPA sandwich
(pIon, P/N 110 163). The filter membranes at the bottom of the
acceptor plate were infused with 5 $L of GIT-0 Lipid Solution and
200 $L of Acceptor Sink Buffer was filled into each acceptor well.
The sandwich was assembled, placed in the GutBoxTM, and left
undisturbed for 16 h. Then, it was disassembled and samples
(150$L) were transferred from each donor and acceptor well to UV
plates for determination of the UV/Vis spectra. Effective permea-
bility (log Pe) was calculated from the compound flux deduced
from the spectra, the filter area, and the initial sample concentra-
tion in the donor well with the aid of the PAMPA Explorer Soft-
ware (pIon, version 3.5).
Caco-2 cell permeation assay
Caco-2 cells were cultivated in tissue culture flasks (BD Biosci-
ences, Franklin Lakes, New Jersey) with DMEM high glucose me-
dium containing L-glutamine (2 mM), nonessential amino acids
(0.1 mM), penicillin (100 U/mL), streptomycin (100 $g/mL), and FBS
(10%). The cells were kept at 37 °C in humidified air containing 5%
CO2, and the medium was changed every second day. When ap-
Table 2. Compound classification based on estimated
log P values.
Compound type log P Ratios (1-octanol:buffer)
Hydrophilic <0 30:140,40:130
Moderately lipophilic 0−1 70:110, 110:70
Lipophilic >1 3:180, 4:180
Schönemann et al. 917
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proximately 90% confluence was reached, the cells were split in a
1:10 ratio and distributed to new tissue culture flasks. At passage
numbers between 60 and 65, they were seeded at a density of 5.3 ×
105 cells/well to Transwell 6-well plates (Corning Inc., Corning,
New York) with 2.5 mL of culture medium in the basolateral and
2 mL in the apical compartment. The medium was renewed on
alternate days. Permeation experiments were performed between
days 19 and 21 postseeding. Previously to the experiment, the
integrity of the Caco-2 monolayers was evaluated by measuring
the transepithelial electrical resistance (TEER) with an Endohm
tissue resistance instrument (World Precision Instruments Inc.,
Sarasota, Florida). Only wells with TEER values higher than
250 !·cm2 were used. To inhibit CES activity, the Caco-2 cell
monolayers were pre-incubated with BNPP (200 "M) dissolved in
transport medium (DMEM without sodium pyruvate and phenol
red) for 40 min.22b Experiments were performed in the apical-to-
basolateral (absorptive) and basolateral-to-apical (secretory) direc-
tions in triplicate. Transport medium was withdrawn from the
donor compartments and replaced by the same volume of com-
pound stock solution (10 mM in DMSO) to reach an initial sample
concentration of 62.5 "M. The Transwell plate was shaken
(600 rpm, 37 °C) on a Heidolph Titramax 1000 plate-shaker. Sam-
ples (40 "L) were withdrawn from the donor and acceptor com-
partments 30 min after initiation of the experiment and the
concentrations were determined by LC-MS (see below). Apparent
permeability (Papp) was calculated according to eq. 2:
(2) Papp #
dQ
dt
× 1
A × c0
where dQ/dt is the compound flux (mol s−1), A is the surface area of
the monolayer (cm2), and c0 is the initial concentration in the
donor compartment (mol cm−3).33 After the experiment, TEER
values were measured again and results from wells with values
below 250 !·cm2 were discarded.
Aqueous solubility
Solubility was determined in a 96-well format using the "SOL
Explorer solubility analyzer (pIon, version 3.4.0.5). For each com-
pound, measurements were performed in triplicate. Three wells
of a deep well plate were filled with 300 "L of PRISMA HT univer-
sal buffer, adjusted to pH 7.4 by adding the requested amount of
NaOH (0.5 M). Aliquots (3 "L) of a compound stock solution (40–
100 mM in DMSO) were added and thoroughly mixed. The final
sample concentration was 0.4–1.0 mM and the residual DMSO
concentration was 1.0% (v/v). Fifteen hours after initiation of the
experiment, the solutions were filtrated (0.2 "m 96-well filter
plates) using a vacuum to collect manifold (Whatman Ltd., Maid-
stone, UK) to remove any precipitates. Equal amounts of filtrate
and 1-propanol were mixed and transferred to a 96-well plate for
UV detection (190–500 nm). The amount of material dissolved was
calculated by comparison with UV spectra obtained from refer-
ence samples, which were prepared by dissolving compound
stock solution in a 1:1 mixture of buffer and 1-propanol (final
concentrations 0.067–0.167 mM).
Enzymatic hydrolysis by liver microsome associated CES
Incubations were performed in triplicate in a 96-well format on
an Eppendorf Thermomixer Comfort. The reaction mixture
(270 "L) consisting of liver microsomes (0.139 "g/mL), TRIS–HCl
buffer (0.1 M, pH 7.4), and MgCl2 (2 mM) was preheated (37 °C,
500 rpm, 10 min), and the incubation was initiated by adding
30 "L of compound solution (20 "M) in TRIS–HCl buffer. The final
concentration of the compound was 2 "M, and the microsomal
concentration was 0.125 mg/mL. At the beginning of the experi-
ment (t = 0 min) and after an incubation time of 2, 5, 10, 20, and
30 min, samples (40 "L) were transferred to 120 "L of ice-cooled
MeOH and centrifuged (3700 rpm, 4 °C, 10 min). Then, 80 "L of
supernatant was transferred to a 96-well plate for analysis by
LC-MS (see below). Themetabolic half-life (t1/2) was calculated from
the slope of the linear regression from the log percentage remain-
ing compound versus incubation time relationship. Control ex-
periments were performed in parallel by preincubating the
microsomes with the specific CES inhibitor BNPP (1 mM) for 5min
before addition of the compound solution.20
Isozyme specific inhibition of CES-mediated hydrolysis
Test compounds were dissolved in DMSO to 1 mM and then
diluted with TRIS–HCl buffer (0.1 M, pH 7.4) containing MgCl2
(2mM) to a concentration of 6"M. Loperamide hydrochloride was
dissolved in DMSO to 20, 2, and 0.2 mM and then diluted with
TRIS–HCl buffer containing MgCl2 to a concentration of 750, 75,
and 7.5 "M. HLM were suspended in TRIS–HCl buffer containing
MgCl2 to a concentration of 30 "g/mL. Compound solution
(100 "L) and microsomal suspension (200 "L) mixed with
loperamide solution or blank buffer (50"L) were preheated (37 °C,
500 rpm, 15 min) in separate wells of a 96-well plate. The incuba-
tion was initiated by transferring 200 "L of microsome suspen-
sion containing loperamide to the compound solution. The final
compound concentration was 2 "M, the microsomal concentra-
tion was 0.02 mg/mL, and the loperamide concentration was 100,
10, 1, and 0 "M (blank). At the beginning of the experiment (t =
0 min) and after an incubation time of 10, 20, 30, 45, and 60 min,
samples (20 "L) were transferred to 60 "L of ice-cooled MeOH and
analyzed by LC-MS (see below). The metabolic turnover was as-
sessed as accumulation of product 4a versus incubation time.30
LC-MS measurements
Analyses were performed using a 1100/1200 Series HPLC system
coupled to a 6410 Triple Quadrupole mass detector (Agilent Tech-
nologies, Inc., Santa Clara, California) equipped with electrospray
ionization. The system was controlled with the Agilent Mass-
Hunter Workstation Data Acquisition software (version B.01.04).
The column used was an Atlantis® T3 C18 column (2.1 × 50 mm)with a 3 "m particle size (Waters Corp., Milford, Massachusetts).
The mobile phase consisted of eluent A (10 mM ammonium ace-
tate, pH 5.0 in 95:5 H2O–MeCN) and eluent B (MeCN containing
0.1% formic acid). The flow ratewasmaintained at 0.6mL/min. The
gradient was ramped from 95% A – 5% B to 5% A – 95% B over 1min
and then held at 5% A – 95% B for 0.1 min. The system was then
brought back to 95% A – 5% B, resulting in a total duration of
4 min. MS parameters such as fragmentor voltage, collision en-
ergy, and polarity were optimized individually for each drug, and
the molecular ion was followed for each compound in the multi-
ple reactionmonitoringmode. The concentrations of the analytes
were quantified by the Agilent Mass Hunter Quantitative Analysis
software (version B.01.04).
Supplementary material
Supplementary material is available with the article through
the journal Web site at http://nrcresearchpress.com/doi/suppl/
10.1139/cjc-2015-0582. NMR spectra and HPLC traces to document
purity of the test compounds.
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5 Human Neuraminidase 3 inhibitors 
5.1 Sialic acids 
Sialic acids (or neuramidic acids) are a large family of approximately fifty related acidic 
monosaccharides sharing a common core structure consisting of a nine-carbon 
polyhydroxylated a-keto acid (1). They commonly share a carboxylic acid in the 2-position. At 
physiological pH, the acid is deprotonated, having a strong effect on the physicochemical 
properties. In the 5-position, sialic acids exhibit the broadest variations. In Figure 5.1, the most 
common sialic acids are listed, namely N-acetylneuraminic acid (1, NeuNAc), N-
glycolylneuraminic acid (2, NeuNGc) or deaminoneuraminic acid (3, KDN) (2-4). Sialic acids are 
almost exclusively expressed in higher eukaryotes and in particular groups of eubacteria, and 
are usually terminal residues of cell surface glycoconjugates (1). There, they mediate a broad 
range of cell-cell and cell-molecules interactions by stabilizing of cell membranes, acting as 
chemical messenger in cell-cell regulations and transmembrane receptors, or controlling half-
lives of circulating glycoproteins (5,6). The cell-cell regulations play a major role in cell 
recognition and adhesion processes, such as immune and inflammation responses or nervous 
system embryogenesis (7,8). The importance of sialic acids is impressively demonstrated by the 
death of embryotic mutant mice, in which a gene encoding of a key enzyme for sialic acid 
synthesis was inactivated by gene targeting (9). The synthesis of sialic acids requires the 
coordinated action of several enzymes catalyzing different steps in biosynthesis and 
degradation starting from UDP-N-acetyl-a-D-glucosamine (10,11). The transfer of sialyl 
residues is further regulated by neuraminidases (also named sialydases) and sialyltransferases 
(12). As a result of their broad biological role and presence on cell surfaces, sialic acids are often 
used as a target for pathogens to modulate and evade the immune response (13-15). 
 
Figure 5.1 Common neuraminic acids. 
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5.2 Human Neuraminidases 
The content of sialic acids in humans bound to glycoproteins and glycolipids and in free 
circulation is highly regulated by sialyltransferases and neuraminidases (16). Sialyltransferases 
catalyze the transfer of activated sialic acids (CMP-N-acetylneuraminic acid, CMP-NANA) to 
different glycoconjugates, almost exclusively to the terminal position (4). The family of human 
sialyltransferases includes approximately 20 different enzymes, expressed in a different tissue-
, cell type-, and stage-specific manner to regulate the sialylation pattern (17). Sialic acids are 
primary transferred to galactose moieties of glycoconjugates in a α2,3- or α2,6-linked manner 
(18, 19). 
The hydrolytic cleavage of sialic acids from glycoconjugates is facilitated by neuraminidases 
(NEU). Up to date, four different mammalian NEU (NEU1, NEU2, NEU3 and NEU4) have been 
identified and characterized. Each neuraminidase differs in subcellular locations, enzymatic 
properties and substrate specificity to play its unique role in controlling of the level of sialylation 
(. 
Table 5.1) (20). 
Table 5.1 Human neuraminidases NEU1-4. 
 Localization Substrate specificity Major function 
NEU1 Lysosomes Oligosaccharides 
Glycopeptides 
Degradation in lysosomes 
Exocytosis 
Immune function 
Phagocytosis 
Elastic fiber assambly 
NEU2 Cytosol Oligosaccharides 
Glycopeptides 
Gangliosides 
Myoblast differentiation 
Neural differentiation 
NEU3 Plasma 
membranes 
Gangliosides Neuronal differentiation 
Apoptosis 
Adhesion 
NEU4 Lysosomes 
Mitochondria 
Oligosaccharides 
Glycopeptides 
Gangliosides 
Neuronal differentiation 
Apoptosis 
Adhesion 
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5.2.1 Human neuraminidase 3 
The human neuraminidase NEU3 is preferably cleaving sialic acids linked in an a2-3, a2-8 or 
a2-6 manner to galactose being part of gangliosides. The cleavage of the more common sialic 
acid NeuNAc (1) is faster compared to NeuNGc (2) (21). NEU3 shares a higher homology with 
NEU2 and NEU4 (24-30%) than with NEU1 (19-24%) (22). The expression on the surface of 
plasma membranes implies its important role in regulation of cell surface modulations and 
expressions, effecting for example neuroblastoma growth, insulin signaling, tumor 
transformation and invasiveness (23-27).  
5.3 Neuraminidase inhibitors 
Most synthetic neuraminidase inhibitors are targeted against viral neuraminidases (Figure 
5.2A). During the infection cycle, newly formed influenza virus need neuraminidases to be 
released from human cells by hydrolyzing terminal sialic acids being part of the host cell surface 
(28). Therefore, viral neuraminidases represent a potent target for the treatment of influenza 
infections (29). Potent neuraminidase inhibitors are obtained by mimicking the transition state 
of the hydrolysis by introducing a double bond in the C2/C3 position (® 4, DANA) (30). To 
further improve affinity and specificity for influenza neuraminidases, a guanidinium residue was 
introduced in the 4-position leading to a subnanomolar inhibitor, marketed as zanamivir (® 
5)(31). The large hydrophilic surface and charge at physiological pH does not allow an oral 
administration of zanamivir and therefore it has to be administred by inhalation. By replacing 
the hydrophilic glycerol side chain by the lipophilic isopentoxy moiety, forming an ester prodrug 
and further reducing the polar surface area, the orally bioavailable derivative was obtained, 
marketed as oseltamivir (6) (32, 33). 
The development of selective inhibitors for the human neuraminidases NEU1-4 are of interest 
not only for the development of potential therapeutics against different diseases with 
overexpression of neuraminidases, but also to improve the understanding of the disease-
related role of human neuraminidases (Figure 5.2B). Similar to viral neuraminidase inhibitors, 
high affinity and specificity was achieved by modifications of the glycerol side chain and the 4-
position starting from DANA (4). Specific NEU1 inhibitor 7 was used to study epithal migration 
and bacterial adhesion and the specific NEU4 inhibitor 10 was studied in glioblastoma stem cell 
survival (34-37). The specific NEU2 and NEU3 inhibitors 8 and 9 were developed by Cairo et al. 
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in previous work, however, exhibiting only micromolar affinities (38). Affinities and selectivities 
are listed in Table 5.2. 
 
Figure 5.2. A) Transition state mimetic 4 and the specific viral neuraminidase inhibitor zanamivir (5) and oseltamivir 
(6); B) Selective human neuraminidase inhibitors 7-10. 
Table 5.2. IC50 values and selectivity of human neuraminidase inhibitors. 
Human neuraminidase IC50 [µM] Selectivity  
Cpd. NEU1 NEU2 NEU3 NEU4  
7 10 >1000 >1000 >1000 > 100 fold 
8 >1000 86 >1000 470 12 fold 
9 >1000 920 24 550 38 fold 
10 >1000 >1000 80 0.16 500 fold 
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5.5 Publication 2: Selective Neuraminidase 3 Inhibitors 
This publication describes the synthesis and experimental examination of Neuraminidase 3 
(NEU3) inhibitors and ester prodrugs thereof. A selectivity and affinity improvement towards 
NEU3 was achieved by structural modification of the known neuraminidase inhibitor DANA (4). 
The ester prodrugs did not show a significant improvement in in vitro absorption 
measurements. 
 
Contribution to the Project: 
Philipp Dätwyler was evaluating the physicochemical and pharmacokinetic properties of the 
ester prodrugs and active principle. He further contributed to the writing and arrangement of 
the publication. 
The publication was published in the peer-reviewed Journal of Medicinal Chemistry in Februar 
2018. 
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ABSTRACT: Human neuraminidases (NEU) are associated with human
diseases including cancer, atherosclerosis, and diabetes. To obtain small
molecule inhibitors as research tools for the study of their biological functions,
we designed a library of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid
(DANA) analogues with modifications at C4 and C9 positions. This library
allowed us to discover selective inhibitors targeting the human NEU3
isoenzyme. Our most selective inhibitor for NEU3 has a Ki of 320 ± 40 nM
and a 15-fold selectivity over other human neuraminidase isoenzymes. This
inhibitor blocks glycolipid processing by NEU3 in vitro. To improve their
pharmacokinetic properties, various esters of the best inhibitors were
synthesized and evaluated. Finally, we confirmed that our best compounds
exhibited selective inhibition of NEU orthologues from murine brain.
■ INTRODUCTION
Neuraminic acids (also known as sialic acids) form a large
family of α-keto acid monosaccharides containing a nine-carbon
backbone.1 They are diverse in structure and widely distributed
among organisms in nature. The most common form of
neuraminic acid in humans is Neu5Ac (5-acetamido-3,5-
dideoxy-D-glycero-D-galacto-non-2-ulosonic acid).2 Generally,
neuraminic acids are the terminal residues in glycan chains,
playing crucial roles in molecular recognition.3 The neuraminic
acid content in human cells is controlled by enzymes including
sialyltransferases and neuraminidases (NEU; also known as
sialidases).4 In humans, four neuraminidase isoenzymes have
been identified: NEU1, NEU2, NEU3, and NEU4.5 They
exhibit different subcellular localization and show different
preferences toward glycan substrates.5 Abnormal activity of
human neuraminidases has been linked to diseases including
lysosomal storage disorders,6,7 cardiovascular diseases,8,9 and
cancer.10−12 Selective inhibitors of NEU4 have been used to
investigate the role of NEU4 in glioblastoma,13 and NEU1
inhibitors have been employed to study epithelial migration and
bacterial adhesion.14 Thus, isoenzyme-selective inhibitors of
human neuraminidases are potential tools to study the
biological function of these enzymes.15
Although there has been significant efforts to develop potent
inhibitors of viral neuraminidases,16 inhibitors of human
neuraminidases are not as thoroughly explored,15 and most
viral neuraminidase inhibitors have only weak or limited activity
for the human neuraminidases.15,17,18 The most active viral
inhibitor against the human isoenzymes is zanamivir (6, Figure
1), which has low micromolar activity for NEU2 and
NEU3.17,19 Most human neuraminidase inhibitors reported
to-date are based on 2-deoxy-2,3-didehydro-N-acetylneuraminic
acid (DANA, 1; Figure 1).15,20 Magesh et al. investigated a
series of C9-amide analogues of DANA and reported a NEU1-
selective inhibitor containing a C9-pentylamide with an IC50 of
10 μM (C9-BA-DANA,21 2; Figure 1).22 Modifications of the
C5 and C9 positions of DANA improved potency for DANA
analogues against NEU2.19,23 Selective inhibitors for NEU2 (3,
Figure 1) and NEU3 (4, Figure 1) were identified in a library of
DANA analogues when the glycerol side chain was replaced by
oxime- and amino-linked aromatic groups.24 Inhibitor 3 has a
reported IC50 of 86 μM against NEU2 with 12-fold selectivity.
Inhibitor 4 was the most selective compound reported to date
for NEU3 with a 38-fold selectivity (IC50 = 24 μM). We
previously examined triazole modifications at the C5 and C9
positions in DANA and found improved potency of C9-
triazolyl DANA analogues toward NEU3.25 When evaluated
against the full panel of NEU isoenzymes, C9-4-hydroxyme-
thyltriazolyl DANA (C9-4HMT-DANA, 5; 500-fold selective,
Ki = 30 nM, Figure 1) turned out to be the most selective
inhibitor for NEU4 identified to date. This compound has
remained the only reported inhibitor with submicromolar
activity for any human NEU.26 We, therefore, considered that a
more extensive library of triazole analogues might take
advantage of the hypothesized large C9-pocket of NEU3 and
could provide selective inhibitors of NEU3 with further
improvements in potency. Furthermore, the activity of
Received: October 23, 2017
Published: February 9, 2018
Article
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zanamivir 6 against NEU3 suggested that an appropriate C4
moiety could contribute to increased activity.
In this work, we designed and synthesized a series of
compounds featuring a C9-triazolyl group combined with
guanidino and other groups at C4. The first series of C9-
triazolyl DANA derivatives exhibited remarkably increased
potencies relative to the parent compound 1 toward NEU3 and
NEU4 (7, Figure 1). Although the combination of the best C9-
triazolyl fragments with a guanidino group at C4 provided only
small gains in potency for NEU3, we found that selectivity for
NEU3 over NEU4 was remarkably improved (8, Figure 1). The
inhibitors presented here constitute the most potent and
selective compounds identified for NEU3 so far. In addition, we
have established a rationale for the development of future
selective inhibitors of NEU3.
■ RESULTS
Inhibitor Design and Synthesis. To date, X-ray crystal
structure data is only available for human NEU2, including co-
crystal data with inhibitors.27,28 Homology models for
NEU329−31 have suggested that its glycerol binding pocket is
larger than in NEU2. The homology models of NEU3 also
indicate that the glycerol side chain interacts with Y179 and
Y181. Earlier work reported that large groups, such as a C9-
phenyltriazolyl, were tolerated by the C9 pocket of NEU3,25
but no fragment has been identified which substantially
improved potency. We first hypothesized that an appropriate
aromatic group at C9 would provide additional interactions and
could improve NEU3 potency over other isoenzymes. We
therefore explored C9-4-aryl-triazolyl DANA derivatives with
variations in electron-donating groups, charge, as well as larger
phenyl and phenoxyl groups (7, Figure 1). We also considered
that a guanidino group at C4 could improve activity for NEU2
and NEU317,19 and, therefore, investigated C9-triazolyl DANA
derivatives with nitrogen-containing groups at C4, including
guanidino, azido, and amino groups.
To prepare analogues with substituted phenyltriazolyl groups
at C9, we started from the reported C9-azido-DANA methyl
ester (9, Scheme 1), which was synthesized from Neu5Ac in six
steps.25 The library of triazolyl derivatives 10a−j was obtained
by CuAAC (Cu-catalyzed azide−alkyne cycloaddition) by
following reported conditions (Scheme 1).25,32,33 Finally,
deprotection yielded the test compounds 7a−j, in moderate
to good yields.
For compounds with combined C4,C9-modifications (8,
Figure 1), two strategies were adopted. Starting from the C9-
triazolyl DANA analogue 10h, a C4-azido group was
introduced according to a reported procedure via nucleophilic
ring opening of an oxazoline intermediate 11 to yield
compound 12 (Scheme 2).33 Reduction of the C4-azido of
compound 12 via Staudinger reduction provided the C4-amino
compound 14.34,35 After deprotection, the C4-azido and C4-
Figure 1. Inhibitor targets.
Scheme 1. Synthetic Route to C9-Phenyltriazole DANA Analogues 7a−j
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amino intermediates 12 and 14 gave the test compounds 13
and 15. Furthermore, the amino group in 14 was converted to a
guanidino group using N,N′-di-Boc-1H-pyrazole-1-carboxami-
dine, yielding the final C4, C9-modified test compound 8a after
deprotection. To obtain an alternative polar group at C4, a C4-
N-alkyl urea compound was prepared by treatment of 14 with
1,1′-carbonyldiimidazole and β-alanine methyl ester. Finally,
hydrolysis provided test compound 18.
An alternative strategy (Scheme 3) allowed preparation of
compound 8b by reversing the order of the modifications at the
4- and 9-position. First, O-acetyl protected C4-amino-DANA
19 was prepared as reported.34 Protection of the amino group
with Boc, followed by acetate deprotection (20) and
subsequent tosylation at C9 (21) allowed for displacement to
the C9-azido group (22).25 Next, the guanidino group was
introduced at C4 to provide compound 23. Subsequent
CuAAC with a biphenyl ethyne allowed for installation of the
C9-triazolyl group, forming compound 24, which gave test
compound 8b after deprotection.
Additional compounds for testing included a small series of
C4-amides, prepared starting from compound 19 by treatment
with the appropriate anhydride or acyl chloride to yield the
amido compounds 25a−d (Scheme 4) after hydrolysis of the
C1-methyl ester with sodium hydroxide. Compounds 1, 2, and
6 were also prepared for use in the inhibition assays.
Inhibition Assays. To determine the inhibitory potency of
the panel of inhibitors against NEU, isoenzymes were prepared
either recombinantly or by purification.24,26,29 For the
determination of enzyme activity (see Table 1), the fluorogenic
neuraminidase substrate, 2′-(4-methylumbelliferyl)-α-D-N-ace-
tylneuraminic acid (4MU-NANA) was used.36,37 We confirmed
that compound 2 acted as a selective inhibitor of NEU1 (IC50
of 3.4 ± 0.2 μM).22 Compounds 7a−j with C9-phenyltriazolyl
groups were significantly more potent inhibitors of NEU3 and
NEU4 compared to NEU1 and NEU2. For virtually all
Scheme 2. Synthetic Routes to C4,C9-Modified DANA Analogues 8a, 13, 15, and 18
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compounds containing a C9-phenyltriazolyl group, we
observed single-digit micromolar or better IC50 values toward
NEU3. Compounds with an acidic group (7h) or larger
aromatic groups (7i and 7j) showed improved activity against
NEU3 over those with basic groups (7a and 7c) or neutral
electron-withdrawing groups (7f). Among all C9-modified
DANA analogues, the C9-biphenyltriazolyl DANA 7i showed
the highest potency with an IC50 of 0.70 ± 0.10 and 0.52 ± 0.10
μM toward NEU3 and NEU4, respectively. The activity of 7i
showed distinct preferences, with 40-fold greater potency
against NEU3 and NEU4 than for NEU1 or NEU2.
Our library of C4 modifications revealed the importance of
the guanidino group for NEU3 selectivity. The comparison of
DANA (1) and zanamivir (6) was consistent with previous
reports17,19 with potency of 37 ± 6 and 7.8 ± 2.0 μM for NEU2
and 7.7 ± 0.8 vs 4.0 ± 0.6 μM for NEU3. Decreased potency of
49 ± 8 μM and >500 μM was found for NEU1 and 8.3 ± 1.0 vs
47 ± 6 μM for NEU4. Other nitrogen-containing groups at C4,
like azido, amino, or amido moieties (13, 15, 18, and 25),
decreased potency for all isoenzymes. These results are in
agreement with previously reported findings as C4-azido- and
C4-amino-DANA showed improved potency toward NEU2
and significantly decreased potency toward other isoenzymes.24
We therefore concluded that a positively charged group of
appropriate size at C4 was critical for NEU3 selectivity. Thus, a
guanidino group at C4 combined with C9-modification
conferred selectivity for NEU3 over NEU4. Selective and
potent inhibitors for NEU3 were identified, where compound
8a (NEU3 IC50 of 0.6 ± 0.1 μM) showed 40-fold selectivity,
and compound 8b (NEU3 IC50 of 0.58 ± 0.14 μM) had 10-fold
selectivity. Although both 8a and 8b demonstrated unprece-
dented potency for NEU3, we selected 8b for further studies
due to its reduced polarity.
Next, we determined the inhibition constants (Ki) of the best
inhibitors for their active targets (Table 2). The Ki results
showed a trend similar to the IC50 values. When zanamivir 6
was tested against NEU2, NEU3, and NEU4, we found Ki
values of 5.7 ± 1.5, 0.62 ± 0.09, and 26 ± 4 μM, respectively.
Whereas compound 7i showed similar Ki values for NEU3 and
NEU4 (0.28 ± 0.04 and 0.26 ± 0.04 μM, respectively), the 4-
guanidino derivative 8b exhibited 15-fold selectivity for NEU3
(Ki for NEU3 0.32 ± 0.04 μM, and 5 ± 1 μM for NEU4).
Because NEU3 is known to favor glycolipid substrates over
4MU-NANA,38 we also tested the inhibitory activity of the best
NEU3 inhibitors to block GM3 hydrolysis by the enzyme
(Table 3). In comparison with DANA 1, 7i showed a higher
inhibitory potency for GM3 cleavage catalyzed by NEU3 (12 ±
2 vs 54 ± 10 μM) and NEU4 (3.7 ± 0.7 vs 26 ± 8 μM); 8b was
14-fold more potent than DANA (1) (3.8 ± 0.5 vs 54 ± 10
μM).
Pharmacokinetic Evaluation of Active Inhibitors. For
planning future in vivo experiments with this series of potent
NEU3 inhibitors, their pharmacokinetic properties are critical.
Carbohydrate mimetics are typically hydrophilic and are,
therefore, often delivered as lipophilic ester prodrugs to
improve membrane permeability, where the active principle is
Scheme 3. Synthetic Route to C4,C9-Modified DANA Analogue 8b
Scheme 4. Synthetic Route to C4-Amide DANA Analogues 25a−d
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released via hydrolysis by esterases.39,40 Therefore, C1-esters of
inhibitors 1, 2, 5, 7i, and 8b were prepared. The methyl ester of
each compound was obtained after CuAAC as described earlier,
whereas elongated aliphatic esters of 7i were prepared from the
C1 methyl ester of 7i (7i-OMe) via transesterification catalyzed
by LiBr and DBU.41 The octanol−water partition coefficient at
pH 7.4 (log D7.4), membrane permeation (log Pe), kinetic
solubility, and metabolic stability of the selected compounds
were determined.42 The log D7.4 values were determined using
a shake-flask approach.43,44 Membrane permeation log Pe was
determined using a parallel artificial membrane permeability
assay (PAMPA).45 A summary of the pharmacokinetic
parameters is provided in Table 4. A plot of the measured
log D7.4 against log Pe is shown in Figure 2 with indications for
moderate and high absorption potential.46 Passive permeability
(log Pe) of ester prodrugs is dependent on lipophilicity. In
general, the ester prodrugs showed consistently low solubility
and time-dependent precipitation. While the solution of the
dissolved esters appeared clear after the initial dilution of the
DMSO stock with water, turbidity developed after several
hours, indicating the formation of precipitates. Because PAMPA
required 16 h incubation time, measurements of insufficiently
soluble compounds were performed with 10% DMSO.
The passive permeation (log Pe) of all compounds was below
the threshold of −6.3, predicting moderate absorption potential
(Figure 2). Only the largest aliphatic ester prodrug (7i-OBu)
Table 1. IC50 Data for NEU Using 4MU-NANA as the Substrate
Table 2. Ki Determinations
aNone of these compounds showed significant activity toward NEU1,
so only NEU2, NEU3, and NEU4 determinations were made.
bPreviously reported data.26
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reached the lower limit of this threshold. In combination with
the low solubility, the compounds are classified as class IV
compounds in the biopharmaceutical drug classification
system.47 This class of compounds is highly susceptible to
individual transport mechanisms and, therefore,48 we further
explored the permeability of the n-butyl ester of 7i (7i-OBu)
using a colon carcinoma (Caco2) cell-based permeation assay.49
The threshold for a moderate absorption potential is 2.0 × 10−6
cm s−1 in the absorptive direction (apical to basolateral: a−b)42
and was not reached by 7i-OBu. Additionally, the compound
had an efflux ratio of 6.7, predicting active efflux. When the
metabolic stability of the prodrug in human liver microsomes
was assessed (Table 5), the hydrolysis of the ester was slow,
limiting the release of the active principle. A slow release of the
active principle can be beneficial, especially for hydrophilic
carbohydrate mimetics to overcome the common problem of
fast renal excretion, but in our case the active principle is
already lipophilic and the biphenyl moiety is likely prone to
oxidation by cytochromes. In summary, the lead compound 7i-
Table 3. Inhibition of GM3 Cleavage
aRelative activity as compared to DANA.
Table 4. Pharmacokinetic Evaluation of C1-Esters
parent compd C1(O)R clogD7.4
a log D7.4
b log Pe [log cm s
−1]c solubility [μg mL−1]d
DANA, 1 OMe −3.31 <−1.5 nd nd
2 OMe −2.01 −1.0 ± 0.1 −8.3 ± 0.1 nd
5 OMe −3.49 <−1.5 nd nd
8b OMe −1.95 1.2 ± 0.1 −7.4 ± 0.1 nd
7i OMe 0.91 2.3 ± 0.1 −7.8 ± 0.4* Tris pH 7.4:1.5
Prism pH 6.5: >1.0
NaCl 0.9%: >1.0
7i OEt 1.27 3.4 ± 0.1 −8.3 ± 0.3* Tris pH 7.4:13.8
Prism pH 6.5:3.2
NaCl 0.9%: 3.7
7i OPr 1.79 nd −8.2 ± 0.3* Tris pH 7.4:2.8
Prism pH 6.5:1.7
NaCl 0.9%: 2.4
7i OBu 2.23 3.8 ± 0.1 −6.5 ± 0.4* Tris pH 7.4:3.9
Prism pH 6.5:3.2
NaCl 0.9%: 5.0
aclogD7.4 was calculated using Marvin Sketch software (version 16.10.10.0)
bOctanol−water distribution coefficients (log D7.4) were determined at
pH 7.4 by a miniaturized shake flask procedure in sextuplicate in Tris buffer (0.1 M). cPe = effective permeability: diffusion through an artificial
membrane was determined by the parallel artificial membrane permeability assay (PAMPA) in quadruplicate at pH 6.5 in Prism buffer.
Measurements indicated with * indicate inclusive 10% DMSO. dThe kinetic solubility was measured in singlet measurements in three different buffer
systems (Tris 0.1 M, pH 7.4; Prism pH 6.5; 0.9% NaCl in water).
Figure 2. Passive permeability log Pe of ester prodrugs versus
lipophilicity. The dotted lines indicate the threshold for moderate and
high absorption potential.46 Error bars show the standard deviation of
the measurement in six independent measurements of log D7.4 and
four independent measurements of log Pe.
Table 5. Cell Permeability of 7i-OBu
Caco2 Papp [10
−6 cm s−1]a
a−b b−a
b−a/
a−b
MetStab HLM
T1/2 [min]
b
7i-OBu 0.32 ± 0.09 2.2 ± 0.2 6.7 >90
aPapp = apparent permeability: permeation through a Caco-2 cell
monolayer was assessed in the absorptive (a→ b) and secretory (b→
a) direction in triplicate after 30 min. The initial compound
concentration (c0) in the donor chamber was 62.5 μM.
bThe metabolic
stability assay was performed in human liver microsomes (HLM 0.5
mg mL−1) in triplicate.
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OBu showed insufficient solubility, a suboptimal efflux ratio,
and slow permeability in a cell permeation assay and slow
metabolic release of the active principle. Together, these results
predict low oral bioavailability without further modification.
Active Site Models of Human NEUs. To gain structural
insight into the selectivity of active inhibitors, we ran 50 ns
molecular dynamics (MD) simulations of 8b in complex with
NEU2, NEU3, and NEU4. NEU models were based on
reported X-ray or homology models.27,29−31,50 The starting
structures for each simulation are shown in the Supporting
Information. Inhibitor 8b remained bound in the three active
sites throughout the MD simulations (Figure 3) and the parent
DANA ring in 8b maintained the ring conformation that
mimics the proposed transition state of the oxocarbenium ion
intermediate. We analyzed ring conformations of 8b in the
simulations using standard nomenclature for six-membered
monosaccharides, with C2 being the anomeric carbon (Figure
1, 1).51 The population of ring conformations51 observed for
8b were found over E5−6H5−6E and were similar for all three
enzymes, with NEU2 centered at 94° (6H5), NEU3 centered at
Figure 3. Average enzyme structures for (A) NEU2, (B) NEU3, and (C) NEU4 with 8b in the active site. The inhibitor is shown as 10
representative structures taken from the last 25 ns of the MD simulation.
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106° (6H5/6E), and NEU4 centered at 82° (E5/6H5).
52 For
comparison, the ring conformation of DANA 1 bound to
NEU2 is E5 in the co-crystal structure (PDB 1VCU).
27
We had predicted that large groups at C9 would provide
better inhibitors of NEU3 and NEU4 based on previous
inhibitor studies,25 as well as on previous MD simulations.53
One reason for this difference in the C9 binding pocket is
found in the P267−G275 loop of NEU2, which contains an
extra amino acid in comparison to the same loops in NEU3 and
NEU4. In Figure 3, a key residue on this loop is shown for each
enzyme: Q270 for NEU2, H277 for NEU3, and W274 for
NEU4. In NEU2, Q270 forms a H-bond with the triazole of 8b
for 10% of the simulation (Figure 3A, Supporting Information).
Furthermore, the triazole is within 7 Å of Q270 for 30% of the
simulation (6.4 ± 0.6 Å, average distance between triazole N3
of 8b and carbonyl oxygen of Q270). To accommodate the
large biphenyl-triazole, the P267−G275 loop changes position
and moves Q270 in closer contact with the carboxylate of 8b
(5.5 ± 0.8 Å, average distance between carboxylate of 8b and
terminal amide of Q270, as shown in Figure 3A). The
comparable residue in NEU3, H277, forms a H-bond with the
triazole for 17% of the simulation and is within 7 Å of the
triazole for 100% of the time (Figure 3B, 4.7 ± 0.4 Å, average
distance between triazole N3 of 8b and carbonyl oxygen of
H277). While W274 in NEU4 does not form any H-bonds with
8b, it remains within 7 Å of the biphenyl group of 8b for 100%
of the simulation (Figure 3C, 3.8 ± 0.6 Å, average distance
between carbonyl oxygen of W274 and the carbon ortho to the
triazole in 8b). However, this relatively close contact is not
sufficient to prevent rotation of the biphenyl-triazole
substituent. The flexibility of 8b in the active site of NEU4
could be one reason for the higher inhibitory potency for
NEU3 over NEU4.
Looking at the IC50 values for 1 and 6, we sought an
explanation from our MD simulations for the selectivity the C4
guanidine provides for NEU3 over NEU4. The C4 guanidine of
8b forms the most highly populated H-bonds between the
inhibitor and NEU3. The H-bond to E43 is populated for 92%
of the simulation (Figure 3B), whereas the comparable H-
bonds in NEU2 and NEU4 are only populated for 47% (to
E39, Figure 3A) and 52% (to E41, Figure 3C) of the
simulation, respectively (see Supporting Information). Addi-
tionally, there is a water bridge between 8b and D50 of NEU3
that is populated for 88% of the simulation. None of the water
bridges in simulations with 8b and NEU2 or NEU4 are
occupied for as much of the simulation time (Supporting
Information). Thus, we propose that the guanidine moiety
displaces an ordered water from the C4 pocket in the NEU3
active site. In contrast, NEU2 and NEU4 are not able to
maintain contacts to this group.
Activity of Inhibitors Against Murine NEU Ortho-
logues. To confirm the selectivity of our active NEU3
inhibitors in vivo against the mouse orthologues, we assayed
neuraminidase activity in the tissues of previously described
gene-targeted mouse strains deficient in NEU1 (neu1−/−),
NEU3 (neu3−/−), and NEU4 (neu4−/−),54−56 respectively. We
also produced a mouse line with a double NEU3/NEU4
deficiency (neu3−/− neu4−/−) by cross-breeding the individual
Figure 4. Inhibition of NEU activity in murine brain homogenate. Brains were extracted from WT C57Bl6 mice and those KO for the NEU1
(neu1−/−), NEU3 (neu3−/−), NEU4 (neu4−/−), or double KO (DKO) for the NEU3/4 genes (neu3−/−; neu4−/−). Brain homogenates were assayed
for inhibition of neuraminidase activity against 4MU-NANA. The WT brain homogenates (A) showed partial inhibition (up to 70% at 10 μM) of
neuraminidase activity by both 8b and 7i, while the NEU3 KO brain homogenate (B) showed no inhibition with 8b and NEU3/4 DKO brain
homogenate (C) showed no significant inhibition with either compound 8b nor 7i. The NEU1 KO brain homogenate (D) was the only sample to
show dramatic inhibition for both compounds 8b and 7i, consistent with specificity of these compounds for the NEU3/4 isoenzymes. Importantly,
all homogenates showed a complete inhibition of neuraminidase activity at 150 μM of DANA 1 (data not shown). Points are labeled as significantly
different (*, p < 0.05; **, p < 0.01; ***, p < 0.001) from the activity in the absence of the inhibitors according to t test with a Dunlett post-test. Data
are shown as mean values ± SD of 6−12 independent experiments.
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knockouts. As expected, the expression levels of both neu3 and
neu4 were below the detection limit in the tissues of the
neu3−/− neu4−/− mice.54
We assayed neuraminidase activity in the mouse brain tissues,
where comparable amounts of NEU1, NEU3, and NEU4 (and
only negligible amounts of NEU2) were previously described in
the WT mice.57 Acidic neuraminidase activity in the WT brain
homogenate, assayed using the 4MU-NANA substrate, was
reduced to ∼85% in the presence of 10 μM 8b and to ∼60% in
the presence of 50 μM 7i, suggesting that both NEU3 and
NEU4 isoenzymes contribute approximately 10−15% of the
net brain neuraminidase activity against 4MU-NANA. Further
increase of 7i to 150 μM did not reduce activity, indicating that
even at this concentration the compound did not inhibit mouse
NEU1 (Figure 4A). In contrast, the residual neuraminidase
activity levels measured in the brain tissues of NEU1-deficient
mice in the presence of saturating concentrations of 8b and 7i
were drastically different: 8b reduced the activity to about
∼60% of that measured in the absence of inhibitors, whereas 7i
completely inhibited the activity (Figure 4D). In the brain of
NEU3-deficient mice, only 7i could reduce the activity by
approximately 20%, which corresponded to the NEU4 fraction
of the activity, the rest being NEU1 (Figure 4B). Finally, both
8b and 7i failed to cause any inhibition of neuraminidase
activity in the brain homogenates of NEU3/NEU4 double
knockout mice where all activity was presumed to come from
the NEU1 isoenzyme (Figure 4C). Together, our data confirm
that the 8b and 7i can discriminate between isoforms of
mammalian neuraminidases in tissues and could be used to
target the specific isozymes in vivo.
■ DISCUSSION
In glycobiology, human neuraminidases constitute an important
family of enzymes58 because they play crucial roles in numerous
biological processes through the control of sialoglycoconjugate
catabolism. Potent and selective chemical inhibitors represent
valuable tools for investigating the biological functions of these
enzymes. Viral neuraminidase inhibitors with low nanomolar
activities have seen successful clinical application as antiviral
drugs.16 However, there remains a need for strategies to
generate selective and potent inhibitors for human neuramini-
dases.
In this work, we identified selective inhibitors of NEU3 from
a small library of DANA analogues with modifications at C4
and C9. On the basis of previously reported structure−activity
relationship studies (SAR) and protein structures, we
hypothesized that large aromatic groups at C9 could improve
potency against NEU3. In our study, C9 modifications not only
significantly improved the potency toward NEU3 but also for
NEU4. Furthermore, the inhibitory profile of zanamivir 6
toward human neuraminidases encouraged us to also study the
effects of C4 modifications. Surprisingly, among all the
nitrogen-containing groups we tested, only the guanidino
group showed significant improvements. Although compounds
bearing a C4-guanidino group and C9-modification only
slightly improved potency toward NEU3, this modification
substantially decreased the potency toward NEU4. Moreover,
compound 8b, with a biphenyltriazolyl group at C9 and a
guandino group at C4, showed slightly improved potency over
7i, which had only a biphenyltriazolyl group at C9. The
selectivity of compound 8a, which bears a 4-carboxylphenyl-
triazolyl group at C9 and a guanidino group at C4 for NEU3
may be due to the presence of a carboxylate on the aryl group.
Analysis of the pharmacokinetic properties of our lead
compounds 7i and 8b suggested that they are unlikely to be
orally bioavailable. Permeability assays using artificial mem-
branes (PAMPA) showed that the parent compounds 7i and
8b, and most of the C1-ester prodrugs were not sufficiently
permeable for oral bioavailability. Only the most lipophilic n-
butyl ester 7i-OBu reached this limit with a log Pe = −6.5 ± 0.4.
The low solubility of 3−5 μg mL−1 further contributes to poor
pharmacokinetic properties. Furthermore, cell permeability data
for 7i-OBu suggested that the compound was likely subject to
active efflux, which adds to the limitation of its bioavailability.
Finally, the examination of the liver microsome stability of 7i-
OBu showed that the ester was only slowly hydrolyzed. In
summary, esterification did not improve pharmacokinetic
properties sufficiently to allow for oral bioavailability. Future
studies should implement modifications of the active principle
to reduce the risk of insufficient permeability and solubility.
Molecular modeling studies provided insight into the
structural elements responsible for selectivity between NEU3
and NEU4 relative to other isoenzymes. Because only crystal
structures for NEU2 were available, we used homology models
to study NEU3 and NEU4. Our previous hypothesis of larger
C9 pockets available on both NEU3 and NEU4 explained the
activity of compounds such as 7i, which gained substantial
activity over DANA (1) for both NEU3 and NEU4. Inhibitors
of both NEU3 and NEU4 could be useful agents as these
enzymes are known to act on similar substrates and may
compensate for each other in vivo.59 The selectivity over NEU1
and NEU2 can be attributed to the limited size of their C9
pockets. Furthermore, our models provided a rationale for the
observed selectivity of inhibitors with a C4-guanidino group (6,
8a, 8b) for NEU3. The inclusion of the C4-guanidino group
confers a notable improvement in activity against NEU3, and
our data suggested this could be due to the displacement of an
ordered water in the active site.60 The absence of a comparable
ordered water molecule prevented these compounds from
gaining similar activity against NEU4. In general, the C4-
guanidino modification reduced NEU4 activity relative to the
parent structures (compare 1 and 6; 7h and 8a; 7i and 8b).
This finding provides an important design principle for future
NEU3 inhibitor design.
■ CONCLUSION
In this study, we demonstrated that the scaffold of the
neuraminidase inhibitor DANA 1 can be used as a starting
point for the generation of new potent and selective inhibitors
of human neuraminidase isoenzymes. First, aryltriazolyl groups
at C9 greatly improved the potency of inhibitors toward NEU3
and NEU4, and second, the inclusion of a guanidino group at
C4 provided selectivity between NEU3 and NEU4, revealing a
clear strategy for the design of inhibitors with improved
selectivity for NEU3 with submicromolar potencies. These
inhibitors may be adapted as useful tools to study the biological
function of human neuraminidases. In summary, our data
confirmed that divergent structural features of the active site of
human neuraminidase isoenzymes allowed identification of
selective and potent inhibitors of this important family of
human glycosidases. Future studies will address the activity of
these compounds in vivo and provide new tools for dissecting
the specific biological roles of NEU isoenzymes.
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■ EXPERIMENTAL SECTION
General Synthetic Procedures. All reagents and solvents were
purchased from Sigma-Aldrich unless otherwise noted and used
without further purification. Reactions were monitored with TLC
(Merck TLC Silica gel 60 F254), and spots were visualized under UV
light (254 nm) or by charring with 0.5% H2SO4/EtOH. Compounds
were purified by flash column chromatography with silica gel
(SiliCycle SiliaFlash F60, 40−63 μm particle size) or recrystallization
with solvents specified in the corresponding experiments. Proton (1H)
and carbon (13C) NMR spectra were recorded on Varian 400 (400
MHz for 1H; 100 MHz for 13C), Varian 500 (500 MHz for 1H; 125
MHz for 13C), or Varian 700 (700 MHz for 1H; 175 MHz for 13C).
High-resolution mass spectrometry (HR-MS) analysis was performed
on Agilent Technologies 6220 TOF spectrometer. Purity of all final
products used for inhibitor assays and pharmacokinetic studies was
determined to be ≥95% by HPLC or LC-MS (see Supporting
Information for details).
5-Acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-non-
2-enonic Acid (DANA, 1). Compound 1 was synthesized as previously
reported.25 1H NMR (500 MHz, CD3OD) δ 5.67 (d, J = 2.3 Hz, 1H,
H-3), 4.36 (dd, J = 8.6, 2.3 Hz, 1H, H-4), 4.10 (dd, J = 10.9, 1.1 Hz,
1H, H-6), 3.99 (dd, J = 10.9, 8.6 Hz, 1H, H-5), 3.87 (ddd, J = 9.1, 5.4,
3.1 Hz, 1H, H-8), 3.80 (dd, J = 11.4, 3.1 Hz, 1H, H-9), 3.65 (dd, J =
11.4, 5.4 Hz, 1H, H-9′), 3.52 (dd, J = 9.1, 1.1 Hz, 1H, H-7), 2.02 (s,
3H, COCH3).
13C NMR (125 MHz, CD3OD) δ 174.68, 170.02 (2 ×
CO), 149.95 (C-2), 108.34 (C-3), 77.24 (C-6), 71.29 (C-8), 70.22
(C-7), 68.70 (C-4), 64.94 (C-9), 51.96 (C-5), 22.82 (COCH3). HR-
MS (ESI): calcd for C11H16NO8 [M − H]− 290.0876, found 290.0879
Methyl-5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galac-
to-non-2-enonate (DANA-OMe, 1-OMe). Compound 1-OMe was
synthesized as previously reported.25 1H NMR (500 MHz, D2O) δ
6.13 (d, J = 2.4 Hz, 1H, H-3), 4.60 (dd, J = 9.0, 2.4 Hz, 1H, H-4), 4.36
(d, J = 10.9 Hz, 1H, H-6), 4.17 (dd, J = 10.8, 9.0 Hz, 1H, H-5), 4.00
(ddd, J = 9.0, 6.0, 2.7 Hz, 1H, H-8), 3.95 (dd, J = 11.9, 2.7 Hz, 1H, H-
9), 3.90 (s, 3H, COOCH3), 3.77−3.71 (m, 2H, H-7, H-9), 2.15 (s, 3H,
COCH3).
13C NMR (125 MHz, D2O) δ 175.78, 165.30 (2 × CO),
144.37 (C-2), 113.54 (C-3), 77.09 (C-6), 70.84 (C-8), 68.92 (C-7),
68.02 (C-4), 63.99 (C-9), 53.91 (COOCH3), 50.59 (C-5), 23.07
(COCH3). HR-MS (ESI): calcd for C12H19NNaO8 [M + Na]
+
328.1008, found 328.1006.
5-Acetamido-9-pentanamido-2,6-anhydro-3,5-dideoxy-D-glyc-
ero-D-galacto-non-2-enonic Acid (C9-BA-DANA, 2). Compound 2
was synthesized as previously reported.22 1H NMR (500 MHz,
CD3OD) δ 5.93 (d, J = 1.7 Hz, 1H, H-3), 4.43 (dd, J = 8.6, 1.7 Hz, 1H,
H-4), 4.18 (d, J = 10.8 Hz, 1H, H-6), 4.02−3.95 (m, 1H, H-5), 3.95−
3.87 (m, 1H, H-8), 3.59 (dd, J = 13.9, 2.9 Hz, 1H, H-9), 3.43 (d, J =
9.0 Hz, 1H, H-7), 3.32−3.27 (m, 1H, H-9′), 2.22 (t, J = 7.6 Hz, 2H, α-
CH2), 2.03 (s, 3H, COCH3), 1.64−1.54 (m, 2H, β-CH2), 1.35 (dd, J =
15.0, 7.5 Hz, 2H, γ-CH2), 0.92 (t, J = 7.4 Hz, 3H, δ-CH3).
13C NMR
(126 MHz, CD3OD) δ 177.26, 174.88 (N−CO), 165.81 (C-1),
145.81 (C-2), 113.17 (C-3), 77.79 (C-6), 71.50 (C-7), 70.24 (C-4),
68.03 (C-8), 51.97 (C-5), 44.40 (C-9), 36.87 (C-α), 29.28 (C-β),
23.44 (C-γ), 22.86 (COCH3), 14.22 (C-δ). HRMS (ESI): calcd for
C16H25N2O8 [M − H]− 373.1616, found 373.1614.
Methyl-5-acetamido-9-pentanamido-2,6-anhydro-3,5-dideoxy-
D-glycero-D-galacto-non-2-enonate (C9-BA-DANA-OMe, 2-OMe).
Compound 2-OMe was synthesized as previously reported.22 1H
NMR (500 MHz, CD3OD) δ 5.93 (d, J = 2.4 Hz, 1H, H-3), 4.43 (dd, J
= 8.8, 2.4 Hz, 1H, H-4), 4.19 (d, J = 10.6 Hz, 1H, H-6), 3.98 (dd, J =
10.6, 8.8 Hz, 1H, H-5), 3.94−3.89 (m, 1H, H-8), 3.77 (s, 3H,
COOCH3), 3.59 (dd, J = 14.0, 3.1 Hz, 1H, H-9), 3.42 (d, J = 9.1 Hz,
1H, H-7), 3.31 (m, 1H, H-9′), 2.23 (t, J = 7.6 Hz, 2H, α-CH2), 2.03 (s,
3H, COCH3), 1.64−1.54 (m, 2H, β-CH2), 1.40−1.30 (m, 2H, γ-CH2),
0.93 (t, J = 7.4 Hz, 3H, δ-CH3).
13C NMR (125 MHz, CD3OD) δ
177.31, 174.90, 164.34 (3 × CO), 145.18 (C-2), 113.65 (C-3),
77.97 (C-6), 71.50 (C-7), 70.19 (C-4), 67.90 (C-8), 52.90
(COOCH3), 52.01 (C-5), 44.49 (C-9), 36.86 (C-α), 29.27 (C-β),
23.44 (C-γ), 22.85 (COCH3), 14.24 (C-δ). HRMS (ESI): calcd for
C17H29N2O8 [M + H]
+ 389.1924, found 389.1909.
5-Acetamido-2,6-anhydro-4-guanidino-3,4,5-trideoxy-D-glycero-
D-galacto-non-2-enonic Acid (Zanamivir, 6). Compound 6 was
synthesized as previously reported.61,62 1H NMR (500 MHz, D2O) δ
5.70 (d, J = 1.9 Hz, 1H, H-3), 4.54 (dd, J = 9.3, 1.9 Hz, 1H, H-4), 4.46
(m, 1H, H-6), 4.29 (dd, J = 10.5, 9.3 Hz, 1H, H-5), 4.02 (ddd, J = 9.1,
6.2, 2.5 Hz, 1H, H-8), 3.96 (dd, J = 11.9, 2.5 Hz, 1H, H-9), 3.77−3.69
(m, 2H, H-7, H-9′), 2.11 (s, 3H, COCH3). 13C NMR (125 MHz,
D2O) δ 175.38, 170.10 (2 × CO), 157.99 (CN), 150.19 (C-2),
104.79 (C-3), 76.33 (C-6), 70.74 (C-8), 69.11 (C-7), 64.03 (C-9),
52.11 (C-4), 48.71 (C-5), 22.93 (COCH3). HR-MS (ESI): calcd for
C12H21N4O7 [M + H]
+ 333.1405, found 333.1400
General Procedure of CuAAC Reaction and Hydrolysis of
Methyl Ester. To a solution of methyl 5-acetamido-9-azido-2,6-
anhydro-3,5-dideoxy-D-glycero-D-galacto-non-2-enonate (9)25 (1
equiv) and the corresponding alkyne (1.5 equiv) in THF−H2O
(2:1), sodium L-ascorbate (0.5 equiv) and copper(II) sulfate (0.5
equiv) were added sequentially. The reaction mixture was kept stirring
at room temperature and monitored by TLC until no azide remained.
Silica gel was then added to the reaction mixture, and the solvent was
removed under reduced pressure. The residue was separated by flash
chromatography to provide the desired products with yields of 42%−
88%. To hydrolyze the C1-methyl ester, the product was dissolved in
MeOH, and 0.5 M NaOH was added. The mixture was kept stirring at
room temperature. After completion, the pH of the solution was
adjusted to 2 with Amberlite IR-120 (H+). The solution was filtered,
concentrated, and purified by flash chromatography or recrystallization
to provide the desired products with yields of 45%−88%.
5-Acetamido-9-(4-(dimethylamino)phenyl)-2,6-anhydro-3,5-di-
deoxy-D-glycero-D-galacto-non-2-enonic Acid (7a). Compound 7a
was prepared as described above in 62% yield (two steps, 86 mg). 1H
NMR (500 MHz, CD3OD) δ 8.11 (s, 1H, triazole-H), 7.64 (d, J = 8.9
Hz, 2H, Ar-H), 6.81 (d, J = 8.9 Hz, 2H, Ar-H), 5.90 (d, J = 2.3 Hz, 1H,
H-3), 4.49 (dd, J = 14.0, 7.5 Hz, 1H, H-9′), 4.40 (dd, J = 8.7, 2.3 Hz,
1H, H-4), 4.31−4.25 (m, 1H, H-8), 4.14 (dd, J = 10.9, 1.0 Hz, 1H, H-
6), 3.99 (dd, J = 10.9, 8.7 Hz, 1H, H-5), 3.41 (dd, J = 9.2, 1.0 Hz, 1H,
H-7), 2.96 (s, 6H, N(CH3)2), 1.99 (s, 3H, COCH3).
13C NMR (125
MHz, CD3OD) δ 175.16 (CO), 152.12, 127.59, 120.10, 113.93 (Ar-
C), 149.18 (triazole-C4), 121.83 (triazole-C5), 77.67 (C-6), 71.23 (C-
7), 69.79 (C-4), 68.01 (C-8), 55.13 (C-9), 51.96 (C-5), 40.78 (N-
CH3), 22.65 (COCH3). HR-MS (ESI): calcd for C21H26N5O7 [M
−H]− 460.1832, found 460.1834.
5-Acetamido-9-(4-acetamidophenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7b). Compound 7b was
prepared as above in 65% yield (two steps, 90 mg). 1H NMR (500
MHz, CD3OD) δ 8.28 (s, 1H, triazole-H), 7.76 (d, J = 8.2 Hz, 2H, Ar-
H), 7.62 (d, J = 8.2 Hz, 2H, Ar-H), 5.70 (s, 1H, H-3), 4.50 (dd, J =
13.5, 7.7 Hz, 1H, H-9′), 4.35 (d, J = 8.6 Hz, 1H, H-4), 4.30−4.27 (m,
1H, H-8), 4.10 (d, J = 10.7 Hz, 1H, H-6), 4.04−3.96 (m, 1H, H-5),
3.39 (d, J = 7.7 Hz, 1H, H-7), 2.13, 1.98 (2 × s, 3H, 2 × COCH3). 13C
NMR (125 MHz, DDMSO-d6) δ 172.10, 168.34, 168.25, 165.18 (4 ×
CO), 147.63 (C-2), 145.74 (triazole-C4), 121.67 (triazole-C5),
138.80, 138.69, 125.72, 125.44, 119.20, 119.11 (Ar-C), 108.60 (C-3),
75.66 (C-6), 69.95 (C-7), 68.10 (C-4), 65.90 (C-8), 53.70(C-9), 50.81
(C-5), 22.97, 22.49 (2 × COCH3). HR-MS (ESI): calcd for
C21H24N5O8 [M − H]− 474.1625, found 474.1636.
5-Acetamido-9-(4-amidophenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7c). Compound 7c was
prepared as above in 63% yield (two steps, 80 mg). 1H NMR (500
MHz, CD3OD) δ 8.09 (s, 1H, triazole-H), 7.55 (d, J = 8.6 Hz, 2H, Ar-
H), 6.79 (d, J = 8.6 Hz, 2H, Ar-H), 5.88 (d, J = 2.4 Hz, 1H, H-3), 4.82
(dd, J = 14.1, 2.6 Hz, 1H, H-9), 4.48 (dd, J = 14.1, 7.6 Hz, 1H, H-9′),
4.41 (dd, J = 8.7, 2.4 Hz, 1H, H-4), 4.28 (ddd, J = 9.5, 7.6, 2.6 Hz, 1H,
H-8), 4.14 (dd, J = 10.9, 1.0 Hz, 1H, H-6), 4.00 (dd, J = 10.9, 8.7 Hz,
1H, H-5), 3.41 (dd, J = 9.5, 1.0 Hz, 1H, H-7), 1.98 (s, 3H, COCH3).
13C NMR (125 MHz, CD3OD) δ 175.13, 166.94 (2 × CO), 149.13,
148.42 (Ar-C, triazole-C4), 146.69 (C-2), 127.77, 116.96 (Ar-C),
122.01, 121.94 (Ar-C, triazole-C5), 112.19 (C-3), 77.57 (C-6), 71.24
(C-7), 69.81 (C-4), 68.08 (C-8), 55.14 (C-9), 51.93 (C-5), 22.72
(COCH3). HR-MS (ESI): calcd for C19H22N5O7 [M − H]− 432.1529,
found 432.1513.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.7b01574
J. Med. Chem. XXXX, XXX, XXX−XXX
J
NEU3 inhibitors  Publication 2 
 229 
 
5-Acetamido-9-(4-methylphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7d). Compound 7d was
prepared as above in 75% yield (two steps, 100 mg). 1H NMR (500
MHz, CD3OD) δ 8.24 (s, 1H, triazole-H), 7.68 (d, J = 8.0 Hz, 2H, Ar-
H), 7.22 (d, J = 8.0 Hz, 2H, Ar-H), 5.79 (s, 1H, H-3), 4.50 (dd, J =
13.9, 7.4 Hz, 1H, H-9′), 4.39 (d, J = 8.2 Hz, 1H, H-4), 4.29 (brs, 1H,
H-8), 4.13 (d, J = 10.9 Hz, 1H, H-6), 4.06−3.97 (m, 1H, H-5), 3.42
(d, J = 9.0 Hz, 1H, H-7), 2.34 (s, 3H, PhCH3), 1.98 (s, 3H, COCH3).
13C NMR (125 MHz, CD3OD) δ 175.00 (CO), 148.64 (triazole-
C4), 123.08 (triazole-C5), 139.31, 130.58, 129.01, 126.62 (Ar-C),
110.40 (C-3), 77.27 (C-6), 71.24 (C-7), 69.84 (C-4), 68.35 (C-8),
55.16 (C-9), 51.95 (C-5), 22.76 (COCH3), 21.31 (PhCH3). HR-MS
(ESI): calcd for C20H23N4O7 [M − H]− 431.1567, found 431.1568.
5-Acetamido-9-(4-methoxyphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7e). Compound 7e was
prepared as above in 59% yield (two steps, 80 mg). 1H NMR (500
MHz, CD3OD) δ 8.20 (s, 1H, triazole-H), 7.72 (d, J = 8.9 Hz, 2H, Ar-
H), 6.97 (d, J = 8.9 Hz, 2H, Ar-H), 5.77 (d, J = 2.0 Hz, 1H, H-3), 4.49
(dd, J = 14.0, 7.6 Hz, 1H, H-9′), 4.39 (dd, J = 8.7, 2.0 Hz, 1H, H-4),
4.32−4.25 (m, 1H, H-8), 4.12 (d, J = 10.8 Hz, 1H, H-6), 4.00 (dd, J =
10.8, 8.7 Hz, 1H, H-5), 3.81 (s, 3H, PhOCH3), 3.41 (d, J = 9.2 Hz,
1H, H-7), 1.98 (s, 3H, COCH3).
13C NMR (125 MHz, CD3OD) δ
174.96 (COCH3), 161.27, 128.00, 124.40, 115.37 (Ar-C), 148.49
(triazole-C4), 122.59 (triazole-C5), 109.95 (C-3), 77.20 (C-6), 71.26
(C-7), 69.86 (C-4), 68.38 (C-8), 55.80 (PhOCH3), 55.15 (C-9), 51.97
(C-5), 22.74 (COCH3). HR-MS (ESI): calcd for C20H23N4O8 [M −
H]− 447.1516, found 447.1527.
5-Acetamido-9-(4-fluorophenyl)-2,6-anhydro-3,5-dideoxy-D-glyc-
ero-D-galacto-non-2-enonic Acid (7f). Compound 7f was prepared as
above in 62% yield (two steps, 80 mg). 1H NMR (500 MHz, CD3OD)
δ 8.28 (s, 1H, triazole-H), 7.87−7.80 (m, 2H, Ar-H), 7.20−7.13 (m,
2H, Ar-H), 5.92 (d, J = 2.4 Hz, 1H, H-3), 4.86 (dd, J = 14.0, 2.6 Hz,
1H, H-9), 4.51 (dd, J = 14.0, 7.7 Hz, 1H, H-9′), 4.41 (dd, J = 8.7, 2.4
Hz, 1H, H-4), 4.29 (ddd, J = 9.6, 7.7, 2.6 Hz, 1H, H-8), 4.14 (dd, J =
10.8, 1.1 Hz, 1H, H-6), 3.99 (dd, J = 10.8, 8.7 Hz, 1H, H-5), 3.43 (dd,
J = 9.6, 1.1 Hz, 1H, H-7), 1.99 (s, 3H, COCH3).
13C NMR (125 MHz,
CD3OD) δ 175.15 (CO), 164.09 (d, J = 245.9 Hz, Ar-C), 147.63
(triazole-C4), 123.31 (triazole-C5), 128.61 (d, J = 8.2 Hz, Ar-C),
128.34 (d, J = 3.2 Hz, Ar-C), 116.77 (d, J = 22.0 Hz, Ar-C), 112.86 (C-
3), 77.70 (C-6), 71.30 (C-7), 69.80 (C-4), 67.95 (C-8), 55.25 (C-9),
51.96 (C-5), 22.64 (COCH3). HR-MS (ESI): calcd for C19H20FN4O7
[M − H]− 435.1316, found 435.1324.
5-Acetamido-9-(4-(trifluoromethyl)phenyl)-2,6-anhydro-3,5-di-
deoxy-D-glycero-D-galacto-non-2-enonic Acid (7g). Compound 7g
was prepared as above in 19% yield (two steps, 40 mg). 1H NMR (500
MHz, CD3OD) δ 8.44 (s, 1H, triazole-H), 8.02 (d, J = 8.2 Hz, 2H, Ar-
H), 7.72 (d, J = 8.2 Hz, 2H, Ar-H), 5.95 (d, J = 2.4 Hz, 1H, H-3), 4.90
(dd, J = 14.0, 2.6 Hz, 1H, H-9), 4.53 (dd, J = 14.0, 7.7 Hz, 1H, H-9′),
4.42 (dd, J = 8.7, 2.4 Hz, 1H, H-4), 4.37−4.21 (m, 1H, H-8), 4.16 (dd,
J = 10.8, 1.0 Hz, 1H, H-6), 4.00 (dd, J = 10.8, 8.7 Hz, 1H, H-5), 3.45
(dd, J = 9.1, 1.0 Hz, 1H, H-7), 1.99 (s, 3H, COCH3).
13C NMR (125
MHz, CD3OD) δ 175.20 (CO), 147.04 (triazole-C4), 124.50
(triazole-C5), 135.81 (Ar-C), 130.90 (q, J = 32.3 Hz, Ar-C), 127.01
(Ar-C), 126.89 (q, J = 3.8 Hz, Ar-C), 113.43 (C-3), 77.81 (C-6), 71.35
(C-7), 69.80 (C-4), 67.88 (C-8), 55.34 (C-9), 51.95 (C-9), 22.65
(COCH3). HR-MS (ESI): calcd for C20H20F3N4O7 [M − H]−
485.1284, found 485.1282.
5-Acetamido-9-(4-carboxyphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7h). Compound 7h was
prepared as above in 74% yield (two steps, 100 mg). 1H NMR (500
MHz, CD3OD) δ 8.42 (s, 1H, triazole-H), 8.06 (d, J = 8.5 Hz, 2H, Ar-
H), 7.90 (d, J = 8.5 Hz, 2H, Ar-H), 5.84 (d, J = 1.9 Hz, 1H, H-3), 4.88
(dd, J = 14.0, 2.1 Hz, 1H, H-9), 4.54 (dd, J = 14.0, 7.6 Hz, 1H, H-9′),
4.43 (dd, J = 8.7, 1.9 Hz, 1H, H-4), 4.31 (t, J = 7.6 Hz, 1H, H-8), 4.15
(d, J = 10.9 Hz, 1H, H-6), 4.03 (dd, J = 10.9, 8.7 Hz, 1H, H-5), 3.44
(d, J = 7.6 Hz, 1H, H-7), 1.99 (s, 3H, COCH3).
13C NMR (125 MHz,
CD3OD) δ 175.08, 169.69, 167.90 (3 × CO), 147.50 (triazole-C4),
124.53 (triazole-C5), 136.19, 131.49, 126.44 (Ar-C), 111.19 (C-3),
77.37 (C-6), 71.31 (C-7), 69.84 (C-4), 68.24 (C-8), 55.29 (C-9),
51.90 (C-5), 22.82 (COCH3). HR-MS (ESI): calcd for C20H21N4O9
[M − H]− 461.1309, found 461.1316.
Methyl-5-acetamido-9-(4-biphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonate Acid (7i-OMe). C1-Methyl ester of
7i was obtained via CuAAC as described. 69% (71 mg). 1H NMR (500
MHz, DMSO-d6) δ 8.46 (s, 1H, triazole-H), 8.19 (d, J = 7.4 Hz, 1H,
Ar-H), 7.93 (d, J = 7.4 Hz, 2H, Ar-H), 7.74 (d, J = 7.6 Hz, 2H, Ar-H),
7.70 (d, J = 7.0 Hz, 2H, Ar-H), 7.49−7.42 (m, 2H, Ar-H), 7.38−7.32
(m, 1H, Ar-H), 5.81 (s, 1H, H-3), 5.41 (d, J = 5.4 Hz, 1H, OH), 5.36
(d, J = 4.7 Hz, 1H, OH), 5.10 (s, 1H, NH), 4.77 (d, J = 13.4 Hz, 1H,
H-9), 4.38−4.25 (m, 2H, H-9′, H-4), 4.09−3.95 (m, 2H, H-8, H-6),
3.80−3.72 (m, 1H, H-7), 3.69 (s, 3H, COOCH3), 1.90 (s, 3H,
COCH3).
13C NMR (126 MHz, DMSO-d6) δ 172.06, 162.12 (2 ×
CO), 145.50 (triazole-C4), 143.15 (C-2), 139.56, 139.21, 130.05,
128.92, 127.47, 127.04, 126.45, 125.59 (Ar-C), 122.56 (triazole-C5),
113.36 (C-3), 76.40 (C-6), 69.85 (C-7), 68.00 (C-4), 65.47 (C-8),
53.82 (C-9), 52.06 (α-CH2), 50.26 (C-5), 22.52 (COCH3). HR-MS
(ESI): calcd for C26H28N4O7 [M − H]− 509.2031, found 509.2034.
General Procedure of Transesterification for Elongated
Esters of 7i. Compound 7i-OMe was dissolved in corresponding
alcohol, then LiBr (5 equiv) and DBU (0.5 equiv) was added. After
stirring at room temperature overnight, solvents were removed under
reduced pressure and the residue was purified by flash chromatography
to give the desired products (43−62%).
Ethyl-5-acetamido-9-(4-biphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonate (7i-OEt). Yield 10 mg (62%). 1H
NMR (700 MHz, DMSO-d6) δ 8.48 (s, 1H, triazole-H), 8.22 (d, J =
8.1 Hz, 1H, Ar-H), 7.95 (d, J = 8.2 Hz, 2H, Ar-H), 7.76 (d, J = 8.2 Hz,
2H, Ar-H), 7.72 (d, J = 7.7 Hz, 2H, Ar-H), 7.48 (t, J = 7.6 Hz, 2H, Ar-
H), 7.37 (t, J = 7.4 Hz, 1H, Ar-H), 5.82 (d, J = 2.4 Hz, 1H, H-3), 5.42
(d, J = 6.2 Hz, 1H, OH), 5.38 (d, J = 6.5 Hz, 1H, OH), 5.12 (d, J = 4.8
Hz, 1H, NH), 4.80 (dd, J = 13.9, 2.3 Hz, 1H, H-9), 4.38−4.31 (m, 2H,
H-9′, H-4), 4.19−4.13 (m, 2H, α-CH2), 4.06 (ddd, J = 14.8, 8.7, 2.6
Hz, 1H, H-8), 3.99 (d, J = 10.9 Hz, 1H, H-6), 3.79−3.73 (m, 1H, H-
5), 3.35 (dd, J = 8.7, 5.1 Hz, 1H, H-7), 1.92 (s, 3H, COOCH3), 1.21
(t, J = 7.1 Hz, 3H, β-CH3).
13C NMR (175 MHz, DMSO-d6) δ 172.09,
161.55 (2 × CO), 145.49 (triazole-C4), 143.26 (C-2), 139.57,
139.21, 130.08, 128.94, 127.48, 127.06, 126.46, 125.59 (Ar-C), 122.55
(triazole-C5), 113.18 (C-3), 76.47 (C-6), 69.95 (C-7), 68.13 (C-4),
65.49 (C-8), 60.82 (α-CH2), 53.77 (C-9), 50.31 (C-5), 22.53
(COCH3), 13.98 (β-CH3). HR-MS (ESI): calcd for C27H31N4O7 [M
− H]− 523.2187, found 523.2186.
Propyl-5-acetamido-9-(4-biphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonate (7i-OPr). Yield 10 mg (63%). 1H
NMR (700 MHz, DMSO-d6) δ 8.47 (d, J = 5.6 Hz, 1H, triazole-H),
8.22 (d, J = 8.2 Hz, 1H, Ar-H), 7.95 (d, J = 8.2 Hz, 2H, Ar-H), 7.76 (d,
J = 8.2 Hz, 2H, Ar-H), 7.72 (d, J = 7.5 Hz, 2H, Ar-H), 7.48 (t, J = 7.7
Hz, 2H, Ar-H), 7.37 (t, J = 7.4 Hz, 1H, Ar-H), 5.83 (d, J = 2.3 Hz, 1H,
H-3), 5.41 (d, J = 6.2 Hz, 1H, OH), 5.38 (d, J = 6.5 Hz, 1H, OH), 5.12
(d, J = 4.7 Hz, 1H, NH), 4.80 (dd, J = 13.9, 2.1 Hz, 1H, H-9), 4.39−
4.31 (m, 2H, H-9′, H-4), 4.10−4.04 (m, 3H, α-CH2, H-8), 3.99 (d, J =
10.8 Hz, 1H, H-6), 3.77 (dd, J = 10.8, 8.6 Hz, 1H, H-5), 1.92 (s, 3H,
COOCH3), 1.61 (dd, J = 14.1, 7.2 Hz, 2H, β-CH2), 0.88 (t, J = 7.2 Hz,
3H, γ-CH3).
13C NMR (175 MHz, DMSO-d6) δ 172.09, 161.59 (2 ×
CO), 145.49 (triazole-C4), 143.23 (C-2), 139.57, 139.21, 130.08,
128.94, 127.48, 127.06, 126.46, 125.59 (Ar-C), 122.49 (triazole-C5),
113.14 (C-3), 76.47 (C-6), 69.96 (C-7), 68.20 (C-4), 66.14 (C-8),
65.51 (α-CH2), 53.76 (C-9), 50.31 (C-5), 22.53 (β-CH2), 21.42
(COCH3), 10.19 (γ-CH3). HR-MS (ESI): calcd for C28H33N4O7 [M −
H]− 537.2344, found 537.2345.
Butyl-5-acetamido-9-(4-biphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonate (7i-OBu). Yield 7 mg (43%). 1H
NMR (700 MHz, DMSO-d6) δ 8.47 (s, 1H, triazole-H), 8.22 (d, J =
8.2 Hz, 1H, Ar-H), 7.97−7.93 (m, 2H, Ar-H), 7.78−7.74 (m, 2H, Ar-
H), 7.73−7.70 (m, 2H, Ar-H), 7.49−7.46 (m, 2H, Ar-H), 7.39−7.35
(m, 1H, Ar-H), 5.82 (d, J = 2.5 Hz, 1H, H-3), 5.40 (d, J = 6.2 Hz, 1H,
OH), 5.38 (d, J = 6.5 Hz, 1H, OH), 5.12 (d, J = 4.8 Hz, 1H, NH), 4.81
(dd, J = 13.9, 2.5 Hz, 1H, H-9), 4.39−4.31 (m, 2H, H-9′, H-4), 4.11
(td, J = 6.5, 1.1 Hz, 2H, α-CH2), 4.07 (tdd, J = 8.7, 6.3, 2.5 Hz, 1H, H-
8), 3.99 (d, J = 10.6 Hz, 1H, H-6), 3.77 (dt, J = 10.6, 8.5 Hz, 1H, H-5),
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3.36 (dd, J = 8.6, 5.8 Hz, 1H, H-7), 1.92 (s, 3H, COOCH3), 1.60−1.55
(m, 2H, β-CH2), 1.32 (dq, J = 14.7, 7.4 Hz, 2H, γ-CH2), 0.86 (t, J =
7.4 Hz, 3H, δ-CH3).
13C NMR (175 MHz, DMSO-d6) δ 172.10,
161.58 (2 × CO), 145.49 (triazole-C4), 143.23 (C-2), 139.84,
139.57, 139.20, 130.09, 128.94, 127.48, 127.05, 126.46, 125.59 (Ar-C),
122.48 (triazole-C5), 113.15 (C-3), 76.50 (C-6), 69.99 (C-7), 68.27
(C-4), 65.49 (C-8), 64.42 (α-CH2), 53.74 (C-9), 50.32 (C-5), 30.03
(β-CH2), 22.53 (COCH3), 18.59 (γ-CH2), 13.48 (δ-CH3). HR-MS
(ESI): calcd for C29H35N4O7 [M − H]− 551.2500, found 551.2509.
5-Acetamido-9-(4-biphenyl)-2,6-anhydro-3,5-dideoxy-D-glycero-
D-galacto-non-2-enonic Acid (7i). Compound 7i was obtained after
hydrolysis of 7i-OMe as described above in 75% (52 mg). 1H NMR
(500 MHz, CD3OD) δ 8.34 (s, 1H, triazole-H), 7.88 (d, J = 8.1 Hz,
2H, Ar-H), 7.67 (d, J = 8.1 Hz, 2H, Ar-H), 7.62 (d, J = 7.8 Hz, 2H, Ar-
H), 7.42 (t, J = 7.6 Hz, 2H, Ar-H), 7.32 (t, J = 7.4 Hz, 1H, Ar-H), 5.74
(d, J = 1.9 Hz, 1H, H-3), 4.88 (dd, J = 13.9, 2.2 Hz, 1H, H-9), 4.52
(dd, J = 13.9, 7.7 Hz, H-9′), 4.39 (dd, J = 8.7, 1.9 Hz, H-4), 4.37−4.21
(m, 1H, H-8), 4.13 (d, J = 10.8 Hz, 1H, H-6), 4.02 (dd, J = 10.8, 8.7
Hz, 1H, H-5), 3.42 (d, J = 9.3 Hz, 1H, H-7), 2.00 (s, 3H, COCH3).
13C NMR (125 MHz, CD3OD) δ 174.93, 169.51 (2 × CO), 149.28
(triazole-C4), 123.47 (triazole-C5), 148.20 (C-2), 142.24, 141.76,
130.84, 129.94, 128.54, 128.48, 127.86, 127.10 (Ar-C), 77.14 (C-6),
71.34 (C-7), 69.83 (C-4), 68.49 (C-8), 55.25 (C-9), 52.00 (C-5),
22.77 (COCH3). HR-MS (ESI): calcd for C25H25N4O7 [M − H]−
493.1723, found 493.1729.
5-Acetamido-9-(4-phenoxyphenyl)-2,6-anhydro-3,5-dideoxy-D-
glycero-D-galacto-non-2-enonic Acid (7j). Compound 7j was
prepared as above in 40% (two steps, 40 mg). 1H NMR (500 MHz,
CD3OD) δ 8.24 (s, 1H, triazole-H), 7.78 (d, J = 8.7 Hz, 2H, Ar-H),
7.35 (dd, J = 8.7, 7.4 Hz, 2H, Ar-H), 7.12 (t, J = 7.4 Hz, 1H, Ar-H),
7.05−6.98 (m, 4H, Ar-H), 5.93 (d, J = 2.4 Hz, 1H, H-3), 4.85 (dd, J =
14.0, 2.5 Hz, 1H, H-9), 4.50 (dd, J = 14.0, 7.7 Hz, 1H, H-9′), 4.42 (dd,
J = 8.7, 2.4 Hz, 1H, H-4), 4.30 (ddd, J = 10.0, 7.7, 2.5 Hz, 1H, H-8),
4.16 (m, 1H, H-6), 4.01 (dd, J = 10.8, 8.8 Hz, 1H, H-5), 3.47−3.41
(m, 1H, H-7), 2.00 (s, 3H, COCH3).
13C NMR (125 MHz, CD3OD)
δ 175.18, 166.12 (2 × CO), 158.95, 158.31, 131.00, 128.28, 126.98,
124.77, 120.19, 119.98 (Ar-C), 148.06 (triazole-C4), 123.10 (triazole-
C5), 145.90 (C-2), 113.04 (C-3), 77.73 (C-6), 71.32 (C-7), 69.83 (C-
4), 67.95 (C-8), 55.25 (C-9), 51.95 (C-5), 22.70 (COCH3). HR-MS
(ESI): calcd for C25H25N4O8 [M − H]− 509.1672, found 509.1674.
5-Acetamido-9-(4-carboxyphenyl)-2,6-anhydro-4-guanidino-
3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid (8a). To a
solution of compound 16 (40 mg) in 1 mL of DCM, 100 μL of TFA
was added. The solution was then stirred at room temperature for 2 h.
After completion, DCM and TFA were removed under reduced
pressure. The residue was dissolved in 2 mL of 0.1 N NaOH and
stirred at room temperature for 1 h. After completion, Amberlite IR
120 (H+) was added to the reaction mixture to adjust the pH of the
solution to 2. The suspension was then filtered, and the filtrate was
concentrated and dissolved in minimum methanol. The desired
product was precipitated with ethyl acetate. Yield 10 mg (41%). 1H
NMR (500 MHz, D2O) δ 8.49 (s, 1H, triazole-H), 8.02 (d, J = 8.2 Hz,
2H, Ar-H), 7.93 (d, J = 8.2 Hz, 2H, Ar-H), 5.68 (d, J = 2.1 Hz, 1H, H-
3), 4.91 (dd, J = 14.4, 2.8 Hz, 1H, H-9), 4.72 (dd, J = 14.4, 6.7 Hz, 1H,
H-9′), 4.48 (dd, J = 9.5, 2.1 Hz, 1H, H-4), 4.46−4.41 (m, 1H, H-8),
4.40 (d, J = 11.0 Hz, 1H, H-7), 4.26 (t, J = 9.5 Hz, 1H, H-5), 3.53 (d, J
= 9.5 Hz, 1H, H-6), 1.99 (s, 3H, COCH3).
13C NMR (125 MHz,
D2O) δ 175.37, 169.94, 163.66 (3 × CO), 157.96 (CN), 150.14
(C-2), 147.81 (triazole-C4), 124.65 (triazole-C5), 133.00, 130.62,
126.33 (Ar-C), 104.76 (C-3), 76.02 (C-6), 69.79 (C-8), 69.00 (C-7),
54.41 (C-9), 51.83 (C-4), 48.65 (C-5), 22.75 (COCH3). HR-MS
(ESI): calcd for C21H24N7O8 [M − H]− 502.1686, found 502.1683.
Methyl 5-Acetamido-9-(4-biphenyl-1H-1,2,3-triazol-1-yl))-4-gua-
nidino-2,6-anhydro-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-
3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate (8b-OMe). A sol-
ution of compound 24 (150 mg) in 3 mL of DCM was charged with
TFA (300 μL), and the solution was stirred at room temperature for 2
h. After completion, DCM and TFA were removed under reduced
pressure. The residue was dissolved in 5 mL of methanol and cooled
to 0 °C, followed by addition of NaOMe (54 mg, 5 equiv). The
reaction mixture was stirred at 0 °C for 1 h. After completion,
Amberlite IR 120 (H+) was added to neutralize the solution. The
suspension was then filtered, and the filtrate was concentrated and
purified by flash chromatography to give the desired product. Yield 50
mg (45%). 1H NMR (500 MHz, CD3OD) δ 8.31 (s, 1H, triazole-H),
7.84 (d, J = 8.1 Hz, 2H, Ar-H), 7.62 (d, J = 8.1 Hz, 2H, Ar-H), 7.57 (d,
J = 7.5 Hz, 2H, Ar-H), 7.38 (t, J = 7.5 Hz, 2H, Ar-H), 7.29 (t, J = 7.3
Hz, 1H, Ar-H), 5.87 (d, J = 2.0 Hz, 1H, H-3), 4.58−4.47 (m, 2H, H-9′,
H-6), 4.43 (d, J = 10.2 Hz, 1H, H-4), 4.33−4.20 (m, 2H, H-8, H-5),
3.72 (s, 3H, COOCH3), 3.58 (d, J = 9.0 Hz, 1H, H-7), 1.97 (s, 3H,
COCH3).
13C NMR (125 MHz, CD3OD) δ 174.57, 163.86 (2 × C
O), 158.95 (CN), 148.23 (triazole-C4), 146.33, 142.29, 141.69,
130.72, 129.94, 128.58, 128.50, 127.84, 127.11 (Ar-C), 123.71
(triazole-C5), 109.28 (C-3), 77.93 (C-6), 71.21 (C-8), 70.11 (C-7),
55.15 (C-9), 53.07 (COOCH3), 51.51 (C-5), 22.69 (COCH3). HR-
MS (ESI): calcd for C27H32N7O6 [M + H]
+ 550.2414, found 550.2395.
5-Acetamido-9-(4-biphenyl-1H-1,2,3-triazol-1-yl))-4-guanidino-
2,6-anhydro-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-3,4,5-tri-
deoxy-D-glycero-D-galacto-non-2-enonic Acid (8b). A solution of
compound 24 (180 mg) in 3 mL DCM was charged with 300 μL of
TFA, and the solution was stirred at room temperature for 2 h. After
completion, DCM and TFA were removed under reduced pressure.
The residue was dissolved in 3 mL of 0.1 N NaOH and stirred at room
temperature for 1 h. After completion, Amberlite IR 120 (H+) was
added to adjust the pH of the solution to 2. The suspension was then
filtered, and the filtrate was concentrated and dissolved in minimum
methanol. The desired product was precipitated with ethyl acetate.
Yield 10 mg (31%). 1H NMR (500 MHz, CD3OD) δ 8.34 (s, 1H,
triazole-H), 7.87 (d, J = 8.1 Hz, 2H, Ar-H), 7.66 (d, J = 8.1 Hz, 2H, Ar-
H), 7.61 (d, J = 7.5 Hz, 2H, Ar-H), 7.41 (t, J = 7.6 Hz, 2H, Ar-H), 7.32
(t, J = 7.3 Hz, 1H, Ar-H), 5.89 (s, 1H, H-3), 4.88 (d, J = 14.3 Hz, 1H,
H-9), 4.60−4.47 (m, 2H, H-9′, H-6), 4.42 (d, J = 10.0 Hz, 1H, H-4),
4.28 (m, 2H, H-5, H-8), 3.57 (d, J = 9.0 Hz, 1H, H-7), 1.98 (s, 3H,
COCH3).
13C NMR (125 MHz, CD3OD) δ 174.56, 165.08 (2 × C
O), 158.96 (CN), 148.25 (C-2), 146.68 (triazole-C4), 123.70
(triazole-C5), 142.30, 141.70, 130.71, 129.95, 128.58, 128.50, 127.85,
127.12 (Ar-C), 109.14 (C-3), 77.79 (C-6), 71.21 (C-8), 70.06 (C-7),
55.19 (C-9), 51.53 (C-5), 22.72 (COCH3). HR-MS (ESI): calcd for
C26H28N7O6 [M − H]− 534.2101, found 534.2105.
2-Methy l -4 ,5 -d ihydro - (methy l (7 , 8 -d i -O -ace ty l -9 - (4 -
(methoxycarbonyl)phenyl)-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-
talo-non-2-en)onate)[5,4-d]-1,3-oxazole (11). A solution of com-
pound 10h (250 mg, 1 equiv) in anhydrous pyridine was cooled to 0
°C, followed by dropwise addition of acetic anhydride (230 μL, 4.5
equiv). The reaction mixture was allowed to warm to room
temperature and kept stirring overnight. After completion, the reaction
was quenched with methanol and the solvents were removed under
reduced pressure. The residue was dissolved in ethyl acetate and
carefully washed with 0.05 M HCl, water, and brine sequentially and
dried over Na2SO4. The solution was then concentrated and purified
by flash chromatography, providing a crude fully protected product,
which was used in the next step without further purification. 370 mg
(quant, crude product). The obtained crude protected product (800
mg, 1 equiv, several batches’ product of last step) was dissolved in 10
mL of ethyl acetate. The solution was warmed to 40 °C and TMSOTf
(408 μL, 3 equiv) was added dropwise. The resulting solution was kept
stirring at 50 °C for 4 h. After completion, the solution was added to a
vigorously stirred cold saturated sodium bicarbonate solution. The
aqueous phase was separated and extracted with ethyl acetate. The
organic phase was combined, dried over Na2SO4, concentrated, and
purified by flash chromatography to give the desired product (430 mg,
60%). 1H NMR (500 MHz, CD3OD) δ 8.49 (s, 1H, triazole-H), 8.03−
7.97 (d, J = 8.5 Hz, 2H, Ar-H), 7.88 (d, J = 8.5 Hz, 2H, Ar-H), 6.39 (d,
J = 4.0 Hz, 1H, H-3), 5.65−5.57 (m, 2H, H-7, H-8), 5.22 (dd, J = 14.8,
2.6 Hz, 1H, H-9), 4.94 (dd, J = 9.5, 4.0 Hz, 1H, H-4), 4.79 (m, 1H, H-
9′), 4.02 (t, J = 9.5 Hz, 1H, H-5), 3.87, 3.79 (2 × s, 2 × 3H, 2 ×
COOCH3), 3.60 (dd, J = 9.5, 2.3 Hz, 1H, H-6), 2.17 (s, 3H, oxazole-
CH3), 1.97, 1.95 (2 × s, 2 × 3H, 2 × COOCH3). 13C NMR (125
MHz, CD3OD) δ 171.55, 171.32, 168.03, 163.34 (4 × CO), 170.12
(oxazole-O-CN), 148.09 (triazole-C4), 124.39 (triazole-C5), 147.66
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(C-2), 136.30, 131.27, 130.78, 126.55 (Ar-C), 109.05 (C-3), 78.35 (C-
6), 74.22 (C-4), 73.52 (C-8), 70.86 (C-7), 62.68 (C-5), 53.27, 52.81
(2 × COOCH3), 51.09 (C-9), 20.73, 20.67 (COCH3), 14.06 (oxazole-
CH3). HR-MS (ESI): calcd for C26H28N4NaO10 [M + Na]
+ 579.1703,
found 579.1697
Methyl 5-Acetamido-7,8-di-O-acetyl-9-(4-(methoxycarbonyl)-
phenyl)-2,6-anhydro-4-azido-3,4,5-trideoxy-D-glycero-D-galacto-
non-2-enonate (12). To a solution of compound 11 (430 mg, 1
equiv) in dry tBuOH, TMSN3 (507 μL, 5 equiv) was added and the
resulting solution was stirred at 80 °C under a nitrogen atmosphere for
12 h. After completion, the solution was cooled to room temperature,
concentrated, and purified by flash chromatography to give the desired
product. Yield 470 mg (quant). 1H NMR (500 MHz, CD3OD) δ 8.51
(s, 1H, triazole-H), 8.07−8.02 (m, 2H, Ar-H), 7.92−7.87 (m, 2H, Ar-
H), 5.97 (d, J = 2.2 Hz, 1H, H-3), 5.57−5.56 (dd, J = 3.3, 2.2 Hz, 1H,
H-4), 5.52 (dt, J = 9.1, 2.9 Hz, 1H, H-8), 5.29 (dd, J = 14.8, 2.7 Hz,
1H, H-9), 4.71 (dd, J = 14.8, 9.1 Hz, 1H, H-9′), 4.49 (dd, J = 10.3, 1.9
Hz, 1H, H-6), 4.27−4.18 (m, 2H, H-5, H-7), 3.89, 3.80 (2 × s, 2× 3H,
2 × COOCH3), 2.13, 1.93, 1.92 (3 × s, 3 × 3H, 3 × COCH3). 13C
NMR (125 MHz, CD3OD) δ 173.49, 171.83, 171.42, 168.09, 163.07
(5 × CO), 147.64 (triazole-C4), 124.51 (triazole-C5), 146.32 (C-
2), 136.25, 131.26, 130.85, 126.54 (Ar-C), 109.74 (C-3), 78.44 (C-6),
73.96 (C-8), 69.60 (C-7), 60.46 (C-4), 53.21, 52.74 (2 × COOCH3),
51.17 (C-9), 48.39 (C-5), 22.89, 20.88, 20.63 (3 × COCH3). HR-MS
(ESI): calcd for C26H29N7NaO10 [M + Na]
+ 622.1874, found
622.1866
5-Acetamido-9-(4-(methoxycarbonyl)phenyl)-2,6-anhydro-4-
azido-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic Acid (13). A
sample of 60 mg of compound 12 was dissolved in 2 mL of 0.5 N
NaOH, and the solution was stirred under room temperature for 1 h.
After completion, Amberlite IR 120 (H+) was added to adjust the pH
of the solution as 2. The suspension was then filtered, and the filtrate
was concentrated and purified by flash chromatography to give the
desired product. Yield 32 mg (66%). 1H NMR (500 MHz, CD3OD) δ
8.43 (s, 1H, triazole-H), 8.06 (d, J = 8.2 Hz, 2H, Ar-H), 7.91 (d, J = 8.2
Hz, 2H, Ar-H), 5.73 (s, 1H), 4.53 (dd, J = 14.0, 7.6 Hz, 1H, H-9′),
4.32−4.25 (m, 2H, H-4, H-8), 4.23 (d, J = 10.8 Hz, 1H, H-6), 4.18−
4.10 (m, 1H, H-5), 3.45 (d, J = 9.3 Hz, 1H, H-7), 1.98 (s, 3H,
COCH3).
13C NMR (125 MHz, CD3OD) δ 174.32 (CO), 147.53
(triazole-C4), 124.47 (triazole-C5), 136.17, 131.48, 126.42 (Ar-C),
104.50 (C-3), 77.02 (C-6), 71.03 (C-8), 69.86 (C-7), 60.23 (C-4),
55.25 (C-9), 48.53 (C-5), 22.78 (COCH3). HR-MS (ESI): calcd for
C20H20N7O8 [M − H]− 486.1373, found 486.1378
Methyl 5-Acetamido-7,8-di-O-acetyl-9-(4-(methoxycarbonyl)-
phenyl)-2,6-anhydro-4-amino-3,4,5-trideoxy-D-glycero-D-galacto-
non-2-enonate (14). To a solution of compound 12 (50 mg, 1 equiv)
in THF (2 mL), 0.5 N HCl (200 μL, 2 equiv) was added, followed by
triphenylphosphine (29 mg, 1.1 equiv). The resulting mixture was
stirred at room temperature overnight. After completion, solvents were
removed under reduced pressure and the residue was purified by flash
chromatography, providing the desired product. Yield 39 mg (84%).
1H NMR (500 MHz, CD3OD) δ 8.57 (s, 1H, triazole-H), 8.05 (d, J =
8.4 Hz, 2H, Ar-H), 7.92 (d, J = 8.4 Hz, 2H, Ar-H), 6.06 (d, J = 2.3 Hz,
1H, H-3), 5.63−5.55 (m, 2H, H-7, H-8), 5.29−5.21 (m, 1H, H-9),
4.74 (dd, J = 14.7, 8.4 Hz, 1H, H-9′), 4.64 (dd, J = 10.0, 1.1 Hz, 1H,
H-6), 4.35 (t, J = 10.0 Hz, 1H, H-5), 4.15 (dd, J = 10.0, 2.3 Hz, 1H, H-
4), 3.90, 3.81 (2 × s, 2 × 3H, 2 × COOCH3), 2.12, 1.97, 1.95 (3 × s, 3
× 3H, 3 × COCH3). 13C NMR (125 MHz, CD3OD) δ 174.28, 171.71,
171.31, 168.15, 162.80 (5 × CO), 147.66 (triazole-C4), 124.59
(triazole-C5), 147.29, 136.28, 130.84, 126.56 (Ar-C), 107.15 (C-3),
77.96 (C-6), 73.34 (C-8), 69.49 (C-7), 53.34, 52.78 (2 × COOCH3),
51.67 (C-4), 51.31 (C-9), 46.73 (C-5), 23.14, 20.89, 20.66 (3 ×
COCH3). HR-MS (ESI): calcd for C26H31N5NaO10 [M + Na]
+
596.1969, found 596.1967.
5-Acetamido-7,8-di-O-acetyl-9-(4-(methoxycarbonyl)phenyl)-
2,6-anhydro-4-amino-3,4,5-trideoxy-D-glycero-D-galacto-non-2-
enonic Acid (15). A sample of 35 mg of compound 14 was dissolved
in 400 μL of 1N NaOH, and the solution was kept stirring at rt for 1 h.
After completion, the reaction mixture was adjusted to pH 2 with
Amberlite IR 120 (H+). The suspension was then filtered, and the
filtrate was concentrated and dissolved in minimum methanol. The
desired product was precipitated with ethyl acetate. Yield 20 mg
(71%). 1H NMR (500 MHz, CD3OD) δ 8.47 (s, 1H, triazole-H), 8.08
(d, J = 8.2 Hz, 2H, Ar-H), 7.94 (d, J = 8.2 Hz, 2H, Ar-H), 5.84 (s, 1H,
H-3), 4.89 (d, J = 14.4 Hz, 1H, H-9), 4.56 (dd, J = 14.0, 7.5 Hz, 1H,
H-9′), 4.41−4.26 (m, 3H, H-8, H-6, H-5), 4.18 (d, J = 7.1 Hz, 1H, H-
4), 3.56 (d, J = 9.1 Hz, 1H, H-7), 2.03 (s, 3H, COCH3).
13C NMR
(125 MHz, CD3OD) δ 174.86, 169.48 (2 × CO), 147.50 (triazole-
C4), 124.66 (triazole-C5), 136.29, 131.48, 131.25, 126.45 (Ar-C),
103.03 (C-3), 77.01 (C-6), 70.71 (C-8), 70.03 (C-7), 55.19 (C-9),
51.29 (C-4), 47.54 (C-5), 23.03 (COCH3). HR-MS (ESI): calcd for
C20H22N5O8 [M − H]− 460.1468, found 460.1482.
Methyl 5-Acetamido-9-(4-(methoxycarbonyl)phenyl-1H-1,2,3-tri-
azol-1-yl))-4-[2,3-bis(tert-butoxycarbonyl)guanidino]-7,8-di-O-ace-
tyl-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate
(16). To a solution of compound 14 (40 mg, 1 equiv) in 2 mL of
anhydrous DCM, TEA (40 μL, 4 equiv) was added. The solution was
cooled to 0 °C, and N,N′-Di-Boc-1H-pyrazole-1-carboxamidine (42
mg, 2 equiv) was added. The reaction mixture was allowed to warm to
room temperature and kept stirring overnight. After completion, the
reaction was quenched with water and extracted with ethyl acetate.
The organic phase was washed with brine, dried over Na2SO4,
concentrated, and purified by flash chromatography to give the desired
product. Yield 40 mg (crude product, 72%). 1H NMR (500 MHz,
CD3OD) δ 8.55 (s, 1H, triazole-H), 8.06 (d, J = 8.3 Hz, 2H, Ar-H),
7.92 (d, J = 8.3 Hz, 2H), 6.00 (d, J = 2.3 Hz, 1H, H-3), 5.58 (d, J = 1.5
Hz, 1H, H-7), 5.56−5.52 (m, 1H, H-8), 5.31 (dd, J = 14.8, 2.4 Hz, 1H,
H-9), 5.02 (dd, J = 10.2, 2.3 Hz, 1H, H-4), 4.74 (dd, J = 14.8, 9.0 Hz,
1H, H-9′), 4.53 (dd, J = 10.2, 1.5 Hz, 1H, H-6), 4.27 (t, J = 10.2 Hz,
1H, H-5), 3.91, 3.80 (2 × s, 2 × 3H, 2 × COOCH3), 2.12, 1.94, 1.85
(3 × s, 3 × 3H, 3 × COCH3), 1.51, 1.46 (2 × s, 2 × 9H, 2 × Boc). 13C
NMR (125 MHz, CD3OD) δ 173.57, 171.77, 171.41, 168.07, 164.32,
163.39, 158.01 (7 × CO), 153.82 (CN), 147.64 (triazole-C4),
124.50 (triazole-C5), 145.61 (C-2), 136.34, 131.27, 131.27, 126.55
(Ar-C), 111.83 (C-3), 84.84, 80.57 (2 × tBoc-C(CH3)3), 78.89 (C-6),
74.00 (C-8), 69.87 (C-7), 53.07, 52.74 (2 × COOCH3), 51.27 (C-9),
50.84 (C-4), 47.90 (C-5), 28.59, 28.26 (2 × tBoc-C(CH3)3), 22.77,
20.86, 20.65 (3 × COCH3). HR-MS (ESI): calcd for C37H49N7NaO14
[M + Na]+ 838.3235, found 838.3226.
Methyl 5-Acetamido-9-(4-(methoxycarbonyl)phenyl-1H-1,2,3-tri-
azol-1-yl))-4-(3-(3-methoxy-3-oxopropyl)ureido)-7,8-di-O-acetyl-
2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonate
(17). A solution of compound 14 (100 mg, 1 equiv) and TEA (56 mg,
2 equiv) in anhydrous DCM was cooled to 0 °C and charged with
1,1′-carbonyldiimidazole (39 mg, 1.2 equiv). The reaction mixture was
then warmed to room temperature and kept stirring for 2 h until TLC
showed consumption of the amine. The solution was then cooled to 0
°C, and the methyl ester of β-alanine (56 mg, 2 equiv) was added. The
solution was warmed to room temperature and kept stirring overnight.
After completion, the reaction was quenched with water and extracted
by ethyl acetate. The organic layer was washed with water and brine,
and dried over Na2SO4. After subsequent concentration, the residue
was purified by flash chromatography to give the desired product.
Yield 140 mg (quant). 1H NMR (500 MHz, CD3OD) δ 8.54 (s, 1H,
triazole-H), 8.07 (d, J = 8.7 Hz, 2H, Ar-H), 7.92 (d, J = 8.7 Hz, 2H, Ar-
H), 5.92 (d, J = 2.5 Hz, 1H, H-3), 5.55 (m, 2H, H-8, H-4), 5.31 (dd, J
= 14.8, 2.6 Hz, 1H, H-9), 4.73 (dd, J = 14.8, 8.9 Hz, 1H, H-9′), 4.55
(dd, J = 9.9, 2.5 Hz, 1H, H-7), 4.46 (dd, J = 10.2, 2.0 Hz, 1H, H-6),
4.10 (t, J = 10.2 Hz, 1H, H-5), 3.91, 3.78, 3.66 (3 × s, 3 × 3H, 3 ×
COOCH3), 3.36 (td, J = 6.6, 1.9 Hz, 2H, CH2), 2.48 (t, J = 6.5 Hz,
2H, CH2), 2.10, 1.93, 1.87 (3 × s, 3 × 3H, 3 × COCH3). 13C NMR
(125 MHz, CD3OD) δ 174.12, 173.59, 171.79, 171.41, 168.13, 163.56,
160.42 (7 × CO), 147.66 (C-2), 145.10 (triazole-C4), 124.46
(triazole-C5), 136.30, 131.26, 130.88, 126.54 (Ar-C), 114.06 (C-1),
79.10 (C-6), 73.99 (C-8), 69.97 (C-7), 52.96, 52.70, 52.15 (3 ×
COOCH3), 51.26 (C-9), 50.38 (C-5), 36.92, 35.64 (CH2CH2), 22.85,
20.84, 20.59 (COCH3). HR-MS (ESI): calcd for C31H39N7N6O13 [M
+ Na]+ 703.2575, found 703.2571.
5-Acetamido-9-(4-carboxyphenyl)-2,6-anhydro-4-(3-(2-
carboxyethyl)ureido)-3,4,5-trideoxy-D-glycero-D-galacto-non-2-
enonic Acid (18). A sample of 140 mg of compound 17 was dissolved
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in 5 mL of 0.1 N NaOH and stirred at room temperature for 1 h. After
completion, the reaction mixture adjusted to pH 2 with the addition of
Amberlite IR 120 (H+). The suspension was then filtered, and the
filtrate was concentrated and dissolved in minimum methanol. The
desired product was precipitated with ethyl acetate. 88 mg (77%). 1H
NMR (500 MHz, CD3OD) δ 8.44 (s, 1H, triazole-H), 8.07 (d, J = 8.4
Hz, 2H, Ar-H), 7.93 (d, J = 8.4 Hz, 2H, Ar-H), 5.66 (d, J = 1.9 Hz, 1H,
H-3), 4.57 (dd, J = 9.8, 1.9 Hz, 1H, H-4), 4.52 (dd, J = 14.0, 7.7 Hz,
1H, H-9′), 4.30 (dd, J = 12.1, 4.8 Hz, 1H, H-8), 4.19 (d, J = 10.8 Hz,
1H, H-6), 4.02 (t, J = 10.3 Hz, 1H, H-5), 3.44 (d, J = 9.3 Hz, 1H, H-
7), 3.37 (t, J = 6.4 Hz, 2H, CH2), 2.46 (t, J = 6.4 Hz, 2H, CH2), 1.94
(s, 3H, COCH3).
13C NMR (125 MHz, CD3OD) δ 175.74, 174.73,
160.76, 169.64 (4 × CO), 147.51 (triazole-C4), 124.40 (triazole-
C5), 136.24, 131.68, 131.45, 126.42 (Ar-C), 109.35 (C-3), 77.81 (C-
6), 71.36 (C-8), 69.80 (C-7), 55.31 (C-9), 37.00, 35.78 (CH2CH2),
22.74 (COCH3). HR-MS (ESI): calcd for C24H27N6O11 [M − H]−
575.1738, found 575.1738
Methyl 5-Acetylamino-4-(tert-butoxycarbonyl)amino-2,6-anhy-
dro-3,5-dideoxy-D-glycero-D-galacto-non-2-enonate (20). To a
solution of compound 19 (600 mg, 1 equiv) and TEA (389 μL, 2
equiv) in 20 mL of anhydrous DCM at 0 °C, di-tert-butyl dicarbonate
(456 mg, 1.5 equiv) was added dropwise. The mixture was them
warmed to room temperature and kept stirring overnight. After
completion, solvent was removed and the residue was purified by flash
chromatography to give the desired compound in 350 mg (crude
product, 47%). The crude product (350 mg, 1 equiv) was dissolved in
10 mL of methanol, and cooled to 0 °C, followed by addition of
NaOMe (92 mg, 3 equiv). The solution was kept stirring at 0 °C for 1
h until no starting material remained. The solution was adjusted to pH
2 by addition of Amberlite IR 120 (H+). The suspension was then
filtered, and the filtrate was concentrated and purified by flash
chromatography to give the desired product. Yield 190 mg (71%). 1H
NMR (500 MHz, CD3OD) δ 5.82 (d, J = 2.2 Hz, 1H, H-3), 4.46 (d, J
= 10.1 Hz, 1H, H-4), 4.23 (d, J = 10.1 Hz, 1H, H-6), 4.05 (t, J = 10.1
Hz, 1H, H-5), 3.88 (ddd, J = 9.2, 5.4, 2.9 Hz, 1H, H-8), 3.81 (dd, J =
11.4, 2.9 Hz, 1H, H-9), 3.65 (dd, J = 11.4, 5.4 Hz, 1H, H-9′), 3.58 (dd,
J = 9.3, 1.1 Hz, 1H, H-7), 1.98 (s, 3H, COOCH3), 1.44 (s, 9H,
tBoc-
C(CH3)3).
13C NMR (125 MHz, CD3OD) δ 174. 65, 164.26, 158.35
(3 × CO), 145.71 (C-2), 112.19 (C-3), 80.56 (tBoc-C(CH3)3),
78.62 (C-6), 71.13 (C-8), 70.00 (C-7), 64.90 (C-9), 52.79 (C-4),
50.26 (C-5), 28.70 (tBoc-C(CH3)3), 22.70 (COCH3). HR-MS (ESI):
calcd for C17H29N2O9 [M + H]
+ 405.1873, found 405.1875
Methyl 4-(tert-Butoxycarbonyl)amino-5-acetylamino-9-(4-meth-
ylbenzenesulfonate)-2,6-anhydro-3,5-dideoxy-D-glycero-D-galacto-
non-2-enonate (21). A solution of compound 20 (190 mg, 1 equiv) in
anhydrous pyridine was cooled down to 0 °C, TsCl (98 mg, 1.1 equiv)
was then added slowly under stirring. The solution was warmed to
room temperature and kept stirring overnight. After completion, the
reaction was quenched by methanol. The solution was concentrated
and purified by flash chromatography to give the desired product.
Yield 200 mg (76%). 1H NMR (500 MHz, CDCl3) δ 7.78 (d, J = 8.1
Hz, 2H, Ar-H), 7.33 (d, J = 8.1 Hz, 2H, Ar-H), 6.93, 5.23, 5.11, 3.59 (4
× d, 4H, 2 × NH, 2 × OH), 5.82 (d, J = 2.3 Hz, 1H, H-3), 4.55 (td, J =
9.6, 2.2 Hz, 1H, H-8), 4.40−4.31 (m, 1H, H-6), 4.21−4.17 (m, 1H, H-
5), 4.15−4.11 (m, 2H, H-9′, H-4), 4.01−3.95 (m, 1H, H-9′), 3.71 (s,
3H, COOCH3), 3.56−3.48 (m, 1H, H-7), 2.43 (s, 3H, PhCH3), 2.00
(s, 3H, COCH3), 1.42 (s, 9H,
tBoc-C(CH3)3).
13C NMR (125 MHz,
CDCl3) δ 174.01, 162.21, 156.80 (3 × CO), 145.07 (C-2), 144.86,
132.59, 129.91, 128.02 (Ar-C), 109.92 (C-3), 80.60 (tBoc-C(CH3)3),
72.56 (C-9), 68.53 (C-7), 67.90 (C-8), 52.38 (C-6), 50.19 (C-4),
48.68 (C-5), 28.26 (tBoc-C(CH3)3), 22.86, 21.63 (COCH3, PhCH3).
HR-MS (ESI): calcd for C24H35N2O11S [M + H]
+ 559.1962, found
559.1966.
Methyl 5-Acetamido-7,8-di-O-acetyl-9-azido-2,6-anhydro-4-[2,3-
bis(tert-butoxycarbonyl)guanidino]-3,4,5-trideoxy-D-glycero-D-gal-
acto-non-2-enonate (23). Compound 21 (200 mg, 1 equiv) was
dissolved in 3 mL of acetone−water (2:1), and NaN3 (117 mg, 5
equiv) was added. The solution was heated at 67 °C under N2 for 2
days. After completion, the solution was concentrated and purified by
flash chromatography to give 100 mg of compound 22 (crude product,
75%), which was used in the next step without further purification.
The crude product was dissolved in 2 mL of anhydrous DCM, and 200
μL of TFA was added. The solution was kept stirring at room
temperature until no starting material remained. Solvent was then
removed under vacuum, and the residue was dissolved in 2 mL of
anhydrous DCM, and TEA (140 μL, 4 equiv) was added. After the
solution was cooled down to 0 °C, N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (150 mg, 2 equiv) was added. The reaction mixture was
allowed to warm up to room temperature and kept stirring overnight.
After completion, the reaction was quenched with water and extracted
with ethyl acetate. The organic phase was washed with brine, dried
over Na2SO4, concentrated, and purified by flash chromatography to
give the desired product. Yield 108 mg (82%). 1H NMR (500 MHz,
CDCl3) δ 8.63, 8.15, 7.70, 6.43 (2 × d, 2 × brs, 4 H, 2 × NH, 2 ×
OH), 5.82 (d, J = 2.4 Hz, 1H, H-3), 5.20 (ddd, J = 10.2, 8.1, 2.4 Hz,
1H, H-4), 4.22−4.15 (m, 2H, H-6, H-5), 4.02 (td, J = 10.2, 6.1 Hz, 1H,
H-8), 3.72 (dd, J = 12.6, 2.8 Hz, 1H, H-9), 3.60−3.53 (m, 2H, H-9′,
H-7), 2.04 (s, 3H, COCH3), 1.52 (2 × s, 2 × 9H, 2 × tBoc-C(CH3)3).
13C NMR (125 MHz, CDCl3) δ 174.04, 162.29, 162.08, 157.56 (4 ×
CO), 152.70 (CN), 146.31 (C-2), 107.51 (C-3), 84.39, 80.11 (2
× tBoc-C(CH3)3), 69.14 (C-6), 54.89 (C-9), 52.53 (C-7), 51.53 (C-8),
48.33 (C-5), 28.23, 28.04 (2 × tBoc-C(CH3)3), 22.96 (COCH3). HR-
MS (ESI): calcd for C23H38N7O10 [M + H]
+ 572.2680, found
572.2681.
Methyl 5-Acetamido-9-(4-biphenyl-1H-1,2,3-triazol-1-yl))-4-[2,3-
bis(tert-butoxycarbonyl)guanidino]-2,6-anhydro-4-[2,3-bis(tert-
butoxycarbonyl)guanidino]-3,4,5-trideoxy-D-glycero-D-galacto-
non-2-enonate (24). Compound 23 (200 mg, 1 equiv) and 4-
ethynylbiphenyl (32 mg, 1.5 equiv) were reacted following the
protocol above to provide the desired product. Yield 180 mg (69%).
1H NMR (700 MHz, CDCl3) δ 8.55, 8.06 (2 × d, 2H, 2 × NH), 7.94
(s, 1H, triazole-H), 7.81 (d, J = 8.3 Hz, 2H, Ar-H), 7.57 (dd, J = 13.1,
7.8 Hz, 4H, Ar-H), 7.39 (t, J = 7.7 Hz, 2H, Ar-H), 7.31 (t, J = 7.4 Hz,
1H, Ar-H), 5.75 (d, J = 2.3 Hz, 1H, H-3), 5.51 (brs, 1H, OH), 5.16−
5.10 (m, 1H, H-4), 4.90 (dd, J = 14.0, 1.7 Hz, 1H, H-9), 4.54 (dd, J =
14.0, 6.7 Hz, 1H, H-9′), 4.48−4.43 (m, 1H, H-8), 4.20 (d, J = 10.4 Hz,
1H, H-6), 3.96 (td, J = 10.4, 6.2 Hz, 1H, H-5), 3.69 (s, 3H,
COOCH3), 3.34 (d, J = 9.0 Hz, 1H, H-7), 1.90 (s, 3H), 1.47, 1.43 (2
× s, 2 × 9H, 2 × tBoc-C(CH3)3). 13C NMR (176 MHz, CDCl3) δ
174.10, 162.26, 162.03, 157.37 (4 × CO), 152.66 (CN), 146.98
(C-2), 146.26 (triazole-C4), 121.69 (triazole-C5), 140.63, 140.43,
129.41, 128.77, 127.37, 126.86, 125.99 (Ar-C), 107.54 (C-3), 84.22,
79.96 (2 × tBoc-C(CH3)3), 69.33 (C-6), 68.54 (C-4), 53.90 (C-9),
52.42 (C-8), 51.58 (C-7), 48.37 (C-5), 28.17, 27.99 (tBoc-C(CH3)3),
22.86 (COCH3). HR-MS (ESI): calcd for C37H48N7O10 [M + H]
+
750.3463, found 750.3454.
General Procedure for Synthesis of Compounds 25a−d. A
solution of compound 19 (1 equiv) and TEA (3 equiv) in anhydrous
DCM was cooled to 0 °C, and the corresponding anhydride or acyl
chloride (3 equiv) was added dropwise. The resulting mixture was
warmed to room temperature and kept stirring overnight. After
completion, the reaction was quenched with water and extracted with
ethyl acetate. The organic layer was collected and washed with
saturated NaHCO3 and brine, and sequentially and dried with Na2SO4.
Solvents were removed under reduced pressure, and the residue was
separated by flash chromatography to give the desired crude products.
For hydrolysis of the C1-methyl ester, the crude product was dissolved
in MeOH, and 0.5 M NaOH was added. The mixture was kept stirring
at room temperature. After completion, the pH was adjusted to 2 with
Amberlite IR-120 (H+). The solution was then filtered and purified by
flash chromatography to provide the desired products with yields of
42%−68% (over two steps).
5-Acetamido-2,6-anhydro-4-propionamido-3,4,5-trideoxy-D-
glycero-D-galacto-non-2-enonic Acid (25a). Yield 28 mg (68%, over
two steps). 1H NMR (500 MHz, CD3OD) δ 5.49 (d, J = 2.0 Hz, 1H,
H-3), 4.75 (dd, J = 9.7, 2.0 Hz, 1H, H-4), 4.20 (d, J = 10.8 Hz, 1H, H-
6), 4.10−4.06 (m, 1H, H-5), 3.86−3.85 (m, 1H, H-8), 3.79 (dd, J =
11.4, 3.0 Hz, 1H, H-9), 3.63 (dd, J = 11.4, 5.4 Hz, 1H, H-9′), 3.55 (d, J
= 9.0 Hz, 1H, H-7), 2.17 (q, J = 7.6 Hz, 2H, α-CH2), 1.93 (s, 3H,
COCH3), 1.09 (t, J = 7.6 Hz, 3H, β-CH3).
13C NMR (125 MHz,
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CD3OD) δ 177.40, 174.17 (2 × CO), 106.15 (C-3), 77.49 (C-6),
71.46 (C-8), 70.05 (C-7), 64.88 (C-9), 49.64 (C-5), 30.40 (α-CH2),
22.78 (COCH3), 10.59 (β-CH3). HR-MS (ESI): calcd for C14H21N2O8
[M − H]− 345.1298, found 345.1302
5-Acetamido-2,6-anhydro-4-pentanamido-3,4,5-trideoxy-D-glyc-
ero-D-galacto-non-2-enonic Acid (25b). Yield 25 mg (56%, over two
steps). 1H NMR (500 MHz, CD3OD) δ 5.47 (d, J = 2.2 Hz, 1H, H-3),
4.76 (dd, J = 9.8, 2.2 Hz, 1H, H-4), 4.19 (d, J = 10.8 Hz, 1H, H-6),
4.09−4.05 (m, 1H, H-5), 3.87−3.85 (m, 1H, H-8), 3.78 (dd, J = 11.5,
3.1 Hz, 1H, H-9), 3.66 (dd, J = 11.5, 5.1 Hz, 1H, H-9′), 3.57 (t, J = 7.8
Hz, 1H, H-7), 2.17 (t, J = 7.5 Hz, 2H, α-CH2), 1.94 (s, 3H, COCH3),
1.60−1.51 (m, 2H, β-CH2), 1.34−1.29 (m, 2H, γ-CH2), 0.90 (t, J = 7.4
Hz, 3H, δ-CH3).
13C NMR (125 MHz, CD3OD) δ 176.55, 174.18,
170.01 (3 × CO), 151.02 (C-2), 105.96 (C-3), 77.51 (C-6), 71.55
(C-8), 69.91 (C-7), 64.71 (C-9), 49.60 (C-4), 49.00 (C-5), 37.02 (α-
CH2), 29.24 (β-CH2), 23.31 (γ-CH2), 23.31 (COCH3), 14.19 (δ-
CH3). HR-MS (ESI): calcd for C16H25N2O8 [M − H]− 373.1611,
found 373.1612.
5-Acetamido-2,6-anhydro-4-cyclopropanecarboxamido-3,4,5-
trideoxy-D-glycero-D-galacto-non-2-enonic Acid (25c). Yield 22 mg
(44%, over two steps). 1H NMR (500 MHz, CD3OD) δ 5.54 (d, J =
2.1 Hz, 1H, H-3), 4.77 (dd, J = 9.8, 2.1 Hz, 1H, H-4), 4.20 (d, J = 10.7
Hz, 1H, H-6), 4.11−4.07 (m, 1H, H-5), 3.90−3.82 (m, 1H, H-8), 3.79
(dd, J = 11.4, 3.0 Hz, 1H, H-9), 3.66 (dd, J = 11.4, 5.2 Hz, 1H, H-9′),
3.57 (d, J = 9.0 Hz, 1H, H-7), 1.94 (s, 3H, COCH3), 1.58−1.53 (m,
1H, α-CH), 0.88−0.78 (m, 2H, β-CH2), 0.74−0.72 (m, 2H, β-CH2).
13C NMR (125 MHz, CD3OD) δ 176.90, 174.36, 169.54 (3 × CO),
150.41 (C-2), 106.92 (C-3), 77.64 (C-6), 71.52 (C-8), 69.95 (C-7),
64.77 (C-9), 49.92 (C-4), 49.28 (C-5), 22.87 (COCH3), 15.05 (α-
CH), 7.57, 7.49 (2 × β-CH2). HR-MS (ESI): calcd for C15H21N2O8
[M − H]− 357.1298, found 357.1305.
5-Acetamido-2,6-anhydro-4-cyclobutanecarboxamido-3,4,5-tri-
deoxy-D-glycero-D-galacto-non-2-enonic Acid (25d). Yield 19 mg
(42%, over two steps). 1H NMR (500 MHz, CD3OD) δ 5.49 (d, J =
2.2 Hz, 1H, H-3), 4.75 (dd, J = 9.8, 2.2 Hz, 1H, H-4), 4.21 (d, J = 10.8
Hz, 1H, H-6), 4.10−4.06 (m, 1H, H-5), 3.88−3.84 (m, m, 1H, H-8),
3.78 (dd, J = 11.5, 3.1 Hz, 1H, H-9), 3.66 (dd, J = 11.5, 5.2 Hz, 1H, H-
9′), 3.56 (d, J = 9.3 Hz, 1H, H-7), 3.09−3.02 (m, 1H, α-CH), 2.27−
1.77 (m, 6H, 3 × CH2), 1.93 (s, 3H, COCH3). 13C NMR (125 MHz,
CD3OD) δ 178.06, 174.20, 169.63 (3 × CO), 150.52 (C-2), 106.54
(C-3), 77.53 (C-6), 71.55 (C-8), 69.94 (C-7), 64.77 (C-9), 49.57 (C-
4), 49.14 (C-5), 40.90 (α-CH), 26.44, 26.02, 19.09 (3 × CH2), 22.88
(COCH3). HR-MS (ESI): calcd for C16H23N2O8 [M − H]− 371.1454,
found 371.1458.
Inhibition Assay. Inhibition assays against 4MU-NANA cleavage
and GM3 cleavage were performed using protocols reported
previously.24 NEU3 and NEU2 were expressed as N-terminal MBP
fusion proteins in Escherichia coli and purified as previously reported.29
NEU4 was expressed as an MBP fusion protein in E. coli and purified
(see Supporting Information).18
NEU1 was overexpressed as a (His)6 fusion protein in HEK293
cells and used as a crude preparation from cell lysate.63 The CathA-
IRES-NEU1(His)6 biscistronic recombinant plasmid was constructed
by removing the hIL12 and CD19tmpk from pDy.hIL12.IR-
ES.CD19tmpk.WS vector kindly provided J. Medin (University of
Toronto Health Network) and replaced respectively by human
cathepsin A (CathA) and NEU1(His)6 cDNA. The NEU1(His)6
cDNA was PCR-amplified and inserted in the MCS of the
pDy.hIL12.IRES.CD19tmpk.WS between the XbaI and BamHI sites.
The CathA cDNA was PCR-modified and inserted into the MCS of
pDy.hIL12.IRES.NEU1-GFP and pDy.hIL12.IRES.NEU1 between the
EcoRI and AscI sites. All constructs were verified by PCR, enzymatic
digestions, and DNA sequencing. The final CathA-IRES-NEU1(His)6
construct was assessed for sialidase activity in transfected HEK293T
cells. The CathA-IRES-NEU1(His)6 biscistronic HIV-1-based re-
combinant vesicular stomatitis virus glycoprotein-pseudotyped
(VSVg) LV was generated by transient transfections of HEK293T
cells by LV plasmid construct, packaging plasmid pCMVDR8.91, and
the VSV-g envelope-coding plasmid pMD.G as described previously.64
HEK293T cells were cultured in DMEM supplemented with 10% FBS,
1% streptomycin−penicillin at 37 °C in a humidified 5% CO2
atmosphere. To overexpress NEU1, cells were transduced with
CathA-IRES-NEU1(His)6 lentivirus at 6 MOI in the presence of
polybrene (8 μg mL−1). Five, 8, and 10 days after transduction, a
portion of the cells was harvested to verify NEU1 expression by
measuring acidic neuraminidase activity in the cell lysate. The
transduced cells showed significantly higher neuraminidase activity in
the cell lysates (76−85 nmol h−1 mg−1 of protein) as compared with
the lysate of wild-type HEK293T cells (1.7−2.0 nmol h−1 mg−1 of
protein).
All assays were conducted in 0.1 M sodium acetate buffer at
optimum pH for each enzyme (pH 4.5 for NEU1, NEU3, and NEU4;
pH 5.5 for NEU2).24 To get comparable IC50 values among the four
isoenzymes, similar activity of each enzyme was used in the assay based
on 4MU-NANA activity.
For assays using 4MU-NANA as the substrate, inhibitors in 3-fold
serial dilutions were incubated with enzyme at 0 °C for 15 min. 4MU-
NANA was then added to the mixture, making the final concentration
of 4MU-NANA as 50 μM and the total volume of the reaction mixture
as 20 μL. After incubation at 37 °C for 30 min, the reaction was
quenched with 100 μL of 0.2 M sodium glycine buffer (pH 10.2). The
reaction mixture was transferred to 386-well plate, and the enzyme
activity was determined by measuring fluorescence (λex = 365 nm; λem
= 445 nm) using a plate reader (Molecular Devices, Sunnyvale CA).
Assays were performed with duplicates for each point, and IC50 was
obtained by plotting the data with Graphpad Prism 7.0. For curves that
showed less than a 50% decrease in signal, fits were conducted using
maximum inhibition values found for DANA.
For inhibition assays against GM3 cleavage, a method developed by
Markely and co-workers was adopted.65 The assay was conducted in
0.1 M sodium acetate buffer (pH 4.5). After inhibitors in serial
dilutions were incubated with enzyme at 0 °C for 15 min, GM3 was
added, making the final concentration of GM3 500 μM and the total
volume of the reaction mixture 20 μL. The reaction mixture was
incubated at 37 °C for 30 min and quenched with 100 μL of freshly
made 0.2 M sodium borate buffer (pH 10.2). Then 0.8% malononitrile
solution (40 μL) was added to form a fluorescent adduct with the free
sialic acid. Fluorescence was obtained (λex = 357 nm; λem = 434 nm),
and the data were processed using Graphpad Prism 7.0. For curves
that showed less than a 50% decrease in signal, fits were conducted
using maximum inhibition values found for DANA.
Ki Determinations. Enzymes were incubated with inhibitors in
serial dilutions at 0 °C for 15 min and serial concentrations of 4MU-
NANA were added. The reaction mixture was transferred to a 386-well
plate immediately, and the rate of product formation was obtained by
measuring fluorescence (λex = 315 nm; λem = 450 nm) every 1 min for
30 min. The obtained data were processed with Graphpad Prism 7.0
for Ki determination.
clogD7.4 Calculation. The clogD7.4 was calculated using
MarvinSketch (Chemaxon, version 16.10.10.0). The consensus
method was used with 0.1 M Cl− and 0.1 M Na+ ions and pKa
correction library.
Log D7.4 Determination (Shake-Flask Method). Equal amounts
of TRIS-HCl buffer (0.1 M, pH 7.4) and 1-octanol were mixed and
vigorously shaken for 5 min to saturate the phases. The mixture was
left until complete separation of the phases occurred and the buffer
was retrieved. The stock solutions of test compounds (DMSO, 10
mM) were diluted to 10 μM in saturated buffer (final DMSO
concentration; 0.1%). The buffer was transferred to a 96-well plate and
saturated 1-octanol was added, resulting in a 40/140 and 30/150 1-
octanol to water ratio, respectively (140/40 and 150/30 for
compounds with clogD7.4 below 0). Each ratio was measured in
triplicate, and simultaneous measurements were conducted with
codeine as control. The plate was sealed with aluminum foil, shaken
(1350 rpm, 25 °C, 2 h) on a Heidolph Titramax 1000 plate-shaker
(Heidolph Instruments GmbH & Co. KG, Schwabach, Germany), and
centrifuged (2000 rpm, 25 °C, 5 min, 5804 R Eppendorf centrifuge,
Hamburg, Germany). The aqueous phase was transferred to a 96-well
plate for analysis by liquid chromatography−mass spectrometry (LC-
MS, see below). The logD7.4 coefficients were calculated from the 1-
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octanol:buffer ratio (o:b), the initial concentration of the analyte in
buffer (10 μM), and the concentration of the analyte in buffer (cb)
with eq 1:
= μ − ×
⎛
⎝⎜
⎞
⎠⎟D
c
c
log log
10 M 1
o:b7.4
b
b (1)
Parallel Artificial Membrane Permeation Assay. Effective
permeability (log Pe) was determined in a 96-well format with parallel
artificial membrane permeation assay (PAMPA).45 For each
compound, measurements were performed at pH 7.4 in quadruplicate.
Four wells of a deep well plate were filled with 500 μL of Prisma HT
buffer (pH 7.4, pION P/N 110 151). Then analyte dissolved in
DMSO (10 mM) was added to the buffer to yield 50 μM solutions
(containing 0.5% DMSO). Afterward, 200 μL was transferred to each
well of the donor plate of the PAMPA sandwich (pIon Billerica, USA,
P/N 110 163). The filter membranes at the bottom of the acceptor
plate were infused with 5 μL of GIT-0 lipid solution (pIon, P/N 110
669), and 200 μL of acceptor buffer (pION, P/N 110 139) was filled
into each acceptor well. The experiment was conducted with 10%
DMSO in Prisma HT buffer and acceptor buffer for compounds with
insufficient solubility. The sandwich was assembled, placed in the
GutBoxTM (pION), and left undisturbed for 16 h. Then it was
disassembled and the compound concentration of donor, acceptor,
and reference compartment was measured by LC-MS (see below).
Effective permeability (log Pe) was calculated from the compound flux
deduced from the concentration in the donor and acceptor
compartment as well as the retention in the filter area with the aid
of the PAMPA Explorer Software (pIon, version 3.5).
Metabolic Stability in Human Liver Microsomes. Incubations
were performed in triplicate in a 96-well format on an Eppendorf
Thermomixer Comfort. The reaction mixture (270 μL) consisting of
liver microsomes, TRIS-HCl buffer (0.1 M, pH 7.4), and MgCl2 (2
mM) was preheated (37 °C, 500 rpm, 10 min), and the incubation was
initiated by adding 30 μL of compound solution (200 μM) in TRIS-
HCl buffer. The final concentration of the compound was 20 μM,
including 0.5 mg mL−1 human liver microsomes. At the beginning of
the experiment (t = 0 min) and after an incubation time of 10, 30, 60,
and 90 min, samples (40 μL) were transferred to 120 μL of ice-cold
MeOH and centrifuged (3700 rpm, 4 °C, 10 min). Then 80 μL of
supernatant was transferred to a 96-well plate for analysis by LC-MS
(see below). The metabolic half-life (t1/2) was calculated from the
slope of the linear regression from the log percentage remaining
compound versus incubation−time relationship. Control experiments
were performed in parallel with control substance as positive control
or containing 1 mM bis(4-nitrophenyl) phosphate (esterase inhibitor,
negative control). Compounds with t1/2 > 90 min were considered to
be metabolically stable.
Colorectal Adenocarcinoma (Caco-2) Cell Permeation Assay.
Cultivation, splitting, seeding of Caco-2 cells as well as the assay
protocol previously described by Schönemann et al.39 Permeation
assays were conducted in triplicate at a concentration of 62.5 μM
containing 0.6% DMSO. Samples (40 μL) were withdrawn after 30
min and analyzed by LC-MS (see below), and the apparent
permeation (Papp) was calculated according to eq 2. The compound
flux (mol/s) is dQ/dt, A is the surface area of the monolayer (cm2),
and c0 is the initial concentration.
= × ×P
Q
t A c
d
d
1
app
0 (2)
Compounds with a Papp < 2 × 10−6 cm/s are considered as low
permeable according to Hou et al. (2007).42,46
Solubility. A sample of 5 μL of predesolved compounds (DMSO,
10 mM) were added to 500 μL of buffer (Tris-HCl 0.1 M pH 7.4, μL
Prisma HT buffer, pH 7.4, pION P/N 110 151) and water containing
0.9% NaCl) ending in 1% DMSO. The vials were put into supersonic
bath (Branson 2510, Danbury, USA) for 30 min at 25 °C and then left
at 25 °C for 24 h to equilibrate. The dispersion was filtered (0.2 μm),
diluted in MeOH, and analyzed by LC-MS (see below).
Liquid Chromatography−Mass Spectrometry Measure-
ments (LC-MS). Analyses were performed using a 1100/1200 series
HPLC system coupled to a 6410 triple quadrupole mass detector
(Agilent Technologies, Inc., Santa Clara, CA, USA) equipped with
electrospray ionization. The system was controlled with the Agilent
MassHunter Workstation Data Acquisition software (version B.03.01).
The column used was an Atlantis T3 C18 column (2.1 mm × 50 mm)
with a 3 μm particle size (Waters Corp., Milford, MA, USA). The
mobile phase consisted of eluent A, 0.1% formic acid in water, and
eluent B, MeCN containing 0.1% formic acid. The flow rate was
maintained at 0.6 mL/min. The gradient was ramped from 95% A/5%
B to 5% A/95% B over 1 min, and then hold at 5% A/95% B for 0.1
min. The system was then brought back to 95% A/5% B, resulting in a
total duration of 4 min. Fragmentor voltage and collision energy were
optimized for the analysis of compounds in multiple reaction
monitoring mode in positive mode. The concentrations of the
analytes were quantified by the Agilent Mass Hunter Quantitative
Analysis software (version B.04.00).
Molecular Dynamics (MD) Simulations. MD simulations were
run for the inhibitor 8b bound to NEU2, NEU3, and NEU4. Inhibitor
8b was simulated in its zwitterionic form, i.e., as a carboxylate at C1
and as a guanidinium at C4. For simulations with NEU2, we used the
crystal structure of NEU2 bound to 1 (PDB 1VCU)27 as a starting
structure for the enzyme. The nonterminal residues G227, E228, S284,
G295, P286, and G287 were added to the crystal structure for NEU2
using Modeler in Chimera.58,66−68 We used our previously reported
homology model for NEU3,29,30 and we used the SWISS-MODEL
Web site69−73 to generate a homology model for NEU4 based on the
1VCU structure.27 The portion of NEU4 between N289 and F368 is
not homologous to NEU2, therefore, residues 290−367 (78 in total)
were removed from the NEU4 model before running MD simulations.
The coordinates for 8b were based on those of 6 bound to NEU2
(PDB 2F0Z)50 with the biphenyl-triazole and hydrogens added in
Avogadro.74,75 To obtain the initial position for 8b in the active site of
Neu2, we aligned it to 6 in the crystal structure 2F0Z,50 and we kept
the active site waters for our simulations. For simulations with NEU3
and NEU4, each enzyme was aligned separately with the starting
structure for NEU2 using the MatchMaker tool in Chimera.58,67,68 The
starting positions for 8b in the active sites of NEU2, NEU3, and NEU4
are shown in the Supporting Information.
All simulations were run in AMBER 1576 using pmemd.cuda (GPU
acceleration) on Nvidia GeForce GTX 980 GPUs. The f f14SB force
field77 was used for NEU2, NEU3, and NEU4, while the general
AMBER force field (GAFF)78 was used for 8b. Partial charges for 8b
were assigned using the AM1 with bond charge correction (AM1-
BCC) model79 in the antechamber module of AmberTools15.76 The
enzyme−inhibitor complexes with NEU2 and NEU3 were neutralized
with the addition of Na+ ions and that for NEU4 were neutralized with
the addition of Cl− ions. All complexes were solvated in a box of
TIP3P water80 with 10 Å between the solute and the edges of the box
in all three dimensions. For all systems, the water was first minimized
using 100 steps of steepest descent, followed by 4900 steps of
conjugate gradient. Then the entire system was minimized with 100
steps of steepest descent, followed by 4900 steps of conjugate gradient.
The systems were further equilibrated by heating from 5 to 300 K over
50 ps, followed by cooling back to 5 K over an additional 50 ps. After
the annealing step, the systems were again heated from 5 to 300 K
over 100 ps then allowed to run at 300 K for 100 ps before the
production simulations were started. Production was run for 50 ns.
The time step was 2 fs, bonds to hydrogen were constrained with the
SHAKE81 algorithm, and the cutoff for nonbonded interactions was
8.0 Å. The temperature was maintained with the Berendsen
thermostat82 (ntt = 1) with velocities rescaled every 1 ps. The final
25 ns of the simulations were used for analysis with the cpptraj module
of AmberTools15.76,83
Neuraminidase Assay in Mouse Brain Tissue. Mice with
targeted disruption of the neu1 (neu1−/−), neu3 (neu3−/−), and neu4
(neu4−/−) genes have been previously described.54,56,84 Mice with a
combined deficiency of NEU4 and NEU3 were obtained by
intercrossing neu4 and neu3 knockout (KO) mouse strains.84 Mice
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were housed in an enriched environment with continuous access to
food and water, under constant temperature and humidity, on a 12 h
light:dark cycle. Approval for the animal care and the use in the
experiments was granted by the Animal Care and Use Committee of
the Ste. Justine University Hospital Research Center.
At the age of 12 weeks, mice were sacrificed using a CO2 chamber
and their brains extracted, snap-frozen with liquid nitrogen, and kept at
−80 °C. For measurement of neuraminidase activity, 100 mg of frozen
brain tissue was homogenized in water in a ratio of 100 mg of tissue
per 500 μL of water in the 1.5 mL Eppendorf tubes using a Kontes
Pellet motorized pestle. Protein concentration in the homogenate was
measured by the Bradford method using the Bio-Rad reagent. Acidic
α-neuraminidase activity was assayed at pH 4.6 using fluorogenic 4-
methylumbelliferyl-N-acetyl neuraminic acid (4MU-NANA) substrate
as previously described.54 The reaction mixture contained an aliquot of
homogenate corresponding to 300 μg of total protein, neuraminidase
inhibitor in a concentration of 0−150 μM and substrate in a final
concentration of 200 μM. The reaction was carried on at 37 °C for 30
min, after which it was terminated by the addition of 1900 μL of 0.4 M
glycine buffer, pH 10.5. For blank samples, the reaction mixture
contained buffer, inhibitor, and substrate only, but the same volume of
homogenate was added after the termination of reaction.
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6 Conclusion and outlook 
Carbohydrate mimetics are a challenging class of molecules for the development of drug 
candidates. Their large hydrophilic surface and the inherent complexity requires a consequent 
structural modification to enhance pharmacokinetic properties. The aim of this thesis was to 
obtain orally bioavailable carbohydrate mimetics and further improve the predictive power of 
the in vitro assays implemented in the PADMET-platform. Specific assays have been advanced 
(e.g. phase II metabolism, carboxylesterase specificity and metabolite analysis), leading to a 
PADMET-platform that can address characteristic questions to certain problems. In the case 
of E-selectin antagonists, the predictive power of the PADMET-platform was further tested in 
animal studies in mice.  
The PK properties of FimH antagonists have been excessively studied previously (1-5). In this 
thesis, E-selectin antagonists and NEU3 inhibitors are newly assessed by the PADMET-
platform to optimize their PK properties. According to the Biopharmaceutics Drug Distribution 
and Classification System (BDDCS), the currently developed E-selectin and FimH antagonists, 
as well as the NEU3 inhibitors, can be classified differently, as illustrated in Table 6.1 (6). 
Table 6.1 The classification of the different lead structures discussed in this thesis according to the BDDCS (6). 
 High solubility Low solubility 
Hi
gh
 p
er
m
ea
bi
lit
y  
Class 1 
• Extensive metabolism 
• Minimal transporter effects 
Class 2 
• Extensive metabolism 
• Efflux transporter effects 
predominate in the gut, while 
absorptive and efflux transporter 
effects occur the in liver 
Lo
w
 p
er
m
ea
bi
lit
y 
Class 3 
• Poor metabolism 
• Absorptive transporter effects 
• Efflux transporter effects possible 
Class 4 
• Poor metabolism 
• Absorptive and efflux transporter 
effects could be important 
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E-selectin antagonist 
The development of E-selectin antagonists is demanding, since they are derived from the 
highly polar tetrasaccharide sLex. Lead development studies done by Norman et al. introduced 
compound GCP69669A, a tetrasaccharide mimetic showing good affinity towards E-selectin 
with a reduced complexity and polarity (7). GCP69669A, still a highly hydrophilic molecule 
containing two carbohydrate moieties and a carboxylic acid, was chosen as the starting point 
for further development of E-selectin antagonists with improved pharmacokinetic properties. 
Attempts to further reduce the polar surface area and molecular weight in order to achieve 
the structural properties advocated by Lipinski et al. and Veber et al. were not successful 
(Chapter 3.5) (8, 9). Besides the loss in affinity, the molecule did not show sufficient absorption 
potential in PAMPA and Caco-2 cell based assay.  
Therefore, other approaches were followed to improve the pharmacokinetic properties of E-
selectin antagonists. Firstly, ester prodrugs were developed (Manuscript 1). The 
implementation of large aliphatic promoieties increased the passive permeation of the ester 
prodrugs, reaching high absorption potential in PAMPA. Combining the results of PAMPA, the 
hydrolysis rate in liver microsomes, and carboxylesterase specificity, a O-methyl-cyclohexyl 
promoiety was identified as promising starting point. However, all ester prodrugs showed 
active efflux in a Caco-2 cell based assay. Furthermore, the observed hydrolysis of the ester 
bond by pancreatic enzymes in a simulated gastrointestinal fluid could be avoided by reducing 
the size of the lactic acid residue. Additionally, metabolic studies in liver microsomes showed 
that the promoiety is partly susceptible for oxidation, leading to a metabolite, which no longer 
can be converted to the active principle by carboxylesterases. Unfortunately, the ester 
prodrug did not show any oral bioavailability in in vivo studies in mice. Nevertheless, the ester 
prodrug approach was able to show a promising approach to address the short half-life of 
carbohydrate mimetics. Once in circulation, the slow hydrolysis of the ester prodrug and 
therefore prolonged release of the active principle led to a longer apparent plasma half-life.  
As a different strategy, a bioisosteric replacement of the carboxylic acid (Manuscript 2) was 
introduced into the ligand scaffold. By forming amides, not only the affinity, but also the 
pharmacokinetic properties were improved. The amidic replacement enhanced the 
lipophilicity of the molecules but did not improve the passive permeability. Two different 
molecules containing a terminal isopropyl moiety on the amide were identified to show active 
uptake in a Caco-2 cell permeation assay. In vivo, the E-selectin antagonist featuring a 
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cyclobutylamine-2-isoproxy moiety showed the highest oral bioavailability (7.7 %). 
Furthermore, the molecule has good aqueous solubility and sufficient stability in liver 
microsomes. Therefore, other structural modifications to improve the affinity were 
implemented. Even though the active uptake was no longer observable in Caco2 cells, the 
highly affine compound showed an oral bioavailability of 4.3 % in mice.  
The ester prodrug and amide approach showed the importance of the active transport of E-
selectin antagonists to reach oral bioavailability. Therefore, currently developed E-selectin 
antagonists can be classified in the BDDCS as class 3. Even though beneficial for the affinity, 
the observed drop in solubility of E-selectin antagonists with a CF3-group in the 6-position of 
the fucose moiety (Chapter 3.5 and Manuscript 3) has to be monitored carefully.  
Overall, the complexity, size, and polarity of the core structure of E-selectin antagonists 
promotes molecules with low passive permeability. Thus, oral bioavailability most likely has 
to be achieved by active transport and future work to reach higher oral bioavailability should 
focus on the identification of the responsible transporter for the active uptake of amidic E-
selectin antagonists and further evaluate the potential thereof. 
FimH antagonists 
Previous work by Kleeb et al. showed the potential of biphenyl α-D-manno-pyranosides with 
a bioisosteric replacement of the terminal carboxylic acid to get orally bioavailable FimH-
antagonists with a promising PK/PD profile (3). Further improvements of the arene-arene 
interactions by forming polyfluorinated FimH antagonists did not alter the physicochemical 
properties (e.g. solubility, logD7.4, passive permeability in PAMPA) of the antagonists 
(Manuscript 6). Therefore, we assume that those molecules have a similar PK/PD profile as 
previously reported.  
Starting from a well soluble, but insufficiently permeable bioisostere, ester prodrugs attached 
to the C-6 moiety of the mannose were synthesized (Publication 1) (4). Several short-chain 
aliphatic acids were identified as useful promoieties for optimizing the intestinal absorption 
potential, whilst sufficient solubility could be sustained. The downside of acylation of a 
hydroxyl group of the sugar moiety is the premature cleavage of the promoiety by CES2 
located in the enterocytes. Therefore, choosing the appropriate prodrug moiety should be 
guided by enzymatic stability studies addressing the carboxylesterase specificity. 
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Overall, the FimH antagonists reported in Manuscript 6 have a high potential to show good 
pharmacokinetic properties and are classified as class 1 in the BDDCS. As a next step, the 
primary findings should be confirmed in vivo and further ADMET properties, especially the 
toxicity, should be evaluated.  
NEU3 inhibitors 
Specific NEU3 inhibitors and ester prodrugs thereof were developed (Publication 2) (10). 
Analysis of the pharmacokinetic properties suggested that they are unlikely to be orally 
bioavailable. Permeability assays using artificial membranes (PAMPA) and Caco-2 cells showed 
that the compounds were not sufficiently permeable and furthermore showed active efflux. 
The low solubility of 3–5 μg/mL further contributes to poor pharmacokinetic properties. 
Therefore, the inhibitors have to be classified as class 4 in the BDDCS. Finally, the examination 
of the liver microsomal stability showed that the ester was only slowly hydrolyzed. In 
summary, esterification did not improve pharmacokinetic properties sufficiently to allow for 
oral bioavailability. Future studies should implement modifications of the active principle to 
enhance permeability and solubility. 
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